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Abstract 
 
Primary open-angle glaucoma (POAG) is a multifactorial disease with a strong genetic 
component. Notably however, few genes have been robustly associated with POAG in 
the general population. Genes in which mutation causes anterior segment angle 
anomalies, including LMX1B  and  FOXC1  are associated with a high incidence of 
glaucoma to about 33-75% and are strong candidates for glaucoma susceptibility. In 
addition, growth factors including TGFβ2 and BMP4 act in concert to maintain a 
balance between extracellular matrix (ECM) deposition and degradation and may play a 
role in glaucoma pathogenesis through misregulation of ECM synthesis of the 
trabecular meshwork (TM). Furthermore, OPTN E50K mutation, a known genetic locus 
for POAG, has been shown to account for a high percentage of 13.5% of familial 
normal-tension glaucoma (NTG) in individuals of white British origin. In this study, the 
contribution of variation at the LMX1B,  FOXC1, TGFβ2  and BMP4 loci to risk of 
glaucoma was investigated in a case-control genetic association study in a cohort of 
white British descent recruited in the North-East of England comprised of 272 patients 
with high-tension glaucoma (HTG), 37 patients with NTG, 58 patients with ocular 
hypertension (OHT), and 276 normal controls. The role of OPTN E50K mutation in 
these unrelated white British individuals with POAG was also examined. No significant 
associations were identified for FOXC1, TGFβ2 and BMP4. The OPTN E50K mutation 
was also absent in this cohort. The study identified a significant under representation of 
two LMX1B haplotypes [ATG; P = 5.0E-4 (permutation P = 0.01), GCAGAC; P = 
5.0E-4 (permutation P = 0.0150)] among the POAG individuals compared to the control 
population, consistent with a 0.3 fold decreased risk of developing POAG. A replication 
study involving a second cohort of 222 NTGs and 108 HTGs recruited in London 
showed a similar distribution of the ATG haplotype (P = 0.0047) but did not withstand 
permutation testing.  
 
In conclusion, LMX1B haplotypes may influence susceptibility to develop POAG in the 
white British population, suggesting altered LMX1B function predisposes to 
glaucomatous damage.                                                                                                                                                             Contents 
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Chapter 1  Introduction 
 
1.1  Definition of glaucoma 
Glaucoma is a common and heterogeneous group of optic neuropathies which is broadly 
classified into three main types: open angle, closed angle, and developmental (Shields et 
al., 1996). The aetiology of glaucoma is retinal ganglion cell death resulting in a 
characteristic visual field loss and a typical excavation of the optic nerve head. 
Glaucoma is frequently associated with raised intraocular pressure (IOP>21mmHg), 
which is recognised as one of the strongest known risk factors (Wilson and Martone, 
1996). The statistical ‘normal range’ for the IOP is 11 to 21 mmHg (2 standard 
deviation on either side of the mean IOP of 16 mmHg). It is of note that this is a 
statistically derived figure and does not suggest that disease is present if the IOP level 
exceeds this value. Hence, although there appears to be no absolute cut-off level, any 
value above 21 mmHg should be considered as suspicious. The Baltimore Eye Survey 
showed that the risk of glaucomatous optic nerve damage increased with raised level of 
IOP, especially at levels above 22 mmHg (Sommer et al., 1991). However, despite this 
proven risk factor, there seems to be no clearly defined level of “safe” IOP. 
Glaucomatous damage can occur even with an IOP of 12mmHg and, on the other hand, 
be absent in eyes with IOP of 30mmHg (Infeld and O'Shea, 1998). 
 
This study investigates several developmental glaucoma genes and a known genetic 
locus for familial normal-tension glaucoma (NTG), as genetic risk factors for primary 
open-angle glaucoma (POAG) and ocular hypertension (OHT) (IOP > 21 mmHg) in a 
cohort of white British individuals.  
 
1.2  Classification of glaucoma 
Glaucoma can be classified into three basic subtypes: 
•  Open angle  
•  Closed angle 
•  Developmental  
                                                                                                                                     Chapter 1 Introduction 
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Differentiation of open angle glaucoma from closed angle glaucoma is considered 
crucial from a therapeutic point of view. In addition, glaucomas can be further 
categorized into primary or secondary glaucoma. Primary glaucomas such as POAG are 
not associated with known ocular or systemic disorders that cause increased resistance 
to aqueous outflow (American Academy of Ophthalmology, 2004b). On the other hand, 
secondary glaucomas are associated with either ocular or systemic disorders that lead to 
increased resistance to aqueous outflow. Examples of POAGs include high-tension 
glaucoma (HTG) and NTG, with OHT being an important risk factor for POAG. 
 
1.2.1  Primary open angle glaucoma 
 
1.2.1.1  High tension glaucoma (HTG) 
HTG is the commonest form of glaucoma with an estimated prevalence of 1.2% for the 
age group 40-89 years in the white population of the United Kingdom (Tuck and Crick, 
1998). Its diagnosis is reached through exclusion of any identifiable cause (hence 
otherwise known as primary open angle glaucoma) and it is characterized by (Figure 1-
1 and 1-2): 
•  Open anterior chamber angle on gonioscopic evaluation 
•  IOP > 21 mmHg at some stage during the course of disease 
•  Glaucomatous damage of the optic nerve head 
•  Characteristic visual field loss 
•  Adult onset (> 40 years of age) 
 
1.2.1.2  Normal-tension glaucoma (NTG) 
At the opposite end of the IOP spectrum is NTG, an important subtype of POAG. This 
is an optic neuropathy similar to HTG (i.e. open, normal appearance of anterior chamber 
angles, with presence of glaucomatous optic neuropathy) but with IOP levels within the 
statistically “normal range”. Although by definition, IOP should never be above 
21mmHg, it tends to be higher than those in the normal individuals (Gramer and 
Leydhecker, 1985). Whilst the bulk of the evidence has shown a significant effect of 
IOP on optic nerve damage in NTG (Araie et al., 1994; Jonas et al., 1998; Koseki et al., 
1997), some have shown no effect (Noureddin et al., 1991). Hence, other factors may                                                                                                                                     Chapter 1 Introduction 
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Ai)                      Aii)  
B i)                Bii)           
C)         
Figure 1–1: Characteristic features of glaucoma.  
(Ai) Cross section of the optic nerve in a normal eye and (Aii) the corresponding frontal 
view of the optic disc. (Bi) Cross section of the optic nerve in an eye with raised 
intraocular pressure and (Bii) the corresponding frontal view of the optic nerve showing 
end stage cupping of the optic head. (C) Humphrey’s visual field (a form of a static 
perimetry which involves presentation of non-moving stimuli of varying illuminance) 
showing advanced visual field loss. Diagrams adapted from Clinical Ophthalmology, 
Kanski and from Merick Frosst Canada LTD. 
Edge of 
optic disc  cup 
------------ 
------------                                                                                                                                    Chapter 1 Introduction 
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Figure 1–2:  Width of the anterior chamber.  
(a) Shaffer grading of anterior chamber angle width ranging from grade 4 being the 
widest (open) angle to grade 0 being the narrowest (closed) angle. (b) Cross section of 
the anterior segment with an open angle appearance which is typically found in POAG. 
(c) Cross section of the anterior segment with a closed angle appearance. Diagrams 
adapted from Clinical Ophthalmology, Kanski, and from Merick Frosst Canada LTD. 
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play an important role in NTG, most of which are still unknown. Studies have shown 
that individuals with NTG have higher prevalence of pressure independent associations 
such as abnormal ocular blood flow from vasospastic disorders (e.g. migraine and 
Raynaud’s phenomenon (Corbett et al., 1985; Phelps and Corbett, 1985), systemic 
hypotension (Bonomi et al., 2000; Leske et al., 2002; Leske et al., 2008; Libby et al., 
2005) and coagulopathies (Drance et al., 1973b)). 
 
The prevalence of NTG in individuals over the age of 40 years is 0.2%, increasing up to 
1.6% in those over 75 years of age (Klein et al., 1992). It has been proposed that NTG 
has a predilection for females. Levene‘s review (Levene, 1980) showed an increased 
prevalence in females ranging from 6% to 75%. However, the Beaver Dam Eye Study 
found equal prevalence among sexes (Klein et al., 1992).  
               
The relation between NTG and HTG is debatable, with some supporting the idea that 
these two conditions are separate entities (Caprioli and Spaeth, 1984; Chumbley and 
Brubaker, 1976) whilst others support the idea that they are simply phenotypic 
variations of the same disease (Drance et al., 1973a; Drance et al., 1973b; Lewis et al., 
1983). In both NTG and HTG, the cupping of the optic disc, the visual field loss and the 
angle configuration are similar. On the other hand, shallower cupping, or saucerisation 
of the optic nerve head has been more commonly documented in NTG than HTG, with 
visual field defects in NTG appearing deeper and steeper. In addition, disc hemorrhages 
are more commonly encountered features of NTG (Sowka 2004).  
 
Both HTG and NTG appear to represent a spectrum of glaucomas in which the 
mechanism of the glaucomatous optic disc damage shifts from predominantly elevated 
IOP in the former to additional IOP-independent factors in the latter, with a 
considerable overlap of causative factors. For the purpose of this study, NTG is 
considered as a subgroup of POAG. 
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1.2.2   Ocular hypertension 
Ocular hypertension (OHT) is a term reserved for eyes in which the IOP is raised above 
the normal Caucasian population range of 21mmHg (i.e. two standard deviation above 
the mean IOP) (Leske, 1983). There are no clinical signs of a glaucomatous optic 
neuropathy (as evidenced by a normal appearance of the optic nerve and normal visual 
fields), and there is no ocular co-morbidity. OHT is an important risk factor for POAG, 
and the risk of POAG has been shown to increase with higher IOP (Gordon et al., 
2002). Due to its skewing of the normal distribution to the right, the prevalence of OHT 
is estimated to range from 4.5% to 9.4% for those who are >40 years old (Leske, 1983) 
rather than the expected 2.5% from a true normal distribution. The Ocular Hypertension 
Treatment Study (OHTS) has shown approximately 10% of  individuals with OHT will 
convert to POAG over a ten year period (Kass et al., 2002). 
 
1.2.3   Angle closure glaucoma 
Angle closure glaucomas comprise a diverse subgroup of glaucomas where the unifying 
theme is the presence of peripheral anterior synechiae (where the peripheral iris attaches 
anteriorly in the anterior chamber angle) and/or iridotrabecular apposition (American 
Academy of Ophthalmology, 2004a). As a result of this, there is reduced drainage of 
aqueous humor through the anterior chamber angle. The commonest cause of angle 
closure is a pupillary block (Figure 1-3). The flow of aqueous through the pupil from 
the posterior chamber is impeded. This leads to increase pressure in the posterior 
chamber causing the peripheral iris to bow forward against the trabecular meshwork 
(TM). For the purpose of this study which has assessed developmental genes and a 
known genetic locus for familial NTG as genetic risk factors for POAG, angle closure 
glaucomas have not been mentioned further. 
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Figure 1–3: Pupillary block glaucoma. 
A cross section view of the anterior chamber angle illustrating the presence of a 
functional block between the iris and the lens (A) causing a raised pressure in the 
posterior chamber (arrows) with a forward shift of the peripheral iris and closure of the 
anterior chamber angle (B). 
 
 
 
1.2.4  Developmental glaucoma 
Developmental glaucoma defines glaucomas that are associated with dysgenesis of the 
anterior segment. Anterior segment dysgenesis (ASD) are an ill-defined, genetically 
heterogeneous group of developmental abnormalities that share some common ocular 
features and a high prevalence of associated glaucoma (Gould and John, 2002). Since 
ASD may lead to an incomplete development or dysfunction of the structures that form 
the aqueous drainage pathway and are associated with glaucoma, they may provide 
important insights into one of the most common forms of glaucoma- POAG. The 
anomalies that make up the clinical spectrum of ASD including infantile congenital 
glaucoma, iris hypoplasia/iridogoniodysgenesis, Axenfeld and Rieger anomaly, Peters 
anomaly, congenital hereditary endothelial dystrophy, sclerocornea and megalocornea 
(Idrees et al., 2006).   
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1.3  Ocular anatomy and physiology relevant to glaucoma 
IOP is one of the strongest risk factors for the development of glaucoma (Wilson and 
Martone, 1996). Intraocular pressure is regulated by a balance between the secretion and 
drainage of aqueous humor. Hence IOP is affected by;  
1)  the rate of aqueous humor production by the ciliary body,  
2)  its drainage through the outflow channels of the angle of the anterior chamber 
angle,  
3)  the episcleral venous pressure. 
 
Raised IOP is predominantly caused by increased resistance to drainage of aqueous 
humor (Gabelt and Kaufman, 2005; Tamm and Fuchshofer, 2007). 
 
1.3.1  Aqueous humor secretion 
Active secretion by the non-pigmented ciliary epithelium accounts for approximately 
80% of aqueous production, whereas passive secretion (dependent on the level of blood 
pressure in the ciliary capillaries, plasma oncotic pressure and the level of IOP) 
contributes approximately 20% towards aqueous secretion (American Academy of 
Ophthalmology, 2008). Aqueous fluid flows from the posterior chamber (defined by the 
ciliary body, the lens and the posterior surface of the iris) into the anterior chamber 
(defined by the cornea, anterior surface of the iris and the iridocorneal junction) via the 
pupil (Figure 1-4). 
 
1.3.2  Aqueous outflow physiology 
Aqueous humor exits the anterior chamber into the venous circulation predominantly by 
two different routes: via the TM and independently through the uveoscleral outflow 
pathway (Figure 1-4). 
 
The conventional route through the sieve-like TM accounts for the majority (90%) of 
aqueous outflow. Here, the aqueous flows through the trabeculum, and into the 
Schlemm canal. It exits the eye by draining into the episcleral veins (Kanski, 2003).  
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Figure 1–4: Cross section of the anterior chamber showing aqueous drainage 
pathways;  
(a) through the trabecular meshwork and; (b) through the uveoscleral pathway. 
Modified from Clinical Ophthalmology, Kanski. 
 
 
 
 
 
 
 
 
 
Figure 1-4: Cross section of the anterior chamber showing aqueous drainage 
pathways 
(a) through the TM and; (b) through the uveoscleral pathway; and (c) through the iris. 
Adapted from Clinical Ophthalmology, Kanski. 
 
 
cornea 
Ciliary 
body  lense 
iris 
Anterior segment of eye 
The drainage structures 
are located at the anterior 
chamber angle                                                                                                                                    Chapter 1 Introduction 
  28
The unconventional route through the uveoscleral drainage pathways (Figure 1-4) 
accounts for the remaining 10% of aqueous outflow. It flows across the face of the 
ciliary body into the suprachoroidal space. This drains into the venous circulation 
situated within the choroid and the sclera. A small minority of aqueous fluid is drained 
by the iris. 
 
In most cases of glaucoma, there is an increased resistance to aqueous humor drainage 
through the trabecular pathway (Gabelt and Kaufman, 2005; Tamm and Fuchshofer, 
2007). 
 
 
1.3.3  Applied anatomy of the optic nerve head 
Axons of retinal ganglion cells comprise the retinal nerve fibre layer, the innermost 
layer of the retina. These axons converge on the optic disc and form the optic nerve 
which contains about 1.2 million axons (Figure1-5). These ganglion cell fibres exit the 
eye by traversing through the lamina cribrosa (a series of perforated connective tissue 
sheets) and become myelinated and synapse in the lateral geniculate ganglion (Jakobiec, 
1982; Kanski, 2003; Snell and Lemp, 1998). The distribution of these axons provide 
important clues for the interpretation of visual field loss in relation to glaucomatous 
optic nerve cupping since the axons’ pattern of convergence dictates the pattern of 
visual field loss (Figure 1-6).  Fibres arising from the macula travel a straight course to 
the optic nerve head forming the papillomacular bundle, with those arising from the 
nasal retina also following a relatively straight course to the optic nerve. Fibres situated 
temporal to the macula follow an arcuate path around the papillomacular bundle to 
reach the optic nerve. The optic cup is a central depression of the optic nerve devoid of 
any neural tissue. In contrast, the neuroretinal rim contains the exiting axonal fibres and 
is defined by the outer edge of the cup and the outer margin of the disc (Figure 1-7). 
The appearance of a normal rim has a uniform width and has a pink colour appearance. 
The degree of glaucomatous optic nerve head damage can be determined by the cup-
disc (C/D) ratio. The diameter of the cup can be expressed as a fraction of the diameter 
of the disc, both in the vertical and horizontal meridians. The normal vertical C/D ratio 
is 0.3 or less and 2% of normal eyes have a ratio of more than 0.7 (Kanski, 2003).  
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Figure 1–5: The anatomy of retinal fibres illustrating the pattern of convergence of 
ganglion cell fibres (depicted in yellow colour) towards the optic nerve. 
Fibres arising from the macula travel a straight course to the optic nerve head forming 
the papillomacular bundle, with those arising from the nasal retina also following a 
relatively straight course to the optic nerve. Fibres situated temporal to the macula 
follow an arcuate path around the papillomacular bundle to reach the optic nerve.  
Adapted from Clinical Ophthalmology, Kanski.  
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Figure 1–6: Diagrammatic illustration of the pattern of convergence of ganglion 
cell fibres on the optic disc, which dictates the pattern of visual field defect.  
In this case, damage to the inferotemporal retinal nerve fibres (a) results in a superior 
arcuate field defect as shown in a Humphery’s visual field (b). Adapted from Clinical 
Ophthalmology, Kanski. 
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Figure 1–7: Cup-disc ratio of optic nerve head. 
A photograph of the left optic disc with an enlarged cup-disc (C/D) ratio. Provided by 
Thomas Ressioniotis, University of Newcastle. 
 
 
 
1.4  Epidemiology of glaucoma  
Glaucoma presents a significant public health problem as it is the second leading cause 
of blindness world-wide. It is estimated that 67 million people are affected by this 
condition, with over 6.7 million people being bilaterally blind from glaucoma (Quigley, 
1996). The prevalence of glaucoma has been studied extensively and has been shown to 
vary extensively between ethnic and racial groups (Table1-1). In addition, population-
based studies have shown estimated prevalence rates varying greatly between different 
populations (Figure 1-8 and Table 1-1), ranging from 1-3% in Europe, 2-3% in 
Australia, 1-4% in Asia (Quigley and Broman, 2006; Rudnicka et al., 2006), and high 
prevalence of 7-9%. among African-Caribbeans originating from West Africa (Leske et 
al., 1994; Mason et al., 1989). Within the African continent,  prevalence varied from 
1% in Nigeria (Murdoch et al., 2001) to greater than 8% in Ghana (Ntim-Amponsah et 
al., 2004). It is of note that these figures are confounded by differences in definitions 
and classifications of glaucoma. (Foster et al., 2002). 
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Table 1–1: Population-based prevalence surveys of open angle glaucoma.  
Adapted from Shield’s Textbook of Glaucoma, Allingham. 
Location Age  group 
(years) 
Number of 
participants 
Prevalence of 
POAG 
Black      
Baltimore (USA, 1991)  >40  2396  4.7% 
Barbados (1994)  40-84  4709  6.6% 
Kongwa (Tanzania, 2000)  >40  3268  3.1% 
St. Lucia (1989)  30-86  1679  8.8% 
Temba (South Africa, 2003) 
 
>40 839  2.9% 
Hispanic 
Arizona (USA, 2001) 
 
>40 4774  2.0% 
Asian      
Andhra Pradesh (India, 2000)  >40  1399  2.6% 
Japan (1991)  >40  8126  2.6% 
Mongolia (1996)  >40  1000  2.2% 
Singapore 
 
40-79 1717  2.4% 
White      
Baltimore (USA, 1991)  >40  2913  1.3% 
Beaver Dam (USA, 1992)  43-84  4926  2.1% 
Bedford (UK, 1968)  >30  5941  0.7% 
Blue Mountains (Australia, 1996)  >49  3654  3% 
Egna-Neumarket (Italy, 1998)  >40  5816  1.4% 
Melbourne (Australia, 1998)  40-98  3271  1.7% 
Rhonda Valley (UK, 196)6  40-74  4231  0.3% 
Rotterdam (Netherlands, 1994)  >55  3062  3.1% 
Reykjavik (Iceland, 2003)  >50  1045  4.0%                                                                                                                                    Chapter 1 Introduction 
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Figure 1–8: Estimates of global prevalence of open angle glaucoma in individuals 
>40 years of age.  
Adapted from Leske M, 2007.                                                                                                                                    Chapter 1 Introduction 
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Primary open angle glaucoma is more prevalent in older individuals (Figure 1-9), and 
the number of people at risk of developing glaucoma is increasing rapidly as the elderly 
population grows disproportionately. Over 8.4 million people will be bilaterally blind 
from glaucoma in 2010, rising to 11.1 million by 2020 (Quigley and Broman, 2006). 
The danger of glaucoma is that substantial visual damage can occur before diagnosis 
since POAG is an asymptomatic disease. Indeed, late presentation is an important risk 
factor for subsequent blindness in glaucoma (Fraser et al., 2001). It is estimated that 
approximately 50% of patients with POAG remain undiagnosed in most Western 
communities (Kroese et al., 2002).  
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Figure 1–9: Age specific prevalence of POAG increases with age but varies 
between different ethnic groups. 
Adapted from Shield’s Textbook of Glaucoma, Allingham. 
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The sensitivity of current diagnostic technique is suboptimal and the diagnosis of 
glaucoma is usually made once irreversible damage has already occurred. As 
glaucomatous visual loss is preventable in the majority of cases, there is an urgent need 
for methods to identify individuals at risk of developing glaucoma, so that early 
treatment can prevent visual loss. Early disease detection will substantially reduce the 
burden on health care expenditures on glaucoma treatment and improve quality of life. 
 
1.5  Management of glaucoma 
The aim of treatment for patients with POAG is to prevent functional impairment of 
vision within the patient’s lifetime and to avoid an adverse impact on quality of life. 
Currently the best method of achieving this goal is by lowering the IOP. Medical 
therapy is usually the first line treatment for POAG. These anti-glaucoma eye drops 
lower the IOP either by reducing aqueous production (e.g. beta-blockers, alpha2-
adrenergic agonists) or increase uveoscleral outflow (e.g. prostaglandin analogues, 
alpha2-adrenergic agonists) or the trabecular outflow (e.g. parasympathomimetic 
(miotic) agents, prostaglandin analogues (e.g. bimatoprost)). Generally, drugs are 
initiated one at a time but subsequent addition of further drugs may be necessary if IOP 
remains unsatisfactorily high. Traditionally, beta-blockers were the preferred first 
option but prostaglandin analogues are now often favoured as they are as efficient with 
fewer side effects. For patients who do not respond to medical therapy, laser 
trabeculoplasty or incisional surgery are further methods that can be used to facilitate 
the aqueous outflow and lower the IOP (Lee and Higginbotham, 2005). 
 
Topical therapy with anti-glaucoma drops or treatment with argon laser trabeculoplasty 
has been shown to significantly reduce progression in 50% of cases (Leskea et al., 
2004). However, despite the efficacy of medical and laser treatment for POAG, a study 
from the United States in a predominantly Caucasian population showed that the 
cumulative probability of undergoing filtration surgery in at least 1 eye was estimated to 
be 23% (Hattenhauer et al., 1999). Furthermore, about 22% of individuals with POAG 
continued to develop blinding glaucomatous neuropathy over a 20-year period despite 
treatment (Hattenhauer et al., 1998). 
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1.6  Clinical risk factors for glaucoma 
Understanding the relative importance of and identifying risk factors for developing 
glaucoma is important as this will help to identify those at risk of developing glaucoma 
so that close medical supervision and early treatment can be initiated. Clinical risk 
factors are categorized into general risk factors, ocular risk factors, and systemic risk 
factors. 
 
1.6.1  General risk factors 
 
1.6.1.1  Age 
Increased age is an important risk factor on the prevalence of POAG (Figure 1-9, Table 
1-2, Table 1-4). In the Baltimore Eye Study (Tielsch et al., 1991), the prevalence of 
glaucoma among blacks increased dramatically with age, rising above 11% in 
individuals who were 80 years or older. The Collaborative Initial Glaucoma Treatment 
Study (CIGTS) (Gillespie et al., 2003) showed visual field defects were 7 times more 
likely to develop in patients who were 60 years old or older than those who were under 
40 years of age. In the Early Manifest Glaucoma Trial (EMGT) (Leske et al., 2003a), 
the relative risk for progression of early glaucoma was 1.5 for those of 68 years of age 
or older compared to those younger than 68 years. Hence age appears to be an important 
risk factor for developing glaucoma. 
 
1.6.1.2  Race 
On the whole, the prevalence of POAG is highest in black populations and lowest in 
northern Asian populations. The Baltimore Eye Survey found the prevalence of POAG 
was four times higher in blacks compared to whites (Tielsch et al., 1991). A recent 
Meta-analysis study (Rudnicka et al., 2006) confirmed that black populations had the 
highest POAG prevalence at all ages whilst white populations showed the steepest 
increase in POAG prevalence with age. In addition, the Advanced Glaucoma 
Intervention Study (AGIS) (AGIS Investigators, 2002) found that black race was a risk 
factor for progression (Wilson et al., 1985). As shown by the Collaborative Normal 
Tension Glaucoma Study (CNTGS) (Drance et al., 2001),  Chinese individuals had a 
significantly reduced risk compared to white patients, of progression.                                                                                                                                    Chapter 1 Introduction 
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1.6.1.3  Family history 
A positive family history is known to be an important risk factor for POAG (Table 1-4). 
Prevalence studies have shown a consistent association with an increased risk of POAG 
in individuals with a first degree relative with glaucoma. In the  Baltimore Eye Survey, 
association between POAG and family history appears to be stronger when the affected 
relative is a sibling (odds ratio (OR) = 3.7) (see section 2.8.3 for further description of 
OR) rather than a parent (OR = 2.2) or child (OR = 1.1) (Tielsch et al., 1994). Although 
this prevalence might not be high enough to justify a simple Mendelian pattern of 
inheritance, it suggests that a polygenic or multifactorial influence may contribute to the 
expression of the disease  (Lichter 1994).  A population-based study in Rotterdam 
examined familial members of individuals with and without POAG, and found that first 
degree relatives of an affected individual had a 22% risk of developing POAG 
compared to only 2.3% risk among familial members of controls (Wolfs et al., 1998). 
This study also suggested that enlarged C/D ratio was the earliest and most prominent 
feature of familial aggregation. A case control study involving Caucasian individuals 
Table 1–2: Age specific prevalence of open angle glaucoma.  
(Adapted from Shield’s Textbook of Glaucoma, 2005) 
  White  Blacks  Hispanic  Asian 
Age 
(years) 
Eye disease 
prevalence 
group 
(Friedman 
et al., 2004) 
Baltimore 
Eye Survey 
(Tielsch et 
al., 1991) 
Baltimore 
Eye Survey 
(Tielsch et 
al., 1991) 
Proyecto Ver 
(Arizona, 
USA) 
(Quigley et 
al., 2001) 
Tamil Nadu 
(India) 
(Ramakrishnan 
et al., 2003) 
40-49  0.6 0.9 1.2 0.5  0.3 
50-59  1.5 0.4 4.1 0.6  1.6 
60-69  2.7 0.9 5.5 1.7  1.8 
70-79  5.1 2.9 9.2 5.7  2.9 
80+  7.3 2.2 11.3  12.6 ---- 
Overall  ---- 1.3 4.7 2.0  1.2                                                                                                                                    Chapter 1 Introduction 
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with 175  POAG cases and 175 controls showed that, a family history of POAG was a 
major risk factor for first degree relatives (OR = 7.7) (Charliat et al., 1994). More 
specifically, there appears to be a strong familial component to the development of 
NTG, where the presence of a positive family history is reported to be about 40 % 
(Geijssen H, 1991). With regards to OHT, a clinic based study involving 150 patients, 
showed 43% of patients with OHT had a positive family history (Shin et al., 1977) 
despite family history of glaucoma not being identified as a risk factor for developing 
glaucoma in the OHTS study. 
 
Further evidence that genetics is an important factor is supported by twin studies which 
have shown a higher degree of concordance among monozygotic twin (Gottfredsdottir 
et al., 1999; Teikari, 1987). In particular, Gottfredsdottir et al showed the concordance 
of open angle glaucoma in monozygotic twin pairs was significantly higher at 98 % 
compared to their spouses (70%).  
 
Taken together, these evidences strongly suggest that specific genetic defects contribute 
to the pathogenesis of POAG. 
 
1.6.2  Ocular risk factors 
 
1.6.2.1  IOP 
Elevated intraocular pressure (IOP) has played an important role in the diagnosis and 
management of glaucoma and is currently the only treatable risk factor. There is sound 
evidence that IOP is a strong risk factor for glaucoma (Table 1-4). Numerous prevalence 
surveys (Table 1-3) and longitudinal studies have consistently shown a dose-response 
relationship between IOP and glaucoma (Le et al., 2003; Leske et al., 2002). Recent 
decisive results published from randomised clinical trials have shown that lowering IOP 
reduced incidence (OHTS) (Kass et al., 2002) and progression of glaucoma (EMGT and  
CNTGS) (Collaborative Normal Tension Glaucoma Study Group, 1998; Heijl et al., 
2002) compared with no treatment. Baltimore Eye Survey showed prevalence of POAG 
increased with age, this being 40 times greater in those with an IOP of ≥ 35mmHg, 
compared to those with an IOP of ≤ 15 mmHg (Sommer et al., 1991). 
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Table 1–3: Prevalence and relative risk of POAG with increasing IOP. 
(Adapted from Shield’s Textbook of Glaucoma, 2005) 
IOP (mmHg)  Prevalence  Relative risk 
<15 0.7  1.0 
16-18 1.3  2.0 
19-21 1.8  2.8 
22-24 8.3  12.8 
25-29 8.3  12.8 
30-34 25.4  39.0 
≥35 26.1  40.1 
 
 
In the Barbados Eye Study, the incidence of POAG steadily increased with IOP (Leske 
et al., 2001). More importantly, a reduction in the IOP by average of 23% decreased the 
incidence of POAG by 60% in the OHTS (Kass et al., 2002). Both EMGT and CNTGS 
showed an IOP reduction of 25% and greater than 30% reduced the risk of progression 
by 33% and 50% respectively when compared to no treatment (Collaborative Normal 
Tension Glaucoma Study Group, 1998; Heijl et al., 2002). Overall, in addition to raised 
IOP contributing to POAG, these data suggest that IOP may contribute towards the 
onset of glaucoma even in patients when the untreated IOP is in the normal range and 
that individual may benefit from IOP reduction. 
 
1.6.2.2  Features of the optic nerve head 
An enlarged optic disc has been generally considered as a risk factor for developing 
glaucoma (Armaly et al., 1980; Hart, Jr. et al., 1979; Yablonski et al., 1980). Recent 
evidence from the OHTS has shown support for this association by showing that for 
every 0.1 unit increase in the baseline C/D ratio, there was a 1.4 fold increase in the 
incidence of POAG among OHT individuals. 
 
Optic disc haemorrhages have also been associated with an increased risk for 
progression of visual field loss, as shown by the EMGT (relative risk (RR) =1.02;                                                                                                                                    Chapter 1 Introduction 
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relative risk is defined as incidence of disease rate in exposed divided by incidence rate 
in non-exposed group) and the CNTGS (RR = 2.72). Higher prevalence of glaucoma 
(10 fold increase) was found with disc haemorrhage, and disc haemorrhage was more 
commonly associated with NTG (25%) than HTG (8%) (Healey et al., 1998). 
 
1.6.2.3  Central corneal thickness 
An association of the central corneal thickness (CCT) with POAG has been a recent 
finding and has shown to be a predictive factor for developing glaucoma. This 
association came to light in the Ocular Hypertension Treatment Study, where thinner 
CCT was a strong risk factor for developing POAG in individuals with OHT (Gordon et 
al., 2002). 
 
The average CCT is between 537 to 554 µm in normal individuals (Shah et al., 1999; 
Wolfs et al., 1997). Variation of the CCT in normal individuals can alter the 
measurement of IOP, with thicker corneas leading to falsely higher IOP reading and 
falsely lower measurements with thinner corneas. So far, there has been a lack of 
agreement for a standard algorithm to provide correction for IOP readings with varying 
CCT and the relationship between CCT and POAG remains unclear. The implication for 
clinical practice is that pachymetry should be performed on all newly diagnosed patients 
with OHT/POAG and the corneas should be categorized as thin, average or thick. This 
has implications on management of POAG/OHT since patients with POAG with thin 
corneas will require a lower threshold for starting treatment or intensifying treatment, 
whereas, patients with thicker corneas would require a higher threshold for either 
starting treatment or intensifying treatment (Brandt, 2007). 
 
Of greater clinical significance, a thinner CCT has been identified as a risk factor in 
POAG, with the exact underlying mechanism yet to be determined. CCT has been found 
to be thicker in individuals with OHT (Brandt et al., 2001; Herndon et al., 1997) and 
thinner in individuals with NTG (Copt et al., 1999).  Recent results from a population-
based study among individuals of African descent involving 3222 individuals in the 9 
year follow-up in the Barbados Eye Studies showed thinner CCT as a risk factor in 
POAG (Leske et al., 2008). Studies have further demonstrated that CCT varies between 
racial and ethnic groups (Nemesure et al., 2003; Shimmyo et al., 2003). In particular,                                                                                                                                    Chapter 1 Introduction 
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thinner corneas have been associated with African-Americans compared to Caucasians. 
Furthermore, CCT has been linked to other factors that may be associated with 
glaucoma, including disc size (Pakravan et al., 2007), with thicker corneas associated 
with smaller disc, and another study involving twins suggesting that genetic factors 
were shown to be of major importance in CCT (Toh et al., 2005). Interestingly, a recent 
study has suggested thinner CCT may have biomechanical properties such as increased 
elasticity, which in turn increases the susceptibility of the optic nerve to glaucomatous 
damage (Herndon et al., 1997; Leske et al., 2008).  
 
1.6.2.4  Myopia 
Numerous case series (Fong et al., 1990; Perkins and Phelps, 1982), case reports (Daubs 
and Crick, 1981; Wilson et al., 1987) and large population-based prevalence surveys 
(Weih et al., 2001; Wong et al., 2003) have shown an association of myopia with 
POAG. However, longitudinal studies such as OHTS or EMGT have failed to identify 
an association between myopia as a risk factor for POAG. The difficulty with myopia is 
that optic disc changes make accurate assessment of the C/D ratio difficult as well as 
giving rise to visual field defects resembling those seen in POAG (Leske, 1983). 
 
1.6.3  Systemic risk factors 
1.6.3.1  Diabetes mellitus 
Studies have shown a higher prevalence of both elevated IOP and POAG among 
individuals with diabetes (Dielemans et al., 1996; Klein et al., 1994; Leske et al., 
2003a; Leske et al., 1995; Mitchell et al., 1997; Tielsch et al., 1995b). However, despite 
the weight of this evidence in support of diabetes as a risk factor for glaucoma, this 
remains controversial due to inconsistent findings (ARMSTRONG et al., 1960; Kahn et 
al., 1977; Tielsch et al., 1995b). In OHTS, diabetes was not associated with an 
increased risk of progression to glaucoma. 
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1.6.3.2  Blood pressure, migraine 
There is evidence to suggest that a diastolic perfusion pressure of below 55mmHg is an 
risk factor for glaucoma (Bonomi et al., 2000; Leske et al., 2002; Tielsch et al., 1995a). 
In addition, nocturnal arterial hypotension has been associated especially with NTG 
(Kaiser et al., 1993; Meyer et al., 1996), and the progression of NTG (Graham et al., 
1995). Recently, the Barbados Eye Studies and the EMGT have shown good evidence 
that a lower systolic BP was a long term risk factor for POAG (Leske et al., 2008) and 
was associated with progression of POAG (Leske et al., 2007).  
 
Despite there being numerous studies associating migraine with NTG (Collaborative 
Normal Tension Glaucoma Study Group, 1998; Cursiefen et al., 2000), this link 
remains inconclusive based on two large population-based studies (Klein et al., 1993; 
Wang et al., 1997). 
 
1.7  Pathophysiology of glaucomatous damage of optic nerve 
1.7.1  Apoptosis 
Although the pathophysiology of glaucomatous neurodegeneration is not understood, 
current available data suggest that POAG is a multifactorial disease influenced by a 
complex interplay between environmental and genetic factors. This illustrates that 
glaucoma is a complex disease, where factors that regulate IOP and factors that 
determine ganglion cell viability interact to influence the final course of the disease. 
Irrespective of the cause of glaucoma, it is known that the common final pathway is 
ganglion cell death by apoptosis leading to glaucomatous optic neuropathy (Quigley, 
1995). Animal studies have provided support for this biological mechanism (Garcia-
Valenzuela et al., 1995; Huang et al., 2005; Nickells, 1999; Quigley et al., 1995). For 
example, studies on monkey eyes have demonstrated morphologic features of apoptosis, 
including chromatin condensation and formation of apoptotic bodies within affected 
ganglion cells in glaucoma eyes, that was only rarely seen in control eyes (Quigley et 
al., 1995). In another study, raised IOP in adult rats led to cell death by apoptosis, as 
demonstrated by DNA breaks in nuclei that were labelled in situ, using a method that 
specifically incorporated biotinylated deoxynucleotides by exogenous terminal 
deoxynucleotidyl transferase to the 3’-OH ends of DNA (TUNEL).                                                                                                                                     Chapter 1 Introduction 
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Table 1–4: Summary of clinical risk factors for POAG 
(Adapted from Shield’s Textbook of Glaucoma, 2005) 
Good evidence 
Risk factor  Relative risk 
Age (per decade over 40)  2 (Congdon et al., 2004; Dielemans et al., 
1994; Klein et al., 1992; Sommer et al., 
1991) 
Black ethnicity  4 (Tielsch et al., 1991) 
First degree family history  2 to 4 (Le et al., 2003; Leske et al., 1996; 
Tielsch et al., 1994; Wolfs et al., 1998) 
IOP compared to 15mmHg   
                          19-21 mmHg  3 (Ekstrom, 1993; Le et al., 2003; Leske et 
al., 2001; Leske et al., 2003a) 
                           22-29 mmHg  13 
                           >30 mmHg  40 
Myopia  1.5 to 3 (Ekstrom, 1993; Mitchell et al., 
1999; Weih et al., 2001; Wong et al., 2003) 
Diastolic perfusion pressure (<55 mmHg)  3 (Bonomi et al., 2000; Leske et al., 1996; 
Leske et al., 2003b; Tielsch et al., 1995b) 
Fair evidence 
Large C/D ratio, diabetes mellitus, optic disc haemorrhage 
Weak evidence 
Migraine (for NTG) 
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The active nature of the death mechanism was shown by the reduction in numbers of 
biotin-labelled nuclei after administration of the protein synthesis inhibitor, 
cyclohexidine (Garcia-Valenzuela et al., 1995). Similarly, elevated IOP in rat RGCs has 
been found to activate both caspases –8 and –9, initiating both the extrinsic and intrinsic 
apoptotic cascades. Activation of both caspases was demonstrated by the presence of 
cleaved forms of the caspases and the detection of cleaved Bid and PARP, downstream 
consequences of caspase activation (Huang et al., 2005). 
 
Apoptosis was also found be a mechanism of cell death in human eyes with POAG. 
Fixed, paraffin-embedded retinal sections were assayed by the TUNEL method to detect 
DNA fragmentation. A positive TUNEL reaction was observed among ganglion layer 
cells in 10 of 18 cases with glaucoma, compared with 1 of 11 control cases without 
confounding systemic disease. The frequency of TUNEL-positive cells in the ganglion 
cell layer in cases with POAG was 15.2 times greater than the control frequency 
(Kerrigan et al., 1997). Similar immunohistological evidence of apoptosis was detected 
in the ganglion cells of 2 glaucomatous eyes with recent sight loss from POAG 
(Okisaka et al., 1997).  
 
Retinal ganglion cell apoptosis in POAG is thought to be triggered by several 
mechanisms including neurotrophic factor deprivation, hypoperfusion/ischaemia, glial 
cell activation, glutamate excitotoxicity, abnormal immune response and raised IOP 
(Kuehn et al., 2005). 
 
1.7.2  Mechanical and vascular theories of POAG 
In order to provide an explanation for the development of glaucomatous optic nerve 
damage, two concepts on the pathogenesis of glaucomatous optic neuropathy were 
introduced in the mid-19
th century. In 1858, Muler (Muler, 1858) suggested that 
elevated IOP resulted in direct compression and death of the neurons (the mechanical 
theory), whilst von Jaeger (von Jaeger, 1858) proposed that a vascular abnormality was 
responsible for optic nerve damage.  
 
The mechanical theory suggests the underlying cause of optic nerve damage is as a 
result of raised IOP above the physiological level (as a result of increased resistance to                                                                                                                                    Chapter 1 Introduction 
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aqueous outflow), creating a pressure gradient across the lamina cribrosa and inducing 
mechanical stress and deformation of the axonal fibres at the lamina cribosa (Bellezza et 
al., 2003). Experimental models of glaucoma have shown IOP induced interruption of 
axoplasmic flow at the lamina cribrosa (Weinreb et al., 1997). In particular, research in 
animal models involving rat have proposed that impaired axonal neurotrophic factor 
delivery to the retina may contribute to retinal ganglion cell death (Quigley et al., 2000). 
Injection of neurotrophic factor, in particular brain-derived neurotrophic factor (BDNF) 
into the vitreous cavity of rats with experimentally elevated IOP increased the survival 
rate of retinal ganglion cells compared with untreated eyes (Ko et al., 2001). Contrary to 
these findings, another study involving a rat model of glaucoma with raised IOP showed 
apoptosis of retinal ganglion cells prior to axonal obstruction and alteration in 
neurotrophin levels (Johnson et al., 2000). In addition, all of these studies have 
demonstrated the interruption of axonal transport occurred at IOP levels of 40mmHg or 
even higher, which however, does not correlate to the lower IOP readings normally seen 
in patients with POAG. 
 
On the other hand the ischaemic theory stresses the importance of other factors 
independent of, or in addition to, IOP. Since the retina and the optic disc are dependent 
on local blood supply to replenish their high metabolic needs, local dysfunction of 
vascular autoregulation resulting in local ischaemia-hypoxia have been implicated to 
cause optic nerve damage (Pillunat et al., 1997; Sossi and Anderson, 1983; Ulrich et al., 
1986). Animal studies involving rat have demonstrated that RGC death can occur with 
exogenous application of the vasoactive peptide endothelin-1, despite normal or low 
IOP (Chauhan et al., 2004). An immunohistochemical study has shown that the 
expression of hypoxia-induced factor 1a (HIF-1a) is raised in the human glaucomatous 
retina and optic nerve head compared with healthy controls. This transcription factor is 
produced in response to low-cellular oxygen tension and induces activation of apoptotic 
genes whose functions are related to oxygen delivery and metabolic adaptation (Tezel 
and Wax, 2004). However, due to its difficulty in its access for experimental 
assessment, the exact role of the ischaemic theory remains difficult to establish.  
 
Both theories have been recognised as a causative factor in the search for assessing the 
aetiology of glaucomatous optic nerve damage. For example, the observed differences 
in glaucomatous visual field defects in patients with NTG and HTG may suggest that                                                                                                                                    Chapter 1 Introduction 
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ischaemia may be a predominant factor in glaucomatous eyes with IOP in the lower end 
of the scale, whereas a more direct mechanical damage of the pressure may exist in 
patients with raised IOP (Caprioli and Spaeth, 1984) (Figure 1-10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1–10: Theoretical representation of relative influence exerted by 
mechanical and vascular factors on the development of glaucomatous optic 
neuropathy at different levels of IOP.  
Adapted from Caprioli et al., 1984.  
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1.7.3  Other factors contributing to glaucomatous optic nerve damage 
Glial cell activation may also be contributing to RGC death in POAG. Glial cells 
support neuronal function by removing extracellular glutamate and synthesizing growth 
factors and metabolites. These cells appear to become activated in POAG. Glial cell 
activation as evidenced by an upregulation of glial fibrillary acidic protein is 
characteristic of central nervous system injury, and is significantly elevated in POAG 
(Wang et al., 2000). In another animal study involving monkeys with elevated IOP 
showed increased elastin expression in astrocytes of the lamina cribrosa, and may alter 
the environment of the axons that is detrimental to the survival of healthy retinal 
ganglion cells (Pena et al., 2001). 
 
Furthermore, excessive stimulation of the glutaminergic system, in particular the N–
methyl–D–aspartate subtypes, has been suggested to be involved in glaucomatous cell 
death (Dreyer et al., 1996; Lipton, 2003; Yoles and Schwartz, 1998). However, it still 
needs to be decided whether excess glutamate has a positive or negative effect on RGC, 
and whether various types of cells respond differently to glutamate. Other proposed 
factors involved in ganglion cell death include oxidative stress and formation of free 
radicals, inflammatory cytokines (nitric oxide and tumour necrosis factor) (Liu and 
Neufeld, 2001; Yan et al., 2000), and aberrant immunity (Schwartz, 2003; Tezel et al., 
1999) (Figure 1-11). Interestingly, the response towards the initial optic nerve injury in 
glaucoma may also affect the remaining surviving ganglion cells and their fibres leading 
to secondary neurodegenerative damage (Liu and Neufeld, 2001; Schwartz, 2003). 
According to this suggestion, the primary insult does not directly involve the RGC or its 
fibres, but causes changes in the neuronal environment which in turn increases the 
susceptibility of the remaining neurons towards ganglion cell death.  
 
1.8  Genetics of POAG  
The link to hereditary predisposition to glaucoma was first identified more than 150 
years ago and subsequent epidemiological studies have ascertained genetic factors as a 
major role in the aetiology of glaucoma and these studies were discussed in section 
1.6.1.3 (Klein et al., 2004; Leske, 1983). Some forms of glaucoma exhibit a Mendelian 
pattern of inheritance consistent with the presence of a single gene defect                                                                                                                                     Chapter 1 Introduction 
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Figure 1–11: Diagrammatic representation of the possible factors contributing 
towards glaucomatous optic nerve damage. 
Raised intraocular pressure can cause blockade cribrosa of axonal protein transport at 
the lamina, causing neuronal retinal ganglion cell death by trophic insufficiency. Other 
factors implicated in ganglion cell death include local ischaemia-hypoxia, aberrant 
immunity, excessive stimulation of the glutamatergic system, and alterations in glial 
cells or astrocytes. Diagram obtained from Weinreb & Khaw, 2004.                                                                                                                                    Chapter 1 Introduction 
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(Raymond, 1997). Although these are a minority of the total glaucoma cases, studies on 
such rarer glaucomas offer new insight into glaucoma pathology. These include the 
developmental glaucomas, caused by dominant mutations in genes encoding 
transcription factors (for example, FOXC1), as well as primary congenital glaucoma 
caused by recessive mutation of the cytochrome mono-oxygenase, CYP1B1 (reviewed 
by Gould et al., 2004). POAG, the most common form of glaucoma is more complex 
and does not usually show Mendelian inheritance (Netland et al., 1993) but does exhibit 
a significant heritability. A family history has been known to be an important risk factor 
for POAG, implying the involvement of genetic factors towards the pathogenesis of 
POAG. It has been shown that 20-60% of patients with POAG have a family history, 
and under-reporting of a family history is a documented feature in glaucoma (McNaught 
et al., 2000; Nemesure et al., 1996; Nemesure et al., 2001; Wolfs et al., 1998). This is 
supported by twin studies which have shown a higher degree of concordance among 
monozygotic twin, as mentioned earlier (Gottfredsdottir et al., 1999; Teikari, 1987). 
 
The search for the underlying pathogenic mechanism for POAG has been challenging 
because of: 1) the limited understanding of the biochemical and cellular mechanism 
involved in the IOP control and retinal ganglion cell function; 2) the complex genetics 
of POAG; and 3)  because each causal gene is presumed to only make a small 
contribution to overall phenotype. POAG is considered to be a complex, heterogeneous, 
multifactorial disease, resulting from interactions between multiple genetic factors.  
 
The two main methods used to identify susceptibility genes for POAG have been 
(Figure 1-12): 
1.  Genome-wide linkage studies. 
2.  Association studies using either a candidate-gene association approach or a 
genome-wide association approach. 
 
1.8.1  Genome-wide linkage studies 
In genome-wide linkage analysis, genes are mapped by typing genetic markers in 
families to identify regions that segregate with the disease or trait within pedigrees more                                                                                                                                     Chapter 1 Introduction 
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than is expected by chance, since such linked regions are more likely to have a causal 
genetic variant. The advantage of this method is that it provides a comprehensive, 
unbiased search across the genome for the causal gene and has been successful in 
identifying many monogenic Mendelian diseases (Jimenez-Sanchez et al., 2001). It has 
been applied to the study of eye disease and has lead to the discovery of several disease 
genes including RP31 for autosomal dominant retinitis pigmentosa (Papaioannou et al., 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1–12: Genome-wide and candidate gene approaches towards gene mapping.  
Adapted from Fan et al., 2006. 
Candidate gene studies  Genome-wide studies 
Linkage analyses  Association analyses 
Re-sequencing 
Disease-causing mutations 
Disease genes 
Association analysis                                                                                                                                    Chapter 1 Introduction 
  51
 
Genome-wide linkage analysis has also been utilized for many common but complex 
diseases and quantitative traits, for which it has been less successful. This has been 
because of its reduced power to detect common genetic variants that have modest 
effects on disease. However, such methods have identified 9 genetic loci for POAG in 
families showing clear Mendelian patterns of inheritance (GLC1A-H) (Table 1-5) 
(Monemi et al., 2005; Sarfarazi et al., 1998; Sheffield et al., 1993; Stoilova et al., 1996; 
Suriyapperuma et al., 2007; Trifan et al., 1998; Wirtz et al., 1999; Wirtz et al., 1997), 
including POAG candidate genes MYOC (GLC1A), OPTN (GLC1E) and WDR36 
(GLC1G). Notably however, few genes have been robustly associated with POAG in 
the general population. Among the three identified genes, only MYOC is established as 
directly causative, while due to conflicting results, the exact roles of OPTN and WDR36 
in POAG remain uncertain. Mutations in MYOC account for a small proportion of 
approximately 2-4% of POAG (Alward et al., 1998; Alward et al., 2002; Fingert et al., 
1999; Stone et al., 1997; Suzuki et al., 1997). For example, Alward et al. screened 716 
patients with primary open-angle glaucoma and 596 control subjects for sequence 
changes in the MYOC gene and found 4.6% of cases had mutations. Fingert et al. on the 
other hand screened 1703 patients from five different populations (including 
Caucasians, African Americans and Asian patients from Japan) and despite different 
frequencies of specific MYOC mutations being found in each of the five populations, 
the overall frequency of MYOC mutations was similar (~ 2-4%) in all populations. The 
combined contribution of MYOC, OPTN and WDR36 to POAG add up to only 10% 
(Fan et al., 2006b). Hence it is highly likely that other unidentified loci or genes still 
exist.  
 
1.8.2  Association studies  
While linkage studies have been the predominant method used to identify POAG loci, 
with advances in genome technology and bioinformatics it has become feasible to 
undertake studies to unravel the complex genetics of glaucoma. In particular, 
association studies using single nucleotide polymorphisms (SNPs) offer a powerful 
method for assessing candidate genes with small effects (Hirschhorn and Daly, 2005) 
and are increasingly being applied to elucidate genetic mechanisms in complex disease                                                                                                                                    Chapter 1 Introduction 
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(Edwards et al., 2005). Even small cohorts have proved to be remarkably powerful 
(Klein et al., 2005).  
 
1.8.2.1  Single nucleotide polymorphism (SNP)  
A SNP is defined as a polymorphic variation at a single nucleotide that occurs in at least 
1% of the population. They make up about 90% of all human genetic variation and 
occur every 100 to 300 bases along the 3 billion base human genome (International 
HapMap Project; http://www.hapmap.org/whatishapmap.html.en). SNPs can occur in 
both coding and non-coding regions of the genome. SNPs are examples of the newest 
generation of genetic markers. 
 
One approach, which has proved useful in other complex diseases including association 
between variation in the gene encoding apolipoprotein E (APOE) and Alzheimer’s 
disease (Corder et al., 1993), and recently was used to demonstrate the role of the 
complement factor H gene in age-related macular degeneration (Edwards et al., 2005; 
Ennis et al., 2008) is to use SNP genotyping. This method can be used as a means to test 
candidate genes as genetic susceptibility factors (candidate genetic studies) or search 
across a region of the genome where markers segregate with the disease or trait, for 
susceptibility genes (genome-wide studies) (Hirschhorn and Daly, 2005). Because the 
majority of heterozygosity in the human population is attributable to common variants 
and because the evolutionary history of common human diseases is not yet known, one 
promising approach is to assess common genetic variations (such as SNPs) for 
association to medical conditions (Collins et al., 1997; Lander, 1996; Risch and 
Merikangas, 1996). This approach is feasible because 4 million (Sachidanandam et al., 
2001; Venter et al., 2001) of the estimated 10 million SNPs (Kruglyak and Nickerson, 
2001) are already known. 
 
This approach relies on selection of SNPs to tag disease-associated alleles (Johnson et 
al., 2001). In essence, this method compares the frequency of alleles or genotypes of a 
particular variant between cases and controls. If a particular SNP is more common 
among individuals with glaucoma, that SNP could be used as a pointer to locate and 
identify the gene involved in the disease. However, testing all of the 10 million common 
SNPs present in a patient’s chromosome is extremely expensive (International HapMap                                                                                                                                    Chapter 1 Introduction 
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Project). The problem is finding which SNPs are biologically significant, as most have 
no effect. Commonly, for reasons of limited resources, only a few representative SNPs 
on the chromosomes of interest are genotyped. The hope is that by determining the 
pattern of bases at a few selected positions, these can infer values of bases at 
intermediate SNPs which are not being measured. The premise of this approach is that 
mutations will have occurred on a background of mutations that are already present, and 
over small evolutionary distances, the rate at which this background pattern is disrupted 
will be fairly low. As genetic variants that are near each other tend to be inherited 
together (on average genotypes at SNPs which are < 10 kb apart tend to be correlated) 
(Carlson et al., 2004), one can capture the majority of the diversity within a region 
using a subset of SNPs. This is called haplotype tagging and relies on selecting a 
sufficiently representative set of tagging SNPs (tSNPs) covering the region of the 
genome under study (Figure 1-13). The number of tSNPs that are informative of the 
remaining SNPs is estimated to be about 300,000 to 600,000 which is far fewer than the 
10 million common SNPs in the genome (International HapMap Project; 
http://www.hapmap.org/whatishapmap.html.en).  
 
1.8.2.2  Haplotype and Linkage disequilibrium 
In interpreting genetic association studies, it is essential to understand the structure of 
haplotypes in the human genome. A haplotype is defined as a combination of alleles at 
multiple loci that are transmitted together on the same chromosome and yields 
information about recombination. When a new mutation occurs, it is located on a 
specific haplotype. The association between each mutant allele and its ancestral 
haplotype is disrupted in subsequent generation by recombination. It should thus be 
possible to locate disease-causing mutations through linkage methods using information 
on recombination. More specifically, statistical associations are assessed between two 
SNPs in the genome and this is known as linkage disequilibrium (LD) (defined as the 
non-random association of alleles at two or more loci). 
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 Figure 1–13: tagging SNP. 
(a) SNPs are identified in DNA samples from multiple individuals. (b) Adjacent SNPs 
that are inherited together are compiled into "haplotypes." (c)  "Tag" SNPs within 
haplotypes are chosen that uniquely identify those haplotypes. Diagram obtained from 
the International HapMap Project (http://www.hapmap.org).                                                                                                                                    Chapter 1 Introduction 
  55
  
 
There are basically two measures of LD: D’ (a measure of how much two loci are 
associated together i.e. co-variance between loci) and r
2 (the square of correlation co-
efficient). Both measures are calculated, firstly by estimating pairwise haplotype 
frequencies through expectation-maximisation (EM) (see section 1.8.2.3 below for more 
details on EM), then by assessing the statistical strength of association through a 
likelihood ratio test, by comparing the EM frequencies with haplotype frequencies 
estimated assuming no LD. Both measures of LD are based upon D, the basic pairwise 
disequilibrium coefficient, the difference between the probabilities of observing the 
alleles independently in the population: D = f(A1B1) - f(A1)f(B1)  (Lewontin, 1964). A 
and B refer to two genetic markers and f is their frequency. D' is obtained from D/Dmax 
and does not take into account allele frequencies. r
2 has a more strict interpretation than 
D' as it takes into account both LD and allele frequency. However since D' is more 
accurate with larger sample sizes and higher allele frequencies, if the population group 
is large enough and rarer SNPs are excluded then D' is utilised. D’ varies from 0 
(complete equilibrium) to 1 (complete disequilibrium). When D’ = 0, typing one SNP 
provides no information on the other SNP. When r
2 = 1, two SNPs are in perfect LD 
(Carlson et al., 2004; Pritchard and Przeworski, 2001) and allele frequencies are 
identical from both SNPs, and typing one SNP provides complete information on other 
untyped SNPs that are in LD. A relatively stringent r
2 threshold of > 0.8 would allow a 
selected tSNP to improve the correlation and resolve >80% of all existing haplotypes. 
Most studies use r
2 > 0.8 when deciding on their study design but when viewing 
haplotype blocks, common SNPs are of value and these are represented more clearly 
with D' which calculates a fairly accurate LD among such SNPs. The disadvantage of 
using D’ is that it is less sensitive to marginal allele frequencies.                                                                                                                                    Chapter 1 Introduction 
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1.8.2.3  Statistical inference using Haploview 
To obtain information on haplotypes from the genotype data, phase information (the 
relation between alleles at two linked loci) is required. However, from case-control data, 
it is not possible to infer the phase of an individual’s genotypes (i.e. on which of the two 
chromosomes a series of markers lie for a given individual) and therefore the 
haplotypes, and it is necessary to resort to estimation. There are several statistical 
methods (e.g. Arlequin, Clark, HAPLO, Haplotyper and PHASE) for inferring unknown 
haplotypes from genotype data. These are all ultimately based on the idea that among 
many of possible haplotypes, few will actually be observed in any population. Thus, 
phase resolution is achieved by looking for the haplotype pair that is most commonly 
occurring in the population among those pairs consistent with the genotype. Some of the 
programs used for inferring phase (based on the maximum likelihood method) employ 
EM algorithms (Long et al., 1995). This is a class of algorithm that allows estimation of 
the optimal set of parameters to a hypothesised model. This algorithm is easily 
generalised and can be applied to any situation where a set of data is available for which 
a model with unknown parameters is estimated. More specifically, EM algorithms set 
out to estimate a minimum number of haplotypes consistent with the data by first 
identifying the known haplotypes (individuals who are homozygous for all sites and 
individuals who are heterozygous for only one site) and then searching for genotype 
combinations that are consistent with the known haplotype.  
 
1.8.2.4  International HapMap Project 
The international HapMap project is a freely-available public resource to increase the 
power and efficiency of genetic association studies to medical traits. It provides 
information on SNP/haplotype frequencies and linkage disequilibrium within several 
population samples, including one with northern European ancestry (CEPH). The 
principle behind the method utilized by Gabriel et al., ((Gabriel et al., 2002) was 
implemented by the HapMap project to constructed LD blocks. This is a methological 
and quantitative way of constructing a haplotype map of the human genome by using 
common SNP markers to capture the majority of the diversity within a region of 
interest.                                                                                                                                    Chapter 1 Introduction 
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1.8.2.5  Candidate gene studies 
Candidate gene studies rely on having correctly predicted the identity of a disease gene 
based on biological hypothesis or its location within a known POAG locus. This 
approach, which utilises common genetic variants, is simpler and cheaper than complete 
re-sequencing of candidate genes, and offers a proficient way of identifying common 
genetic variants that underlie complex disease. 
 
1.8.2.6  Genome-wide association studies 
By contrast, genome-wide association approaches survey most of the genome for the 
causal variants. In a sense, the entire genome is tested for a relationship between a 
marker and a phenotype. This approach has the advantage of making no assumptions 
about the location of the causal variants, and represents an unbiased as well as a 
comprehensive method, when there is no pre-existing evidence about the underlying 
biological mechanism of the disease. Because segments of LD are analysed using tens 
of thousands of bases, this approach has a greater power to identify the effects of 
common variants. However, as more markers are required, this approach is a more 
expensive method. 
 
1.8.3  Classification of genetic loci for POAG  
For the purposes of genetic nomenclature, glaucoma loci have been classified into three 
groups: GLC1 refers to POAG, GLC2 to Primary Closed Angle Glaucoma and GLC3 to 
Congenital Glaucomas. An alphabetical capital letter is added after the GLC prefix for 
every novel locus (For example, the first genetic locus for POAG is GLC1A). All of the 
9 genetic loci for adult onset POAG show an autosomal dominant inheritance pattern 
(Table 1-5).                                                                                                                                     Chapter 1 Introduction 
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Table 1–5: Genetic loci for adult onset POAG 
Chromosomal 
location 
Name of 
locus 
Identified 
gene 
Inheritance 
pattern 
Phenotype  Original 
study 
Contribution to 
familial POAG 
Contribution to 
POAG in general 
population 
1q21-q31 GLC1A  MYOC  AD HTG  (Sheffield et 
al., 1993; 
Stone et al., 
1997) 
4.4% (Stone et 
al., 1997; 
Suzuki et al., 
1997) 
2 - 4.6%  (Alward et 
al., 1998; Alward et 
al., 2002; Fingert et 
al., 1999) 
2p16.3-p15 GLC1H  -  AD  HTG  (Suriyapperu
ma et al., 
2007) 
  
2cen-q13 GLC1B  -  AD  HTG (Stoilova et 
al., 1996) 
  
3q21-q24 GLC1C  -  AD  HTG (Wirtz et al., 
1997) 
  
5q22.1 GLC1G  WDR36  AD: 
complex 
HTG + 
NTG 
(Monemi et 
al., 2005) 
6.92% 
(Monemi et al., 
2005) 
1.1% (Monemi et al., 
2005) 
 
Association study; 
3.7% in POAG and 
0.2% in controls (P = 
0.0005) (Pasutto et 
al., 2008) 
 
Association study; 
3.6% in POAG and 
1.6% in controls (no 
significant 
association; P = 0.24) 
(Fingert et al., 2007) 
 
7q35-q36 GLC1F  -  AD  HTG (Wirtz et al., 
1999) 
  
8q23 GLC1D  - AD HTG  (Trifan et al., 
1998) 
  
10p15-p14 GLC1E  OPTN  AD HTG  + 
NTG 
(Sarfarazi et 
al., 1998) 
16.7% of 
familial NTGs 
(when all 
variants of 
OPTN are 
combined) 
(Rezaie et al., 
2002) 
1.5% for E50K for 
NTG but none among 
controls  (Aung et 
al., 2003) 
 
0.1% (1 NTG with 
family history out of 
1048 individuals with 
POAG; cohort 
consisted of 2 
different ethnic 
origins- Asian and 
Caucasian) (Alward 
et al., 2003) 
 
15q11-q13 GLC1I  -  AD    (Allingham 
et al., 2005)  
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1.8.3.1  GLC1A- Myocilin (MYOC; OMIM 601652) 
The candidate gene for the GLC1A locus, MYOC (also known as the TM inducible 
glucocorticoid response (TIGR) gene) was the first POAG gene to be identified 
(Sheffield et al., 1993; Stone et al., 1997). The GLC1A locus was mapped to 
chromosome 1 band q21-q31 through linkage study involving a single large Caucasian  
family in America, in which 22 out of 37 family members had juvenile open angle 
glaucoma (JOAG), a more severe form of POAG that has an earlier age of onset of 35 
years or below (c.f. age of onset is after 35 years it is considered as POAG) (Wiggs et 
al., 1998). Subsequent studies involving several different populations, including French 
Canadian (Morissette et al., 1995), American (Richards et al., 1994; Wiggs et al., 
1995), Danish (Graff et al., 1995), French (Meyer et al., 1994) and Panamanian (Lichter 
et al., 1997a) have consolidated this finding. In Caucasians, MYOC mutations accounts 
for up to 36% in JOAG individuals (Shimizu et al., 2000) and a smaller proportion of 4 
% of POAG individuals (Fingert et al., 1999). The protein encoded by this gene is 
located in several glaucoma relevant ocular tissues including the TM, aqueous humor, 
ciliary body, and retinal ganglion cells (Tamm, 2002). It consists of 501 amino acids, a 
myocilin like domain, a leucine zipper domain, and an olfactomedian domain where the 
majority of the known mutations occur. Studies have shown that mutant MYOC 
molecules result in accumulation of misfolded proteins, which induce stress of the 
endoplasmic reticulum (Liu and Vollrath, 2004), which in turn induces apoptosis (Rao 
et al., 2004). 
 
1.8.3.2  GLC1B 
Stoilova et al. identified the GLC1B locus through linkage analysis involving 6 
Caucasian families in the UK within a region of 11.2 cM flanked by markers D2S2161 
and D2S176 at chromosome 2cen-q13. Patients who had POAG within these families 
had phenotypes of low to moderately raised IOP, age of disease onset towards the late 
40s and good response rate to topical anti-glaucoma medication. 
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1.8.3.3  GLC1C 
The third locus for POAG (GLC1C) was identified within a region of 11.1 cM flanked 
by markers D3S3637 and D3S1744 at chromosome 3q21-q24 (Wirtz et al., 1997) 
following a linkage study on a single large Caucasian pedigree with POAG from 
America. Clinical phenotypes of these individuals included adult-onset disease with an 
average onset of over 40 years, moderate to high IOP and abnormal cup disc ratio. 
 
 
1.8.3.4  GLC1D 
The GLC1D locus was mapped within a 6.3 cM region on chromosome 8q23, flanked 
by markers D8S1830 and D8S592 from a linkage study involving a North American 
family composed of 4 generations (Trifan et al., 1998). This family showed a variable 
phenotype with glaucomatous visual field defects developing in the younger age group 
of third or fourth decade, followed by mild to modest increase in IOP with disease 
progression in the older age group.  
 
1.8.3.5  GLC1E- Optineurin (OPTN; OMIM 602432) 
The candidate gene for the GLC1E locus, OPTN was identified from a linkage study 
performed on a large study involving 54 families of British origin, where 15 out of 46 
family members had NTG. From this study, the GLC1E locus was mapped within a 
region of 21 cM (and subsequently reduced to 5 cM), on chromosome 10p15-p14, 
flanked by markers D10S1729 and D10S1664 (Sarfarazi et al., 1998).  
 
1.8.3.5.1  Molecular structure of OPTN 
There are 16 exons within the OPTN gene covering 38 kb of genomic sequence. 
Translation initiates in the 4
th exon and alternative splicing of the first three non-coding 
exons produces at least three different isoforms. All, however, encode for a 577 amino 
acid protein with a molecular weight of approximately 66 kDa. Optineurin
  is a 
cytoplasmic protein that is preferentially expressed in
  RGCs (De et al., 2006; Kroeber 
et al., 2006). This protein has been shown to interact with several proteins with diverse 
functions such
 as Rab8, Huntington, adenovirus E3 14.7-kDa protein, myosin
 VI, and 
transcription factor IIIA (Anborgh et al., 2005; Hattula and Peranen, 2000; Li et al.,                                                                                                                                    Chapter 1 Introduction 
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1998; Sahlender et al., 2005; Schwamborn et al., 2000). Expression
  of optineurin 
mRNA and protein is induced by treatment of cells
 with tumor necrosis factor α and 
interferons (Hattula and Peranen, 2000; Li et al., 1998).  
 
1.8.3.5.2  OPTN mutations 
Three sequence variants of OPTN have been considered as disease causing (Figure 1-
14) (Rezaie et al., 2002; Sarfarazi et al., 1998): E50K in exon 4, c.691-692insAG 
located in exon 6, and R545Q located in exon 16. M98K was suggested to confer 
increase susceptibility to glaucoma (Rezaie et al., 2002). Amongst these, the missense 
mutation E50K (c.458G>A transition in which
 glutamic acid in position 50 is replaced 
by lysine) (Figure 1-15) is the most frequent OPTN mutation in familial adult onset 
POAG (Rezaie et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1–14: Diagrammatic representation of the 3 disease causing OPTN 
mutations (E50K, c.691-692insAG, and R545Q) and one proposed risk factor 
(M98K) for POAG. 
E50K mutation is located in exon 4, M98K in exon 5, c.691-692insAG in exon 6, and 
R545Q in exon 16. Exons are indicated as solid boxes and numbered accordingly. 
Untranslated exons are shown as open box.                                                                                                                                     Chapter 1 Introduction 
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Figure 1–15: A diagrammatic representation (from DNA sequence analysis) of the 
OPTN E50K mutation as a result of c.458G>A transition.  
Adapted from Rezaie et al., 2002. 
 
However, little is known about the molecular mechanisms responsible
  for the 
pathogenesis of glaucoma caused by such mutations. 
 
1.8.3.5.3  NTG as the phenotype of OPTN  
OPTN mutations accounted for 16.7% of hereditary NTG cases (Rezaie et al., 2002). In 
particular, Rezaie et al. found that seven out of 52 families with POAG (13.5%) 
harboured a Glu50Lys (E50K) sequence variation, 18.4% of which had elevated IOP 
and the remaining individuals having normal IOP. The mean age of diagnosis was 44 
years (ranging from 23 to 65 years). In subsequent studies when the prevalence of E50K 
mutation was assessed among sporadic POAG cases in the general population, a much 
smaller prevalence was observed (Table 1-6). One study including more than 1000 
POAG patients containing a mixture of participants of various ethnicity implicated 
E50K mutation with POAG in only one patient (Alward et al., 2003). This patient had 
the same E50K mutation that accounted for most of the POAG in the initial study 
(Rezaie et al., 2002). Interestingly, the patient with the E50K mutation and all of the 
patients from the original study were of British descent and had familial type glaucoma. 
This suggests that perhaps a founder effect may be responsible for the presence of                                                                                                                                     Chapter 1 Introduction 
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Table 1–6: Prevalence of OPTN E50K mutation within the general population of 
different ethnic origins.  
Prevalence rate varied from 1.5% from a UK study involving 2 British individuals (Aung et 
al., 2003), 1.5%  (Hauser et al., 2006) and 0.4% (Alward et al., 2003) from 2 separate US 
studies, each involving a single patient with a family history of glaucoma, and 3.0% from a US 
study involving a single Caucasian Hispanic individual (Ayala-Lugo et al., 2007). 
Reference  Phenotype  Number of patients according to their 
ethnicity 
Number of 
patients with 
OPTN E50K 
mutation 
Presence of 
family 
history of 
glaucoma 
 
Prevalence 
 
NTG 1  Hispanic 
4 Africans (US., Ghana, Nigeria, Caribbean) 
2 Asians (Korea, China, Philippines) 
26 Caucasians (Europe and Middle East ) 
1 from Hispanic 
origin 
Yes 
(autosomal 
inheritance) 
1 out of 33 
POAG = 3.0% 
 
(note: the total 
number of 
participants 
consists of 
individuals of 
different 
ethnicity) 
 
HTG 7  Hispanics 
63 Africans  
159 Caucasians (Europe and Middle East) 
1 Asians (Korea, China, Philippines) 
----    
(Ayala-Lugo et 
al., 2007) 
 
 
control 50  Hispanics 
116 Caucasians (Europe and Middle East) 
117 Asians (Korea, China, Philippines) 
88 Africans (US, Ghana, Nigeria, Caribbean) 
----    
NTG  59 US Caucasians   
8 Asians 
3 African-Americans 
1 from US 
Caucasian origin  
 
Yes  1 out of 67 = 
1.5% 
 
(note: the total 
number of 
participants 
consists of 
individuals of 
different 
ethnicity) 
 
HTG 
 
76 US Caucasians 
9 African-Americans 
2 Asians 
---- 
 
 
 
 
 
(Hauser et al., 
2006) 
 
 
 
controls  90 US Caucasians 
2 African-Americans 
8 Asians 
---- 
 
 
 
 
 
NTG 132  2  from  UK 
Caucasian origin 
No 1.5%   
HTG 183 
 
   ---- 
(Aung et al., 
2003) 
 
 
 
 
control 
 
95 
 
   ---- 
(Alward et al., 
2003) 
NTG  29 US Caucasians with family history of 
glaucoma 
247 Japanese 
1 US Caucasian 
origin 
Yes- 
(father’s side 
of the family  
was of 
British 
origin) 
1 out of 276 = 
0.4% 
 
(note: the total 
number of 
participants 
consists of 
individuals of 
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E50K mutation in OPTN amongst British individuals (Alward et al., 2003). Since then, 
E50K mutation has been found in 3 further studies (Table 1-6) where the prevalence 
rate varied from 1.5% from a UK study involving 2 British individuals (Aung et al., 
2003), 1.5% (Hauser et al., 2006) from a US study, and 3.0% from a US study 
involving a Caucasian Hispanic individual (Ayala-Lugo et al., 2007). The first study 
involved sporadic NTG cases, whereas the latter two involved familial NTG cases. All 
of these studies showed an absence of E50K mutation among the HTG cases. A similar 
result was shown by an additional US study involving familial HTGs (Wiggs et al., 
2003) as well as by other studies involving different ethnic populations of sporadic 
HTG or NTG cases (Table 1-7) including German (Weisschuh et al., 2005),  Japanese 
(Funayama et al., 2004; Fuse et al., 2004; Tang et al., 2003; Toda et al., 2004; Umeda 
et al., 2004), Australian (Baird et al., 2005), Chinese (Leung et al., 2003), Spanish 
(Lopez-Martinez et al., 2007), Italian (Ariani et al., 2006) and Indian (Sripriya et al., 
2006). Hence, there appears to be an absence of correlation between E50K mutation and 
HTG, and with NTG individuals of various ethnic origins other than British and US 
ethnicity. Hence the E50K mutation should be considered mainly in the context of 
British and to a lesser extent in US subjects.  
 
1.8.3.5.4  Expression and role of OPTN 
OPTN is expressed in various ocular tissues including the human TM, Schlemm canal, 
non-pigmented ciliary epithelium, optic nerve and ganglion cells (De et al., 2006; 
Kroeber et al., 2006; Obazawa et al., 2004; Rezaie et al., 2005; Rezaie et al., 2002; 
Rezaie and Sarfarazi, 2005; Sarfarazi and Rezaie, 2003). As it is expressed in the 
neuronal and the glial cells of the optic nerve and the retina, it has been speculated that 
optineurin has a neuroprotective
 role in the eye and optic nerve (Rezaie et al., 2002). In 
addition, OPTN expression was also found in aqueous humor samples obtained from 
humans suggesting it is a secreted protein (Rezaie et al., 2002).  
ethnicity) 
 
HTG  441 US Caucasians 
84 Australians 
----    
control 
 
162 US Caucasians  
89 Japanese 
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Table 1–7: Absence of E50K mutation among populations of various 
non British ethnic origins  
Reference 
 
Ethnicity 
 
Phenotype  Number of 
patients 
 
Presence of 
familial 
glaucoma 
Presence of 
E50K 
mutation 
 
(Lopez-
Martinez et al., 
2007) 
Spanish HTG 
OHT  
Control  
110 
40 
98 
nil  nil 
(Sripriya et al., 
2006) 
Indian HTG 
NTG 
Control 
170 
50 
100 
nil  nil 
(Ariani et al., 
2006) 
Italian HTG 
 
NTG 
Control 
35 (familial) 
18 sporadic 
--- 
--- 
yes  nil 
(Weisschuh et 
al., 2005) 
German HTG 
NTG 
Control 
--- 
112 
--- 
nil  nil 
(Toda et al., 
2004) 
Japanese HTG 
NTG 
Control 
165 
148 
196 
nil  nil 
(Umeda et al., 
2004) 
Japanese HTG 
NTG 
Control 
55 
28 
58 
nil  nil 
(Fuse et al., 
2004) 
Japanese HTG 
NTG 
Control 
89 
65 
100 
nil  nil 
(Funayama et 
al., 2004) 
Japanese HTG 
NTG 
Control 
194 
217 
218 
nil  nil 
(Baird et al., 
2004) 
Australian HTG 
NTG 
Control 
18 
27 
108 
nil  nil 
(Tang et al., 
2003) 
Japanese HTG 
NTG 
Control 
165 
148 
196 
nil  nil 
(Leung et al., 
2003) 
Chinese POAG 
Control 
199 
126 
nil  nil 
(Wiggs et al., 
2003) 
US HTG 
NTG 
Control 
86 (familial) 
--- 
80 
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1.8.3.5.5  Role of OPTN 
The function of OPTN  is still unknown, but the protein interacts with the tumour 
necrosis factor α (TNFα) signalling pathway. Studies have shown that it may directly 
regulate cell death (Chen et al., 1998; Li et al., 1998) by interacting with proteins 
involved in apoptosis and by inducing TNFα. It has been shown that expression of 
optineurin in cells infected with adenovirus E3-14.7K results in protection from tumor 
necrosis factor induced cytolysis and that interferon and TNF can induce a de novo 
expression of optineurin (Schwamborn et al., 2000). TNFα increases the severity of 
damage of optic nerve heads of POAG individuals (both HTG and NTG) (Danson, 
1988; Haramaki et al., 1997). Hence wild-type optineurin may act via the TNFα 
pathway and provide a neuroprotective role in the optic nerve, and when defective, 
causes glaucomatous optic neuropathy. 
 
Recently, Park et al (Park et al., 2006) showed that over expression of E50K in human 
TM and retinal pigment epithelial cells resulted in Golgi fragmentation and cell death. 
In addition, a study which explored functional features of OPTN showed that proteins 
with the E50K mutation acquired the ability to selectively induce cell death in retinal 
ganglion cells which was mediated by oxidative stress (Chalasani et al., 2007). 
Furthermore, OPTN has shown to provide a protective role within the TM. Vittitow and 
Borras (Vittitow and Borras, 2002) assessed the effect of glaucomatous insults from 
raised IOP, tumor necrosis factor-alpha, and dexamethasone on the expression of OPTN 
in human TM maintained in organ culture. All of these 3 factors resulted in an up 
regulation of OPTN expression.  
 
1.8.3.5.6  Conclusion 
When combining all of the available results on OPTN,  OPTN  mutations may be 
involved in the aetiology of familial glaucoma and its E50K mutation appears to be a 
cause of NTG in individuals of British and US origin. In addition, there appears to be no 
association between E50K mutation and unrelated cases of HTG.  
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1.8.3.6  GLC1F 
Through a genome wide study of a large POAG family, GLC1F locus was localised 
within a region of 5.3 cM on chromosome 7q35-q36, flanked by markers D7S2442 and 
D7S483 (Wirtz et al., 1999). All of the 10 members of the family had IOPs of more 
than 22 mmHg, a vertical C/D ratio of 0.6 or more, with 5 individuals having 
glaucomatous visual field defects. 
 
1.8.3.7   GLC1G- WD repeat domain 36 (WDR36; OMIM 609669) 
The third candidate gene for POAG for the GLC1G locus, WDR36, was localized on 
chromosome 5q22.1, in a region of 2 Mb between D5S1466 and D5S2051 (Monemi et 
al., 2005). Four mutations (N355S, A449T, R529Q and D658G) were identified in 17 
(5-7%) unrelated POAG subjects, 11 of which were HTGs and six were NTGs. 
However, Fingert et al (Fingert et al., 2007) were unable to confirm this association in 2 
large cohorts of POAG individuals. 
 
WDR36 gene is composed of 23 exons and its protein is expressed in a number of 
ocular tissues including TM, ciliary body, ciliary muscles, retina, optic nerve, lens, iris, 
and sclera (Monemi et al., 2005).  
 
Studies have shown that WDR36 may be involved
 in T-cell activation (Mao et al., 2004) 
and recently, it was hypothesized that T-cell-mediated responses
 may participate in 
glaucomatous optic neuropathy (Mao et al., 2004). However, the exact role in glaucoma 
pathogenesis
 remains unclear.  
 
1.8.3.8  GLC1H 
Suriyapperuma et al. (2007) mapped a new genetic locus for adult-onset primary
 open-
angle glaucoma (POAG) by using families previously unlinked
  to  GLC1A-GLC1F.
 
Through performing a genome-wide study in 322 individuals with POAG from 91 
unrelated families, a consistent linkage to chromosome 2p16-p15 in 7 families was 
found. Analysis in 1 large family with 12 affected members revealed a common 
haplotype within a region of approximately 11 Mb flanked by markers D2S123 to 
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that overlapped with that of the first large family, but with no founder effect. Combined 
analysis of the 7 families produced the highest lod score of 9.30 with marker D2S2320. 
Age of diagnosis ranged from 32 to 78 years with an average age at onset of 64 years. 
IOPs varied from 24 mmHg to 60 mmHg with C/D ratio ranging from 0.6 to 0.9.  
 
1.8.3.9  GLC1I 
Using ordered subset analysis on 86 POAG families in which age of onset was used as 
covariate, Allingham et al. (2005) identified an 11 cM linkage interval in chromosome 
15q11-q13 in a subset of 15 families (Allingham et al., 2005). The mean age of 
diagnosis of the affected families was 44 years compared to the mean age of diagnosis 
of 61 years for the complementary group. 
 
1.8.3.10 Summary 
Based on the current available evidence, mutations in MYOC account for a small 
proportion of 2 to 4.6 % of non-familial POAG, whereas variations in OPTN and 
WDR36 show varying evidence for association with POAG in the general population 
depending on the ethnicity. The emerging view is that POAG is a complex, 
multifactorial disease resulting from interactions between several genetic factors, and it 
is highly likely that other unidentified loci or genes still exists. It would be interesting to 
assess the role of other loci once the genes have been identified. 
 
1.8.4  Genes associated with POAG 
The development of genetic screening programmes to identify high risk glaucoma gene 
variants in populations is a realistic future goal made possible with the current pace of 
technological advances in high throughput genotyping using association studies. To 
achieve this goal, association studies need to first prove the role of susceptibility genes 
in large well-defined cohorts. This field is in its infancy and so far, studies have focused 
on analysis of genes that are suggested to increase susceptibility to glaucomatous 
damage (retinal ganglion cell death). Often using relatively small cohorts, some studies 
have found associations between polymorphisms in genes thought to affect ganglion 
cell survival, including p53, APOE, OPA1, IGF2 and TNFα, (see Table 1-8 for other                                                                                                                                    Chapter 1 Introduction 
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genes associated with POAG). The majority of these genes have been assessed in single 
studies, whilst some have some conflicting results, and none has been definitely shown 
to be a major factor (Libby et al., 2005).  
 
To date, at least 22 genes have been associated with POAG (Table 1-8).  
 
 
 
Table 1–8: Reported genes associated with POAG.  
Cohort size which is ≥ 200, P ≤ 0.05 and studies with adjustment for multiple testing are high-
lighted in bold. 
 
Gene 
symbol 
 
Chromosomal 
location 
Function  Size of cohort  Association with 
POAG 
Reference  Adjusted for 
multiple testing or 
2
nd cohort study 
performed 
AGTR2  Xq22–q23 Regulation  of 
aqueous humor 
dynamics  
190 POAG,  268 NTG, 
240 controls  
P = 0.0095 for 
female NTG but 
not for male NTG 
(Hashizume et 
al., 2005) 
nil 
ANP  1p36.2  Involved in the 
homeostatic control 
of body water, 
sodium, potassium 
and fat 
53 familial POAG, 60 
controls 
No association  (Tunny et al., 
1996) 
nil 
APOE  19q13.2  Essential protein in 
lipid transport- 
notably in the 
metabolism of 
neuronal membrane 
242 POAG,  
187 controls 
 
294 POAG, 106 NTG, 
300 controls 
 
 
310 POAG,   
179 controls 
 
140 POAG,  
73 controls 
 
155 NTG, 349 controls 
 
137 POAG, 75 controls 
 
 
No association 
 
 
P = 0.008 for 
NTG 
(protective effect) 
 
P = 0.018 
 
 
No association 
 
 
No association 
 
No association 
(Zetterberg et 
al., 2007a) 
 
(Lam et al., 
2006) 
 
 
(Mabuchi et al., 
2005) 
 
(Ressiniotis et 
al., 2004c) 
 
(Lake et al., 
2004) 
(Ressiniotis et 
al., 2004a) 
nil 
 
 
nil  
 
 
 
Adjusted for age 
 
 
nil  
 
 
nil  
 
Logistic 
regression 
analysis used 
P21  6p21.2 An  important 
protective component 
of the apoptotic 
140 POAG, 73 controls 
 
 
No association 
 
 
(Ressiniotis et 
al., 2005) 
 
nil  
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pathway, regulating 
cellular arrest in the 
presence of DNA 
damage 
58 POAG, 59 controls  P = 0.0078  (Tsai et al., 
2004) 
CDH-1  16q22.1 Cell  adhesion 
molecule 
60 POAG 
103 controls 
P < 0.000  (Lin et al., 
2006) 
nil 
CYP1B1  2p22–p21  1) Modifier of  
MYOC 
 
2) Causative gene for 
primary congenital 
glaucoma 
 
 
264 POAG, 95 controls 
 
 
134 POAG (30 of which 
are JOAG), 200 
controls 
 
224 POAG, 47 controls 
 
P =  0.0001 
 
 
P = 0.006 
 
 
P = 0.0036 
(protective effect) 
(Bhattacharjee 
et al., 2008) 
 
(Chakrabarti et 
al., 2007) 
 
(Melki et al., 
2005) 
nil  
 
 
nil  
 
 
Bonferroni 
correction made 
EDNRA  4q31.2 Endothelin-1 
(EDN1), a potent 
physiologic 
vasoconstrictors 
67 NTG, 100 controls 
 
 
250 NTG, 176 POAG 
P = 0.028 
 
 
No association 
(but genotype 
associated with 
worse visual field 
defects in NTG 
patients (P = 
0.014)) 
(Kim et al., 
2006) 
 
(Ishikawa et al., 
2005) 
nil  
 
 
Adjusted for age 
 
GSTM1  1p13.3 Multifunctional 
detoxification 
enzyme 
250 POAG, 202 
controls 
 
 
144 POAG, 121 
controls (Turkish 
ethnicity) 
 
200 POAG, 200 
controls 
P = 0.002 
 
 
 
P < 0.001 
 
 
 
No association 
(Juronen et al., 
2000) 
 
 
(Unal et al., 
2007) 
 
 
(Jansson et al., 
2003a) 
Bonferroni 
correction made 
 
 
nil  
 
 
 
nil 
HSPA1A  6p21.3 Heat-shock  proteins 
expressed in response 
to heat shock 
and a variety of other 
stressful stimuli, 
including oxidative 
free radicals 
211 POAG, 290 NTG 
241 controls 
P = 0.007 
(POAG vs 
controls) 
P = 0.032 (NTG 
vs controls) 
(Tosaka et al., 
2007) 
nil 
IGF2  11p15  Neurotrophic agent  60 POAG, 104 controls  P = 0.010 
 
(Tsai et al., 
2003) 
nil  
IL1β  2q14 Immune  response 
mediator 
58 POAG, 105 controls 
(Chinese) 
231 NTG, 245 controls 
(Chinese) 
P = 0.035 
 
No association 
(Lin et al., 
2003b) 
(Wang et al., 
2007) 
nil 
 
 
nil 
MTHFR  1p36.3 Regulates 
homocystein 
76 POAG, 71 controls 
 
P = 0.01 
 
(Junemann et 
al., 2005) 
nil  
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metabolism, reduced 
activity of which 
causes 
hyperhomocysteinae
mia (risk factor for 
vascular disease) 
 
78 NTG, 100 controls 
 
 
243 POAG, 187 
controls 
 
133 POAG, 131 NTG, 
106 controls 
 
204 POAG, 138 
controls 
 
P = 0.006 
 
 
No association 
 
 
No association 
 
 
No association 
 
(Woo et al., 
2007) 
 
(Zetterberg et 
al., 2007b) 
 
(Mabuchi et al., 
2006) 
 
(Mossbock et 
al., 2006a) 
 
nil  
 
 
nil  
 
 
nil  
 
 
nil 
NOS3   7q36 Regulation  of 
microcirculation 
(produces nitric oxide 
which causes 
vasoconstriction) 
56 POAG, 100 controls 
 
58 POAG, 76 NTG, 30 
controls 
 
 
 
66 POAG, 100 controls 
 
P < 0.01 
 
P = 0.06  
P < 0.001 (in 
POAG patients 
with migraine) 
 
No association 
 
(Tunny et al., 
1998) 
(Logan et al., 
2005) 
 
 
 
(Lin et al., 
2005) 
nil  
 
nil  
 
 
 
 
nil  
 
NPPA  1p36.2 Regulation  of 
intraocular fluid 
homeostasis and IOP 
 
67 NTG, 100 controls 
 
 
53 familial POAG, 60 
controls 
No association 
 
 
No association 
(Jeoung et al., 
2007) 
 
(Tunny et al., 
1996) 
nil  
 
 
nil 
OCLM  1q31.1 Mechanical  stretch 
response gene in TM 
75 POAG, 29 NTG, 5 
OHT, 50 controls 
 
200 POAG, 200 
controls 
2/75 POAG had 
AA substitution 
 
No association 
(Fujiwara et al., 
2003) 
 
(Jansson et al., 
2003b) 
nil  
 
 
nil 
OLFM2  19p13.2 Myocilin-related 
proteins 
215 POAG, 277 NTG, 
240 controls 
Combination of 
OLFM2 and 
OPTN associated 
with raised IOP 
P = 0.018 
(Funayama et 
al., 2006) 
Adjusted for 
multiple testing 
OPA1  3q28–q29  Component of the 
mitochondrial 
network, mutation of 
which causes an 
autosomal dominant 
optic atrophy 
83 NTG, 100 controls 
 
80 NTG, 86 controls 
(2
nd cohort) 
 
 
 
 
 
 
90 HTG, 186 controls 
 
 
61 NTG, 168 controls 
P = 0.005 (1
st 
cohort) 
P = 0.002 (2
nd 
cohort) 
 
P = 0.00001 
(when both 
cohorts combined) 
 
 
No association 
 
 
P = 0.006 (prior to 
(Aung et al., 
2002b) 
 
 
 
 
 
 
 
 
(Aung et al., 
2002a) 
 
(Powell et al., 
Confirmed in 2
nd 
cohort 
 
 
 
Adjusted for 
multiple testing 
 
 
 
nil  
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65 NTG, 101 controls 
(Korean ethnicity) 
 
48 POAG, 61 NTG, 48 
controls (Barbados 
ethnicity) 
 
194 NTG, 191 HTG, 
185 controls  
 
 
 
Caucasian (279 POAG, 
227controls), African 
American (193 POAG, 
97 controls), Ghanaian 
(170 POAG, 138 
controls) 
bonferroni 
correction) 
 
 
 
No association 
 
 
No association 
 
 
 
P = 0.004 for 
NTG 
 
 
 
No association 
2003) 
 
 
 
 
(Woo et al., 
2004) 
 
(Yao et al., 
2006) 
 
 
(Mabuchi et al., 
2007) 
 
 
 
(Liu et al., 
2007) 
 
significant after 
Bonferroni 
correction 
 
 
nil  
 
 
Bonferroni 
correction made 
 
 
Adjusted for age, 
gender, but not 
for multiple 
testing.  
 
nil  
PON1  7q21.3 Antioxidant  243 POAG, 312 NTG, 
284 controls 
No association   (Inagaki et al., 
2006) 
Bonferroni 
correction made 
TAP1  6p21.3  Delivers peptide to 
the HLA 
class I molecule 
66 POAG, 105 controls   P = 0.01  (Lin et al., 
2004) 
nil  
 
TLR4  9q32-q33  Toll-like receptor  4 
mediates immune 
responses and 
interacts with heat 
shock proteins 
255 NTG, 318 controls  P = 0.0095  (Shibuya et al., 
2008) 
Adjusted for 
multiple testing 
TNF  6p21.3 A  major 
immunomodulator 
and proinflammatory 
cytokine 
POAG 114,  
228 controls  
 
60 POAG, 103 controls  
No associations 
 
 
P = 0.00016 
(Mossbock et 
al., 2006b) 
 
(Lin et al., 
2003a) 
nil  
 
 
As above 
 
TP53  17p13.1 Regulator  of 
apoptosis 
282 HTG, 62 NTG, 178 
controls  
 
140 HTG, 73 controls 
 
 
 
67 HTG, 112 controls  
(Asian ethnicity) 
 
58 POAG, 59 controls  
No associations 
 
 
P < 0.0001 for 
haplotype 
distribution 
 
No association 
 
 
P = 0.00782 
(Dimasi et al., 
2005) 
 
(Ressiniotis et 
al., 2004b) 
 
 
(Acharya et al., 
2002) 
 
(Lin et al., 
2002) 
nil  
 
 
nil  
 
 
 
nil  
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To date, 52 association studies have been performed on POAG, 23 of which have 
shown no association. Of the ones that have shown association, only 7 genes have 
showed significant association in more than 1 study with POAG (APOE, CYP1B1, 
GSTM1, MTHFR, NOS3, OPA1, and TP53) using sample sizes in the majority of cases 
of less than 200 with the exception of 5 studies (involving APOE, CYPB1, GSTM1) 
which have used sample sizes ranging from 224 to 310. When adjusted for multiple 
testing which is considered a standard statistical requirement for this type of analysis 
(Miller, 1981), only 6 genes (CYP1B1, GSTM1, OLFM2, OPA1, PON1 and TLR4) have 
produced significant associations. Among these, only one gene (OPA1) has shown 
reproducible association in a 2
nd independent cohort. Based on these finding, OPA1, 
CYP1B1 and GSTM1 have demonstrated the best association with POAG. 
 
1.8.5  Conclusion 
The exact mechanism of these genes in POAG susceptibility remains unknown. It is still 
controversial as to whether the inheritance pattern of POAG is a simple monogenic 
inheritance or a complex polygenic inheritance. It could well be that variable 
expressivity, reduced penetrance or even phenotypic alteration by genetic modifiers 
(where certain mutations may only cause disease when present in a susceptible genetic 
context as in OPTN mutations) may confound genotypic-to-phenotypic associations and 
make it difficult to ascertain a monogenic inheritance. On the other hand, there are 
several pieces of evidence to suggest that glaucoma may be affected by multiple 
interacting genes.  For example APOE has been shown to interact with the MYOC to 
increase IOP (Copin et al., 2002). Another study showed interaction between MYOC 
and  CYP1B1 through a common pathway with the inheritance of glaucoma being 
digenic in some cases (Vincent et al., 2002). In addition, a possible interaction between 
OPTN and TNF was identified to increase the risk of glaucoma (Funayama et al., 2004). 
More recently, possible gene–gene interactions between MYOC, OPTN and APOE was 
identified which collectively contributed to POAG (Fan et al., 2005). Evidence to 
further support the polygenetic inheritance of POAG include type II diabetes mellitus 
and steroid responsiveness from endogenous steroids (i.e. stress) and pharmacologic 
steroids  increasing the risk of glaucoma (Pasquale et al., 2006; Zhang et al., 2005).                                                                                                                                     Chapter 1 Introduction 
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Current evidence reveals only a small proportion of POAG exhibit Mendelian 
inheritance as evidenced by the known POAG genes (MYOC, OPTN, WDR36) 
accounting together for 10% of all POAG patients. It remains to be proven whether 
variants of several genes, each contributing small effects in a given individual increase 
the risk for developing POAG (Fan et al., 2005), or whether there exist a single locus of 
large effect. In addition, OPTN mutations, in particular E50K mutation, appear to be a 
suitable candidate gene to further assess its role in POAG within a cohort of individuals 
of British descent. 
 
For the purpose of this study, from this point onwards, POAG has been considered as a 
complex polygenic disease. 
 
1.9  Developmental glaucoma genes 
An obvious group of genes to test as genetic susceptibility factors for POAG are the 
developmental glaucoma genes which have not been analysed in any association studies 
to date with the exception of the CY1B1 gene.  CYP1B1 causes primary congenital 
glaucoma. It is also involved in cases of juvenile open angle glaucoma (JOAG) 
(Acharya et al., 2006; Vincent et al., 2002) and a recent study identified a CYP1B1 
polymorphism as a susceptibility factor for POAG (Bhattacharjee et al., 2008; Melki et 
al., 2005). Developmental glaucoma defines glaucomas that are associated with 
dysgenesis of anterior segment. Anterior segment dysgenesis (ASD) are an ill-defined, 
genetically heterogeneous, autosomal-dominant group of developmental abnormalities 
that share some common ocular features and a high prevalence of associated glaucoma 
(Gould and John, 2002).  Clinical features of ASD includes combinations of congenital 
abnormalities affecting the cornea (e.g. posterior embryotoxon, corneal opacities), iris 
(polycoria, corectopia, iris hypoplasia), lens and anterior chamber angle (peripheral 
anterior synechiae) 
 
1.9.1  Development of eye and anterior chamber 
 
An understanding of the embryonic development of the anterior segment of the eye is 
essential to understand the association of ASD with glaucoma. The anterior segment of                                                                                                                                    Chapter 1 Introduction 
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the eye consists of the cornea, iris, lens, ciliary body and the ocular drainage structures, 
which contains the TM and the Schlemm’s canal. The drainage structures are located at 
the iridocorneal angle where the cornea and the iris meet. These structures are formed 
by coordination of events involving induction and differentiation of three primary 
embryonic tissues: surface ectoderm, neural ectoderm and the periocular mesenchyme 
(Snell and Michael, 1998) (Figure 1-16 and 1-17). Through the course of ocular 
development the surface ectoderm will form the corneal epithelium and the lens while 
the neural ectoderm will form the retina and epithelia of both the iris and ciliary body 
(Kaufman, 1995). The corneal stroma, corneal endothelium, sclera, iris stroma, ciliary 
muscle, ciliary stroma and TM are all derived from periocular mesenchyme, which 
consists of neural crest cells. These cells are neuroectodermal cells that migrate from the 
crest of the developing neural tube at about the 24
th day of gestation (Tripathi and 
Tripathi, 1989). Schlemm’s canal is formed by remodeling of vasculature in the 
corneoscleral  transition zone (Hamanaka et al., 1992) and is also derived from 
periocular mesenchyme. Hence, cells that are derived from the neural crest, and the 
accurate specification and differentiation of mesenchymal progenitor cells, is essential 
for anterior segment development (Kupfer and Kaiser-Kupfer, 1979). 
 
At the 6
th week of embryonic development, a bi-layered embryonic optic cup from the 
forebrain neuroectoderm has formed, whilst the lens vesicle has formed through 
invagination and separation from the overlying surface ectoderm. The primordial eye is 
now surrounded by mesenchymal progenitor cells which are of predominantly of neural 
crest origin (Figure 1-16a). 
 
As early as the 12
th week a roughly wedged-shaped distinctive mass of mesenchyme, 
the trabecular primordium, is detected at the junction of the pupillary membrane (a thin 
central portion of the iridopupillary lamina occluding the pupil in fetal life which exist 
as a source of blood supply to the lens) and lateral margins of the cornea i.e. the anterior 
chamber angle (McMenamin, 1989a). The trabecular primordium consists of a dense 
collection of stellate mesenchymal cells and some loosely arranged extracellular matrix.  
The deep aspect of the wedge-shaped primordium is characterized by a row of small 
capillaries and is lined by mesoderm-derived vascular endothelial cells. 
 
                                                                                                                                    Chapter 1 Introduction 
  76
                                       
 
 C 
           
 
 
 
 
Figure 1–16: The development of the anterior segment of the embryonic and fetal 
eye.  
(a) At 5 weeks of gestation, the optic cup is surrounded by mesenchymal progenitor 
cells, mainly of neural crest origin. (b) Formation of the anterior segment is visible at 5 
months of human gestation. (c) Fully developed anterior segment depicting the lens, iris, 
irido-corneal angle, and the cornea. The diagrams are colour coded to represent the 
embryonic origin of the anterior segment structures. Adapted from Sowden, 2007. 
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Figure 1–17  Cross section of a mature anterior segment chamber high-lighting 
important structures at the anterior chamber angle: 
(left); in depth view of the angle showing the different layers of trabecular meshwork; 
(center) gonioscopic view of a normal angle with a slit-lamp beam; (right) 
embryological derivatives forming the structures of the anterior chamber  (red = surface 
ectoderm; blue = neuroectoderm; green = cranial neural crest cells).  
Cep = corneal epithelium; Cen = corneal endothelium; Cstr = corneal stroma; 
*= 
Schwalbe's line; ss = scleral spur; CB = ciliary body; Cp = Ciliary process; Cm = ciliary 
muscle; PCE = pigmented ciliary epithelium; SC = Schlemm's canal; TM = trabecular 
meshwork; IP = iris process; Iris S = iris stroma; L = lens; Z = zonule/suspensory 
ligament of lens. Adapted from Idrees et al., 2006.                                                                                                                                    Chapter 1 Introduction 
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By 20-22 weeks of gestation, the anterior chamber is formed and well demarcated. The 
trabecular primordium consists of flattened endothelial-lined sheets and cords (early 
trabeculae) separated by intervening spaces (Figure 1-18) (McMenamin, 1989b; 
McMenamin, 1991; McMenamin and Krause, 1993). On the deep aspect of the 
undeveloped TM, the collection of small capillaries fuses to form a single elongated 
canal of Schlemm lined by endothelial cells derived from mesoderm. The giant vacuoles 
within the endothelium which are responsible for the passage of aqueous across the 
canal, appear around 18-20 weeks of gestation. At 28 weeks (7 months) the TM is 
separated from the anterior chamber by the layer of neural crest cells and is capable of 
aqueous drainage to a small degree (Kupfer and Ross, 1971). During the later stages of 
fetal development the meshwork becomes further specialized into three 
morphogenically distinct layers- cord like inner uveal trabeculae, intermediate layers of 
lamellar corneoscleral trabeculae, and a deep loosely arranged cribriform meshwork. 
 
1.9.2  FOXC1 and LMX1B as genetic risk factors in POAG 
 
Since neural crest cells are a major contributing factor towards anterior segment 
development, one hypothesis for the underlying molecular mechanism involved in 
anterior segment dysgenesis is that defects in migration and/or differentiation of neural 
crest derived periocular mesenchyme could lead to abnormal anterior segment 
development and subsequently, raised IOP and glaucoma. Evidence in support of this 
proposal has been shown by fate mapping of cranial neural crest cells using quail-chick 
chimeras (Kaiser-Kupfer, 1989; Kupfer and Kaiser-Kupfer, 1979; Kupfer and Kaiser-
Kupfer, 1978). These have lead to the creation of the model which has suggested that 
the majority of the anterior segment is derived from neural crest cells and that the 
developmental arrest of these cells causes ASD in humans. Indeed, transcription factors 
expressed in the periocular mesenchyme (FOXC1 and LMX1B) (Gage et al., 2005; 
Pressman et al., 2000) play an important role in normal morphogenesis of the anterior 
segment and provide important insight to the underlying genetic mechanism of 
glaucoma.                                                                                                                                    Chapter 1 Introduction 
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Figure 1–18: Embryonic development of the anterior chamber angle. 
(a) Electron micrograph of the trabecular primordium in a 13 week-old fetus. Arrows 
point to two small capillaries on the deep aspect of the trabecular anlage (TA). AC, 
anterior chamber; PM, pupillary membrane. (b) Electron micrograph of the TM in a 22-
week-old human fetus. Note the intratrabecular spaces separated by connective tissue 
trabeculae and the Schlemm’s canal (SC) which posses giant vacuoles (GV) in its inner 
wall. (c) Scanning electron micrograph of the inner surface of the trabecular anlage in a 
13-week-old human fetus showing numerous perforations to allow communication 
between the anterior chamber and the developing meshwork. (d)  Summary of the 
morphogenetic changes that occurs during remodeling of the loose mesenchyme of the 
trabecular anlage to form the TM. Adapted from McMenamin, 1989.                                                                                                                                     Chapter 1 Introduction 
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1.9.2.1  FOXC1 (OMIM; 601090)  
 
1.9.2.1.1  General role 
Transcription factors of the forkhead box (FOX) family were first identified as a region 
of homology between the Drosophila ogaster melan protein forkhead and rat hepatocyte 
nuclear factor 3 proteins (Weigel and Jackle, 1990). These transcription factors have 
been shown to be key regulators of diverse cellular functions including development of 
many organ systems, oncogenesis and energy homeostasis (Carlsson and Mahlapuu, 
2002; Lehmann et al., 2003a). In addition, FOX proteins have been identified as 
important gene regulators within a broad range of species from yeast to human and have 
been involved in a variety of biological processes including tumorigenesis and even in 
language acquisition (Lai et al., 2001).  
 
1.9.2.1.2  Structure of forkhead domain and FOXC1 
These transcription factors consist of a well conserved monomeric 110 amino acid 
DNA-binding domain, known as the forkhead domain (FHD). The DNA binding motif 
is a variant of the helix-turn-helix, and consists of three α-helices, two β-sheets and two 
large loops that form ‘wing-like’ structure (Figure 1-19) (Clark et al., 1993). This 
domain binds to DNA and localizes FOXC1 to the nucleus of the cell, and is likely to be 
involved in protein-protein interaction as evidenced by missense mutations in the FHD 
reducing the ability for FOXC1 to transactivate, and affecting protein stability and DNA 
binding (Saleem et al., 2001; Saleem et al., 2003b; Saleem et al., 2003a). The FOXC1 
gene (formerly known as FKHL7) is located at chromosome 6 at p25 and was first 
shown to cause ASD in 1998 (Mears et al., 1998; Nishimura et al., 1998).  It is a 
member of the winged-helix family of the transcription factors as it contains the 
conserved FHD (Larsson et al., 1995; Mears et al., 1998; Nishimura et al., 1998) and is 
comprised of 1 exon of 1.6 kb which encodes a 533 amino acid protein (Larsson et al., 
1995; Mears et al., 1998; Nishimura et al., 1998).                                                                                                                                     Chapter 1 Introduction 
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Figure 1–19: Diagrammatic representation of the sub-domains of the FOXC1 
forkhead domain.  
Region 1 and 2 represent the N-terminal portion of FHD. α-helix 1 permits organization 
of FHD for transactivation, DNA binding and nuclear localization. Region 3 represents 
α-helix 3 which is involved in DNA binding specificity of FHD, and allows 
organization of the FHD with respect to nuclear localization and binding. Region 4 
represents the wing 2 region which allows organization of FHD for transactivation and 
DNA binding. Adapted from Saleem et al., 2004. 
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1.9.2.1.3  Phenotypes of FOXC1 mutations (Axenfeld-Reiger malformation and 
Axenfeld-Reiger syndrome) 
ASD comprises a spectrum of inherited mainly autosomal-dominant diseases that result 
from maldevelopment of the anterior segment of the eye, with the development of 
glaucoma as one of the serious ophthalmic consequences, in which only 18% responds 
to non-invasive medical treatment (Strungaru et al., 2007). Within the broad disease 
spectrum of maldevelopment of the anterior segment caused by FOXC1 mutation, iris 
hypoplasia falls towards the mild end of the spectrum, with iridogoniodysgenesis (iris 
hypoplasia and goniodysgenesis with excess tissue in the angle and anomalous angle 
vascularity (Mears et al., 1996)) being at the intermediate end of the spectrum, and 
Axenfeld-Rieger malformations (ARM) of the eye (iris hypoplasia, correctopia, 
goniodysgenesis, prominent and displaced Schwalbe’s line (posterior embryotoxon) and 
peripheral anterior synechiae)) situated at the most severe end of the disease spectrum 
(Walter, 2003). 
 
A recent study involving 126 patients with ARM showed up to 75% of such individuals 
developed glaucoma (Strungaru et al., 2007). In addition, non-ocular manifestations 
such as facial malformations (hypoplasia of the maxillary bones), dental dysgenesis 
(hypodontia and microdontia), umbilical anomalies, sensorineural hearing loss, 
congenital cardiac defects and even pituitary abnormalities can occur in individuals with 
FOXC1 mutations with incomplete penetrance and varying in expressivity (Shields et 
al., 1985; Swiderski et al., 1999; Winnier et al., 1999). ARM of the eye in association 
with extraocular malformations is known as Axenfeld-Rieger Syndrome (ARS). This is 
a rare syndrome with the incidence estimated to be around 1:200,000 (Gorlin et al., 
1976). There are four known genetic loci associated with ARM/ARS, including FOXC1 
and PITX2, which are located in chromosome 6p25 and 4q25 respectively (Nishimura et 
al., 1998; Semina et al., 1996). The third locus has been mapped to chromosome 13q14 
and the gene is yet to be identified (Phillips et al., 1996). Interestingly, an isolated case 
of ARM has shown to carry a deletion in the PAX6 gene (Riise et al., 2001). The broad 
range of clinical features suggests that FOXC1 has an extensive role in the 
developmental process. 
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1.9.2.1.4  Expression of FOXC1 
FOXC1 is expressed in the human fetus as well as in human adults (Mears et al., 1998; 
Nishimura et al., 1998; Pierrou et al., 1994). Analysis of the function of FOXC1 in 
animal models has provided a comprehensive insight into the embryonic origin of the 
malformation. In the developing mouse eye, Foxc1 is expressed in the periocular 
mesenchyme, and mesenchymal cells that have migrated into the eye (Kidson et al., 
1999; Kume et al., 1998), TM (Kidson et al., 1999), and in the developing skeleton and 
organ structures including the heart and kidney (Hiemisch et al., 1998; Kume et al., 
2000; Kume et al., 1998). Since Focx1 is expressed in the developing embryonic TM, 
mutations or altered expression of FOXC1 could interfere with normal function of the 
tissue and lead to increased risk of glaucoma. Although expression of FOXC1 is yet to 
be studied in adults, it is highly possible that continued expression of the abnormal gene 
product (from age-related, subclinical mutations) throughout life, or altered levels of 
expression of FOXC1 could interfere with normal function of the TM, thereby leading 
to increased risk of glaucoma through the effects of raised IOP. This notion is supported 
by the fact that glaucoma associated with mutations in the developmental glaucoma 
genes can present at any time from birth to adulthood (Cella et al., 2006; Idrees et al., 
2006), and in some instances above 70 years of age (Shields, 1983).  
 
Mice with homozygous loss of function of Foxc1 die at birth. In addition, they have 
profound failure of the normal development of the anterior segment as well as absence 
of anterior chamber (Hong et al., 1999; Kidson et al., 1999; Kume et al., 1998). Similar 
studies on mice with heterozygote mutations show milder anterior segment defects, 
similar to those found in humans with FOXC1 mutations. These include iris 
malformations, iridocorneal adhesions, hypoplastic TM, small or absent Schlemm’s 
canal (Smith et al., 2000). Notably, the iridocorneal angle structures showed paucity of 
extracellular matrix (ECM) including collagen and elastic tissues (Smith et al., 2000). 
Considering the important developmental contribution of ECM to the formation of the 
anterior segment and the TM (reviewed by(Acott and Kelley, 2008; Gould et al., 2004), 
altered ECM regulation as a result of mutations in FOXC1 may predispose to glaucoma. 
 
Furthermore, the penetrance of these anterior segment defects has been shown to vary 
with genetic backgrounds. For example, although subtle iris and corneal abnormalities                                                                                                                                    Chapter 1 Introduction 
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occur which are not clinically obvious in certain mice with heterozygote mutations on 
some genetic backgrounds, all of the mice have histologically abnormal TM and 
Schlemm’s canal (Smith et al., 2000). This suggests genetic modifiers have a 
differential effect on the development of iris and cornea in comparison to the 
development of iridocorneal angle, and possibly suggest that the development of the 
latter is more sensitive to levels of FOXC1.   
 
1.9.2.1.5  Molecular mechanisms underlying ASD 
Numerous mutations have been identified in FOXC1, including missense mutations 
insertions, deletions, duplications, and translocations (Komatireddy et al., 2003; 
Lehmann et al., 2002; Lehmann et al., 2000; Mears et al., 1998; Mirzayans et al., 2000; 
Nishimura et al., 2001; Swiderski et al., 1999). These mutations lead to ARS via 2 main 
mechanisms: 1) by affecting the ability of the transcription factor protein to bind to 
DNA and either increasing or decreasing the trans-activation activity through mutations 
causing gain, or loss, of transcription factor function (Kozlowski and Walter, 2000; 
Priston et al., 2001); and 2) via alteration in the level of functional protein through 
chromosomal deletions or duplication. Both mutations and duplications of FOXC1 have 
been shown to produce a similar Axenfeld-Rieger phenotype (Ekong et al., 2004; 
Lehmann et al., 2000; Nishimura et al., 2001). Furthermore, missense or frameshift 
mutations as well as segmental and telomeric deletions of FOXC1 produce a spectrum 
of ARM phenotype (Kawase et al., 2001; Lines et al., 2002; Mears et al., 1996; 
Mirzayans et al., 2000; Murphy et al., 2004; Nishimura et al., 2001; Nishimura et al., 
1998; Saleem et al., 2001; Saleem et al., 2003b; Saleem et al., 2003a; Suzuki et al., 
2001; Swiderski et al., 1999), whilst duplication of the 6p subtelomeric region results in 
iridogoniodysgenesis (Ekong et al., 2004; Saleem et al., 2003a). Hence, when taking 
account of these results as a whole, both a lower and an upper threshold may exist for 
normal FOXC1 activity, where ARM can result from loss-of-function mutation where 
FOXC1 expression is below 80% of the normal FOXC1 activity, or from increased 
expression of FOXC1 above 150% of the wild type activity (FOXC1 duplication) 
(Ekong et al., 2004; Saleem et al., 2001). However, the level of FOXC1 activity does 
not correlate with the severity of ASD (Walter, 2003). A recent finding that FOXC1 and 
PITX2 proteins interact with each other to negatively regulate the activity of FOXC1 
may provide an explanation for this not straight forward observation (Walter, 2003). In                                                                                                                                    Chapter 1 Introduction 
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vitro assays demonstrate that in cells expressing both FOXC1 and PITX2, PITX2 binds 
to FOXC1 and inhibits FOXC1 target genes. Loss of function of PITX2  leads to 
inappropriate activation of FOXC1. Interestingly, this may be equivalent to a 
duplication of a FOXC1 gene giving rise to increased levels of FOXC1 protein. 
Identifying the downstream target genes of FOXC1 would provide a more 
comprehensive understanding of the molecular pathogenesis of ASD. To date, the 
known downstream targets of FOXC1 protein are FGF19 (a member of the fibroblast 
growth factor family, the reduced activity of which give rise to ASD in zebrafish) 
(Tamimi et al., 2006) and FOXO1A (a key protein involved in the cellular stress 
response and apoptotic pathways) (Berry et al., 2008). 
 
Furthermore, a recent study has shown that FOXC1 mutations have a milder and hence 
a better prognosis for the development of glaucoma, whereas individuals with FOXC1 
duplications have a more severe and worse prognosis for glaucoma development 
(Strungaru et al., 2007). More specifically, patients with FOXC1 duplication had 
iridogoniodysgenesis and a higher incidence of raised IOP and glaucoma compared with 
those with FOXC1 mutations. On the contrary, individuals with FOXC1 mutations had a 
diverse clinical presentation, including iris hypoplasia, correctopia, posterior 
embryotoxon and anterior synechiae. Iris malformation can range from normal to severe 
defects which are clinically obvious (polycoria and correctopia) (Smith et al., 2000). 
Similar changes have been found in the TM. This suggests that patients with FOXC1 
mutations appeared to be more diverse phenotype than in the patients with FOXC1 
duplication, and the relatively milder phenotype is as a result from changed levels of 
expression of  (and not from mutant) protein through duplication. In some affected 
family members with glaucoma, the anterior segment malformation may be very subtle, 
and easily missed in clinical examination (Lehmann et al., 2002; Shields, 1983), a 
feature more in keeping with POAG. In addition, the risk of developing glaucoma is not 
related to the severity of the phenotype (Shields et al., 1985; Shields, 1983), suggesting 
that subtle dysfunction of the angle drainage structures may be contributing towards 
glaucoma (Chisholm and Chudley, 1983; Heon et al., 1995).  
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1.9.2.1.6  Summary- FOXC1 as a genetic risk factor for POAG 
Taking into account the essential role of FOXC1 for the development of the anterior 
segment and in the development of TM implies that FOXC1 is crucial for the normal 
development of drainage structures and preservation of normal IOP. This is evidenced 
by targeted heterozygous mutation in animal models resulting in malformation of the 
drainage structures with a high incidence of glaucoma to about 75% or above. 
Therefore, these features of FOXC1 provide a strong basis to consider FOXC1 as a 
candidate for the more common adult-onset POAG through hypothesizing that sub-
clinical mutations/polymorphisms in FOXC1 gene may produce subtle and undetected 
abnormalities in anterior segment structure and function through age related changes, 
which predispose to glaucoma and may be a significant susceptibility factor for the 
development of POAG. 
 
1.9.2.2  LMX1B and Nail-patella syndrome (OMIM 161200) 
 
Nail-patella syndrome (NPS; OMIM # 161200), also known as hereditary osteo-
onychodysplasia, Fong  disease, Turner-Keiser syndrome, and Osterreicher-Turner 
syndrome, is a rare autosomal dominant (Lucas and Wiffler, 1966; Turner, 1933), 
pleiotropic disorder with an estimated incidence of 1 in 50,000 (Sweeney et al., 2003). 
NPS was initially recognized in 1883 as a familial patellar abnormality (Pye-Smith, 
1883) and as a familial nail abnormality in 1897 (Little, 1897). NPS is characterized by 
(Dreyer et al., 1998) dysplastic nails (Guidera et al., 1991) (98%), hypoplastic or absent 
patella (92%), elbow/arm abnormalities (90%) (Figure 1-20), iliac horns (70%) and 
nephropathy (38%) (HAWKINS and SMITH, 1950), epilepsy (6%) and 
neurological/vasomotor abnormalities of the peripheral limbs (25%) (Sweeney et al., 
2003). Glaucoma is now recognized as part of the syndrome (9.6-31%). Clinical 
manifestations of NPS vary widely in both frequency and severity, as well as showing 
inter- and also intrafamilial heterogeneity (Beals and Eckhardt, 1969; Turner, 1933). On 
one hand, clinical features can be very mild and not associated with any disabilities, and 
on the other hand, skeletal malformation can be severe, even at birth (Morita et al., 
1973). In addition, individuals may be more severely affected by one component of the 
illness and exhibit a less severe form elsewhere. Hence, despite diagnosis being made at 
birth (Guidera et al., 1991) it is more common for individuals                                                                                                                                     Chapter 1 Introduction 
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Figure 1–20: Clinical features of NPS; (A) dysplastic changes of the nails, (B) 
absent or hypoplastic patellae (absent patellae on x-ray), and (C) arm/elbow 
abnormality (underdeveloped triceps, flexion contracture of elbow). 
Adapted from Mimiwati et al., 2007. 
A 
B 
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as well as families to remain undiagnosed for generations despite having been reviewed 
by several doctors of various disciplines (Lucas and Wiffler, 1966). 
 
1.9.2.2.1  Linkage of NPS  
One of the first linkages established in humans was between NPS and the blood ABO 
group (RENWICK and LAWLER, 1955). Further refinement of the location of NPS 
was made to a 1-2 cM interval on 9q34.1 (Campeau et al., 1995). Involvement of 
Lmx1b in the dorso-ventral patterning of limb during vertebrae development was first 
established from studies assessing limb development in chick embryos (Riddle et al., 
1995). Knock-out mice lacking Lmx1b were then created to investigate this further 
(Dreyer et al., 1998). Findings from phenotypic abnormalities in these Lmx1b null mice 
with  absence of nails and patellae (Dreyer et al., 1998) and independently through 
positional cloning (Vollrath et al., 1998),  revealed that the NPS gene encoded the LIM- 
homeodomain transcription factor LMX1B. 
 
1.9.2.2.2  The role of LMX1B in development 
LMX1B is a member of the LIM-homedomain (LIM-HD) family of transcription 
factors involved in: 
1)  Body pattern formation during embryonic development in invertebrates and 
vertebrates (Riddle et al., 1995; Vogel et al., 1995). 
2)  Directing the initial trajectory of motor axonal fibres in developing limb (Kania 
et al., 2000). 
3)  Regulation of the development of the anterior segment of murine eyes 
(Pressman et al., 2000). 
4)  Formation of podocytes in the kidney (Rohr et al., 2002). 
5)  Regulation of expression of type IV collagen (Morello et al., 2001). 
 
1.9.2.2.3  LMX1B, the NPS gene 
The LMX1B gene is composed of 8 exons, giving rise to a ~7kb mRNA when spliced 
(Dreyer et al., 1998; Vollrath et al., 1998) (Figure 1-21 A). Two isoforms exist (372 and 
379 amino acids) as a result of alterative splicing of exon 7 at the 3’ end                                                                                                                                     Chapter 1 Introduction 
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Figure 1–21: (A) LMX1B gene structure. 8 coding exons are indicated as solid 
boxes and numbered accordingly. Untranslated exons are shown as open boxes (B) 
Schematic of the LMX1B protein showing LIM domains (encoded by exons 2 and 
3) and homeodomain (encoded by exons 4, 5, and 6). (C) Location of mutations in 
LMX1B protein.  
Adapted from McIntosh et al., 2005).  
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(Seri et al., 1999). The functional differences between the two spliced isoforms are still 
unknown. Detailed analysis of the structure of LMX1B gene revealed the ~7kb transcript 
was composed of a long 1.3 kb 5’-untranslated region (UTR), 4.6 kb 3’UTR, and a 
coding region of 1206 nucleotides (Dunston et al., 2004). The basal promoter activity 
extended 112 bp upstream. An interesting feature of note is the long non-coding intron 
2, where 5 regions of longer than 250 bp with greater than 85% of sequence 
conservation were observed between mouse and human, a feature suggestive of a 
functional role possibly as a regulatory region involved in gene expression (Dunston et 
al., 2004).  
 
The LMX1B gene encodes a transcription factor protein that contains cysteine-rich LIM 
A and LIM B domains (each binding 2 zinc ions) at the N-terminal followed by a 
homeodomain at the C-terminal end (Figure 1-21 B). The LIM domain is named from 3 
proteins found with this domain: C. elegans  Lin-11 (Freyd et al., 1990), rat Isl-1 
(Karlsson et al., 1990), and C. elegans Mec-3 (Way and Chalfie, 1988). LIM domains 
are involved in protein-protein interaction, whereas, the homeodomain is a 60 amino 
acid domain necessary for DNA binding and transcriptional activation (reviewed in 
(Curtiss and Heilig, 1998; Dawid et al., 1995). LIM domains regulate LIM-
homeodomain activity in a positive manner by encouraging protein-protein interaction. 
This enables cooperative binding to regulatory regions within tissue-specific promoters. 
 
Most mutations in LMX1B occur in the LIM domain or homeodomain protein (Bongers 
et al., 2005; Clough et al., 1999; Hamlington et al., 2001) (Figure 1-21 C) and NPS is 
the result of haploinsufficiency of LMX1B (Dreyer et al., 1998; Vollrath et al., 1998). 
Whereas the majority of missense mutations are found in the homeodomain and in the 
canonical residues of the LIM domains, frameshift and nonsense mutations are found 
more widely spread within the coding regions. Large deletions of the coding sequence 
have been shown by analysis of intragenic variations and through Southern blotting 
(Clough et al., 1999). Deletions involving various parts of the gene, including a whole 
gene deletion, were found in 9 of 28 unrelated families (Dunston et al., 2004). In 
particular, one deletion extended from 100kb upstream to at least exon 4 in a sporadic 
case of NPS, with a 50% probability of extension into the 3’ flanking region. Deletions 
of all or part of LMX1B represented ~5% of NPS mutations (Bongers et al., 2005;                                                                                                                                    Chapter 1 Introduction 
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Dunston et al., 2004).  In addition, balanced translocations have been reported in NPS, 
resulting in defective LMX1B (Duba et al., 1998; Hamlington et al., 2001).  
 
To date, 137 mutations (excluding large deletions) within the coding sequence have 
been identified in LMX1B among NPS. Interestingly, no missense mutations have been 
identified downstream of the homeodomain, possibly suggesting that sequence 
alteration of this region could result in a phenotype separate from NPS (Bongers et al., 
2005; Dunston et al., 2004). Co-transfection of  the wild type with mutant LMX1B 
construct showed NPS mutations failing to act in a dominant-negative manner on wild-
type LMX1B (Dreyer et al., 2000). In addition, no variations in the severity of clinical 
features were noted between patients with nonsense, missense, splice or frameshift 
mutations as well as those with large deletions. This evidence suggests and support 
haploinsufficiency as the underlying mechanism of NPS (Clough et al., 1999; Dunston 
et al., 2004; McIntosh et al., 1998). 
 
1.9.2.2.4  LMX1B as genetic risk factor for POAG  
More importantly, NPS has been shown to cosegregate with raised IOP and POAG in 
humans (Lichter et al., 1997b; McIntosh et al., 1998; Vollrath et al., 1998). In 
particular, POAG exhibited an age-dependant penetrance (Vollrath et al., 1998). One 
study involving 29 families showed that POAG was present in 31% of cases (McIntosh 
et al., 1997). A large review evaluating 123 NPS patients revealed 9.6% of NPS had 
glaucoma and an additional 7.2% had ocular hypertension (Sweeney et al., 2003). These 
figures rose to 16.7% and 11.9% when individuals under the age of 40 were excluded. 
The mean age of diagnosis of OHT or glaucoma was 47.9 years (range 23-75). 
 
Another study which involved 106 subjects from 32 NPS families found glaucoma and 
OHT were present in 35.3% (Bongers et al., 2005). Open angle glaucoma was present 
in 3.9%, whilst OHT was present at 3.9%, and surprisingly, NTG was present at a 
higher percentage of 7.8%. The mean age of diagnosis of OHT was 63.4 years (range 
55-72 years). Over the age of 50 years, a higher percentage of 13.3% had open angle 
glaucoma, 26.7% had NTG, and 6.7% had OHT.  
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Interestingly, a higher frequency of  11.1% of open angle glaucoma and 11.1% of OHT 
was shown by a recent study involving 52 subjects with NPS (Mimiwati et al., 2006). 
This figure increased to 33% of glaucoma cases when individuals over the age of 40 
years were considered. The mean age at diagnosis for glaucoma was 48 years and for 
OHT 24 years. Of note was the presence of one NPS case with NTG. This patient was 
diagnosed with NTG at 63 years and had advanced cupping. 
 
In addition to determining dorsal limb patterning during vertebrate development 
(Dreyer et al., 2000), the transcription factor LMX1B  regulates programs of gene 
expression essential for normal morphogenesis and cell differentiation of the anterior 
segment (Pressman et al., 2000). Targeted homozygous mutation in animal models 
resulted in eye phenotypes comprised of iris and ciliary body hypoplasia, and corneal 
stromal defects in which defective collagen fibrillogenesis was observed.  
 
Notably, Lmx1b is expressed in the TM and ciliary body, the sites of aqueous drainage 
and production respectively (Pressman et al., 2000). Although, mutations in the LMX1B 
gene can cause a spectrum of ocular phenotypes that vary in severity including rare 
anterior segment anomalies of iris processes, ptosis, hypertelorism, epicanthal folds, 
bilateral sclerocornea, microcornea, keratoconus, congenital cataracts, mircophakia 
(Bongers et al., 2005; Lichter et al., 1997b; Spitalny and Fenske, 1970), developmental 
abnormalities of the anterior segment are not always clinically detectable in patients 
carrying LMX1B mutation in the majority of cases
 (Mimiwati et al., 2006; Sweeney et 
al., 2003), a feature consistent with POAG. 
 
Furthermore, animal models have also shown LMX1B plays an important role in the 
expression of other ECM. It directly regulates expression of the basement membrane 
collagens Col4a3 and Col4a4, and in the formation of podocytes in the kidney (Morello 
et al., 2001; Rohr et al., 2002). Expression of Col4a4 is reduced in the glomerular 
basement in Lmx1b
-/- mice. Considering the important developmental contribution of 
ECM to the formation of the TM (reviewed by (Acott and Kelley, 2008; Gould et al., 
2004), in particular, towards its structural and physiological role, altered ECM 
regulation as a result of mutations in LMX1B may predispose to glaucoma. Though 
there is not yet evidence that Lmx1b regulates Col4a1, mutations in the collagen Col4a1                                                                                                                                    Chapter 1 Introduction 
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gene resulted in ASD with optic nerve hypoplasia, with raised as well as low IOP 
(Gould et al., 2007).  
 
Thus, taking all the evidence into consideration, LMX1B appears to be a strong 
candidate gene for adult onset POAG through the hypotheses that subclinical 
mutations/polymorphisms in LMX1B gene may result in subtle and undetected 
abnormalities in the anterior segment structure and function, and predispose to 
glaucoma through its effect on the regulation of ECM of the TM. 
 
1.9.3  TGFβ2 and BMP4 as genetic risk factors for POAG  
There is increasing evidence to suggest that growth factors may be important in 
maintaining normal homeostasis in the ocular tissues that are involved in the 
pathogenesis of glaucoma (Fleenor et al., 2006; Gottanka et al., 2004; Lutjen-Drecoll, 
2005; Pena et al., 1999; Tamm and Fuchshofer, 2007; Wordinger et al., 1998; 
Wordinger et al., 2002; Wordinger et al., 2007; Wordinger and Clark, 2007). The TM 
expresses a range of growth factors and growth factor receptors including BMPs (as 
well as BMP4), BMP receptors, and TGFβ2 (Tripathi et al., 1993a; Tripathi et al., 
1993b; Tripathi et al., 1994c; Tripathi et al., 1994a; Wordinger et al., 1998; Wordinger 
et al., 1999; Wordinger et al., 2007). TGFβ2 and BMP4 are also expressed in the human 
optic nerve head (Pena et al., 1999; Wordinger et al., 1998; Wordinger et al., 2002). In 
addition, the aqueous humor contains a variety of growth factors including FGF2, EGF, 
HGF and TGFβ (Hu and Ritch, 2001; Tripathi et al., 1992; Wordinger et al., 2007). 
More specifically, elevated levels of TGFβ2 have been found in POAG patients. In 
addition, studies have shown that raised IOP in POAG is as a result of increased 
resistance to aqueous outflow (Grant, 1963) and this is associated with biochemical and 
morphological changes in the TM (Rohen, 1983). There is an accumulation of ECM in 
the TM of glaucoma patients, and this may be as a result of disruption of the balance 
between ECM deposition and degradation (Lutjen-Drecoll, 2005; Rohen, 1983). Hence, 
growth factors such as BMP4 and TGFβ2 appears to be strong candidate genes that may 
be involved in glaucoma pathogenesis through its influence on the normal development 
or function of the TM and optic nerve head. 
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1.9.3.1  TGFβ2 and BMP4 signaling pathways 
TGFβ2 and BMP4 are secreted signaling molecules that constitute the TGFβ super-
family. They are multifunctional growth factor proteins and exhibit a spectrum of 
biological processes which includes inflammation, wound repair, ECM accumulation, 
tissue development, cell differentiation, cell proliferation, cell death, and bone 
morphogenesis (Barnard et al., 1990; Graham et al., 1994; Hogan, 1996; Hogan, 1999; 
Janssens et al., 2005; Mabie et al., 1999). In keeping with its diverse role, abnormal 
TGFβ signalling pathway results in a variety of clinical disease processes (Miyazono et 
al., 2001). TGFβ molecules activate the Smad family of signal transducers, which form 
complexes with specific DNA-binding proteins to regulate gene expression (Massague, 
2000; Whitman, 1998). Two similar but discrete Smad-dependent signaling pathways 
have been identified: TGF, Activin and Nodal signal via the Smad2 (or Smad3)–Smad4 
complex, whereas BMP signals via the Smad1–Smad4 complex (Massague, 2000; 
Whitman, 1998). Activation of each signaling pathway involves an extracellular ligand 
binding to a membrane bound Type I and Type II serine/threonine kinase receptors. 
This initiates a cascade of cytoplasmic signaling that activates SMAD proteins. These 
activated SMAD proteins enter the nucleus and associate with transcription factors and 
take part in transcriptional regulation of target genes (Miyazono et al., 2001). 
 
1.9.3.2  TGFβ2 (OMIM; 190220) 
1.9.3.2.1  Function of TGFβ2 in ocular development 
Studies on animal models have shown that TGFβ2 is important in anterior segment 
development. The corneas of mice with homozygous mutations have less deposition of 
ECM and appear thin (Saika et al., 2001). In addition, the corneal endothelium fails to 
differentiate whilst there is absence of anterior chamber development. The TM in mice 
is yet to be assessed. Interestingly, a study not directly involving TGFβ2 but rather 
involving inactivation of TGFβ signalling in neural crest cells showed that normal 
formation of the ciliary body and TM requires TGFβ signalling in these cells, and the 
phenotypic abnormalities found in Tgfbr2- mutant mice were characteristic of those 
found in ARM (Ittner et al., 2005).                                                                                                                                    Chapter 1 Introduction 
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1.9.3.2.2  Function of TGFβ2 in adult ocular development 
In POAG, the resistance to aqueous outflow in the trabecular outflow is abnormally 
raised (Gabelt and Kaufman, 2005; Tamm and Fuchshofer, 2007). Despite there being 
inconclusive evidence for the underlying mechanism responsible for the increase in 
outflow resistance in POAG, there is growing evidence that changes in the ECM of the 
TM may play an important role (Fleenor et al., 2006; Lutjen-Drecoll, 2005; Tamm and 
Fuchshofer, 2007; Wordinger et al., 2007). 
 
The structural changes characteristically found in the juxtacanalicular tissue of the TM 
in individuals with POAG is an accumulation of plaque-like material (derived from 
thickened sheaths of elastic fibres within the juxtacanalicular tissue) in addition to an 
increase in ECM (Rohen and Witmer, 1972). Although the underlying regulatory 
mechanism of ECM turnover in the normal TM and its increase in POAG is still poorly 
understood,  TGFβ2 appears to be a strong candidate involved in the pathogenic 
structural changes in TM. In addition to TGFβ2 being expressed in human TM 
(Wordinger et al., 1998), several independent studies have shown presence of higher 
concentrations of TGFβ2 in the aqueous humor of individuals with POAG (Inatani et al., 
2001; Ochiai and Ochiai, 2002; Picht et al., 2001; Tripathi et al., 1994b). These initial 
reports have been followed by in vitro studies showing that TGFβ2 acts via several 
pathways on human TM to increase ECM deposition and cross linkage that hinders 
degradation. More specifically, exogenous treatment of TGFβ2: 
1)  Increases in vitro synthesis of ECM  molecules in cultured human TM cells 
(Welge-Lussen et al., 2000), and within the perfused anterior segment organ 
culture model (Gottanka et al., 2004). 
2)  Increases expression of plasminogen activator inhibitor which inhibits activation 
of matrix metalloproteinases via tissue plasminogen activator and/or urokinase 
(Fuchshofer et al., 2003). This, in turn results in an increase in ECM in TM of 
individuals with POAG. 
3)  Increases irreversible cross-linkage of ECM components (fibronectin) in TM cells 
via tissue transglutaminase  (Welge-Lussen et al., 2000), the effects of which are 
inhibited by BMP4 (Wordinger et al., 2007). In perfused anterior segment culture 
model, TGFβ2 induced focal accumulation of fine fibrillar ECM in the TM as well                                                                                                                                    Chapter 1 Introduction 
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as an increase in fibronectin, both of which were correlated with a reduction in 
outflow facility (Fleenor et al., 2006; Gottanka et al., 2004). Interestingly, a 
correlation was found between the amount of ECM underneath the inner wall of 
Schlemm’s canal and the degree of axonal loss within the glaucomatous optic 
nerve head (Gottanka et al., 1997). 
4)  Inhibits TM cell proliferation (Gottanka et al., 2004; Wordinger et al., 1998). 
 
In addition to its effect on TM, the effects of TGFβ2 have also been assessed on the 
optic nerve head. Support for the involvement of TGFβ2 in glaucomatous optic nerve 
heads was provided by a study which showed expression of TGFβ2 was elevated 70-
100 fold more in the astrocytes of the human glaucomatous optic nerve heads (Pena et 
al., 1999) compared to controls. When astrocytes from optic nerve head were treated 
with TGFβ2 in the same concentration used for TM cells, this resulted in an increased 
expression of fibronectin, type I as well as type IV collagen, tissue transglutaminase and 
plasminogen activator inhibitor (Fuchshofer et al., 2005). 
 
1.9.3.3  BMP4 (OMIM; 112262) 
BMP proteins are phylogenetically conserved signalling molecules that constitute the 
largest subfamily within the TGFβ superfamily of growth factors (Attisano and Wrana, 
1996; Canalis et al., 2003; Massague and Chen, 2000; Reddi, 2001). Although BMP 
proteins were originally identified as osteoinductive cytokines that regulated bone and 
cartilage formation (Reddi, 2000; Wozney et al., 1988), subsequent studies have now 
shown that BMPs have a more diverse role including body patterning and 
morphogenesis (Hogan, 1996; von and Cho, 2001). In addition, BMPs have important 
roles in adults in the pathophysiology of several diseases, including osteoporosis, cancer, 
kidney diseases, pulmonary hypertension and cerebrovascular disease (Chang et al., 
2003; Howe et al., 2001; Hruska et al., 2004; Klahr, 2003; Miyazono et al., 2001; 
Morse et al., 2001; Reddi, 2000; Wang, 1993; Zeisberg et al., 2004). 
                                                                                                                                    Chapter 1 Introduction 
  97
1.9.3.3.1  Function of BMP4 in ocular development 
Several studies have shown that BMP4 is important in ocular development, in particular, 
for the development in the anterior segment. All mutant mice with heterozygous 
mutations for BMP4 showed severely malformed anterior segment with raised IOP 
(Chang et al., 2001). The phenotype was similar to ASD in humans, and was variable as 
it depended on specific genetic background. In particular, all of the tissues within the 
anterior segment, including the TM and Schlemm’s canal, were affected. The TM 
appeared hypoplastic with reduced ECM. In addition, abnormalities of the optic nerve 
were frequently present, with even absence of the optic nerve on certain genetic 
background. Furthermore, BMP signalling has shown to be required for the 
development of the ciliary body. Noggin, a BMP antagonist, blocked BMP signalling in 
mouse eye, and this resulted in the failure of the formation of the ciliary process (Zhao 
et al., 2002). 
 
Although BMP4 has no known targets in the periocular mesenchyme, BMP4 receptors 
are present in mesenchyme (Furuta and Hogan, 1998) and mesenchyme-derived tissues 
are malformed in mice with heterozygous mutations in BMP4. It is therefore a 
possibility that BMP4 may directly affect the mesenchyme. In such mice with 
heterozygous loss of BMP4, the mesenchyme-derived TM show significant deficiencies 
of ECM. It is known that ECM is developmentally important as it regulates 
developmental processes such as proper migration and differentiation (Adams and Watt, 
1993; Lin and Bissell, 1993; Perris, 1997). Hence BMP4 may influence the 
morphogenesis of the TM by regulating the compositions of ECM that are crucial for 
mesenchymal migration, differentiation and remodelling. 
 
1.9.3.3.2  Function of BMP4 in adult ocular tissue 
Studies involving cultured human TM cells have shown that BMP4 is capable of 
inhibiting the effects of TGFβ2 on the induction of fibronectin and thereby modulating 
the effects of TGFβ2 in TM cells (Wordinger et al., 2007). Furthermore, gremlin, a 
BMP antagonist which is expressed in TM cells, is able to block the inhibitory effects of 
BMP4 on TGFβ2 (Figure 1-22). 
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Figure 1–22: Diagrammatic representation of the interactions of TGFß2, BMP4, 
and Gremlin within the TM.  
Elevated TGFß2 are found in the aqueous humor of individuals with POAG, and this 
may lead to increased deposition of ECM proteins in the TM. Increased ECM 
deposition results in increased resistance to aqueous humor outflow and raised IOP. 
BMP4 inhibits TGFß2 upregulation of ECM deposition and maintains a normal balance 
of ECM synthesis, deposition, and degradation within the human TM. The 
overexpression of Gremlin, a secreted BMP antagonist, in glaucomatous TM, inhibits 
the effect of BMP4 and leads to an imbalance in TGFß2 action. Adapted from 
Wordinger et al ., 2007. 
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1.10 Summary of literature review 
Taken together, these reports suggest that both TGFβ2 and BMP4 are strong candidate 
genes that act in concert to maintain a balance between ECM deposition and 
degradation, and may play an important role in glaucoma pathogenesis through mis-
regulation of ECM synthesis and cross-linkage of ECM components of the TM and in 
the optic nerve head (Table 1-9).  
 
Genes in which mutation causes anterior segment angle anomalies and glaucoma are 
strong candidates for glaucoma susceptibility and may contribute to glaucoma more 
frequently than expected, and possibly play an important role in the common forms of 
POAG. The fact that around 1-2% of individuals who are ≥40 years of age in the 
general population develop POAG (Fraser, 2004), compared with 33-75% of patients 
who have mutations in the developmental glaucoma genes FOXC1 and LMX1B suggests 
that these genes are very good candidate risk factors (Table 1-9). 
 
In addition, the E50K OPTN mutation is a candidate susceptibility gene for POAG in 
patients of white British origin (Table 1-9). 
 
1.11 Hypotheses and aims of study 
1.11.1  Hypotheses  
1)  Sub-clinical mutations/polymorphisms in LMX1B, FOXC1, TGFβ2 and BMP4 may 
produce subtle and undetected age-related abnormalities in anterior segment 
structure and function, which predispose to glaucomatous optic neuropathy and may 
be a significant susceptibility factor for the development of OHT and POAG. 
2)  The OPTN E50K mutation may be a significant POAG risk factor for the white 
British acting via a defective neuroprotection on the optic nerve head.                                                                                                                                    Chapter 1 Introduction 
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Table 1–9: Summary of supporting evidence for LMX1B, FOXC1, TGFβ2, BMP4 and 
OPTN as candidate genes for POAG 
NTG (Rezaie
et al., 2002) 
ARS (Chang 
et al., 2001)
Peters’ like 
anomaly 
(Saikeet al., 
2001)
ARS (Smith et 
al., 2000)
Nail-Patella 
Syndrome 
(Dreyer et al., 
1998)
Phenotype
Mean age of NTG patients; 44 
years (ranging from 23 to 65 
years) (Rezaie et al., 2002) 
Yet to be assesed In adult human TM and 
aqueous humor (Rezaie et al.,
2002) (and monkey’s optic 
nerve) (Rezaie et al., 2005)
In 0.1-16.7% 
individuals with 
NTG 
(predominantly 
found in 
individuals from 
British descent)
OPTN
In ~40% (mice)
(Chang et al., 
2001)
Elevated levels 
of TGFß2 in 
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(Tripathi et al, 
1994)
In ~50-75% of 
ASD (Strungaru
et al., 2007)
In 33% of NPS  
(Mimiwati et al.,
2007)
Raised IOP
Bmp4 +/- showed 
hypoplastic trabecular
meshwork with raised 
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optic nerve (Chang et 
al., 2001)
Tgfß2-/- mutant mice 
showed absent anterior 
chamber (Saike et al., 
2001). The TM in mice 
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TGFß signal 
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resulted in absent Tm 
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BMP4 inhibited TGFß2 
upregulation of ECM deposition 
in adult TM cell lines 
(Wordinger et al.,2007)
Age range from birth to above 
70 years (Shields et al., 1983)
NTG present in 26.7% 
(Bongers et al., 2005)
OHT present in 11.9% 
(Sweeney et al., 2003) 
Additional supporting features 
as candidate genes for 
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et al., 2007)
BMP4
In developing TM of mice 
(Smith et al, 2000) 
FOXC1
In developing TM of mice and 
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Expression in trabecular
meshwork +/- optic nerve head
Developmental 
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1.11.2  Aims of the study 
The aims of the study are as follows: 
1)  To recruit adequate numbers of matched POAG patient/control cohorts to achieve a 
study power of 80%, using explicit inclusion/exclusion criteria. 
2)  The selection of appropriate tagging single nucleotide polymorphisms (tSNPs) using 
the HapMap resource, or in the case of OPTN, selecting the SNP responsible for 
E50K mutation. 
3)  To ascertain whether alleles of LMX1B, FOXC1, TGFβ2,  BMP4  predispose to 
POAG in the general population composed of white British subjects by performing 
a case-control genetic association study to compare the prevalence of tSNPs of 
LMX1B, FOXC1, TGFβ2, BMP4 in four groups, HTG, NTG, OHT and a normal 
control group.  
4)  To validate any significant findings in a 2
nd independent cohort study. 
5)  To assess the prevalence of OPTN E50K mutation in unrelated glaucoma patients of 
white British origin comprising of HTG, OHT, NTG and normal controls, in 
addition to investigating the clinical features of individuals with the OPTN E50K 
mutation in order to assess whether this mutation imparts a characteristic glaucoma 
phenotype. 
6)  To validate the prevalence of OPTN E50K mutation using an independent 
sequencing method.  
 
In the short term, this study aims to offer an opportunity to unravel the complex 
genetics of POAG and hence provide a better understanding of the aetiology of 
glaucoma in the UK population. In the long term, it may contribute towards 
development of screening tests. This will offer the prospect of pre-symptomatic 
diagnosis of at risk individuals to allow early implementation of treatment to prevent 
visual loss. This will substantially relieve health care expenditures on glaucoma 
treatment and more importantly, improve quality of life. Identification of the genes 
involved in glaucoma pathology will also provide new targets for the development of 
new molecular based therapies in the future. In addition, the panel of DNA samples 
from this study will be useful for assessing the role of other genes in glaucoma. 
Glaucoma genetic screening is an important tool for reducing the incidence of blindness                                                                                                                                    Chapter 1 Introduction 
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and vision loss from a predominantly asymptomatic disease and is now a feasible goal 
made possible with recent scientific and technological advances. 
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Chapter 2  Methods and Materials 
2.1  Overview of study design 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion criteria for cases: 
•  Adult individuals (≥ 40 years) of white British descent with a diagnosis of HTG, NTG or OHT 
after the age of 40 years. 
 
•  Presence of glaucomatous optic neuropathy (defined by loss of neuroretinal rim) with 
compatible and reproducible visual field loss for HTG and NTG, and absence of a detectable 
glaucomatous damage or field loss for OHT cases. 
 
•  Open drainage angles on gonioscopy. 
•  IOP consistently ≥ 22mmHg on diurnal testing for HTG and OHT, and ≤ 21 mmHg for NTG 
 
•  Absence of a secondary cause for glaucomatous optic neuropathy; 
•  Absence of non-glaucomatous field losses and disc changes (i.e. high myopia). 
1) Assessment of LMX1B, FOXC1, BMP4 and TGFβ2 as candidate genes for HTG, NTG and OHT 
2) Evaluation of prevalence of OPTN E50K mutation among HTG, NTG and OHT 
 
•  DNA extraction from peripheral blood mononuclear cells. 
 
•  Selection of tSNPs using the HapMap resource (minor allele frequency ≥ 0.1, minimum 
r
2=0.8).  
 
•  Application of  a) Pyrosequencing/real time PCR to obtain preliminary results 
 b)  Sequenom  MassARRAY
TM System to allow high-throughput SNP   
 genotyping. 
 
•  Evaluation of the prevalence of each tSNP for LMX1B, FOXC1, BMP4, TGFβ2, and E50K 
mutation for OPTN, in cases and controls. 
 
•  Validation of the prevalence of OPTN E50K mutation using an independent sequencing 
method. 
Replication study for any significant association with an independent ethnically matched cohort  
 
•  108 HTG 
•  222 NTG 
 
Recruitment of 367 cases and 276 controls 
 
•  272 HTG 
•  58 OHT 
•  37 NTG                                                                                                                   Chapter 2 Materials and Methods 
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2.2  Recruitment of patients 
2.2.1  First cohort  
All of the participating subjects for the first cohort (cohort 1) were recruited from 
glaucoma outpatient clinics between February 2005 and October 2005 at the Sunderland 
Eye Infirmary in the North-East of England, UK, a secondary ophthalmology referral 
centre. The research followed the tenets of the Declaration of Helsinki. Informed 
consent was obtained from all participants after the nature and possible consequences of 
the study were explained (Appendix I and II). The study had Local Research Ethics 
Committee approval (research ethics committee number: 06/Q0508/8). A cohort of 
HTG cases (n=272), and unrelated controls (n=276) matched for ethnicity, were 
recruited to the study. Cases with NTG (n= 37) and OHT (n= 58) were also collected. 
All cases (n=367) and controls were of white British descent. Of these, I recruited, 
collected and performed ophthalmic examination on 483 individuals. Dr Daniela 
Vaideanu (Specialist Ophthalmic Registrar based in the Northern Deanery) recruited 
and examined a further 160 subjects using the same inclusion/exclusion criteria. All 
clinical examination and diagnosis were performed under the supervision of Mr Scott 
Fraser who is a Consultant Ophthalmologist with a special interest in glaucoma.  
 
Control participants (n=276), either accompanying spouses or friends of individuals 
with glaucoma, were recruited randomly. All controls underwent a complete ophthalmic 
examination in order to exclude individuals with glaucoma from the control group, and 
were confirmed to have no visual complaints and IOP of < 22mmHg with a normal disc 
appearance. Control individuals with a family history of glaucoma were excluded.  
 
All case subjects underwent a complete ophthalmic examination including best visual 
acuity, and visual field testing using a Humphrey SITA standard 24-2 perimetry (Carl 
Zeiss Meditec AG, Jena, Germany) (a form of a static perimetry which involves 
presentation of non-moving stimuli of varying illuminance), slit lamp examination of 
the anterior segment (including gonioscopy using a single mirror goniolens: this is 
applied to the surface of the eye, thereby preventing total internal reflection at surfaces 
within the eye, notably at the cornea:air interface and hence allows visualization of the 
anterior chamber angle), measurement of IOP by Goldmann applanation tonometer (this                                                                                                                   Chapter 2 Materials and Methods 
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is applied to the cornea with sufficient force to produce a standard area of contact of a 
diameter of 3.06mm: such applanation tonometry is based on the Imbert-Fick principle, 
which states that for an ideal, dry, thin-walled sphere, the pressure inside the sphere (P) 
equals the force necessary to flatten its surface (F) divided by the area of flattening (A) 
i.e. P = F/A), posterior segment examination of the retina and optic disc following pupil 
dilation and measurement of the C/D ratio. An arbitrary assessment of the severity of 
the visual field defect was not recorded, nor was the CCT measured, as a pachymeter 
was not available. However, all the visual field tests showed reproducible field defects, 
and were ensured to have a satisfactory reliability scores of ≤20% fixation loss, false 
positive of ≤33% and/or false negative of ≤33%. 
 
Adult individuals with a diagnosis of HTG, NTG or OHT from the age of 40 years were 
enrolled based on the following clinical criteria: 
i)  Presence of glaucomatous optic neuropathy (defined by loss of neuroretinal rim) 
with compatible and reproducible visual field loss for HTG and NTG, and absence 
of detectable glaucomatous damage or field loss for OHT; 
ii)  Open drainage angles on gonioscopy; 
iii) IOP consistently ≥ 22mmHg on diurnal testing for HTG and OHT, and ≤ 21 mmHg 
for NTG; 
iv) Absence of a secondary cause for glaucomatous optic neuropathy; 
v)  Absence of non-glaucomatous field losses and disc changes (i.e. high myopia). 
 
Clinical details of all the participants were recorded onto a clinical sheet as shown in 
Figure 2-1. 
 
2.2.2  Second cohort  
In order to assess whether any of the significant findings could be replicated, a second 
ethnically matched cohort consisting of HTG cases (n = 108) and NTG cases (n = 222) 
was provided from a tertiary referral clinic at Moorfields Eye Hospital (London). These 
white/Caucasian individuals which may represent a more diverse ethnicity, were already 
recruited and were previously investigated for the prevalence of OPTN and OPA1 
mutation (Aung et al., 2003; Aung et al., 2002b). Glaucoma  was  defined  by  a  similar  
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Name…………………………………….. Date  of  examination……………….. 
Age………………………………………. 
Sex……………………………………….. 
 
A. Diagnosis 
1. Ocular hypertension (i.e. IOP ≥ 22mmHg and absence of detectable glaucomatous optic nerve damage 
or field loss)                      Yes  No R L  
                           
2. Primary open angle glaucoma 
    a) High tension glaucoma- IOP ≥ 22mmHg  Yes  No R L  
  b) Normal tension glaucoma- IOP < 22mmHg   Yes  No R L  
 
3. Secondary glaucoma (e.g. pseudoexfoliation, pigmentary, others) 
   Yes  No R L  
Date of diagnosis of OHT or POAG…………………….. 
 
B. Risk factors 
  a) Family history    
 b)  Myopia     
 c ) Afro-Caribbean origin     
 
C. Ocular findings 
Visual acuity……………………… ………… R   6/………    L  6/……… 
IOP-   most recent……………….... ………… R…………..   L………….  Instrument used……………..          
      Highest- Date………………………… R…………..  L………….  Instrument used…………….... 
Angle appearance……………………………. R…………..    L………….    
Optic disc appearance     
   Cup/disc ratio ………………………... R  0. …………  L  0……..... 
Presence of reproducible visual field defect… R  ……….. L  ………  Nil   
 Instrument  used……………………………………………………… 
  Character of field loss………………... R……………  L…………… 
 Evidence  of  deterioration……………………………………………. 
 
D. Therapy 
  a. Medication   R…………………………..  L………………………………..     Nil   
 b.  Laser  R…………………………..  L………………………………..  Nil   
 c.  Surgery  R…………………………..  L………………………………..  Nil   
 
Signature…………………………………………... Name…………………………...  Date………… 
 
 
 
Figure 2–1: An example of the clinical sheet used to gather the details of the 
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strict inclusion/exclusion criteria: 
i)  Presence of typical glaucomatous optic neuropathy with compatible visual field 
loss; 
ii)  Open drainage angles on gonioscopy; 
iii) Patients with NTG had a mean IOP without treatment that was consistently 21 
mmHg or less on diurnal testing; 
iv) Patients with HTG had a mean IOP consistently above 21 mm Hg;  
v)  Absence of a secondary cause for glaucomatous optic neuropathy such as a 
previously raised IOP after trauma, a period of steroid administration, or uveitis; 
vi) Patients showed no evidence of high myopia or congenital abnormality. 
 
The same control individuals used in cohort one was re-utilised for cohort two. 
 
2.3  DNA extraction 
20 ml of venous blood was extracted from the participant’s arm and distributed into 4 
5ml ethylenediaminetetraacetic acid (EDTA) tubes. This was stored in a -80ºC freezer at 
the Institute of Child Health until the laboratory work started. 
 
Genomic DNA was extracted from peripheral blood leucocytes using a standard salting-
out procedure. At the start of each experiment, two 500ml bottles of reverse osmosis 
(RO) water and one bottle of 0.1% Igepal solution were placed in the fridge to cool. 3ml 
of thawed blood sample was transferred into a labeled 15ml Falcon tube. Empty EDTA 
blood tubes were discarded into 300ml of 10% Chloros (sodium hypochlorite) for 2 
hours for disposal. Ice-cold RO water was poured into each Falcon tube to produce a 
final volume of 15ml. This was inverted to mix and lyse red blood cells, followed by 
centrifuging for 20 minutes at 4°C and 2900 revolutions per minute (rpm) (1800 times 
gravity (g)) in a Sorvall® Legend RT centrifuge. Supernatant was dispensed into 10% 
Chloros. Ice-cold 0.1% Igepal was poured onto the white cell pellet and the volume was 
made up to 6ml for cell membrane degradation. The pellet was resuspended by 
vortexing, followed by spinning for 20 minutes at 4°C and 2900 rpm in the same 
centrifuge. Supernatant was discarded into 10% Chloros and 1ml of Nuclei Lysis Buffer 
(containing 10Mm of Tris at pH 8.2; 400mM of sodium chloride; 2mM of EDTA) was 
added to each 15ml Falcon tube for nuclei lysis. The sample was vortexed to re-suspend                                                                                                                   Chapter 2 Materials and Methods 
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the pellet completely. For protein degradation, 67µl of 10% SDS and 200µl Proteinase 
K solution were added to each 15ml Falcon Tube. The sample was mixed by gentle 
inversion and incubated in a water bath at 60°C for 1.5 hours (or overnight at 37°C). 
Following incubation, 0.3ml of saturated ammonium acetate was poured into each 15ml 
Falcon tube. Each tube was shaken vigorously for 15 seconds and left to stand at room 
temperature for 10-15 minutes. Each tube was then spun for 20 minutes at 3300 rpm 
and at 24°C. Meanwhile, for each sample, another 15ml Falcon and a 1.5ml eppendorf 
was labeled identically. The supernatant was poured into the corresponding new Falcon 
tube. Onto the supernatant, two volumes of absolute ethanol (approximately 2ml) were 
poured and the DNA was precipitated by gentle inversion. The tip of a glass pasteur 
pipettes (unplugged: Fisherbrand) was gently melted using a flame from a Bunsen 
burner and shaped into a loop. This was then used to scoop and lift the DNA out into the 
corresponding new eppendorf containing 500µl of Tris EDTA (TE) and was submerged 
for dissolving.  
 
2.4  Agarose gel electrophoresis  
A 1 % (w/v) agarose gel was prepared by heating 1 g of agarose (Flowgen Bioscience, 
Nottingham, UK) in 100 ml TAE electrophoresis buffer (containing 40mM Tris at pH 
7.2; 0.114% (v/v) glacial acetic acid; 1mM EDTA) for 2 minutes in a 900 W microwave 
oven. One microlitre per milliliter of 0.0025% (v/v) ethidium bromide was added to aid 
DNA detection; it intercalates between DNA molecules and fluoresces under UV light. 
The liquid gel was left to slightly cool for approximately 30 minutes and poured into a 
gel tray containing appropriate sized combs. The gel was allowed to solidify at room 
temperature for at least 30 minutes. It was then placed into an electrophoresis tank, 
Horizon®11.14 (Life Technologies, Gaithersburg, MD) and completely submerged with 
TAE buffer and the comb was then removed. 2µl of 5x Orange G loading buffer was 
added and mixed into each 8 µl of diluted DNA and loaded into the corresponding well. 
5 µl of 1 kb DNA ladder, Hyperladder
TM IV (Bioloine, London) was loaded to reference 
the product size. The gel was run at 100 mV at 80-100 mA for at least 40 minutes.  Gels 
were then imaged using UV light with a camera capture system (Uvidoc system, 
Uvitec). 
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The quality of the DNA was assessed by examining for the presence of; a) any smearing 
of the fluorescent bands to detect for any DNA fragmentation, or; b) for faint 
fluorescent bands that signify the presence of any contamination.  
 
2.5  Spectrophotometric determination of the amount of DNA  
Nanodrop (ND-1000 Spectrophotometer V3.2, NanoDrop Technologies, Inc.) was used 
to quantitate the amount of DNA by loading 1 µl of the diluted DNA onto the 
spectrophotometer. Readings were taken at wavelengths of 260 nm and 280 nm. The 
reading at 260 nm allowed calculation of the concentration of nucleic acid in the 
sample. A reading of 1 optical density at 260 nm corresponds to 50 µg/ml of double 
stranded DNA. The ratio between readings at 260 nm and 280 nm provided an estimate 
of the purity of the nucleic acid. Pure preparations of DNA had ratio of 1.8.  
 
2.6  HapMap resource and selection of SNPs   
The HapMap resource (www.hapmap.org) was used to guide selection of SNPs from 
candidate genes. A tSNP approach was employed to screen FOXC1, BMP4, TGFβ2, 
and LMX1B including 10 kb of upstream and downstream flanking sequence in patient 
and control groups (HapMap Data Release #22/Phase II Apr 2007). By using the 
algorithm tagger which was implemented in Haploview v.4.0 (Carlson et al., 2004) 
(www.broad.mit.edu /mpg/haploview) to select tSNPs that capture untyped SNPs with a 
minimum r
2 value of 0.8, 4 SNPs for FOXC1 (Figure 2-2, Table 2-1), 5 SNPs for BMP4 
(Figure 2-3, Table 2-2), 20 SNPs for TGFβ2 (Figure 2-4, Table 2-3), and 26 SNPs for 
LMX1B (Figure 2-5, Table 2-4), were analysed. Selection was restricted to SNPs with a 
minor allele frequency (MAF) of ≥10% (i.e. SNPs with a high degree of polymorphism) 
as relatively abundant SNPs rather than rare mutations were more likely to contribute to 
complex traits and improve the chances of detecting associations. Selection was also 
focused on identifying polymorphic SNPs which caused amino acid substitutions as 
they were most likely to impact gene function and may represent functional variants 
rather than indirect markers of functional variation. Individually chosen possible 
functional SNPs included rs1091993 for FOXC1 (5 SNPs in total when combined with 
SNPs selected from HapMap), rs28939692 for LMX1B  (27 SNPs in total when 
combined with SNPs selected from HapMap), and rs28939688 for OPTN                                                                                                                    Chapter 2 Materials and Methods 
  110
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2–2: The relative position of 5 SNPs for FOXC1, on chromosome 6p25. 
The relative position of the 4 tSNPs chosen from Haploview v.4.0 with the additional 
non-synonymous SNP (chosen manually) is shown. The coding exon is indicated as a 
solid box. 
 
 
 
 
 
Table 2–1: Selected SNPs for FOXC1 
 
tSNP 
no 
Reference ID  Position  Type  Polymorphism  Amino acid 
change 
1 rs2235715    1543941  upstream  (intergenic)  C/T   
2 rs2569889  1548686  upstream  (intergenic) G/C   
3 rs2235716  1552115  upstream  C/T   
Manually 
chosen 
rs1051933   1556955 
(c.1276G>A) 
exon (non-
synonymous) 
G/A 
 
aspartic acid 
to asparagine 
4 rs984253    1558528  3’  UTR  A/T                                                                                                                     Chapter 2 Materials and Methods 
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Figure 2–3: The relative position of 5 tSNPs for BMP4, on chromosome 14q21. 
The relative position of the 5 tSNPs is shown. 4 coding exons are indicated as solid 
boxes and numbered accordingly. Untranslated exons are shown as open boxes.  
 
 
Table 2–2:  Selected tSNPs for BMP4 
tSNP 
no 
Reference ID  Position  Type  Polymorphism  Amino acid 
change 
1 rs8014363  53501325  promoter  C/T   
2 rs8014071  53501250  promoter  A/G     
3 rs2761884  53490802  intron  1  G/T   
4 rs17563  53487272 
(c.455T>C) 
exon 3 (non-synonymous)  T/C  valine to alanine 
5 rs11623717  53483882  downstream  (intergenic)  A/G                                                                                                                       Chapter 2 Materials and Methods 
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Figure 2–4: The relative position of 22 SNPs for TGFβ2, on chromosome 1q41. 
The relative position of the 20 tSNPs with 2 additional 5’ UTR SNPs (chosen manually) 
is shown. 8 coding exons are indicated as solid boxes and numbered accordingly. 
Untranslated exons are shown as open boxes. 
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Table 2–3: Selected SNPs for TGFβ2 
tSNP no  Reference ID  Position  Type  Polymorphism 
1 rs10495098  216582933    Upstream  G/T 
Manually chosen  rs114663679   216586555  5’UTR  C/A 
Manually chosen  rs17026738   216586556  5’UTR  A/C 
2 rs17047682  216589648  Intron  1  A/G 
3 rs2799097  216591255  Intron  1  A/G 
4 rs17047703  216592211  Intron  1  C/A 
5 rs17558745  216615144  Intron  1  C/T 
6 rs2796817  216617631  Intron  1  T/G 
7 rs2799085    216619078  Intron  1  A/C 
8 rs3892225  216619920  Intron  1  A/G 
9 rs2009112  216620152  Intron  1  C/T 
10 rs10482751  216622920  Intron  1  C/T 
11 rs2027566  216624950  Intron  1  C/A 
12 rs2027567  216625211  Intron  1  G/A 
13 rs2796814  216628204  Intron  1  C/G 
14 rs947712  216631504  Intron  1  C/T 
15 rs10779329  216640364  Intron  1  T/C 
16 rs1317681  216641825  Intron  1  G/A 
17 rs2796821  216652444  Intron  2  C/T 
18 rs1342586  216664482  Intron  2  C/T 
19 rs2798631  216678501  Intron  6  A/G 
20 rs1473526  216687370  Downstream  T/C                                                                                                                   Chapter 2 Materials and Methods 
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Figure 2–5: The relative position of 27 SNPs for LMX1B, on chromosome 9q32-
q34.1. 
The relative position of the 26 tSNPs with the additional non-synonymous SNP (chosen 
manually) is shown. 8 coding exons are indicated as solid boxes and numbered 
accordingly. Untranslated exons are shown as open boxes. 
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Table 2–4: Selected SNPs for LMX1B  
tSNP 
no 
Reference ID  Position  Type  Polymorphism  Amino acid 
change 
1 rs10760443  128435167  Intron  2  C/T   
2 rs10448285  128436835  Intron  2  C/T   
3 rs12336217  128439691  Intron  2  A/G   
4 rs7859156  128439849  Intron  2  C/T   
5 rs7858338  128446465  Intron  2  T/C   
6 rs10819190  128448334  Intron  2  G/A   
7 rs6478750  128449019  Intron  2  C/T   
8 rs10987385  128453030  Intron  2  G/A   
9 rs13285227  128453119  Intron  2  C/T   
10 rs944103  128453311  Intron  2  C/T   
11 rs12555176  128454124  Intron  2  G/T   
12 rs7854658  128454759  Intron  2  G/A   
13 rs10987386  128456138  Intron  2  C/T   
14 rs7857133  128460457  Intron  2  G/A   
15 rs10819195  128462604  Intron  2  G/A   
16 rs12343574  128480661  Intron  2  A/C   
17 rs10987411  128490260  Intron  2  C/T   
Manually chosen  rs28939692 
(c.599G>A) 
128495350 Exon  4  (non 
synonymous) 
G/A arginine  to 
glutamine 
18 rs10987413  128499259  Downstream  G/A   
19 rs10760450  128499449  Downstream  C/T   
20 rs16929236  128499806  Downstream  A/G   
21 rs10733682  128500735  Downstream  A/G   
22 rs4083644  128501535  Downstream  C/T   
23 rs10987417  128502322  Downstream  G/T   
24 rs867559  128505146  Downstream  A/G   
25 rs13287548  128506277  Downstream  C/T   
26 rs2149724  128506589  Downstream  C/G                                                                                                                     Chapter 2 Materials and Methods 
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Figure 2–6: The relative position of the chosen SNP (rs28939688) in OPTN in exon 
4 (on chromosome 10p15-p14) which causes a c.458G>A transition (otherwise 
known as E50K mutation).  
16 coding exons are indicated as solid boxes and numbered accordingly. Untranslated 
exons are shown as open boxes. 
 
 
 
 
 
Table 2–5: Selected SNP for OPTN 
tSNP 
no 
Reference ID  Position  Type  Polymorphism  Amino acid  
change 
1 rs28939688  28495350 
( c.148G>A) 
exon 4 (non- 
synonymous) 
G/A glutamic  acid 
to lysine                                                                                                                   Chapter 2 Materials and Methods 
  117
(Figure 2-6, Table 2-5). For TGFβ2, two 5’ UTR SNPs rs114663679 and rs17026738 
were chosen (22 SNPs in total when combined with SNPs selected from HapMap). The 
5' UTR is a particular section of messenger RNA (mRNA) and precedes the translation 
initiation site of the gene, bounded on the 5' end by the start of transcription and on the 
3' end by the start codon. Several regulatory sequences may be found in the 5' UTR, 
such as binding sites for proteins that may affect the mRNA's stability or translation, 
and sequences that promote the initiation of translation. In addition, as genes were likely 
have long range regulatory sequences (Flomen et al., 1998), in silico sequence 
alignment analysis using zPicture software programme (available at 
zPicture.decode.org) was performed on 100kb of flanking sequences in addition to 
introns, and polymorphic SNPs within the identified evolutionarily conserved regions 
between chick/mouse/human genome sequences were sought. However, common SNPs 
were not present within these regions and were not selected for any of the candidate 
genes. A total number of 58 SNPs were analysed in cohort 1.  
 
For the replication study using cohort 2, out of the initial 26 tSNPs chosen for LMX1B, 
11 tSNPs (rs12336217, rs7859156, rs10819190, rs10987385, rs13285227, rs944103, 
rs12555176, rs7854658, rs10987386, rs16929236, and rs867559) were analysed. 
 
2.7  Application of Pyrosequencer, real time PCR and Sequenom iPLEX
TM Assay 
MassARRAY® 
 
Due to the ease of access of an onsite pyrosequencer, SNPs were genotyped initially 
using a Pyrosequencer (PyroMark Q96 MD, Qiagen; Hilden, Germany) to obtain 
preliminary results. However, the pyrosequencing technique proved to be a costly and 
laborious method and was subsequently discontinued from further SNP genotyping. 
Instead the one-step TaqMan assays with an ABI 7500 Fast Real-Time PCR System 
(Applied Biosystems; Foster City, CA) was utilized. Subsequently, to achieve high-
throughput genotyping, Sequenom iPLEX
TM assay MassARRAY® was utilized through 
a commercially available service based at the Wellcome Trust Centre for Human 
Genetics in Oxford (http://www.well.ox.ac.uk/).  
 
A pilot study previously performed by Mr Fraser and Dr Daniela Vaideanu (Sunderland 
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of 105 glaucoma patients. Their preliminary analysis suggested a significantly increased 
prevalence in the disease population of a single polymorphic SNP rs2739202 in the 
untranslated region of PITX2. To explore this observation in a larger cohort, by using 
the algorithm tagger in Haploview v.4.0, 7 tSNPs in the PITX2 gene with a MAF of 
≥10% and a minimum r
2 value of 0.8 were selected (Table 2.6).  However, analysis of 
139 HTG subjects found no evidence for variation of the putative rs2739202 SNP and 
further analysis of this gene was not carried out. Overall, 4 to 5 months of laboratory 
work was spent on pyrosequencing and determining the best genotyping methodology. 
 
2.7.1  Pyrosequencer 
Pyrosequencing is a direct DNA sequencing technique which enables high capacity 
genetic analysis. Each nucleotide is dispensed and tested individually for its 
incorporation into the emerging DNA template. Short stretches of sequence are 
examined adjacent to a defined start point. By using a cocktail of enzymes, it performs 
DNA sequencing through a synthesis approach, where by, it couples the release of 
pyrophosphate that occurs when deoxyribonucleotide triphosphate (dNTP) is added to a 
growing DNA chain, to light emission (Figure 2-7). It is catalysed by four enzymes, 
DNA polymerase, ATP sulfurylase, luciferase, and apyrase. For every base 
incorporated, there is a quantitative release of light where the peak height represents the 
amount of nucleotide incorporated, and this is represented as a pyrogram. Nucleotide 
sequence is determined from the order of which the nucleotide is dispensed and peak 
height in the program.  
 
In this study, the template DNA required for pyrosequencing was obtained from 
polymerase chain reaction (PCR), which amplified the region of the genomic DNA of 
interest, to a significant amount to allow for sequencing. Three primers were utilised for 
this reaction; a) 2 primers for PCR, one of which was biotinylated, to allow separation 
of double stranded PCR product into a single stranded DNA and; b) a sequencing 
primer to enable pyrosequencing (Figure 2-8). 
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Figure 2–7: Summary of pyrosequencing reaction.  
Sequencing primer hybridises to PCR amplified single standed DNA template. 
Pyrosequencer adds enzymes (DNA polymerase, ATP sulfurylase, luciferase and 
apyrase) and substrates (adenosine 5’phosphosulphate, luciferin). Individual bases are 
added one at a time. Each incorporation event is accompanied by release of 
pyrophosphate (PPi) in a quantity equimolar to the amount of incorporated nucleotide. 
Sulfurylase converts PPi to ATP. ATP drives luciferin to oxyluciferase which generates 
visible light in amounts that are proportional to the amount of incorporated nucleotide. 
Unincorporated dNTPs and ATP are degraded by apyrase. Next base is added once all 
previous dNTPs and ATPs have been removed. The complementary DNA strand is built 
up and the nucleotide sequence is determined from the order of which the nucleotide is 
dispensed and the light peak in the program. Adapted from 
http://www.pyrosequencing.com/DynPage.aspx?id=8726&mn1=1366. 
 
 
 
luciferin  oxyluciferin 
APS+PPi
ATP
light 
time 
pyrogram 
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Figure 2–8: Primers for PCR/Pyrosequencing. 
A forward primer and a biotinylated reverse primer is used for PCR. Separation of 
double stranded DNA template to allow pyrosequencing is achieved through binding of 
biotinylated DNA strand to a stepavidin-coated solid phase. A separate sequencing 
primer is used for pyrosequencing. 
 -Biotin 
ACGGTGTTCAGTGC/TAGAGATTTGCCTG 
Forward PCR primer 
Reverse PCR primer 
(biotinylated)
TGCCACAAGTCACG/ATCTCTAAACGGAC-Biotin
Biotinylated lower strand
TGCCACAAGTCACG/ATCTCTAAACGGAC  
Sequence to analyze: GC/TAGAG
Seq. primer
Separation of dsDNA through binding of biotinylated 
DNA strand to a stepavidin-coated solid phase 
Pyrosequencing 
SNP
PCR                                                                                                                   Chapter 2 Materials and Methods 
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2.7.1.1  Primers 
Primer sequences were designed using the Biotage assay design software version 1.0.6 
(Table 2-6) and the primers were obtained from Operon. Each primer set consisted of a 
high performance liquid chromatography (HPLC) purified, biotinylated forward primer, 
and a standard reverse primer for the PCR, and a HPLC purified sequencing primer (S) 
for pyrosequencing reaction. Biotinylation was required for separation of double 
stranded PCR product into a single stranded DNA for pyrosequencing. This was 
achieved by transferring it through a strepavidin-coated solid phase. These primers were 
15 to 23 base pairs long. The amplified target fragments were 87-198 bp in length. The 
primers contained a relatively balanced GC-AT content (33.3-66.7% GC). 
 
Prior to usage, primer stock solutions were prepared at 100µM with TE followed by 
further dilution by 10 times to 10µM with sterile Milli-Q® water. 
 
2.7.1.2  PCR 
A master mix (Table 2-7) was prepared on ice prior to aliquoting into separate tubes. 
This was to ensure reproducibility of dispensing the same mixture of reagents into each 
tube. All of the reagents were obtained from Roche except for the primers, which were 
obtained from Operon. The PCR machine utilised for this study was a PCR-100™ 
Programmable Thermal Controller (MJ Research). For each PCR reaction, a positive 
control and at least two negative controls (i.e. every thing except the DNA) were 
included. 
 
The PCR consisted of a series of cycles of three successive reactions as shown in table 
2-8.
 The annealing temperature and the number of cycles were optimized empirically 
(Table 2-6) by running a PCR reaction on a temperature gradient (annealing temperature 
varying between 50 to 65 ° C) and varying the number of cycles from 40 to 50 cycles.                                                                                                                   Chapter 2 Materials and Methods 
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Table 2–6: Primers for PITX2 SNPs 
SNP ID  Primer sequences 
(5’-3’) 
Product 
(bp) 
Cycles Tm 
(°C) 
rs976568 
 
(F) AAT AGC TTTG GCC CAG TGG A 
(R) CGC GTG TGA AGG TGT TGT C 
(S) AAG TCG CTG GTG TGC 
134 40  55 
rs1982361  (F) TTC TGC TAC GAG CGC CTC TTA A 
(R) AGT TAC AGG ACA CCG GAA AGT GC 
(S) TGA GTA ATG GGC TAA TAA TC 
156 40  55 
rs2278782  (F) CGG CCT GGT TGC GAG ATT A 
(R) TCG TGA GAT CGC GGG ATG 
(S) GCC TCG GAG AGG GAA 
112 40  60 
rs2595110  (F) TGG ACT TTA ATG GCT CAA GAC AG 
(R) TGC CAA ATA ACC AAT TTC AAG GA 
(S) CAG CCT TGA GCT CAC 
87 40 
 
50 
rs2739202  (F) GCA TGT TAT ACA GAA GCG ATT AGG 
(R) CGA AAT GTT ATA CAC AGG GTA GGT 
(S) CAT CAT TGC ATC CAC C 
198 40  55 
rs4834295  (F) ACC CCC TTA AAA AAA AAA ACT CG 
(R) CCA GGT TCC CAA ACA TTT CAT TA 
(S) ACC ATT TTC TCA AGT TCA 
70 40  55 
rs7668322  (F) AGG AGG GGG CAT TTG CTA A 
(R) ACC TAG GAA AAC TGT GGC AGT AA 
(S) CAG CAT GTT CGT TGA GT 
87 40  55 
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Table 2–7: Reagents for PCR 
1×50 µl reaction  Master mix of 
7 reactions 
Reagent 
volume (µl) volume  (µl) 
10µM primer (forward) 
(Operon) 
1 ---- 
10µM primer (reverse) 
(Operon) 
1          ---- 
FastStart Taq DNA polymerase 
(5U/µl) 
0.2 ---- 
MgCl2 (25mM) 5  35 
dNTPs (2.5mM)  5  35 
Buffer 5  35 
Sterile Milli-Q® water    31.8  222.6 
Genomic DNA (20ng/µl)  1 ---- 
Total volume   50  327.6 
 
 
 
 
 
Table 2–8: Program for PCR cycles  
Reaction step  Temperature 
(°C) 
Duration 
(mm:ss) 
Nature of reaction 
1a 
1b 
95 
95 
04:00 
00:30 
Denaturation 
Separation of DNA strand 
2 50-60  00:30  Primer  annealing 
3a 
3b 
72 
72 
00:30 
05:00 
DNA synthesis (transcription) 
DNA synthesis (elongation) 
Cycle 
repeated 
for 39 
times 
 
3c  4  24:00  DNA preservation following 
end of reaction 
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2.7.1.3  Agarose gel electrophoresis 
The PCR products were run on a 1.5% agarose gel electrophoresis containing 1µl/ml of 
0.0025% ethidium bromide. The same method as described in section 2.4 was used to 
prepare the agarose gel and to analyse the PCR products. The PCR product sizes were 
ensured that they were of correct size and the quality of the DNA was assessed by 
choosing an annealing temperature as high as possible (to increase specificity of 
annealing) that produced a single bright band.  
 
2.7.1.4  Pyrosequencing preparation 
2.7.1.4.1  Preparation of strepavidin-coated sepharose beads 
Strepavidin-coated sepharose beads (from Amersham, catalogue number 17-5113-01) 
was resuspended to obtain a homogenous solution by shaking the the 5ml bottle. 500 µl 
of this was transferred into a sterile eppendorf containing 500 µl of binding buffer (10 
mM Tris-HCL; 2M NaCl; 1 mM EDTA; 0.1 % Tween
TM 20). This was then spun at 
1000 rpm (1300 x g) in a Biofuge Pico Heraeus centrifuge. The supernatant was then 
carefully discarded with a pipette. These steps were repeated once more to provide a 
total of 2 washes. The beads were then resuspended in a 500 µl of binding buffer and 
were stored at 4°C. 
 
2.7.1.4.2  Strand separation 
The prepared streptavidin Sepharose beads were shaken until homogenous solution was 
obtained. 2 µl of bead solution was pipetted into an eppendorf containing 38 µl of 
binding buffer (per sample). This was then mixed to obtain a homogenous solution and 
was added into a skirted 96 well plate (Abgene, catalogue number AB800) containing 
10 µl of PCR product. The 96 well plate was placed onto a Monoshaker at maximum 
setting for at least 5 minutes to maintain dispersion of beads.  During this period, a 
mastermix of 0.3 µM sequencing primer in 15 µl of annealing buffer (pH 7.6 (20mM 
Tris-Acetate; 5 mM MgAc2)) was prepared and 15 µl of this was pipetted into the wells 
of the white pyrosequencing 96 well reaction plate.  The streptavidin-coated Sepharose 
bead and PCR mixture was transferred to a filter plate (Amersham Biosciences) and the                                                                                                                   Chapter 2 Materials and Methods 
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binding buffer was removed by vacuum. The biotinylated DNA attached to the 
streptavidin-coated Sepharose beads was denaturated in 120 ml of denaturation buffer 
(0.2 M NaOH) for 1 minute. The denaturation buffer was then removed by vacuum and 
the DNA was washed in 120 ml of wash Buffer (pH 7.6, 10 mM Tris-Acetate). The 
DNA is resuspended into the white pyrosequencing reaction plate containing the 15 ul 
of annealing buffer.  
 
2.7.1.4.3  Primer annealing 
This plate was covered with an adhesive film and was left on a pyrosequencing heat 
plate set at 80°C for 2 minutes, which allowed the sequencing primer to anneal to the 
target complementary DNA sequence. This was then left to cool for 5 minutes at room 
temperature.  
 
2.7.1.4.4  Sequencing reaction 
The enzyme (DNA polymerase, ATP sulfurylase, luciferase and apyrase) and substrate 
(adenosine 5’phosphate and luciferin) was dissolved in 620 µl of 18.2 mΏ double 
distilled water and swirled gently to mix solution. The reagents were left at room 
temperature for 5 – 10 minutes before loading into the corresponding pyrosequencing 
cartridge. The dNTPs were diluted to 50% using double distilled water and were also 
loaded into the corresponding cartridge. Sequencing of the DNA was commenced once 
the plate was placed on the Pyrosequencer. 
 
2.7.2  Real time PCR and Sequenom iPLEX
TM Assay MassARRAY® 
Due to the simplicity and ease of access of an onsite real time PCR, 4 SNPs in FOXC1 
(rs2235715, rs2569889, rs1051933, and rs984253), and one SNP in each of the 
following genes, LMX1B (rs28939692), BMP4 (rs17563), and OPTN (rs28939688) were 
initially genotyped using TaqMan
TM assays (Table 2-9) with the remaining 51 SNPs 
analysed using Sequenom iPLEX
TM Assay. The reason for choosing the latter method 
was due to its increased cost effectiveness and high-through-put nature for SNP 
genotyping. Array-based technologies such as Affymetrix chips or the Illumina bead 
arrays were not chosen for this study since such costly methods provide efficient SNP 
genotyping for thousands of SNPs, which was not the aim for this study. Solution-based                                                                                                                   Chapter 2 Materials and Methods 
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one-step procedures such as TaqMan assays using real-time fluorescent detection, or 
MALDI mass spectrometry-based procedures are particularly cost-effective in studies 
where up to 50 SNPs require typing.  
 
 
 
2.7.2.1  Real time PCR 
The ease of handling a one-step reaction lasting for less than 2 hours provided a suitable 
platform to initiate small scale SNP genotyping.  
 
2.7.2.1.1  Principles of allelic discrimination with TaqMan SNP genotyping assays 
The TaqMan SNP genotyping assay is a multiplexed, end point assay that detected 
variants of a single nucleic acid sequence. Each assay consists of two primers for 
amplifying the target sequence and two TaqMan minor groove binding (MGB) probes 
for the detection of alleles (Figure 2-9). The presence of two primer/probe pairs in each 
reaction enables analysis of two possible alleles at a SNP site in a target template 
sequence. Each TaqMan MGB probe contained a reporter dye (either VIC for allele 1 or 
FAM for allele 2) at the 5’ end of each probe, a minor groove binder (which produced. 
Table 2–9: ABI Assay ID for SNPs genotyped by real time PCR 
(https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=601283) 
SNP 
no 
SNP ID  Gene  ABI assay ID 
1 rs28939692  LMX1B  C_27541341_10 
2 rs2235715    FOXC1  C_15952927_10 
3 rs2569889  FOXC1 C_16045002_10 
4 rs1051933    FOXC1 C_8770138_10 
5 rs984253    FOXC1 C_11660541_20 
6 rs17563  BMP4  C_9597660_20 
7 rs28939688 
  
OPTN  C_27860341_10                                                                                                                   Chapter 2 Materials and Methods 
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Figure 2–9: Allelic discrimination with TaqMan SNP genotyping assays. 
The presence of 2 MGB probes allows allelic discrimination through selective annealing 
of probes labeled with either a VIC or a FAM reporter dye at the 5’ end. 1) The assay 
components consists of 2 MGB probes containing either VIC for allele C or FAM for 
allele T, a forward and a reverse primer, AmpliTaq Gold, and a double stranded DNA 
template. 2) Denaturing of the double stranded DNA template allows annealing of assay 
components. 3) Polymerisation of the MGB probe for allele C results in subsequent 
cleavage of the reporter dye VIC by AmpliTaq Gold. Note the presence of a non-
fluorescent quencher at the 3’ end which suppresses fluorescence of the reporter dye 
FAM by its close proximity when the probe is not annealed to the complementary DNA. 
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accurate allelic discrimination by increasing the melting temperature (Tm) without 
increasing the probe length), and a non-fluorescent quencher (NFQ) at the 3’ end of the 
probe  When the probe was not hybridised to its complementary sequence and remained 
intact, the quencher dye prevented the reporter dye from fluorescence due to their 
proximity. However, probes that were hybridized to their target sequence were cleaved 
by AmpliTaq Gold
® and as a result separated the reporter dye from the quencher dye. 
This allowed fluorescence by the reporter. Hence fluorescence signaling occurred when 
the target sequence was complementary to the probe, and allelic differentiation was 
indicated by whether the fluorescent signal was a FAM or a VIC dye. 
 
2.7.2.1.2  SNP genotyping for FOXC1, BMP4, LMX1B and OPTN with Applied 
Biosystems 7500 fast real time PCR 
 Four SNPs located in FOXC1 (rs2235715 (intronic), rs2569889 (intronic), rs1051933 
(exonic; non synonymous), and rs984253 (intronic)), and one SNP located in BMP4 
(rs17563; exonic), LMX1B (rs28939692; exonic), and OPTN (rs28939688; exonic) were 
initially evaluated.  
 
The following components were used for the reaction plate: 
•  2× TaqMan Universal PCR Master Mix, No AmpErase UNG 
•  20× SNP Genotyping Assay Mix 
•  1-20 ng of genomic DNA in TE solution 
 
The final volume of the reaction mix was 20 µL. The volume of the components for 
each well on a 96 well reaction plate is shown in Table 2-10. Each well contained 20 ng 
genomic DNA, 1 µL SNP Genotyping Assay mix (containing probes and primers), 10 
µL TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems; 
Foster City, CA), and 9 µL water. Two “no template” controls and a known genomic 
DNA control were included for each reaction plate. This was run on a ABI 7500 Fast 
system with the program outlined in Table 2-11. The DNA was amplified with the cycle 
settings as follows: 95ºC for 10 min, followed by 40 cycles of 92ºC for 15 sec and 60ºC 
for 1 min. Fluorescent signals were detected and analysed for allelic discrimination 
using the Sequence Detection System version 1.3.1 software (Applied Biosystems). 
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Table 2–10: Real time PCR reaction components 
Component  Volume 
(µL/reaction) 
2× TaqMan Universal PCR Master Mix, 
No AmpErase UNG 
10 
2× SNP Genotyping Assay Mix  1 
Genomic DNA (1-20 ng)  9 
Total 20 
Table 2–11: Program for real time PCR cycles 
Reaction step  Temperature 
(°C) 
Duration 
(mm:ss) 
Nature of reaction 
1  95  10:00  AmpliTaq Gold® DNA 
polymerase activation 
 
Cycle  
repeated  
for 40  
times 
2a 
 
2b 
 
92 
 
60 
00:15 
 
01:00 
Separation of DNA 
strand 
 
Primer annealing/DNA 
synthesis                                                                                                                   Chapter 2 Materials and Methods 
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2.7.2.2  Sequenom iPLEX
TM Assay MassARRAY® 
 
The remaining tSNPs, including one tSNP in FOXC1, 26 SNPs in LMX1B, 4 tSNPs in 
BMP4 and 22 SNPs in TGFβ2, were genotyped using Sequenom iPLEX
TM  Assay 
MassARRAY technology through a commercially available service based at the 
Wellcome Trust Centre for Human Genetics in Oxford (http://www.well.ox.ac.uk/). For 
the replication study on cohort two, Sequenom Mass Array technology was also utilized 
to genotype 11 tSNPs in LMX1B (rs12336217, rs7859156, rs10819190, rs10987385, 
rs13285227, rs944103, rs12555176, rs7854658, rs10987386, rs16929236, and 
rs867559). 
 
2.7.2.2.1  The principles of Sequenom iPLEX Assay MassARRAY 
The main differences with Sequenom MassARRAY from that of TaqMan SNP 
genotyping assays is that no labeling and clustering of signals are required for 
Sequenom, and instead the detection is based on a physical property (the mass to charge 
ratio) of target sequences by using the matrix-assisted laser desorption-ionisation time-
flight mass spectrometry (MALDI-TOF MS) based technology. This allows a direct 
detection of the end product and the speed and accuracy of MALDI-TOF MS offers 
high-throughput   genotyping.  In addition, Sequenom is capable of performing multiple 
PCR and iPLEX reactions in a single well (multiplexing) which allows further increase 
in throughput and reduced cost per genotyping reaction. 
 
The iPLEX assay is based on the annealing of a specific oligonucleotide primer adjacent 
to the SNP of interest (Figure 2-10). The addition of a mixture of a DNA polymerase 
with terminator nucleotides allows the extension of the primer into the SNP site and 
generates an allele of specific mass, which is terminated after a single base extension. 
Each allele-specific extension product has a unique molecular mass which is then 
analysed by MALDI-TOF MS and a genotype is assigned in real time. Since the mass 
separation of small base extension (SBE) is small, this prohibits the routine use of high  
throughput SNP genotyping. The iPLEX assay alleviates this problem by incorporating 
mass-modified terminators which increases the mass differences of SBE products. This                                                                                                                    Chapter 2 Materials and Methods 
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Figure 2–10: Sequenom iPLEX Assay MassARRAY 
SNP genotyping with iPLEX assays is divided into 3 parts: 1) primary multiplexing 
PCR amplification of a small region of genomic DNA containing the SNP with a 
forward and a reverse primer; 2) iPLEX reaction to genotype SNP with a single primer; 
and 3) the final spectrum analysis. Genomic DNA is amplified using PCR primers 
tagged to a 10-mer (5’-ACGTTGGATG-3’). The tags increase the masses of unused 
PCR primers, and by doing so falls outside the mass range of analytic peaks. Shrimp 
alkaline phosphatase (SAP) enzyme is utilized to dephosphorylate unincorporated 
dNTPs from the end product of PCR. The iPLEX assay is based on the annealing of an 
oligonucleotide primer adjacent to the SNP of interest. The addition of a mixture of a 
DNA polymerase with terminator nucleotides allows the extension of the primer into 
the SNP site and generates allele and mass specific products and is terminated after a 
single base extension. Each allele-specific extension product has a unique molecular 
mass which is then analysed by MALDI- TOF MS and a genotype is assigned in real 
time. A nanodispenser is used to dispense the reaction products onto a SpectroCHIP 
bioarray, where upon it is analysed. 
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ensures no two alleles are within 15Da of each other. However, if DNA samples are 
contaminated or not properly desalted by either sodium (22Da) and potassium (38Da), 
this can reduce the allelic discriminative ability between A/C (24Da) and C/G (40Da). 
Even in such circumstances, the peaks generated by these contaminates are relatively 
much smaller to their parent signal and this property can be used to distinguish between 
them. 
 
Essentially, SNP genotyping with Sequenom MassARRAY involved three steps, 
requiring 3 primers for each SNP: 
 
1.  Designing assays.  
2.  Carrying out a primary multiplexing PCR reaction to amplify regions of genomic 
DNA containing the SNPs of interest. This involved the presence of several forward 
and reverse primers to cover all the SNPs in each multiplex group (Table 2-12 and 
2-13).  
3.  Performing a multiplexing iPLEX reaction to genotype SNPs using several single 
primers of distinct mass each specific for one genotype.  
 
2.7.2.2.2  Assay design 
PCR and iPLEX assays (including the primers for each SNP) were created by using 
Assay Design 3.0 software (Table 2-14) when the upstream and downstream flanking 
sequences were available. For these assays, a quality control measure was applied, 
whereby, the selected primer assays were tested on CEPH DNAs and the genotypes 
compared with that of the HapMap data. This allows us to assess whether the results 
were either concordant or disconcordant with the HapMap data, with any assays 
producing disconcordant results being excluded from the study. 
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Table 2–12: Two sets of multiplex reactions (Plex 1 and 2) for the first cohort 
as recommended by the MassARRAY Assay Design 3.0 software. 
SNPs are colour coded according to the gene they are representing: colour green 
represents SNPs for TGFβ2; yellow represents SNPs for LMX1B; red represents 
SNPs for BMP4; and purple represents SNPs for FOXC1. 
Multiplex reaction  SNP ID 
Plex 1  rs10448285,  rs10819195,  rs2027567,   
rs10733682,  rs10987386,   rs1473526, 
rs10987411,  rs13287548,  rs17047703,     
rs13285227,  rs12343574,  rs2796817,  
rs16929236,  rs944103,      rs2009112,  
rs2149724,     rs10482751, rs2799085,   
rs6478750,    rs10495098,  rs2796821,       
rs7854658,,   rs2798631,     rs8014363, 
rs7858338,    rs3892225,    rs2761884,     
rs7859156,    rs2027566,     rs11623717, 
rs867559,      rs947712,       rs2235716   
Plex 2  rs10760443,  rs10760450,  rs10779329, 
rs10819190,  rs10987385,  rs1317681, 
rs10987417,  rs12336217,  rs1342586, 
rs10987413,  rs7857133,    rs2799097, 
rs4083644,    rs17047682,  rs2796814, 
rs12555176,  rs17558745,  rs8014071   
Table 2–13: One set of multiplex reactions for the replication study on LMX1B as 
recommended by the MassARRAY Assay Design 3.0 software. 
Multiplex reaction  SNP ID 
Plex 1  rs12336217,  rs7859156,    rs10819190, 
rs10987385,  rs13285227,  rs944103, 
rs12555176,  rs7854658,    rs10987386, 
rs16929236,  rs867559                                                                                                                   Chapter 2 Materials and Methods 
  134
 
 
Table 2–14: Forward, reverse, and extension primers for the selected SNPs in FOXC1, 
BMP4, TGFβ2 and LMX1B for the PCR/iPLEX assays. 
 
SNP ID 
Forward and reverse primer for PCR 
amplification 
Amplification 
Length (bp) 
Extension primer for iPLEX 
reaction 
98 
rs3892225 
F:ACGTTGGATGGTGCCTGGAGTATATGAAGC 
R:ACGTTGGATGTCCACAGTTGGTATTTAGTC    AGCACCGCATCGGTA 
rs7859156 
F:ACGTTGGATGAGAGCCAGCCCAGGTTTCG 
R:ACGTTGGATGCAGTCACCCATCATCACCC  100 CGGCGGGAATTTCCT 
rs13287548 
F:ACGTTGGATGAGTGCAGTGGCAGGTCAATG 
R:ACGTTGGATGACCCAGCAGCCTTCTCCCAA  100 AGGGTGGTCAGCTGG 
rs867559 
F:ACGTTGGATGGAAAGCCCCATTAATCCTCC 
R:ACGTTGGATGCACTGAGGCTCAGAGAAATC  92 GCTGTGCAGTCTGGG 
rs10733682 
F:ACGTTGGATGTGTGTCCCCTTGTTCAGGTG 
R:ACGTTGGATGAGGCAGACTTTAGGGTGGTG  100 GGTGCTCACAACCCT 
rs16929236 
F:ACGTTGGATGCAGGGTGAATCTCTAAGGTC 
R:ACGTTGGATGTGGCACCCTTCCTCTGTTAA  91 GGCCAAATCATTGTCTT 
rs2009112 
F:ACGTTGGATGTACCTATCAAAGTCGCTGCC 
R:ACGTTGGATGAGGGACACATGATTGGTCAC  100 CTCGCATTCATTGGAAG 
rs944103 
F:ACGTTGGATGTCTCCCTCCTTCTCTCCGTG 
R:ACGTTGGATGTTATTTATGCCCAGGAGCAG  97 ACTGATCCTCCTCCATCC 
rs10987386 
F:ACGTTGGATGCAGGCTTGGTCTTGCCAATC 
R:ACGTTGGATGTATCCTAAGAATGGTGGAGC  96 TGCCATACCCCGATC 
rs1473526 
F:ACGTTGGATGAGAGGGTTTCCAACTCCAGG 
R:ACGTTGGATGCAACCCAACTGAAAGAACAC  100 TCGGTGATGTCACCTG 
rs2235716 
F:ACGTTGGATGGAAAAAAGAGAGCTCCTTC 
R:ACGTTGGATGTGTAGGAATGTGTGTGCTGG  99 AGAGCTCCTTCTGGCTCC 
rs10819195 
F:ACGTTGGATGAGAGGGTAAGTGTCTTGTCC 
R:ACGTTGGATGTGTGGATGCTGCAGCCAGGT  100 TGTCTTGTCCAAAGTCTCA 
rs13285227 
F:ACGTTGGATGGATAAAGATAAACGGAATTG 
R:ACGTTGGATGGAGTCCTTCCCCATCACCG  99 GTAATTGAGTCTGCTAAGG 
rs7854658 
F:ACGTTGGATGAAGCAGTGCCCAGTCCAGTC 
R:ACGTTGGATGGCACAGAGTACATCTGCCC  97 CAGATCTGAGTCCCTTCTTT 
rs10987411 
F:ACGTTGGATGCTTCTCCAAAGGCTCAGTGC 
R:ACGTTGGATGACAGATGATACCCTGAGTGG  83 TCAGTGCCGCCATTAC 
rs2027567 
F:ACGTTGGATGCTGTCCACATATTCCAGAGG 
R:ACGTTGGATGGAAGGGTAGAGTAGAATTAG  99 CCAGAGGTCATTCAGAAA 
rs2761884 
F:ACGTTGGATGCTCCGGGCAGATTCAGAAAG 
R:ACGTTGGATGCTCGGCCACATTAAGATCTG  94 TTCAGAAAGAGGCGTC 
rs2149724 
F:ACGTTGGATGGTTGCTCTGAAGTCAAAGCC 
R:ACGTTGGATGTGACTCTATGCCAGGCAGAC  100 CCATGAACAGAGTCCCC 
rs6478750 
F:ACGTTGGATGCGACCCCTTGAACCTTAATG 
R:ACGTTGGATGAGGTCACAGTCTAACAAGGG  98 CTTAATGCTAGAGCACCT 
rs10482751 
F:ACGTTGGATGGGTGGTGTTTCTCTTTTGGC 
R:ACGTTGGATGAAAACAATCTTCTTACCCC  93 TCTCTTTTGGCTACTCATC 
rs10495098 
F:ACGTTGGATGCATTTACGGTTACCAGGGAG 
R:ACGTTGGATGCACCTCTCAAATGATCAGTTC  96 GACAGCTCTAGCAATCTTGCC                                                                                                                   Chapter 2 Materials and Methods 
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rs17047703 
F:ACGTTGGATGCTTCCGCTATCTTGATGTAG 
R:ACGTTGGATGGCAAGCACATCTGGCAAATC  98 GATGTAGCATTTCCGGTA 
rs2796817 
F:ACGTTGGATGACTCTTCTGCTGGTCGCCTG 
R:ACGTTGGATGATAGGCCACGACTGGACTTC  100 CTGGTCGCCTGCCCCTATGT 
rs2799085 
F:ACGTTGGATGTAAAAGCAGACCGAGAACAC 
R:ACGTTGGATGGAGACTCCGTCTCTAAAAAAG  98 GACCGAGAACACATGGTAC 
rs947712 
F:ACGTTGGATGGTGAGTTTTGGGGATTGAATG 
R:ACGTTGGATGTAAATGATACTGCAGGGCAC  100 CATCAACGATTCTTCATTTTATTA 
rs11623717 
F:ACGTTGGATGGTTTCGGCATTTACTATTT 
R:ACGTTGGATGAAAGCAACGCCGAGAATCAC  99 GCATTTACTATTTTTGCCTAATA 
rs7858338 
F:ACGTTGGATGCTATTGATCGACCGACTGGC 
R:ACGTTGGATGTGAGCCTGACTCCACCATC  99 CCAAGTCAGCATTTAAGCTTTAA 
rs2796821 
F:ACGTTGGATGTGAAACAGGAGTGGGTTTGG 
R:ACGTTGGATGAGTACGCACACTGAAACACG  100 GGTTAATTGGTATGCATAGTATTA 
rs10448285 
F:ACGTTGGATGCTACTGTCCAGGTTGTTGTA 
R:ACGTTGGATGTCTTCCAGGTACACTCGCAG  100 TGTTGTAGGGATTAATTTTGTAG 
rs2798631 
F:ACGTTGGATGGCCAAACTCAAGAGTTGATA 
R:ACGTTGGATGGAGAAACGAATTTTCAAGTC  90 AACTCAAGAGTTGATATGAAGTAC 
rs2027566 
F:ACGTTGGATGGAAGGGTTCACTCTGGTTTC 
R:ACGTTGGATGCGATGCCACAATGATGTCAC  99 ATAATAATACGAGCCATCTGCC 
rs12343574 
F:ACGTTGGATGAGGATGGGTGGTTTTCAATG 
R:ACGTTGGATGGCATGTTTTTATCACCTGCC  100 AATGTTAACAAAATTACCAAAGTTTA 
rs8014363 
F:ACGTTGGATGGGCCTAAGAATCTCTAACAT 
R:ACGTTGGATGGGTAAATAAAAGTGATTGTTG  100 AGATTAACATTTAATTTAAATACAACAA 
rs4083644 
F:ACGTTGGATGTCACAAACCCCCGAATCCAG 
R:ACGTTGGATGAACAGTCTGTGGGTCACAAG  99 ACCCCATGCCAGGAG 
rs1342586 
F:ACGTTGGATGCTTCTACATCACCTGGGAAC 
R:ACGTTGGATGCCCCAGAGCCTCTGATTTAA  100 CAGATTCTTGGGCCTC 
rs10779329 
F:ACGTTGGATGTTGTGCTCACTTGGGCATGG 
R:ACGTTGGATGAGTTTTAGGGCAAGGGTCTC  99 GTGACAGGAGACTTTCA 
rs7857133 
F:ACGTTGGATGACTAGCTCTGGATCCCTTTG 
R:ACGTTGGATGGGGGAGGGCCAGCCGAAT  98 GGGTAACAGCAAGCCA 
rs12555176 
F:ACGTTGGATGTCAAGGGTCCTGGCTGTTGG 
R:ACGTTGGATGGTAGTGGCCAGAGATGGGG  100 CCCCAAGCCTTGGAGTAT 
rs12336217 
F:ACGTTGGATGGCCATTGTGGGCTAATGTGT 
R:ACGTTGGATGTCCATACATCACACCCGCAG  100 GGGCTAATGTGTCAGGGC 
rs10760443 
F:ACGTTGGATGGAGTAGGGAGAGTTTTCCAG 
R:ACGTTGGATGTACTCAGGCTGTGGTGGTTG  100 AGAAGAAAGGATGATGGA 
rs2796814 
F:ACGTTGGATGACTGCCTTGGACAGGCAATC 
R:ACGTTGGATGAGCAAAGGGATCAACTGGAG  93 CAGCCTAAACACAGACAGA 
rs10987385 
F:ACGTTGGATGTGCAGAACCCAGCTTTTATG 
R:ACGTTGGATGCTAAATTGGCTACATGACAC  96 CGGGGCACACTTAGA 
rs3796902 
F:ACGTTGGATGAAACTACCCTTTCCGGGTTC 
R:ACGTTGGATGAAAGACCACCTCTTCGTCAG  97 GAGTTTAATATGCCAAGCTC 
rs10760450 
F:ACGTTGGATGCTCTGTTGTCTGGTCTGATG 
R:ACGTTGGATGACCAACTCTAGAGGCAGATG  80 TGGTCTGATGCTACCT 
rs17558745 
F:ACGTTGGATGGGGCCTCTATGTTTCTTTTG 
R:ACGTTGGATGCCAAAGGTTGACATCTTCAC  98 TCTTTTGCTTTGTATAACAGA 
rs10987413 
F:ACGTTGGATGAGAAGGGACAGGGATGCTCA 
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rs10987417 
F:ACGTTGGATGCAAGAGTCAGACCAAGGTGC 
R:ACGTTGGATGTCCTAAGATGCCCAGCCAC  100 ACCAAGGTGCCAGCACA 
rs10819190 
F:ACGTTGGATGTCAGGCACACCTTCCTGCTT 
R:ACGTTGGATGTATGAAGTGACATGTCAGGG  100 ACACCTTCCTGCTTTTTTAGATA 
rs1317681 
F:ACGTTGGATGTCCCGACTGGGCATCAAGG 
R:ACGTTGGATGTTTGACCCTGCCTTTACTTC  100 CATCAAGGGGCCTTTTTG 
  F:ACGTTGGATGGATCCAGTTTATTTCCCCAG    
rs8014071  R:ACGTTGGATGCTTAGTCCCTTAATCACCTG  100  GTTTTAGACGAAATTCAGATAGA 
rs17047682 
F:ACGTTGGATGCCACATTGCTAAAAATATG 
R:ACGTTGGATGTTACAGATTGCTGATAGCCC  89 TATGTAGTCTGAACTTTATAAAATG 
rs2799097 
F:ACGTTGGATGGCTTTATGTAGTAAGCATTT 
R:ACGTTGGATGTATCTCATACACCCACATGC  99 TTACTATTTTATTTTTTAGGATTCTCT 
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2.7.2.2.3  PCR amplification 
Prior to the iPLEX reaction, the genomic DNA was amplified in 384 well plates using 
PCR primers tagged with a 10-mer (5’-ACGTTGGATG-3’). The tags increased the 
masses of unused PCR primers, and by doing so fell outside the mass range of 
analytical peaks. The SNPs were grouped (by the Assay Design 3.0 software to allow 
for multiplex reaction) in such a way that the combination of the assays used in each 
multiplex reaction was compatible with each other. Separate PCR reactions were 
performed for each multiplex group; there were two separate multiplex groups for 
cohort 1 (Plex 1 and 2) (Table 2-12) and one multiplex group for the subsequent cohort 
2 (Table 2-13). Quality control was provided by randomly including a non-DNA 
containing well. The various reagents used for a multiplex PCR reaction are shown in 
Table 2-15. 
Table 2–15: PCR reaction components for Sequenom 
Reagent  Concentration in 5µL  Volume (µl) 
(1 reaction) 
Volume (µl) 
(384 reactions) 
Nanopure H2O 
PCR Buffer with 
NA 3.70  1776 
MgCl2 (10x)   1.25x  1.24  600 
MgCl2 (25mM)   1.625mM  0.65  312 
dNTP mix (25mM)  500µM  0.20  96 
Primer mix  
(500nM each) 
100nM 2.00  960 
Genomic DNA  
(5-10ng/µL) 
5-10ng/reaction 2.00 960 
Hotstar Taq®  
(5U/µL) 
0.5U/reaction 0.20  96 
Total   10.00  4800                                                                                                                   Chapter 2 Materials and Methods 
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PCR reactions were run with the program outlined in Table 2-16 using a final reaction 
volume of 10µl in each well. 5µl of the PCR product was run on a 2% agarose gel to 
ensure that the PCR product was of good quality. The remaining 5µl was utilized for 
SNP genotyping (iPLEX reaction in section 2.7.2.2.4) 
 
 
 
Shrimp alkaline phosphatase (SAP) enzyme was utilized to dephosphorylate 
unincorporated dNTPs from the end product of PCR. This was achieved by adding 2µL 
of the SAP mix to each 10µL PCR reaction (Table 2.17), then gently vortexing the 
mixed samples, followed by incubation in a standard thermocycler with the temperature 
settings as follows: 
•  37°C for 20 minutes 
•  85°C for 5 minutes 
•  4°C until retrieval 
 
Table 2–16: Program for PCR amplification cycles for Sequenom 
Reaction step  Temperature 
(°C) 
Duration 
(mm:ss) 
Nature of reaction 
1a 
1b 
94 
94 
15:00 
00:20 
Denaturation 
Separation of DNA strand 
2 56  00:30  Primer  annealing 
3a 
3b 
72 
72 
01:00 
03:00 
DNA synthesis (transcription) 
DNA synthesis (elongation) 
Cycle 
repeated 
for 45 
times 
 
3c  4  24:00  DNA preservation following 
end of reaction 
Table 2–17: SAP treatment 
SAP Mix 
Reagent 
Volume (µL) 
(1 reaction) 
Volume (µL) 
(384 reactions) 
Nanopure H2O 
 
1.530 
 
734.4 
 
10x SAP buffer 
 
0.170 
 
81.6 
 
SAP enzyme (1U/µL) 
 
0.300 
 
144.0 
 
Total 
 
2.000 
 
960.0 
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2.7.2.2.4  iPLEX reaction 
In a similar fashion to the PCR reaction, iPLEX amplification was performed in 2 
separate multiplex reactions for cohort 1 (Table 2-12) and in 1 multiplex reaction for 
cohort 2 (Table 2-13) in a 384 well plate.  
 
The iPLEX amplification involved aliquoting 5µL of the PCR product into a 384 well 
plate and adding 2µL of the corresponding multiplex reaction mix (Table 2-18) 
followed by gentle vortexing. This was then subjected to a two-step 200 short cycle 
program in a standard thermocycler (Table 2-19).  
 
 
 
 
Table 2–18: iPLEX reaction mix 
Reagent 
(384rxns) 
 
Concentration 
in 9µL 
 
Volume  (1rxn) 
(µL) 
 
Volume  
(µL) 
 
Nanopure H2O  NA  0.755  362.40 
iPLEX Buffer (10x) 
 
0.222X 
 
0.200 
 
96.00 
 
iPLEX termination 
mix 
 
1X 
 
0.200 
 
96.00 
 
Primer mix (7µM: 
14µM- double the concentration 
for high mass primers) 
 
0.625uM (for low 
mass primers) 
1.25uM (for high 
mass primers) 
 
0.804 
 
 
385.92 
 
 
iPLEX enzyme  1X  0.041  19.68 
Total 
  
2.000 
 
960.00 
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During the iPLEX reaction, the reaction mix was denatured at 94°  C. Primers were 
annealed at 52° C for 5 seconds and extended at 80° C for 5 seconds. The annealing and 
extension cycle was repeated four more times for a total of fives cycles and then looped 
back to the denaturation step at 94° C for 5 seconds and proceeded sequentially through 
annealing and extension loop again. This cycle was repeated an additional 39 times to 
complete a total of 40 cycles. This in addition to the 5 cycles of annealing and extension 
steps added up to a total of 200 cycles (5×40). A final DNA extension at 72° C for three 
minutes was performed and then cooled to 4° C. 
 
2.7.2.2.5  Desalting of iPLEX reaction product and dispension onto SpectroCHIP
® 
Bioarrays  
The iPLEX reaction products were desalted by diluting with 25µL of water containing 
6mg of resin, to optimize for mass spectrometric analysis. This was left on a rotator for 
half an hour to ensure good mixture of the resins into the reaction mix followed by 
Table 2–19: Program for PCR cycles for iPLEX reaction 
Reaction step  Temperature
(°C) 
Duration 
(mm:ss) 
Nature of reaction 
1 
2 
94 
94 
00:30 
00:05 
Denaturation 
Separation of DNA 
strand 
3 52  00:05  Primer  annealing 
4 
 
5 
80 
 
72 
00:05 
 
03:00 
DNA synthesis 
(transcription) 
DNA synthesis 
(elongation) 
Cycle repeated 
for:  
   
   40 times 
                    
 
6 4  24:00  DNA  preservation 
following end of 
reaction 
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centrifuging at 4500rpm for 5 minutes to allow the resin to settle to the bottom of the 
well. 
 
A nanodispenser was used to dispense 15nL of the reaction products onto a 384-element 
SpectroCHIP bioarry. MassARRAY Workstation version 3.3 software was used to 
process and analyse iPLEX SpectroCHIP bioarrays (Figure 2-11). 
 
 
 
 
 
 
 
Figure 2–11: An example of the results displayed in Sequenom for rs13285227 
demonstrating a cluster plot (left side of the illustration) and a spectrum plot (on 
the right side of the illustration).  
The cluster plot demonstrates 3 clusters of low mass allele (C/C) and a high mass allele 
(T/T) and an intermediate mass allele (C/T). The spectrum plot shows the presence of a 
C allele and an absent of a T allele. 
Cluster plot 
showing 3 clusters 
of low mass allele 
vs. high mass 
allele 
High mass 
allele (T/T) 
Heterozygote 
cluster (C/T) 
Low mass 
allele (C/C) 
Spectra of the 
assay for 
rs13285227 
Presence of C 
allele  
Absent T allele                                                                                                                    Chapter 2 Materials and Methods 
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2.8  Sequencing of OPTN E50K mutation 
To validate the results of the prevalence of OPTN E50K mutation obtained from using 
TagMan SNP genotyping assay, the region of the genomic DNA containing the E50K 
mutation was sequenced using an Applied Biosystems 3730xl DNA Analyzer. 
Essentially, this method involved amplifying the region around the E50K mutation by 
PCR. Sequencing was achieved using a single primer (either a forward or a reverse 
primer) using Sanger dideoxy terminator method. All reagents for the PCR reaction 
were bought from Bioline other than the primers which were obtained from Invitrogen. 
The reagents used for the sequencing reaction were obtained from Applied Biosystems. 
 
Primer sequences were designed using Primer 3 software [available as a WWW 
interface (http://frodo.wi.mit.edu/)] (Table 2-20). The amplified target fragment was 
358 bp in length.  
 
2.8.1  PCR reaction for sequencing 
A master mix for the PCR reactions was prepared on ice prior to aliquoting into separate 
tubes (Table 2-21). This was to ensure reproducibility of dispensing the same mixture of 
reagents into each MicroAmp™ 8- tube strip (Applied Biosystems). For each PCR 
reaction, the master mix consisted of 2.5 µl of 10x NH4 PCR buffer, 2.5 µl of dNTP mix 
(2mM), 0.75 µl of MgCl2 (50mM), 0.1 µl of forward and reverse primer (100µM), 17.95 
µl of sterile Milli-Q® water, 0.1 µl of Biotaq™ polymerase (5U/µl), and 5-25ng of 
genomic DNA. The Applied Biosystems Veriti™ 96-Well Thermal Cycler PCR 
machine was utilised to carry out the PCR reactions. Quality control was provided for 
each set of PCR reactions by including a positive control and a negative blank control. 
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PCR reactions were run with the program outlined in Table 2-22, with a final reaction 
volume of 25µl. The PCR consisted of a series of cycles of three successive steps as 
shown in table 2-22.
 The annealing temperature was optimized empirically (Figure 2-
10) by running PCR reactions on a temperature gradient (annealing temperature varying 
between 53 to 60 ° C). An annealing temperature of 57° C was chosen as this produced 
the brightest band on 2.0% agarose gel electrophoresis (Figure 2-12).       
 
 
Table 2–20: Forward and reverse primers for PCR and sequencing reactions for 
E50K mutation 
SNP ID  Forward and reverse primer  Amplification 
length (bp) 
rs28939688  F: GGGACAGCTCTATTTTCAACA 
R: CAAATGCTAAATCCTGTGCTT 
358 
Table 2–21: PCR reaction components  
 
Reagent  Volume (µl) 
(1 reaction) 
Volume (µl) 
(10 reactions) 
10x NH4 PCR buffer  2.5  25 
dNTP mix (2mM)  2.5  25 
MgCl2 (50mM)  0.75  7.5 
Forward Primer 
(100µM) 
0.1 1.0 
Reverse Primer 
(100µM) 
0.1 1.0 
Sterile Milli-Q® water  17.95  179.5 
Biotaq™ polymerase (5U/µL) 0.1  1.0 
Genomic DNA  
(5-25ng/µL) 
1.0 960 
Total 25  250                                                                                                                   Chapter 2 Materials and Methods 
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Figure 2–12: Optimisation of annealing temperature.  
Gel electrophoresis showing three PCR products (each containing 2 genomic DNA 
controls and a no template DNA control) for the annealing temperatures 53 ºC, 57 ºC 
and 60 ºC. The annealing temperature of 57 ºC produced the brightest band. 
 
 
Table 2–22: Program for PCR amplification cycles for sequencing 
 
Reaction step  Temperature 
(°C) 
Duration 
(mm:ss) 
Nature of reaction 
1a 
1b 
95 
95 
02:00 
00:20 
Denaturation 
Separation of DNA strand 
2 57  00:20  Primer  annealing 
Cycle 
repeated 
for 35 
times 
 
3  72  00:30  DNA synthesis  
Annealing 
temperature  53ºC 57ºC 60ºC
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2.8.2  Post PCR clean-up 
Shrimp Alkaline Phosphatase (SAP) (Amersham Biosciences) and Exonuclease I (EXO 
I)
  (New England BioLabs) was used to prepare the PCR products for sequencing. 
Exonuclease I digests the single stranded PCR primers whilst SAP removes the 
phosphate groups from the excess dNTPs left over from the PCR. A master mix was 
prepared consisting of 1µl of the SAP, 0.3µl of EXO I, 0.9µl of SAP dilution buffer, 
0.3µl of sterile Milli-Q® water (Table 2.23). 2.5 µl of the master mix was then pipetted 
into 5µl of PCR reaction product. This was gently vortexed and incubated in a standard 
thermocycler with the temperature settings as follows: 
•  37°C for 30 minutes 
•  80°C for 5 minutes 
•  4°C until retrieval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2–23: Reagents used for cleaning of PCR products for sequencing. 
Components   Volume  
(µl/reaction) 
Exonuclease I (20,000 U/µl) 0.3 
Shrimp Alkaline Phosphatase (SAP) 
(1U/µl) 
1.0 
10x SAP Dilution Buffer  0.9 
Sterile Milli-Q® water  0.3 
Total 2.5                                                                                                                   Chapter 2 Materials and Methods 
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2.8.3  Automated cycle sequencing 
Sequencing was performed by Sanger dideoxy Terminator Method using BigDye® v1.1 
chemistry on an Applied Biosystems Veriti™ 96-Well Thermal Cycler PCR machine. 
 
2.8.3.1  Cycle sequencing reaction by Sanger Dideoxy terminator 
method  
The principle of automated cycle sequencing involves utilisation of dideoxynucleotides 
(ddNTPs) which lack the hydroxyl (OH) at the third carbon atom of the nucleotide base 
(3’). This OH group is essential for DNA chain extension since the 5’ phosphate group 
of dNTPs forms a covalent bond with the 3’ OH group, thus linking nucleotide bases. 
The lack of this OH group prevents the bonding of dNTPs to an incorporated ddNTP, 
resulting in the chain being terminated at such sites.  
 
During sequencing, the DNA template is denatured into a single strand. This, along with 
a single primer, four dNTPs, DNA polymerase and fluorescently labelled ddNTPs are 
added into the reaction mix. The primer anneals to its complementary region of the 
DNA and is extended by incorporating dNTPs, the reaction being driven by DNA 
polymerase. Random incorporation of ddNTPs terminates the sequencing reaction such 
that complementary strands of varying lengths are formed. At the end of the cycle, 
numerous fragments are generated, each having different lengths and a tagged 
nucleotide at the end. The reaction components ensure that the fragments of every 
possible length are generated.  
 
All the reagents for the cycle sequencing reactions were obtained from Applied 
Biosystems. Two master mixes was prepared, each consisting of 1µl of either the 
forward and reverse primer respectively (stock solution prepared at 100µM with TE 
followed by further dilution by 20 times to 5µM with sterile Milli-Q® water). Both 
primers were the same primers used for the prior PCR reactions (section 2.8.1). Each 
master mix also contained 0.5µl of BigDye® Terminator v1.1 Cycle Sequencing Ready 
Reaction Mix, 1.5µl of 5x BigDye® Terminator v1.1 sequencing buffer, and 2µl of 
ddH2O (Table 2-24). 5µl of the master mix was then pipetted into another MicroAmp™                                                                                                                   Chapter 2 Materials and Methods 
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8- tube strip (Applied Biosystems) containing 3µl of the PCR product. Using the same 
PCR machine, cycle sequencing reactions were carried out with the parameters as 
shown in Table 2-25.  
 
 
 
 
 
 
 
 
Table 2–24: Cycle sequencing reaction components 
 
Component  Volume 
(µL/reaction) 
BigDye® Terminator v1.1 Cycle 
Sequencing Ready Reaction Mix 
0.5 
5×  BigDye® Terminator v1.1 Cycle 
Sequencing Buffer 
1.5 
Sterile Milli-Q® water  2.0 
Primer (5µM)   1.0 
Total 5.0 
Table 2–25: Parameters for sequencing  
 
Reaction step  Temperature 
(°C) 
Duration 
(mm:ss) 
Nature of reaction 
1a 
1b 
96 
96 
02:00 
00:15 
Hold 
Denaturation 
2 55  00:10  Primer  annealing 
Cycle 
repeated 
for 35 
times 
 
3  60  04:00  Extension                                                                                                                    Chapter 2 Materials and Methods 
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2.8.3.2  Post-sequencing reaction clean-up 
Excess primers, dNTPs and tagged ddNTPs were removed from the reaction products to 
allow for sequencing. To achieve this, the PCR products were loaded into a MicroAmp 
Fast Optical 96 well reaction plate (Applied Biosystems) and 2 µl of 3M sodium acetate 
and 50 µl of 100% ethanol were added. This was left for 30 minutes at room 
temperature and was spun at 3000 x g using a Heraeus® Labofuge® 400 Centrifuge 
(Thermo Scientific). The 96 well plate was gently turned upside down to remove the 
supernatant. 50 µl of 70% ethanol was then added and spun at 3000 x g for 15 minutes. 
The PCR plate was again turned upside down to remove the supernatant and was left to 
dry for 10 minutes. 20 µl of 0.1 x TE was added to resuspend the PCR product, 
following which it was then loaded into the 3730xl  DNA Analyzer for sequence 
analysis. 
 
2.8.3.3  Fragment separation by capillary electrophoresis on ABI 
96-capillary 3730 xl Sequencher 
The Applied Biosystems 3730xl  DNA Analyzer is an automated, high-throughput, 
capillary electrophoresis system which utilises thin capillaries filled with polymer 
matrix. The samples are electrokinetically injected into the array of capillaries. The 
labelled DNA sequence fragments are separated by size as they migrate through the 
polymer-filled capillary array (electrophoresis) toward the anode, with the smallest 
fragments moving the fastest. As they reach the detection window, the laser beam 
excites the dye molecules and causes them to fluoresce. The fluorescence emissions are 
collected and displayed as an electropherogram. 
 
2.8.3.4  Data analysis 
The sequence data was analysed using the Sequencher® 4.9 DNA software (by 
Gencodes; www.genecodes.com).                                                                                                                   Chapter 2 Materials and Methods 
  149
 
2.9    Statistical analysis 
 
2.9.1  Chi-square test (
2) 
2 is a statistical test commonly used between two or more proportions (when there is a 
large number of observations) to compare observed data with the expected data obtained 
according to a specific hypothesis. An example to explain this more clearly would be as 
follows: 
 
According to Mendel’s law, half of 20 (i.e. 10) offspring would be male. But if the 
observed number of males was 8, then one would want to know about the “goodness to 
fit” between the observed and expected. Were the deviations (differences between 
observed and the expected) as a result of chance, or were they due to other factors. The 
2 tests the null hypothesis, which states that there is no significant difference between 
the expected and observed result. More specifically, 
2 is the sum of the squared 
difference between observed and the expected data, divided by the expected data: 
 
 
      
2 = (observed-expected)
2                  2 utilises numerical values, and not percentages or  
                      expected                       ratios.
 
                 
 
Using the chi-square distribution table (Table 2-26), the significance of the value is then 
determined (i.e. P < or > 0.05). In order to calculate this, the degrees of freedom (n–1, 
where n = number of variables) is determined and by finding the location of where this 
row meets the 
2 value, and by moving up this column, will provide the P value.   
 
For this study 
2 goodness-of-fit test was used to test for the following significance test: 
1.  Whether allele frequencies for each SNP conformed to Hardy-Weinberg 
equilibrium (HWE) (see below). 
2.  For differences in the distribution of sex and individuals with a family 
history of glaucoma between cases and controls using SPSS (version 15).                                                                                                                   Chapter 2 Materials and Methods 
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3.  For any significant differences in allele and haplotype frequencies between 
cases and controls using Haploview v.4.0. 
 
 
 
 
 
Degrees of 
Freedom 
(df) 
 
Probability (p) 
   0.95  0.90   0.80  0.70  0.50   0.30  0.20  0.10   0.05  0.01  0.001  
1  0.004 0.02  0.06  0.15   0.46  1.07  1.64   2.71  3.84  6.64   10.83 
2  0.10  0.21  0.45  0.71   1.39  2.41  3.22   4.60  5.99  9.21   13.82 
3  0.35 0.58 1.01 1.42    2.37 3.66 4.64   6.25 7.82  11.34  16.27 
4  0.71 1.06 1.65 2.20    3.36 4.88 5.99   7.78 9.49  13.28  18.47 
5  1.14 1.61 2.34 3.00    4.35 6.06 7.29   9.24 11.07  15.09  20.52 
6  1.63 2.20 3.07 3.83    5.35 7.23 8.56   10.64  12.59  16.81  22.46 
7  2.17 2.83 3.82 4.67    6.35 8.38 9.80   12.02  14.07  18.48  24.32 
8  2.73 3.49 4.59 5.53    7.34 9.52 11.03  13.36  15.51  20.09  26.12 
9  3.32 4.17 5.38 6.39    8.34 10.66 12.24  14.68  16.92  21.67  27.88 
10  3.94 4.86 6.18 7.27    9.34 11.78 13.44  15.99  18.31  23.21  29.59 
   Nonsignificant   Significant 
 
 
2.9.2  Hardy-Weinberg equilibrium (HWE) 
HWE is used to better understand the genetic characteristics of populations. Hardy–
Weinberg principle states that both allele and genotype frequencies in a population 
remain constant, or are in equilibrium from generation to generation, unless specific 
disturbing influences are introduced. Those disturbing influences include non-random 
mating, mutations, selection, limited population size, random genetic drift and gene 
flow. Using this principle, population allele frequencies are used to calculate the 
equilibrium-expected genotypic proportions (Hardy, 1908; Weinberg, 1908). If p is the 
frequency of one allele (A) and q is the frequency of the alternative allele (a) for a 
biallelic locus, then the HWE-expected frequency will be p
2 for the AA genotype, 2pq 
Table 2–26: 
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for the Aa genotype, and q
2 for the aa genotype. The three genotypic proportions should 
sum to 1, as should the allele frequency (Hardy, 1908; Weinberg, 1908). 
  
                                                 p² + 2pq + q² = 1 
The most common method to assess HWE is through a goodness-of-fit 
2 test (Weir, 
2008). The null hypothesis is that alleles are chosen randomly, and the genotypic 
proportions thus follow HWE-expected proportions (i.e. p
2, 2pq, and q
2). In genetic 
association studies, testing for HWE is commonly used for quality control of large-scale 
genotyping and is one of the few ways to identify systematic genotyping errors in 
unrelated individuals (i.e. if P = ≤0.05 for HWE) (Gomes et al., 1999; Hosking et al., 
2004; Weir, 2008). 
 
For this study, allele frequencies
 for each SNP
 were tested for
 agreement with Hardy-
Weinberg
  expectations (P>0.05) using a chi-square (
2) goodness-of-fit test. This 
calculation was performed using a software package (SHEsis) obtained from 
http://analysis.bio-x.cn/myAnalysis.php.  
 
 
2.9.3  Odds ratio 
The odds ratio (OR) is a way of comparing whether the probability of a certain event is 
the same for two groups. As case control studies begin with a selection of individuals 
with the disease (case) and another group without the disease (control), there is no way 
of knowing disease rates because these groups are not determined by nature but by the 
investigators’ selection criteria. Instead, OR is used. OR is defined as the odds that a 
case is exposed divided by the odds that a control is exposed. 
 
                                                         exposure rate to risk factor in cases 
  
 
An OR of 1 implies that the event is equally likely in both groups. An OR greater than 
one implies that the event is more likely to occur in the case group compared to the 
control group. An odds ratio less than one implies that the event is less likely to occur in 
the case group compared to the control group. As it is based on a sample collected from 
a population, it is essentially only an estimate. For this reason it is conventional to 
exposure rate to risk factor in controls 
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calculate the 95% confidence interval (CI) (defined as a 95% chance for the true OR of 
the population to lie within the interval) for the OR.  
 
2.9.4  Adjustment for multiple testing  
Multiple testing corrections adjust P values derived from multiple statistical tests to 
correct for occurrence of false positives. This is considered a stringent and useful 
method for validation of association study data (Miller, 1981). The incidence of false 
positives is proportional to the number of tests performed and the significance level. For 
example, when a single test is performed at the usual 5% significance level, there is 
only a 5% chance of incorrectly rejecting the null hypothesis (this is equivalent to a 
false negative error). However, when performing 100 tests where all the null hypotheses 
are true, the chances of rejecting at least one null hypothesis is relatively much higher 
(the expected number would be 100 × 5% which is exactly 5). The problem of multiple 
comparisons can be described as the potential increase in false positive error that occurs 
when statistical tests are used repeatedly. If n independent comparisons are made, the 
overall significance level α is given by: 
 
                      α = 1- (1 – αper comparison) 
number of comparison 
 
and it increases as the number of comparisons increases (Miller, 1981). 
 
A number of mathematical techniques have been developed to control the false positive 
error rate associated with making multiple statistical comparisons. One such technique 
used for this research study is the permutation test (Westfall and Young, 1993). The 
advantage of this method is that it is not as conservative as the Bonferroni correction 
(which is calculated as the corrected P value = P × number of SNPs being tested) and 
takes into account the dependence structure between genes, by permuting all the genes 
at the same time. The following steps are applied during a permutation test: 
1)  P values are calculated for each gene based on the original data set and ranked. 
2)  The permutation method creates a pseudo-data set by dividing the data into 
artificial patient and control groups. 
3)  P values for all genes are computed on the pseudo-data set.                                                                                                                   Chapter 2 Materials and Methods 
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4)  The successive minima of the new P values are retained and compared to the 
original ones. 
5)  This process is repeated a large number of times (usually 1000 times), and the 
proportion of resampled data sets where the minimum pseudo-P value is less than 
the original P value is the adjusted P value. 
 
For this study, permutation testing was performed using Haploview v.4.0, with 1,000 
simulations to calculate corrected P values for multiple testing. 
  
 
2.9.5  Thesias 
Since haplotypes as a whole may have an impact towards functionality of a variant, it 
has become clear that, in order to assess the role of a candidate gene, the full haplotypic 
information should be evaluated (Hodge et al., 1999; Rieder et al., 1999). Most 
available methods used to estimate haplotype frequencies from the genotype data based 
on statistical inference (Chiano and Clayton, 1998; Clark, 1990; Clark et al., 1998; 
Excoffier and Slatkin, 1995; Stephens et al., 2001), estimate haplotype frequencies from 
genotype data without allowing assessment of interaction between two or more loci, 
which are essential data when dealing with complex diseases. Thesias on the other hand 
(obtained from www.genecanvas.org), is capable of investigating haplotype-phenotype 
associations including haplotype-covariate interactions, in addition to haplotype 
frequencies, through utilizing the maximum likelihood method of inference as described 
in Tregouet et al (Tregouet et al., 2002). Furthermore, since the LD observed between 
SNPs and different functional effects of the haplotypes are potential sources of bias 
when studying multiple SNPs, Thesias overcomes this problem by performing 
haplotype background analysis, where it assesses the effects of the individual SNPs 
among the multiple SNPs found within a haplotype.  
 
2.9.6  Summary of the statistical methods used   
1.  By using the algorithm tagger which was implemented in Haploview v.4.0, tSNPs 
that captured untyped SNPs with a minimum r
2 value of 0.8 were chosen. Selection 
was restricted to SNPs with a minor allele frequency (MAF) of ≥10% (i.e. SNPs 
with a high degree of polymorphism).                                                                                                                   Chapter 2 Materials and Methods 
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2.  Haplotypes were constructed from genotype data
 in the full-size case-control panel 
within LD blocks by using an
 accelerated EM algorithm method in Haoloview v.4.0 
(www.broad.mit.edu /mpg/haploview) (Barrett et al., 2005). Since 3-5 haplotypes in 
general capture >90% of all chromosomes, in each
  haplotype block, common 
haplotypes with frequencies  1% were inferred since this would account for >98% 
of the chromosomes. 
3.  Haplotypes identified within cases and controls were inferred using Haploview 
v.4.0. The method of Gabriel et al., (Gabriel et al., 2002), uses Haploview to 
construct LD blocks from tSNPs with MAF  10%. LD between
  tSNPs was 
measured by the pairwise
 D' statistic and the LD structure was examined using the 
80% confidence bounds
 of D' to define sites of historical recombination between 
tSNPs.  
4.  Associations between tSNPs/haplotypes and POAG were investigated using 
Haploview v.4.0. Differences
 in allele and haplotype frequencies between cases and 
controls were determined
 using a 
2 distribution with 2 degrees of freedom. Only 
SNPs conforming to HWE as tested in SHEsis were analysed. 
5.  SNP and haplotype effects identified from cases and controls were investigated with 
and without adjustment for age and sex covariates using Thesias v.3.1 
(www.genecanvas.org). ORs were calculated using Thesias v.3.1 with 95% 
confidence intervals (CIs) for each genotype with the respective wild type as the 
reference. Covariate-adjusted
 haplotype–phenotype association was calculated by 
comparison to the most frequent haplotype. Haplotype background analysis of the 
effects of the individual SNPs within a given haplotype was performed to correct for 
the potential source of bias created by the presence of the multiple SNPs. 
6. 
2 test was used to calculate for significant differences in the distribution of sex and 
individuals with a family history of glaucoma between cases and controls (using 
SPSS version 15), whereas independent samples t test was used to calculate for 
significant differences in the distribution of age, number of individuals with a family 
history of glaucoma, mean C/D ratio, IOP and individuals with glaucoma filtration 
surgery (using SPSS version 15). The latter method is a significance test for 
quantitative (continuous) data distributed between two distinct groups. When using 
SPSS for the independent samples t test, the case status (i.e. case or control) was set 
as group 1 (case) and 2 (control). The clinical variable (e.g. age, mean C/D ratio, 
IOP etc) was set as a test variable.                                                                                                                   Chapter 2 Materials and Methods 
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7.  Multivariate logistic regression analysis was performed using SPSS under the 
guidance of Dr Yalda Jamshidi (Senior Lecturer in Human Genetics at St George’s 
Hospital). The case status was set as a binary dependant variable (HTG, OHT or 
NTG = 1, control = 0), and age, IOP and tSNP as a covariate, followed by selecting 
the binary logistic regression for analysis. The logistic regression makes use of 
several predictor variables that may be either numerical or categorical (in this case 
IOP, age and tSNP), for predicting the probability of occurrence of an event (i.e. the 
case status). 
 
2.9.7  Power calculation 
The sample size of 276 controls and 367 cases was used in a power calculator 
(StataCorp. 2003. Stata Statistical Software: Release 8.0 College Station, TX: Stata 
Corporation) and showed a power of 80% to identify a difference in genotype and allele 
frequency between 10-18% at a significance level of P < 0.05 between the controls and 
cases. 
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Chapter 3  Analysis of phenotypic variables of cases and 
controls  
 
3.1  Introduction 
 
In this chapter, a comprehensive assessment of the phenotypic variables (including age, 
sex, family history of glaucoma, mean cup-disc ratio (C/D ratio), mean of the highest 
IOP and glaucoma surgery) of HTG, OHT and NTG cases as well as normal controls 
has been performed. The HTG group is characterised by glaucomatous damage, and 
raised IOP, with the other two patient groups OHT and NTG, each having only one of 
these characteristics, either glaucomatous damage without raised IOP (NTG), or raised 
IOP without glaucomatous damage (OHT). Since HTG+OHT and HTG+NTG shared 
the same phenotypic variable of raised IOP or optic nerve damage respectively, they 
have been grouped together according to these variables (i.e. HTG and OHT into group 
1 with raised IOP, and HTG and NTG into group 2 with glaucomatous damage, 
irrespective of IOP). 
 
3.2  Results 
A total of 367 cases and 276 unrelated controls of white British descent were enrolled in 
this study. Recruitment of cases and controls took 6 months to achieve. Among the 
cases, 272 (74.1%) were classified as HTG, 37 (10.1%) as NTG, and 58 (15.8%) as 
OHT (Table 3-1). The phenotypic characteristics of the controls and the HTG, OHT and 
NTG patients are depicted in Table 8-1, 8-2, 8-3 and 8-4, all of which are found in 
Appendix III, IV, V and VI respectively. 
 
3.2.1  Age distribution in cases and controls 
Within the case group, the mean age was as follows (Table 3-1, Figure 3-1): 
•  71.17 years for the HTG group (± SD 10.448, range 40-93) 
•  65.19 years for the OHT group (± SD 11.494, range 41-92) 
•  77.51 years for the NTG group (± SD 8.849, range 60-92)                                                                   Chapter 3 Analysis of phenotypic variables of cases and controls 
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•  70.12 years for the combined HTG and OHT group (± SD 10.863, range 40-93) 
•  And 71.93 years for the combined HTG and NTG group (± SD 10.462, range 
40-93) 
For the normal control group, the mean age was 70.76 years (± SD 9.313, range 40-90).  
 
There was a significant difference between the mean age of the control group and the 
OHT group (Table 3-1). 
 
 
 
 
 
 
Table 3–1: Comparison of age, age at diagnosis, sex, number of individuals with a family 
history of glaucoma, mean CDR, mean of the highest recorded IOP and number of 
individuals with glaucoma surgery between HTG, OHT, NTG, HTG+OHT group (with 
raised IOP), HTG+NTG group (with glaucomatous optic neuropathy) and the control 
group. 
 * indicates significant difference (P > 0.05) between controls and the separate case groups 
(HTG, NTG, OHT). P
1 and
 P
2 indicate significant difference between controls and the 
HTG+OHT group, or the HTG+NTG group, respectively. P values were calculated using 
independent samples t test, except a χ
2 test was used for sex, using SPSS, version 15 (SPSS 
Inc., Chicago, IL, USA). 
 
  HTG  OHT  NTG  Controls  Cases 
combined  
(HTG+OHT) 
P
1  Cases 
combined 
(HTG+NTG) 
P
2 
n  272  58  37  276  330 ----------  309 ---------- 
Mean age 
(SD) 
71.17 
(10.448) 
*65.19 
(11.494) 
77.51 
(8.849) 
70.76 
(9.313) 
70.12 
(10.863) 
0.437 71.93 
(10.462) 
0.158 
Mean age at diagnosis 
(SD) 
60.97 
(10.686) 
58.57 
(10.679) 
72.35 
(9.364) 
---------- 62.71 
(10.836) 
---------- 64.61 
(10.888) 
---------- 
Sex  % Male  *54.4 41.4  *27.0 42.8  52.1  0.022 51.1  0.047 
Number of individuals 
with a family history of 
glaucoma (%) 
*35.7  *46.6  *67.6  0  36.6  < 0.0001  39.5  < 0.0001 
Mean C/D ratio (SD)  *0.72 
(0.182) 
0.36 
(0.138) 
*0.74 
(0.138) 
0.21 
(0.231) 
0.66 
(0.221) 
< 0.0001  0.7204 
(0.177) 
< 0.0001 
Mean of the highest 
recorded IOP (SD) 
*29.13 
(5.506) 
*27.16 
(4.021) 
17.64 
(2.090) 
15.45 
(2.352) 
28.79 
(5.326) 
< 0.0001  27.75 
(6.415) 
< 0.0001 
Number of individuals 
with glaucoma filtration 
surgery (%) 
25.7  5.2  5.4  0  22.1  < 0.0001  23.3  < 0.0001                                                                   Chapter 3 Analysis of phenotypic variables of cases and controls 
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Figure 3–1: Distribution of age among the control group and 5 different case 
groups; HTG, OHT, NTG, HTG+OHT and HTG+NTG.   
The mean age for the NTG group (77.51 years) was the highest among the case groups 
with the OHT group having the lowest mean age (65.19 years). Each group is coded by 
different colours. 
Age (years) 
Number 
of 
subjects                                                                   Chapter 3 Analysis of phenotypic variables of cases and controls 
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On the whole, the mean age and the mean age at diagnosis for the NTG group (77.51 
and 72.35 years respectively) was the highest among the cases groups, with the OHT 
group having the lowest mean age and the mean age at diagnosis (65.19 and 58.57 years 
respectively). All of the case groups have shown a mean age that is well above the age 
of 40 years (i.e. the age at which it is considered to be adult-onset glaucoma). This made 
certain that all of the cases were of adult-onset glaucoma in addition to excluding 
normal controls that may have (as yet undeveloped) glaucoma.   
 
3.2.2  Sex distribution in cases and controls 
Within the cases, the percentage of male was as follows (Table 3-1, Figure 3-2): 
•  54.4% in the HTG group. 
•  41.4% in the OHT group. 
•  27% in the NTG group. 
•  52.1% in the combined HTG and OHT group. 
•  51.1% in the combined HTG and NTG group. 
 
Within the normal control group, 42.8% of individuals were male.  
 
On the whole, the percentage of males was the highest in the HTG group at just above 
50%. As expected, the percentage of male was significantly lower in the NTG group 
(27%) (where the prevalence of female is known to be higher) (Levene, 1980) when 
compared to the control group. In addition, other case groups (including HTG, 
HTG+OHT and HTG+NTG) also showed significant difference in sex distribution 
when compared to the normal controls.  
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Figure 3–2: Distribution of sex within the normal control group and 5 different 
case groups; HTG, OHT, NTG, HTG+OHT and HTG+NTG. 
The percentage of males was significantly different between the cases groups NTG, 
HTG, HTG+OHT, HTG+NTG and the control group. 
 
 
3.2.3  Distribution of individuals with family history of glaucoma 
Within the cases, the percentage of individuals with a family history of glaucoma was as 
follows (Table 3-1, Figure 3-3): 
•  35.7% in the HTG group 
•  46.6% in the OHT group 
•  67.6% in the NTG group 
•  37.6% in the HTG+OHT group 
•  39.5% in the HTG+NTG group 
 
Control individuals with a family history of glaucoma were excluded from this study. 
% 
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Figure 3–3: The distribution of individuals with a family history of glaucoma 
among the case groups HTG, OHT, NTG, HTG+OHT and HTG+NTG. 
The NTG group had the highest percentage of individuals with a family history of 
glaucoma at 67.6%, with the HTG group having the lowest percentage at 35.7%. 
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The NTG group had the highest percentage of individuals with a family history of 
glaucoma at 67.6% whilst the HTG group had the lowest percentage at 35.7%. When 
the phenotypic variables of the individuals with a family history of glaucoma was 
further analysed (Table 3-2), the percentage of females was higher in all groups with a 
family history of glaucoma when compared with those without a family history of 
glaucoma, except for the NTG group where there was a higher percentage of male. Only 
the combined groups HTG+OHT and HTG+HTG showed a significant difference in sex 
distribution between the individuals with and without a family member of glaucoma. In 
addition, there was a higher prevalence of glaucoma surgery for all of the case groups 
(HTG, OHT, NTG, HTG+OHT and HTG+NTG) with a positive family history of 
glaucoma, when compared with those without a family history of glaucoma. However, 
these were not significantly different when tested by a 
2 analysis (Table 3-2). 
Table 3–2: Comparison of age at diagnosis, sex, mean CDR and of the highest 
recorded IOP, and number of individuals with glaucoma surgery between cases with 
a family history of glaucoma and cases without a family history of glaucoma 
* indicates significant difference (P > 0.05) in gender between individuals with a family 
history of glaucoma and individuals without a family history of glaucoma within each case 
group.  P values were calculated using independent samples t test, except a χ
2 test was 
used for sex and family history of glaucoma, using SPSS, version 15 (SPSS Inc., Chicago, 
IL, USA). 
 
  Family 
history of 
glaucoma 
Mean age at 
diagnosis 
(SD) 
Sex  % Male  Mean of the 
highest recorded 
IOP (SD) 
Mean C/D ratio 
(SD) 
Number of 
individuals with 
glaucoma filtration 
surgery (%) 
No  63.65 
(10.549) 
58.3 31.87 
(7.055) 
0.74 
(0.173) 
23.4  HTG 
Yes  63.49 
(10.970) 
47.4 30.14 
(5.362) 
0.74 
(0.159) 
29.9 
No  59.10 
(10.594) 
48.4 28.81 
(3.027) 
0.33 
(0.113) 
0.0  OHT 
Yes  57.95 
(10.946) 
33.3 28.82 
(5.114) 
0.31 
(0.120) 
11.0 
No  74.58 
(9.662) 
25.0 16.5 
(2.576) 
0.75 
(0.131) 
0.0  NTG 
Yes  71.28 
(9.221) 
28.0 18.28 
(19.90) 
0.75 
(0.112) 
8.0 
No  62.96 
(10.665) 
*56.8 31.26 
(6.565) 
0.66 
(0.227) 
19.9  HTG+OHT 
Yes  62.29 
(11.160) 
*44.4 29.83 
(5.312) 
0.64 
(0.232) 
25.8 
No  64.53 
(10.976) 
*56.1 30.40 
(8.162) 
0.74 
(0.169) 
21.9  HTG+NTG 
Yes  64.73 
(10.794) 
*43.4 27.39 
(6.940) 
0.74 
(0.154) 
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3.2.4  Distribution of cup-disc ratio in cases and controls 
Within the cases, the mean C/D ratio was as follows (Table 3-1, Figure 3-4): 
•  0.72 (± SD 0.182, range 0.4 - 1.0) for the HTG group. 
•  0.36 (± SD 0.138, range 0.1 – 0.5) for the OHT group. 
•  0.74 (± SD 0.138, range 0.5 – 0.9) for the NTG group. 
•  0.66 (± SD 0.221, range 0.1 – 1.0) for the HTG+OHT group. 
•  0.72 (± SD 0.177, range 0.4 – 1.0) for the HTG+NTG group. 
 
For the control group, the mean C/D ratio was 0.21 (± SD 0.231, range 0.0 – 0.5). 
 
The mean C/D ratio was the lowest among the OHT group (C/D ratio 0.36) and the 
controls (C/D ratio 0.21), between which the C/D ratio was not significantly distributed. 
This was as expected since there was absence of glaucomatous optic nerve damage 
within these two groups. The group with the worst mean C/D ratio was the NTG group 
(C/D ratio 0.74) followed by the HTG group (C/D ratio 0.72).   
 
3.2.5  IOP distribution in cases and controls 
Within the cases, the mean of the highest recorded IOP was as follows (Table 3-1, 
Figure 3-5): 
 
•  29.13 mmHg (± SD 5.51, range 24 - 65) among the HTG group 
•  27.16 mmHg (± SD 4.02, range 24 - 41) among the OHT group 
•  17.64 mmHg (± SD 2.09, range 10 - 20) among the NTG group 
•  28.79 mmHg (± SD 5.33, range 24 – 65) among the HTG+OHT group 
•  27.75  mmHg (± SD 6.42, range 10 - 65) among the HTG+NTG group 
 
For the control group, the mean of the highest recorded IOP was 15.45 mmHg (± SD 
2.35, range 9 - 20). 
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Figure 3–4: Distribution of cup-disc ratio within the control group and 5 different 
case groups; HTG, OHT, NTG, HTG+OHT and HTG+NTG.   
The controls and the OHT subjects are distributed in the lower end of spectrum of the 
cup-disc ratio, where as the HTG, NTG and HTG+NTG cases are distributed in the 
higher end of the spectrum. Each group is coded by different colours. 
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Number 
of 
subjects                                                                   Chapter 3 Analysis of phenotypic variables of cases and controls 
  165
0
10
20
30
40
50
60
70
80
90
<10 10-11 12-13 14-15 16-17 18-19 20-21 22-23 24-25 26-27 28-29 30-31 32-33 34-35 36-37 38-39 40-41 42-43 44-45 >45
Control
HTG
OHT
NTG
HTG+OHT
HTG+NTG
 
 
 
Figure 3–5: Bimodal distribution of IOP of the control group and 5 different case 
groups; HTG, OHT, NTG, HTG+OHT and HTG+NTG.   
The first peak consisted mainly of control individuals and NTG cases and the second 
peak comprised mainly of HTG, OHT, HTG+OHT and HTG+NTG cases. Each group is 
coded by different colours.  
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As expected, the IOP in the normal controls (range 9 – 20 mmHg) and the NTG group 
(range 10 – 20 mmHg) was consistently within the statistically “normal range” with the 
mean of the highest recorded IOP for the control group being 15.45 mmHg and for the 
NTG group 17.64 mmHg. The IOP was not significantly distributed between these two 
groups. The case group with the highest recorded mean IOP was the HTG group (29.13 
mmHg). Figure 3-4 shows a bimodal distribution of the IOP with the first peak 
consisting mainly of control individuals and NTG cases and the second peak consisting 
mainly of HTGs, OHTs, HTGs+OHTs and HTGs+NTGs. 
 
3.2.6  Percentage of individuals with glaucoma surgery 
 
The percentage of individuals who had glaucoma filtration surgery among the cases was 
as follows (Table 3-1, Figure 3-6): 
•  25.7% in the HTG group 
•  5.2% in the OHT group 
•  5.4% in the NTG group 
•  22.1% in the HTG+OHT group 
•  23.3% in the HTG+NTG group 
 
The case group with the highest percentage of individuals with glaucoma surgery was 
the HTG group (25.7%), with the OHT group having the lowest percentage of 
individuals with glaucoma surgery (5.2%).  
 
3.3  Discussion 
Overall, there were 643 participants recruited for this study, 367 of whom were 
unrelated POAG/OHT cases and the remaining 276 of whom were unrelated normal 
controls. The cases were composed of three homogenous cohorts of HTGs (n = 272), 
OHTs (n = 58) and NTGs (n = 37). All cases and controls were of white British descent 
and were ethnically matched.                                                                   Chapter 3 Analysis of phenotypic variables of cases and controls 
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Figure 3–6: The percentage of individuals with glaucoma filtration surgery within 
the case groups HTG, OHT, NTG, HTG+OHT and HTG+NTG. 
The HTG group had the highest percentage of individuals with glaucoma surgery and 
the OHT group had the lowest percentage individuals with glaucoma surgery. 
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Six phenotypic variables of the cases and controls were assessed (age, sex, number of 
individuals with a family history of glaucoma, mean CDR, highest recorded mean IOP 
and number of cases with glaucoma surgery). In order to ensure that the cases and 
controls were comparable, age and sex distribution between these groups were 
examined to see whether they were equally distributed. On examining the mean age 
between cases and controls, the OHT group had a mean age of 65.19 years, which was 
significantly lower than the mean age of the controls (70.76 years) (P = < 0.05). In 
addition, when the sex distribution was assessed, the percentage of males was 
significantly different (P = < 0.05) between the HTG, NTG, HTG+OHT, HTG+NTG 
and the controls. The uneven distribution of age and sex may produce confounding bias 
and distort any potential association between cases and the controls. Hence, to address 
this problem, calculations for P values in subsequent chapters have adjusted for this 
when assessing the prevalence of genetic variants between these specific groups. 
 
On assessing the individuals with family history of glaucoma, the case group with the 
largest percentage of such individuals was the NTG group at 67.6 % compared to the 
HTG and the OHT group at 35.7% and 46.6% respectively. Despite this being a crude 
assessment because of the small number of participants representing the NTG group, 
based on this result, it can be concluded that there may be a larger contribution of 
genetic factors towards the pathogenesis of NTG within the cohort. This is in line with a 
case control study involving Caucasian individuals of 175 POAG cases and 175 
controls which showed a strong familial component to the development of NTG 
(Charliat et al., 1994). With this in mind, it would be interesting to assess the prevalence 
of OPTN mutation (a dominant NTG gene within British familial cases and to a lesser 
extent in sporadic POAG cases) (Alward et al., 2003; Aung et al., 2003; Ayala-Lugo et 
al., 2007; Hauser et al., 2006; Rezaie et al., 2002), in particular the E50K mutation 
within the cohort of NTG cases as well as the HTG/OHT cases (see Chapter 4).  
 
In addition, when the phenotypic variables of the group of individuals with a family 
history of glaucoma were further analysed, a higher prevalence of females were present 
for all of the case groups except for the NTG group, where the percentage of males were 
higher. This was significantly different only in the combined groups HTG+OHT and                                                                   Chapter 3 Analysis of phenotypic variables of cases and controls 
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HTG+NTG. In addition, a higher prevalence of glaucoma surgery was observed for all 
case groups (albeit not being significantly different) compared to those without a family 
history of glaucoma. This is in agreement with the Canadian Glaucoma Study (Chauhan 
et al., 2008) which showed female gender being a risk factor for progression of POAG. 
However, conflicting results was shown by the AGIS (AGIS Investigators, 2002) in 
which male gender was a risk factor. 
 
With regards to the distribution of mean IOP within cases and controls, there was a 
bimodal distribution with the first peak consisting mainly of control individuals and 
NTG cases and the second peak consisting of HTG, OHT, HTG+OHT and HTG+NTG 
cases (Figure 3-5). Since HTG and OHT shared the same normal distribution on the 
upper end of the IOP spectrum, HTG and OHT were combined as one group (see 
Chapter 5 and 6 for the assessment of IOP as a covariate). In addition, individuals with 
borderline IOPs (21–23 mmHg) (43 subjects in total) were excluded from this study. 
This was to ensure that the participants were correctly assigned to the appropriate 
groups depending on whether the IOP was above the statistically normal upper limit 
(HTG or OHT) or within the statistically normal range (NTG or controls).  
 
When analysing the percentage of individuals with glaucoma surgery, the case group 
with the largest percentage of surgery was the HTG group at 25.7% compared to the 
OHT and the NTG groups at 5.2% and 5.4% respectively. This suggests that the HTG 
group had the highest percentage of the progressive form of POAG. 
 
Other phenotypic characteristics that could have been analysed in order to provide a 
more comprehensive assessment of the study group would be an objective measurement 
of the degree of visual field loss using global indices (mean deviation, pattern standard 
deviation, corrected pattern standard deviation), recording of risk factors associated with 
POAG (e.g. CCT, systolic blood pressure, cardiovascular history, refractive status) as 
well as clinical features associated with POAG (e.g. migraine and NTG). 
 
In summary, a systematic assessment of the phenotypic variables of the study group has 
been made.  
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Chapter 4  The role of OPTN E50K mutation in unrelated 
cases of OHT and POAG 
4.1  Introduction 
Here, the contribution of OPTN E50K mutation to unrelated NTG cases is investigated. 
In addition, given the phenotypic variability of E50K mutation with some affected 
individuals having HTG whilst others having NTG (Rezaie et al., 2002), the role of 
E50K mutation in unrelated HTG and OHT cases is also assessed. Specifically, the 
prevalence of E50K mutation is examined in unrelated glaucoma patients comprised of 
HTG (n = 272), OHT (n = 58), NTG (n = 37) and a normal control group of white 
British origin (n = 276), using TaqMan SNP genotyping assays. The results are then 
validated using cycle sequencing reaction by Sanger’s dideoxy Terminator Method.  
 
OPTN E50K mutation has not been previously identified in unrelated HTG and OHT 
case within the general POAG population, and after detailed analysis, this report 
confirms the absence of the E50K mutation in OHT subjects (a major risk factor for 
HTG), HTG individuals, in addition to NTG individuals. 
 
4.2  Results 
4.2.1  Assessment of prevalence of OPTN E50K mutation in unrelated 
OHT/POAG individuals 
4.2.1.1  Using TaqMan SNP genotyping assay  
Overall, when analysing the results of the automated allelic discrimination plot of the 
TaqMan assay (Figure 4-1), the E50K mutation was identified in one out of 37 NTG 
individuals (patient ID number 522p) (2.7%), and none in the control group. In addition, 
this mutation was found in 3 out of 272 HTG subjects (patient ID numbers 432p, 520p, 
525p) (1.1%) as well as among 1 out of 58 OHT individuals (patient ID number 527p) 
(1.7%). However, given that OPTN E50K mutation is a rare allele (Ariani et al., 2006; 
Baird et al., 2004; Funayama et al., 2004; Fuse et al., 2004; Leung et al., 2003; Lopez-
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et al., 2004; Wiggs et al., 2003) and that there may be a tendency for the allelic 
discrimination plot to miscall genotypes (Callegaro et al., 2006), the amplification plot 
of the individual wells were further analysed despite the cluster plot showing distinct 
clusters (Figure 4-1). And surprisingly, there was an absence of the E50K mutation 
among the five individuals (Figure 4-2., 4-3, 4-4, 4-5 and 4-6) who were suspected to 
have the mutation as shown by the cluster plot. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4–1: A cluster plot from a Fast 7500 Real-Time PCR using TaqMan SNP 
genotyping assay showing allelic discrimination of the SNP rs28939688 responsible 
for OPTN E50K mutation.  
There are 2 signals for AA homozygous (2 copies of mutant allele), 2 signals for GA 
heterozygous (1 copy of mutant A allele) with the majority being GG homozygous 
(absence of E50K mutation). Note the signal for the “no template” control which is 
indicated by a grey box. 
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Figure 4–2: Amplification plots of delta Rn versus cycle number of an individual 
with NTG (patient ID number 522p) showing an increase in FAM fluorescence 
only and absence of VIC fluorescence. 
When the fluorescent reporter signal increases to a detectable level, it is captured and 
displayed as an amplification plot as shown here. As the reporter dye FAM represents 
the wild type allele G and the VIC dye the mutant allele A, the amplification plot which 
shows an increase in FAM fluorescence only hence shows a GG genotype. Rn is the 
normalized reporter signal, where as delta Rn is defined as the magnitude of the 
fluorescence signal generated during the PCR at each time point. The threshold line is 
the point at which the level of fluorescence is above the background intensity 
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Figure 4–3: Amplification plots of delta Rn versus cycle number of an individual 
with HTG (patient ID number 432p) showing an increase in FAM fluorescence and 
absence of VIC fluorescence. 
As the reporter dye FAM represents the wild type allele G and the VIC dye the mutant 
allele A, the component plot shows a GG genotype. Rn is the normalized reporter 
signal, where as delta Rn is defined as the magnitude of the fluorescence signal 
generated during the PCR at each time point. The threshold line is the point at which the 
level of fluorescence is above the background intensity. 
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Threshold line                                     Chapter 4 The role of OPTN E50K mutation in unrelated cases of OHT and POAG 
  174
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4–4: Component plots of delta Rn versus cycle number of an individual 
with HTG (patient ID number 520p) showing an increase in FAM fluorescence and 
absence of VIC fluorescence. 
As the reporter dye FAM represents the wild type allele G and the VIC dye the mutant 
allele A, the component plot shows a GG genotype.  Rn is the normalized reporter 
signal, where as delta Rn is defined as the magnitude of the fluorescence signal 
generated during the PCR at each time point. The threshold line is the point at which the 
level of fluorescence is above the background intensity. 
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Figure 4–5: Component plots of delta Rn versus cycle number of an individual 
with HTG (patient ID number 525p) showing an increase in FAM fluorescence and 
absence of VIC fluorescence. 
As the reporter dye FAM represents the wild type allele G and the VIC dye the mutant 
allele A, the component plot shows a GG genotype.  Rn is the normalized reporter 
signal, where as delta Rn is defined as the magnitude of the fluorescence signal 
generated during the PCR at each time point. The threshold line is the point at which the 
level of fluorescence is above the background intensity. 
Threshold line 
FAM                                    Chapter 4 The role of OPTN E50K mutation in unrelated cases of OHT and POAG 
  176
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4–6: Component plots of delta Rn versus cycle number of an individual 
with OHT (patient ID number 527p) showing an increase in FAM fluorescence and 
absence of VIC fluorescence. 
As the reporter dye FAM represents the wild type allele G and the VIC dye the mutant 
allele A, the component plot shows a GG genotype.  Rn is the normalized reporter 
signal, where as delta Rn is defined as the magnitude of the fluorescence signal 
generated during the PCR at each time point. The threshold line is the point at which the 
level of fluorescence is above the background intensity. 
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4.2.1.2  Using Sanger dideoxy Terminator Method 
To validate the genotyping results obtained using TaqMan SNP assay by automated 
cycle sequencing, the genomic DNA of the five individuals plus a further 20 controls 
samples were sequenced.  
 
4.2.1.2.1  Gel electrophoresis of PCR products for cycle sequencing 
Using the annealing temperature as 57 ºC and the DNAs from 25 individuals [5 cases 
(patient ID number 522p, 432p, 520p, 525p, 527p) and 20 controls (patient ID number 
361, 362, 363, 402, 404_VB, 405, 408, 409, 442, 445, 446, 450, 451, 452, 455, 456, 
457, 462, 465, 466)], in addition to 1 known genomic DNA and 2 no template DNA 
controls, good PCR products were obtained as shown in Figure 4-7 and 4-8. 
 
 
                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4–7: Gel electrophoresis of PCR products of genomic DNA from 5 patients 
with the OPTN E50K mutation (patient ID number 432p, 522p, 520p, 525p and 
527p), as well as from 1 known genomic DNA and 2 no template DNA controls. 
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Figure 4–8: Three gel electrophoresis of PCR products of genomic DNA from 20 
control individuals (patient ID number 361, 362, 363, 402, 404_VB, 405, 408, 409, 
442, 445, 446, 450, 451, 452, 455, 456, 457, 462, 465, 466).  
Lanes labeled with * were excluded from subsequent cycle sequencing due to poor PCR 
product. 
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4.2.1.2.2  Cycle sequencing 
All five individuals were confirmed to have the absence of the mutant A allele and were 
all GG homozygous (Figure 4-9). A further 20 control DNA samples were sequenced 
and confirmed the absence of the E50K mutation.  
 
 
 
 
 
 
 
 
 
 
Figure 4–9: Electropherogram of 5 individuals (patient ID number 522p, 432p, 
520p, 525p, 527p) showing absence of the mutant A allele. 
Patient ID number 522p 
Patient ID number 432p- 
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These data confirmed the discrepancy between the results shown by the automated 
allelic discrimination plot (IQ software; Bio-Rad Laboratories, Hercules, CA) and the 
individual spectral contribution of the reporter dyes of the TaqMan assay. Hence, in 
conclusion, there is absence of E50K mutation among the recruited cohort. 
 
4.3  Discussion 
OPTN, the second POAG gene, was first identified by Rezaie et al (Rezaie et al., 2002) 
who discovered that variations in OPTN were associated with NTG. The most frequent 
OPTN mutation, Glu50→Lys (E50K) was present in 7 out of 52 families (prevalence 
rate of 13.5%) with dominantly inherited POAG (Rezaie et al., 2002). The E50K 
mutation is caused by a c.458G>A transition, so normal individuals without this 
mutation would be homozygous (GG) at this position, and affected individuals with this 
mutation would be either heterozygous (GA) or homozygous (AA). More specifically, 
this mutation converts the DNA codon for glutamic acid (GAA) into that for lysine 
(AAA). Within the 7 affected families, 16 out of the 124 members were asymptomatic 
carriers of the E50K mutation. When this prevalence is compared to a smaller 
percentage of 2-4% of sporadic POAG patients carrying mutations in  MYOC gene 
(Fingert et al., 1999), OPTN appeared to be a promising gene, making it a considerable 
risk associated genetic susceptibility factor for glaucoma. However, in subsequent 
studies when the assessment of OPTN mutation among sporadic NTG was carried out, a 
much smaller prevalence of E50K mutation was observed, and only in specific ethnic 
groups (Table 1-6 in Chapter 1). Prevalence rates varied from 1.5% from a UK study 
involving 2 British individuals out of 132 NTG cases (Aung et al., 2003), 1.5%  (1 out 
of 67 NTG cases) (Hauser et al., 2006) and 0.4% (1 out of 276 NTG cases) (Alward et 
al., 2003) from 2 separate US studies, each involving a single patient with a family 
history of glaucoma, and 3.0% from a US study involving a single Caucasian Hispanic 
individual (1 out of 33 NTG cases) (Ayala-Lugo et al., 2007). Interestingly, the E50K 
mutation has not been identified among NTG individuals of Japanese origin where the 
prevalence of NTG is higher (Funayama et al., 2004; Fuse et al., 2004; Tang et al., 
2003; Toda et al., 2004; Umeda et al., 2004). The high prevalence of the E50K 
mutation from the original study (approximately 10 fold higher) was thought to be due 
to the enrichment of the mutation within the autosomal dominant NTG pedigrees.                                     Chapter 4 The role of OPTN E50K mutation in unrelated cases of OHT and POAG 
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Furthermore, there has been absence of correlation between E50K mutation and HTG 
(Table 1-7 in Chapter 1) (Ariani et al., 2006; Baird et al., 2004; Funayama et al., 2004; 
Fuse et al., 2004; Leung et al., 2003; Lopez-Martinez et al., 2007; Sripriya et al., 2006; 
Tang et al., 2003; Toda et al., 2004; Umeda et al., 2004; Wiggs et al., 2003). In line 
with the results of these studies, this report has confirmed the absence of E50K mutation 
among unrelated NTG cases, in addition to HTG and OHT individuals. More 
specifically, the miscalling of the genotype by the automated allelic discrimination 
software which produced spurious results came into light through detailed assessment of 
the amplification plot and the absence of the E50K mutation was consolidated through 
sequencing. 
 
An important requirement of a SNP genotyping method is to be able to distinguish 
clearly between the allelic variants of homozygous and heterozygous forms. The 
TaqMan assay which was originally designed for quantitative real time PCR, is a 
homogenous assay i.e. a single-phase assay without separation steps, allowing continual 
monitoring during amplification. The TaqMan SNP genotyping assay utilizes the 5’-
exonuclease activity of AmpliTaq Gold DNA polymerase to cleave the MGB probe that 
is hybridized to their target sequence. Cleavage separates a reporter dye (either VIC for 
allele 1 or FAM for allele 2) at the 5’ end from the 3’ quencher, leading to a detectable 
fluorescent signal. Allelic discrimination is determined by the relative amount of 
intensities of the two fluorescent probes at the end of amplification. Thus, instead of 
using the full set of real-time PCR data as in quantitative studies, only the end-point 
data are used. The results of the assay are then automatically determined by a 
genotyping software provided with real time PCR (e.g. Sequence Detection Software of 
Applied Biosystems). As this program utilises autoscaling for generating the allelic 
discrimination plot, caution should be taken when analyzing data for rare alleles as it 
may produce spurious genotypes (Callegaro et al., 2006). For example, when minor 
alleles are absent in the run, the software can miscall genotypes either as heterozygous 
or homozygous. When considering the results of the TaqMan assay in this study, it can 
be thus concluded that the SNP responsible for the E50K mutation (rs28938688) is 
indeed rare and absent among the recruited white British cohort. This is in line with the 
HapMap database where the minor allele frequency of rs28938688 is still unknown. As 
a result of its infrequent prevalence, it has resulted in the miscall of the genotypes and 
thus generating the spurious results indicating the presence of E50K mutation among                                     Chapter 4 The role of OPTN E50K mutation in unrelated cases of OHT and POAG 
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POAG cases when in fact there is no mutation as shown by the individual amplification 
plot. 
 
There is evidence to suggest that OPTN may play a neuroprotective role by reducing 
susceptibility of RGC to apoptosis. The E50K mutation is located within a putative 
leucine zipper-containing bZIP motif, which is conserved in the mouse, bovine and 
macaque genomes and is thought to have a dominant-negative effect (Rezaie et al., 
2002). The bZIP motif is a transcription factor domain that is normally involved in 
DNA binding and protein dimerization. One identified mutation in OPTN is a 2 base 
pair “AG” insertion that truncates the protein by 76% and may lead to loss of function 
or haploinsuffiency (Rezaie et al., 2002). By contrast, Chalasani et al has shown that 
proteins with the E50K mutation acquired the ability to selectively induce cell death in 
retinal ganglion cells which was mediated by oxidative stress (Chalasani et al., 2007). 
OPTN interacts with several proteins, including Rab8 which is a small GTPase that has 
been implicated in various processes, including protein trafficking (Hattula and Peranen, 
2000). De Marco et al (2006) have shown that in response to apoptotic stimuli through 
high oxidative stress, OPTN (a cytoplasmic protein) translocates from the Golgi 
apparatus to the nucleus in a Rab8-dependent manner. Overexpression of OPTN blocks 
cytochrome c release from mitochondria and protects cells from hydrogen peroxide-
induced cell death (Figure 4-10). The OPTN E50K mutation inhibits translocation to the 
nucleus. The Rab8 interaction domain (amino acids 58-209) is situated in the vicinity of 
the E50K mutation. It is speculated that a conformational change induced by E50K 
mutation may alter its interaction with Rab8 and is hence unable to translocate to the 
nucleus to provide protection from oxidative stress (De et al., 2006). Whether the loss of 
interaction with Rab8 is responsible for RGC death is still to be proven. 
 
In studies that have examined the cellular role of OPTN, Zhu et al showed that OPTN 
negatively regulated TNFα-induced NF-κB activation (Figure 4-11A) (Zhu et al., 2007). 
TNFα- stimulated NFκB-dependent gene transcription was greatly enhanced when the 
level of OPTN expression was reduced, which in turn lowered the apoptotic threshold. 
Other studies have revealed that OPTN E50K mutation increased its binding to TANK-
binding kinase 1(TBK1), which formed a complex that regulated TNFα and its pro-
apoptotic effects (Morton et al., 2008). It has been suggested that the OPTN E50K                                     Chapter 4 The role of OPTN E50K mutation in unrelated cases of OHT and POAG 
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mutant may cause aberrant activation of TBK1 which may be the cause of the increased 
susceptibility to ganglion cell loss in subjects with familial NTG.  
 
Hence, the exact function of OPTN in relation to glaucoma pathogenesis is still unclear, 
but the emerging picture is that OPTN protein interacts with the TNFα  signalling 
pathway and that it may regulate cell death (Chen et al., 1998; Li et al., 1998) by 
interacting with proteins involved in apoptosis as well as by inducing TNFα. TNFα 
increases the severity of damage of optic nerve heads of POAG individuals (Danson, 
1988; Haramaki et al., 1997). Hence, it is postulated that the wild-type optineurin may 
act via the TNFα pathway and provide a neuroprotective role in the optic nerve, and 
when defective, causes glaucomatous optic neuropathy. Furthermore, sustained 
elevation of IOP has been shown to result in an upregulation of OPTN expression 
(Vittitow and Borras, 2002) in human TM maintained in organ culture and it is 
speculated whether OPTN may provide a protective effect on TM during raised IOP by 
possibly influencing ECM remodeling and facilitating aqueous humor outflow. In 
another study where the relationship between OPTN and MYOC was assessed, OPTN 
overexpression upregulated endogenous MYOC (which is responsible for 4% of HTG) 
in human TM cells (Park et al., 2007) by prolonging the turnover rate of MYOC 
mRNA. Taken together, these reports suggest that OPTN may provide a defence 
mechanism within TM against raised IOP by facilitating aqueous outflow in the anterior 
segment (and possibly through exerting a regulatory role on MYOC expression) (Figure 
11B), in addition to a neuroprotective role in the optic nerve. OPTN may therefore have 
a potential role in the underlying genetic cause of HTG and OHT, in addition to NTG. 
Thus, taking all the evidence into consideration, OPTN appears to be a strong candidate 
for glaucoma susceptibility. However, in this study, there was an absence of the E50K 
mutation among NTG, HTG and OHT cases. 
 
In conclusion, this study confirms the absence of E50K mutation among unrelated 
POAG individuals from the North-East of England. 
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Figure 4–10: Overview of OPTN response to oxidative stress. 
In response to oxidative stress OPTN translocates from Golgi apparatus to the nucleus 
in a Rab8-dependent manner and prevents release of cytochrome c from mitochondria. 
In doing so, it protects cells from hydrogen-peroxide induced cell death (De et al., 
2006). 
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A. Posterior segment 
                           
 
 
 
 
 
 
 
 
 
B. Anterior segment 
 
 
 
 
 
 
 
 
 
 
Figure 4–11: Summary of the potential cellular role of OPTN in the posterior 
segment (A) and in the anterior segment (B).  
(A) OPTN negatively regulates TNFα-induced NF-κB activation and prevents its pro-
apoptotic effects. OPTN also prevents aberrant activation of TBK1, which in turn 
regulates TNFα and its pro-apoptotic effects (B) Sustained elevation of IOP results in an 
upregulation of OPTN expression in human TM maintained in organ culture. It is 
speculated whether OPTN may provide a protective effect on the TM during raised IOP 
by possibly influencing ECM remodeling and facilitating aqueous humor outflow and 
this may involve exerting a regulatory role on MYOC expression. 
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Chapter 5  The role of transcription factor gene LMX1B in 
OHT and POAG 
 
5.1  Introduction 
This chapter investigates whether variant alleles of LMX1B p l a y  a  r o l e  i n  P O A G  
susceptibility in the general population.  
 
SNP association studies, in particular, genome wide association methods, provide a 
powerful tool for identifying genes for common diseases and complex traits (Hirschhorn 
and Daly, 2005) as evidenced by the mapping of genes for age-related macular 
degeneration (Edwards et al., 2005), myocardial infarction (Ozaki et al., 2002), and 
breast cancer (Kammerer et al., 2005). This has been mainly due to the advent of LD 
maps of SNPs across the whole genome and the development of high-throughput 
technologies for SNP genotyping. Association studies are particularly valuable as they 
should be able to detect significant variations across wide regions of the genomes e.g. 
non-coding changes, or within gene regulatory sequence, that may alter levels of 
functional protein and cause disease.  These types of disease-associated alleles may be 
identified by SNP association studies but would not be identified by standard mutation 
screening of coding sequences. 
 
A case-control genetic association study was performed to compare the prevalence of 
LMX1B SNPs in four groups, HTG (n = 272), OHT (n = 58), NTG (n = 37), and a 
normal control group (n = 276). LMX1B haplotypes were identified and their prevalence 
assessed in patients with glaucomatous optic neuropathy (HTG and NTG patients), and 
in patients with raised IOP (HTG and OHT patients). In order to determine whether the 
initial positive findings could be replicated, a separately ascertained second cohort 
consisting of ethnically matched HTG (n = 108) and NTG (n = 222) cases were assessed 
with the same control group.  
 
LMX1B has not been analysed in any association studies to date and here protective 
LMX1B haplotype associations for both glaucoma and raised IOP were identified.                                                    Chapter 5 The role of transcription factor gene LMX1B in OHT and POAG 
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5.2  Results from the first cohort of HTG, OHT and NTG 
By using the algorithm tagger which was implemented in Haploview v.4.0 to select 
tSNPs that captured untyped SNPs with a minimum r
2 value of 0.8, 26 SNPs for LMX1B 
were chosen. Selection was restricted to SNPs with a minor allele frequency (MAF) of 
≥10% (i.e. SNPs with a high degree of polymorphism). Selection was also focused on 
identifying non-synonymous SNPs and this included rs28939692 (27 SNPs in total 
when combined with SNPs selected from HapMap). Due to poor performing TaqMan 
assays, as evidence by indistinct cluster plots, the SNP assays of rs10819195, rs785713, 
and rs7858338 were excluded from further analysis. Hence a total of 23 tSNPs and a 
manually chosen non-synonymous SNP, all of which spanned a region of 102,314 bp 
(including the 82,314 bp LMX1B gene) were assessed in all individuals (Figure 5-1) 
using Sequenom iPLEX
TM Assay MassARRAY technology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5–1: The relative position of the 23 tSNPs (labeled above with the respective 
haplotype) in LMX1B are shown after having excluded tSNPs rs10819195, 
rs785713, and rs7858338 due to its poor performing assays, and rs28939692 as it 
deviated from HWE (shown in light grey font colour).  
8 coding exons are indicated as solid boxes and numbered accordingly. Untranslated 
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Figure 5–2 (A) Diagram of block structure of LMX1B generated using Haploview 
v.4.0. 
LD plots were identified by strong LD. Depth of red/pink colour indicates the computed 
pairwise D' value; deeper pink indicates a higher D' value. (B) The selected tSNPs and 
estimated haplotype frequencies in the six major haplotype blocks (1-6) are shown. 
Marker numbers and arrows above the haplotypes indicate tSNPs. The frequency of 
each haplotype within a block is given to the right of the haplotype. The thickness of the 
lines connecting the haplotypes across blocks represents the relative frequency [i.e., 
high (thick) versus low (thin)] with which a given haplotype is associated with the 
haplotype in the neigbouring block.                                                   Chapter 5 The role of transcription factor gene LMX1B in OHT and POAG 
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Genotyping success rate varied from 92.0 % and 99.0% for the first cohort of HTG, 
OHT and NTG patients and controls. The genotype distributions of these 23 SNPs
 in the 
controls did not differ from those expected from HWE except for the non-synonymous 
SNP rs28939692 and this was subsequently excluded from further analysis. The 
pairwise LD matrix generated in Haploview v.4.0 of the entire patient and control 
cohort revealed 6 main haplotype
 blocks (Figure 5-2). 
 
 
5.2.1  Associations between individual SNPs and glaucoma  
The
 allele frequencies of the 23 tSNPs between the 3 separate case groups (HTG, NTG, 
OHT) as well as among 2 combined groups (HTG+OHT, HTG+NTG), and controls 
were assessed using Haploview v.4.0 and tSNPs showing significant effects are shown 
in Table 5-1.  
 
In the HTG group, 4 tSNPs (all situated in intron 2) had allele frequencies that differed
 
significantly between patients and controls. Protective allele frequencies of rs7859156, 
rs6478750 and rs7854658 were higher in controls than in HTG patients (P = 0.0015, 
0.0258, 0.0057 respectively), with ORs of 0.64, 0.72 and 0.65
  respectively after 
adjustment for sex. By contrast the risk allele frequency of rs10987385 was higher in 
the HTG patients than in controls (P = 0.0180), with an OR of 1.43
 after adjustment for 
sex.  
  
In the OHT group, 2 of these tSNPs (both situated in intron 2) had allele frequencies 
that differed
 significantly between patients and controls. Protective allele frequencies of 
rs7859156 and rs6478750 were higher in controls than in OHT patients (P = 0.0482 and 
0.0309 respectively), both with ORs of 0.59 after adjustment for age. 
 
In the NTG group 5 tSNPs had allele frequencies that differed
 significantly between 
NTG patients and controls, but only one of these alleles (rs7854658) was in common 
with the significant HTG tSNPS. The protective allele frequency of rs7854658 was 
higher in the controls than in NTG patients (P  = 0.0041) with an OR of 0.30. In 
addition, risk allele frequencies of rs944103, rs16929236, rs10733682 and rs867559
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were higher in NTG patients than in controls (P = 0.0488, 0.0064, 0.0489 and 0.0295 
respectively), with ORs of 1.71,
 2.30, 1.75 or 1.82 respectively, after adjustment for sex. 
 
 
 
 
 
Table 5–1: Distribution of LMX1B tSNPs showing significant effects between HTG, 
OHT, NTG, HTG+OHT and HTG+NTG, compared to the wild type control group. 
tSNPs significantly distributed after 1000 permutation tests are highlighted in bold. Odds 
ratios were calculated using Thesias v.3.1 whereas the remaining columns (including case 
and controls counts, chi-square, P value, permutation P) were generated using Haploview 
v.4.0. 
Phenotype  tSNP 
 
SNP ID    Allele  Case 
counts 
(%) 
Control 
counts 
(%) 
Chi-
square 
P value  Permutation 
P 
Odds ratio 
(95% confidence 
interval) 
4  rs7859156  T  121 (23.1)  171 (31.8)  10.06
  
0.0015 0.0376  0.64  (0.49-0.85) 
6  rs6478750   C  193 (36.3)  236 (42.9)  4.97  0.0258  NS  0.72 (0.55-0.93) 
7  rs10987385  A  147 (27.7)  118 (21.5)  5.59  0.0180  NS  1.43
 (1.07-1.91) 
HTG 
11  rs7854658   A  95 (18.0)  137 (24.9)  7.63  0.0057  NS  0.65
 (0.49-0.89) 
4  rs7859156   T  24 (22.2)  171 (31.8)  3.90  0.0482  NS  0.59 (0.34-1.01)  OHT 
6  rs6478750  C  35 (31.8)  236 (42.9)  4.66  0.0309  NS  0.59 (0.35-0.97) 
9 rs944103 
 
G  41 (55.4)  238 (43.3)  3.88  0.0488  NS  1.71
 (1.06-2.77) 
11 rs7854658 
 
A  7 (9.7)  137 (24.9)  8.25  0.0041  NS  0.30 (0.14-0.64) 
17 rs16929236 
 
G  17 (23.0)  64  (11.6)  7.42
  
0.0064 NS  2.30  (1.30-4.05) 
18 rs10733682 
 
A  44 (59.5)  260 (47.3)  3.88
  
0.0489 NS  1.75  (1.05-2.90) 
NTG 
21 rs867559 
 
G  22 (29.7)  104 (18.9)  4.74  0.0295  NS  1.82 (1.09-3.05) 
4  rs7859156   T  145 (22.9)  171 (31.8)  11.52  7.0E-4  0.0120  0.63
 (0.48-0.82) 
6  rs6478750   C  228 (35.5)  236 (42.9)  6.81  0.0090  NS  0.69 (0.54-0.89) 
7 rs10987385 
 
A  175 (27.3)  118 (21.5)  5.37  0.0205  NS  1.39 (1.05-1.84) 
HTG + 
OHT 
11 rs7854658 
 
A  116 (18.2)  137 (24.9)  7.98  0.0047  NS  0.66 (0.50-0.88) 
4
  
rs7859156 T 
 
138 (23.2)  171 (31.8)  10.40  0.0013  0.0360 
 
0.64
 (0.49-0.84) 
6  rs6478750  C  220 (36.3)  236 (42.9)  5.27  0.0217  NS  0.73 (0.57-0.94) 
7  rs10987385  A  162 (26.8)  118 (21.5)  4.37  0.0366  NS  1.35 (1.02-1.79) 
HTG + 
NTG 
11  rs7854658  A  102 (17.0   137 (24.9)  10.90  0.0010  0.0270  0.62 (0.46-0.83) 
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rs7854658 and rs944103 are situated in intron 2, whereas rs16929236, rs10733682 and 
rs867559 are situated in the 3’ region of LMX1B. After permutation testing, all
 P values 
for these differences between patients in each group and controls
 increased beyond the 
significant level of 0.05, except for rs7859156 which had a permutated P value of 
0.0376 after 1,000 tests in the HTG group. 
 
Next the
 allele frequencies of the 23 tSNPs in the combined groups of all patients with 
raised IOP (HTG and OHT), or all patients with glaucomatous optic neuropathy i.e. all 
the POAG patients (HTG and NTG) were compared with the control group. In both 
groups, HTG+OHT and HTG+NTG, the same four tSNPs had an allele frequency that 
differed
  significantly between patients and controls (Table 5-1). Protective allele 
frequencies of rs7859156, rs6478750 and rs7854658 were higher in controls than cases, 
and risk allele frequencies of rs10987385 were higher in patients than in controls. In 
both combined groups, tSNP rs7859156, remained significantly different after 1,000 
permutation tests (P = <0.05). In addition, in the combined POAG case group 
(HTG+NTG) a second tSNP rs7854658 remained significantly different after 
permutation testing.  
 
Of note are the combined effects of age, IOP and tSNP rs7854658, which was capable 
of correctly guessing the case status 93.8 % of the time in multivariate regression 
analysis. In another words, after adjusting for the effects of IOP and age, rs7854658 was 
not significantly associated with the case status, thus revealing that the influence of 
rs7854658 may be partially explained by its relationship with IOP and age.  
 
5.2.2  Association between haplotypes and HTG 
The difference in the distribution of all common haplotypes between individuals with 
HTG and controls (Table 5-2) was assessed and a significant halotype effect of block 2 
and block 3 was found. Haplotypes ATG and ACG (defined by tSNPs rs12336217, 
rs7859156, rs10819190) were significantly distributed between patients and controls, 
with the haplotype ATG exhibiting the strongest effect. This was less prevalent among  
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the patients compared with the controls (22.8% versus 31.7%; P = 0.0010) and 
remained significant after permutation testing. 
 
Individuals with haplotype ATG were at a reduced risk of developing HTG compared 
with non-carriers (OR 0.75) but this did not remain significant after adjustment for sex 
(P = 0.0750). 
 
Within block 3, 2 haplotypes, (GCAGAC, ACAGGT; defined by rs10987385, 
rs13285227, rs944103, rs12555176, rs7854658, and 10987386) were differentially 
distributed in patients and controls, but these associations did not withstand permutation 
testing (Table 5-2). 
 
 
Table 5–2: Distribution of LMX1B haplotypes between HTG cases and controls. 
Haplotypes significantly distributed after 1000 permutation tests are highlighted. P values 
after adjustment for sex are provided only for haplotypes that are significantly distributed. 
Odds ratios were calculated using Thesias v.3.1 whereas the remaining columns (including 
haplotype, all subject counts, case and controls counts, chi-square, P value, permutation P) 
were generated using Haploview v.4.0. 
Block  Haplotype  
  
 
All subjects 
(%) 
Case 
counts 
(%) 
Control 
counts 
(%) 
Chi-
square 
P value  Permutation P  Odds ratio (95% 
confidence interval) 
P value after 
adjustment for sex 
ACA   35.0    34.8  35.2
  
0.023 0.8804  1.0000   
ACG   28.7    32.2  25.4
  
6.185 0.0129  0.2720  1.39  (1.02-1.90) 
P = 0.0377 
ATG   27.4    22.8  31.7
  
10.775 0.0010  0.0300  0.75  (0.54-1.03) 
P = 0.0750 
2 
(tSNP 3 to 
5) 
GCG 8.6  9.9  7.4
  
2.057 0.1515  0.9770   
GTGGGC   31.8    31.8  31.8
  
0.00 0.9653  1.0000   
GCAGAC   21.1    17.5  24.7
  
8.15 0.0043  0.1040  0.73  (0.52-1.02) 
P = 0.0648 
ACAGGT   11.7    14.2  9.4
  
6.19 0.0128  0.2720  1.64  (1.09-2.48) 
P = 0.0189 
GCGGGC   11.0    12.3  9.8
  
1.78 0.1818  0.9890   
GCAGGC 10.1    9.5  10.6
  
0.49 0.4851  1.0000   
ACATGT   9.2    9.2  9.2
  
0.00 0.9892  1.0000   
3 
(tSNP 7 to 
12) 
ACAGGC   1.4    1.4  1.3
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5.2.3  Associations between haplotypes and raised IOP  
Here, the difference in frequency distribution of all common haplotypes
 between the 
combined raised IOP patient group (HTG+OHT) and the controls were compared 
(Table 5-3) and a significant
 haplotype effect of block 2 and block 3 was found. Within 
block 2, two haplotypes
 (ATG and ACG) were differentially distributed in patients and
 
controls (Table 5-3). Of these haplotype
  ATG was most significant and was less 
prevalent among patients compared with
 controls (22.7% versus 31.7%; P = 0.0005) 
and remained significant after permutation testing. 
 
 
 
 
 
Table 5–3: Distribution of LMX1B haplotypes between HTG+OHT cases and controls.  
Haplotypes significantly distributed after 1000 permutation tests are highlighted. P values after 
adjustment for sex are provided only for haplotypes that are significantly distributed. Odds ratios 
were calculated using Thesias v.3.1 whereas the remaining columns (including haplotype, all 
subject counts, case and controls counts, chi-square, P value, permutation P) were generated using 
Haploview v.4.0. 
Block  Haplotype 
 
 
All 
subjects 
(%)
  
Case 
counts  
(%) 
Control 
counts 
(%) 
Chi-
square 
P value     Permutation P  Odds ratio (95% 
confidence interval) 
P value after 
adjustment for sex 
ACA 
  
35.6
  
35.8 35.2    0.048 0.8269  1.0000   
ACG 
  
28.8
  
31.7 25.4    5.847 0.0156  0.3020  1.33  (0.99-1.78) 
P = 0.0591 
ATG 
  
26.9
  
22.7 31.7    12.223  5.0E-4  0.0100  0.72  (0.53-0.97) 
P = 0.0330 
2 
(tSNP 3 to 5) 
GCG 8.5
  
9.4 
 
  
7.4   1.565
  
0.2110 0.9987   
GTGGGC
  
31.6
  
31.4 31.8    0.02  0.8865  1.0000   
GCAGAC
  
21.0
  
17.8 24.7    8.517 0.0035  0.0710  0.75  (0.54-1.03) 
P = 0.0770 
ACAGGT
  
11.8
  
14.0 9.4    6.005 0.0143  0.2770  1.61  (.08-2.41) 
P = 0.0190 
GCGGGC
  
11.2
  
12.4 9.8    1.999
  
0.1574 0.9875   
GCAGGC
  
10.2
  
9.8 10.6    0.185  0.6668  0.9875   
ACATGT
  
9.5
  
9.8 9.2    0.095  0.7580  1.0000   
3 
(tSNP 7 to 
12) 
ACAGGC
  
1.2
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Haplotype ATG carriers were at a decreased
 risk of developing raised IOP compared 
with non-carriers (OR
 0.72) and this remained significant after adjustment for sex (P = 
0.0330). The LD observed between SNPs and different functional effects of the 
haplotypes are potential sources of bias when studying multiple SNPs. Therefore, 
haplotype background analysis was performed in Thesias v.3.1 and although 
rs12336217, rs7859156 and rs10819190 are in LD, the rs7859156 polymorphism 
exerted an independent decreased risk to glaucoma (OR = 0.54; 95% CI 0.39 - 0.75; P 
=0.0003). 
 
Within block 3, two haplotypes (GCAGAC, ACAGGT) were differentially distributed 
in patients and controls, although these associations did not withstand permutation 
testing (Table 5-3, 5-4).  
 
These data suggest that LMX1B haplotypes, or perhaps an unknown nearby functional 
variant in LD, affect IOP and consequently predispose to glaucoma. 
 
5.2.4  Associations between haplotypes and glaucoma (HTG+NTG) 
Examination of the difference in frequency distribution of all common haplotypes
 
between the combined POAG patient group (HTG+NTG) and the controls (Table 5-4) 
found a significant
 effect of the same block 2 and block 3 haplotypes on glaucoma. 
Within block 2, the ACG and ATG haplotypes
 were differentially distributed in patients 
and
 controls with haplotype
 ATG showing the strongest effect. ATG
 was significantly 
less prevalent among patients compared with
 controls (22.9% versus 31.7%; P = 0.0008 
and remained significant after permutation testing). ATG carriers were at a decreased
 
risk of developing glaucoma compared with non-carriers (OR
 0.73) and this remained 
significant after adjustment for sex (P = 0.0450). Haplotype background analysis was 
performed to see if any of the tSNPs within the haplotype block 2 had an independent 
effect on glaucoma risk. Although rs12336217, rs7859156 and rs10819190 are in LD, 
rs7859156 polymorphism exerted an independent increased risk (OR = 0.54; 95% CI 
0.39-0.75; P =0.0002). 
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Within block 3, three haplotypes (GCAGAC, GCGGGC, ACAGGT defined by 
rs10987385, rs13285227, rs944103, rs12555176, rs7854658, and 10987386) were 
differentially distributed in patients and controls and one of these GCAGAC, was 
significant after permutation testing. Haplotype
  GCAGAC was significantly less 
prevalent among patients compared with
 controls (16.5% versus 24.7%; P = 0.0005 and 
turned into P = 0.0150
 after 1,000 permutation tests). GCAGAC carriers were at a 
decreased
 risk of developing glaucoma compared with non carriers (OR,
 0.70;  P = 
0.0360) after adjustment for sex in multivariate logistic regression analysis.  
 
Crucially, the relation between haplotypes in block 2 and 3 and glaucoma risk did not 
persist after adjusting for CDR in Thesias. CDR is significantly increased in both NTG 
and HTG compared with controls (Table 5-1). Thus, the influence of these LMX1B 
Table 5–4: Distribution of LMX1B haplotypes between HTG+NTG cases and controls. 
Haplotypes significantly distributed after 1000 permutation tests are highlighted. P values after 
adjustment for sex are provided only for haplotypes that are significantly distributed.  Odds 
ratios were calculated using Thesias v.3.1 whereas the remaining columns (including haplotype, 
all subject counts, case and controls counts, chi-square, P value, permutation P) were generated 
using Haploview v.4.0. 
Block  Haplotype 
 
 
All subjects 
(%) 
Case  
Counts 
(%) 
Control 
counts (%)  
Chi-
square 
P value  Permutation P  Odds ratio (95% 
confidence interval) 
P value after 
adjustment for sex 
ACA    35.3  35.3  35.2    0.0010  0.9718  1.0000   
ACG 
  
28.9  32.2  25.4    6.464  0.0110  0.2350  1.36 (1.01-1.83) 
P = 0.0437 
ATG 
  
27.1  22.9  31.7    11.303  8.0E-4  0.0220  0.73 (0.54-0.99) 
P = 0.0450 
2 
(tSNP 3 to 5) 
GCG 
  
8.4 9.3  7.4  1.351  0.2452  1.0000   
GTGGGC   31.6  31.4  31.9  0.024  0.8768  1.0000   
GCAGAC   20.4  16.5  24.7  11.949  5.0E-4  0.0150  0.70 (0.51-0.98) 
P = 0.0360 
GCGGGC 11.9  13.9 9.8  4.444  0.0350  0.5760  1.51  (1.003-2.28) 
P = 0.0480 
ACAGGT 11.7  13.8 9.4  5.392  0.0202  0.3980    1.6  (1.09-2.46) 
P = 0.0170 
GCAGGC   10.5  10.3  10.8  0.086  0.7689  1.0000   
ACATGT   9.1  9.1  9.3  0.015  0.9033  1.0000   
3 
(tSNP 7 to 
12) 
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haplotypes or a nearby functional variant in LD, on glaucoma risk may be partially 
explained by their relation with CDR. 
 
5.2.5  Results from the second cohort 
A smaller number of 11 tSNPs were analysed for the replication study using cohort 2 
comprised of HTG, NTG and controls (Figure 5-3). The association with the OHT 
group was not assessed in the replication study as DNA samples of OHT individuals 
were not available. These tSNPs were chosen either because the individual tSNPs 
(rs7859156, rs10987385, rs944103, rs7854658, rs16929236, rs867559) or groups of 
tSNPs comprising haplotype blocks 2 and 3 showed significant distribution between the 
cases and controls. Genotyping success rate for the second cohort was 99.0%. The 
haplotype block 2 and 3 from the initial study are now depicted as block 1 and 2 (Figure 
5-4) in the replication study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5–3: The relative position of the 11 tSNPs (labeled above with the respective 
haplotype) in LMX1B for the replication study in relation to the original sets of 24 
tSNPs shown in light grey font colour.                                                    Chapter 5 The role of transcription factor gene LMX1B in OHT and POAG 
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Figure 5–4: (A) Diagram of block structure of LMX1B generated for the replication 
study using the Haploview v.4.0 from 11 tSNPs only.  
LD plots were identified by strong LD. Depth of red/pink colour indicates the computed 
pairwise D' value; deeper pink indicates a higher D' value. (B) The selected tSNPs and 
estimated haplotype frequencies in the two major haplotype blocks (1 and 2) are shown. 
Marker numbers and arrows above the haplotypes indicate tSNPs. The frequency of 
each haplotype within a block is given to the right of the haplotype. The thickness of the 
lines connecting the haplotypes across blocks represents the relative frequency [i.e., 
high (thick) versus low (thin)] with which a given haplotype is associated with the 
haplotype in the neighbouring block.                                                   Chapter 5 The role of transcription factor gene LMX1B in OHT and POAG 
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5.2.5.1  Associations between individual SNPs and glaucoma  
A similar pattern of tSNP association was observed in the second cohort (Table 5-5) 
with the protective allele frequency of rs7859156 being significantly associated with 
HTG, NTG and HTG+NTG (P = 0.0387, 0.0470, and 0.0274 respectively), but 
relatively less when compared to those obtained from the first cohort. In addition, a 
tSNP rs12555176 (situated in intron 2) which was not associated with any of the case 
groups in the initial study, had an allele frequency that showed a stronger association (in 
comparison to tSNP rs7859156) with the NTG group (P = 0.0089) as well as the 
HTG+NTG group (P = 0.0274), when compared with the controls. 
 
 
 
5.2.5.2  Association between haplotypes and HTG, NTG and 
HTG+NTG 
When the difference in the frequency distribution of all common haplotypes between 
the cases (including HTG, NTG, HTG+NTG) and the controls was examined within 
block 1 (Table 5-6) of the second cohort, the protective haplotype ATG that was found 
significantly distributed in the initial study, continued to show differential distribution 
in all of the case group (HTG, NTG, HTG+NTG) compared to the controls (P = 0.0150, 
0.0241. 0.0047 respectively). Among the case group, haplotype ATG had a strongest  
Table 5–5: Association of LMX1B tSNPs in the replicate study showing a comparable 
pattern of distribution between HTG, NTG, and HTG+NTG, compared to the wild type 
control group but did not withstand permutation testing. 
Odds ratios were calculated using Thesias v.3.1 whereas the remaining columns (including 
case and controls counts, chi-square, P value, permutation P) were generated using Haploview 
v.4.0. 
Phenotype  tSNP 
 
SNP ID    Allele  Case 
counts 
(%) 
Control  
counts 
(%) 
Chi-square  P value  Permutation P  Odds ratio 
(95% confidence 
interval) 
HTG  4  rs7859156      T  49 
(24.0) 
171 
(31.8) 
4.28 0.0387  NS  0.68  (0.48-0.98) 
4 rs7859156   
 
T 111 
(25.9) 
171 
(31.8) 
3.95 0.0470  NS  0.76
 (0.58-1.00)  NTG 
10 rs12555176 
 
T 23 
(5.2) 
52  
(9.7) 
6.84 0.0089  NS  0.48  (0.29-0.82) 
4
  
rs7859156 T 
 
160 
(25.3) 
171 
(31.8) 
5.99 0.0144  NS 
 
0.74
 (0.57-0.95)  HTG + 
NTG 
10 rs12555176 
 
T   41 
(6.2) 
52  
(9.7) 
4.87 0.0274  NS  0.59  (0.38-0.93) 
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effect on the combined glaucoma group (HTG+NTG) (OR 0.75) and was less prevalent 
among the patients compared with controls (24.6% versus 31.9%). 
 
Within block 2, haplotype ACAGGT which was differentially distributed in the first 
cohort in all of the case groups, showed a similar pattern of association in the 
HTG+NTG group (P = 0.0363). In addition, haplotype frequency of ACATGT which 
did not differ significantly between the cases and the controls in the initial cohort, was 
significantly distributed within both NTG and HTG+NTG groups (P = 0.0106 and 
0.0292 respectively). The remaining haplotypes (GCAGAC, GCGGC) which produced 
significant effects in the first cohort did not maintain its noteworthy effects in the 
second cohort.  
 
Despite the fact that none of the associations between the haplotypes and the case 
groups withstood permutation testing, the replicate study on an independent cohort has 
shown a comparable pattern of SNP and haplotype distribution which provides further 
evidence to support the initial findings of an association between alleles in LMX1B and 
Table 5–6: Distribution of LMX1B haplotypes between HTG, NTG, HTG+NTG cases and 
controls.  
Odds ratios were calculated using Thesias v.3.1 whereas the remaining columns (including 
haplotype, all subject counts, case and controls counts, chi-square, P value, permutation P) were 
generated using Haploview v.4.0. 
Block  Haplotype  Case group 
 
All 
subjects 
(%) 
Case 
counts 
(%) 
Control 
counts 
(%) 
Chi-
square 
P value  Permutation P  Odds ratio 
(95% 
confidence 
interval) 
HTG 29.3  22.9  31.8  5.92  0.0150  0.1610  0.67  (0.44-
1.01)  
NTG 29.1  25.4  32.0  5.09  0.0241  0.2360  0.79  (0.57-
1.08) 
1 
(tSNP 
1 to 3) 
ATG 
HTG+NTG 27.9  24.6  31.9  7.99  0.0047  0.0650  0.75  (0.56-
1.00) 
ACAGGT HTG+NTG  11.3  13.0  9.2
  
4.38 0.0363  0.3690  1.4  (0.97-
2.21) 
NTG 7.3
  
5.0 9.2
  
6.53 0.0106  0.1210  0.52  (0.28-
0.93)  
2 
(tSNP 
4 to 9)  ACATGT 
HTG+NTG 7.4  5.9  9.2  4.76  0.0292  0.3130  0.65  (0.39-
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POAG. It should also be noted that cohort two is considerably smaller than cohort one 
and therefore has less statistical power. 
 
5.2.6  Discussion 
Around 1-2% of individuals ≥40 years of age in the general population develop POAG, 
compared with 33% of patients with the rare condition, NPS (MIM161200) caused by 
dominant mutations in the LMX1B gene. In this study LMX1B has been investigated as a 
candidate genetic risk factor for the most common form of glaucoma and significant 
associations were identified between LMX1B alleles and haplotypes and POAG. 
 
In the large HTG cohort, the frequency of the protective tSNP rs7859156 in intron 2 
was significantly reduced compared with the controls and this effect withstood stringent 
permutation testing. A similar pattern of result was reproduced in the smaller HTG 
group in the replication study. Interestingly, in the first cohort, a number of weak 
associations (with tSNPS rs6478750, rs10987385 and rs7854658) among the HTG 
group were replicated in the smaller OHT and NTG groups. 
 
The HTG group is characterised by glaucomatous damage, and raised IOP. The other 
two patient groups each have only one of these characteristics, either glaucomatous 
damage without raised IOP (NTG), or raised IOP without glaucomatous damage (OHT). 
In order to test the relationship between the variant alleles of LMX1B and these two 
characteristics patients have been grouped into those with raised IOP (HTG and OHT), 
or those with glaucomatous damage irrespective of IOP (HTG and NTG). Notably, in 
both of the combined groups the significant association with the protective tSNP 
rs7859156 in intron 2 was replicated and enhanced. Again, a similar pattern of 
association was reproduced and enhanced in the replication study between tSNP 
rs7859156 with the combined group HTG and NTG. Moreover, tSNPs rs7854658, 
identified in the separate NTG and HTG groups was highly significant and withstood 
permutation testing in the combined NTG+HTG group. This was an interesting result 
and was confirmed by haplotype analysis suggesting that the effect of LMX1B on 
glaucoma susceptibility may involve functions that are broader than effects on IOP. As 
the HTG cases are highly represented in the combined groups, the replication study 
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and haplotypes seen in the initial cohort, but with weaker correlations. Of note is the 
tSNP rs12555176 which emerged to be significantly distributed with the larger NTG 
group, but not with the smaller cohort of the initial study.  
 
 Recent studies have shown that 26.7 % of individuals with NPS above the age of 50 
develop NTG (Bongers et al., 2005), whereas 11.9% of individuals develop OHT over 
the age of 40 (Sweeney et al., 2003). These data are also consistent with the proposal 
that the role of LMX1B in glaucoma pathology may be complex.  
 
Six main haplotype blocks were identified across the LMX1B gene. Haplotypes within 
two of these blocks containing the significantly varying tSNPs were found to show 
significantly altered distributions in the two combined patient groups, POAG 
(HTG+NTG) and raised IOP±HTG (HTG+OHT). The block 2 ATG haplotype is 
associated with both groups and with HTG alone, and a similar pattern of results were 
confirmed with the HTG+NTG in the replication study. Whereas the block 3 GCAGAC 
haplotype shows the strongest association with the HTG+NTG group in the initial study 
but interestingly not in the replication study in which a different haplotype ACATGT 
emerged as having the best association. The block 2 haplotype (spanning a region of 
~6700 bp) and the block 3 haplotype (spanning a region of ~28000 bp) are both located 
within the large intron 2 of LMX1B. This region shows stretches of greater than 85% 
conservation between the sequences of humans and mouse, and a functional role, such 
as gene expression regulatory regions, has been suggested (Dunston et al., 2004). 
Significantly, the block 2 haplotype is in complete LD with the promoter and 5’ 
upstream regions (Dunston et al., 2004). Therefore, despite being an intronic sequence, 
this haplotype may tag important conserved regions involved in gene regulation.  
 
The proposal that levels of LMX1B expression are relevant to risk of elevated IOP and 
glaucoma is in line with the well documented sensitivity of ocular development to gene 
dosage. For example, variations in the copy number of FOXC1 (Lehmann et al., 2002) 
and PAX6 (Dora et al., 2008) which are presumed to alter levels of gene expression, or 
mutations in PITX2 t h a t  i n c r e a s e  o r  d e c r e a s e  l e v e l s  of transcription factor function 
(Kozlowski and Walter, 2000) cause anterior segment anomalies and glaucoma. These 
developmental glaucoma genes are obvious candidates for further association studies for 
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greater association with HTG and/or OHT and may serve as important prognostic 
indicators in the general population.  
 
Despite the progress in identifying genes that are involved in POAG, understanding of 
the underlying pathogenic mechanism is still limited. This is partly because if each 
causal gene only makes a small contribution to the overall phenotype, then unravelling 
the role each plays in the biochemical and cellular pathways involved in IOP control 
and retinal ganglion cell function is complex. New insights into a possible Lmx1b 
pathway relevant to glaucoma pathology was provided by a report showing mutations in 
the collagen Col4a1 gene resulted in ASD with optic nerve hypoplasia, and raised, as 
well as low IOP (Gould et al., 2007). Lmx1b is known to directly regulate expression of 
Col4a3 and Col4a4 in the kidney (Morello et al., 2001; Rohr et al., 2002) and Lmx1b
-/- 
mice showed defective collagen fibrillogenesis in the eye, as well as ciliary body 
hypoplasia (Pressman et al., 2000) though there is not yet evidence that Lmx1b regulates 
Col4a1. Considered together the data from this study and other studies suggest that 
altered LMX1B activity levels cause abnormalities and dysfunction in the IOP-
regulating anterior segment structures that are age-related and are clinically 
undetectable, resulting in POAG. While JOAG can be a consequence of LMX1B 
mutation in NPS (Mimiwati et al., 2006; Sweeney et al., 2003), the mean age at which 
open angle glaucoma or OHT is detected in NPS has been above the age of 40 at 63.4 
(range 55- 72) (Bongers et al., 2005), and 47.9 years (range 23-78) (Sweeney et al., 
2003) a feature more in consistent with POAG. 
 
Summary This is the first study to show an association between variants of LMX1B and 
POAG. These data indicate altered LMX1B function may be associated with the 
common forms of POAG in the general population and provides a platform for further 
investigation of LMX1B as a genetic risk factor for adult-onset glaucoma.   
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Chapter 6  The role of signaling molecules TGFβ2, BMP4 
and transcription factor gene FOXC1 in OHT and 
POAG 
 
6.1  Introduction 
In this chapter, the contribution of variations at the TGFβ2, BMP4 and FOXC1 loci to 
risk of OHT and POAG was assessed within the general population. A case-control 
genetic association study was performed to compare the prevalence of TGFβ2, BMP4 
and FOXC1 SNPs in four groups, HTG (n = 272), OHT (n = 58), NTG (n = 37), and a 
normal control group (n = 276). TGFβ2, BMP4 and FOXC1 haplotypes were identified 
and their prevalence assessed in patients with glaucomatous optic neuropathy (HTG and 
NTG patients), and in patients with raised IOP (HTG and OHT patients). 
 
This is the first association study to assess TGFβ2, BMP4 and FOXC1 as candidate 
genetic risk factors for OHT/POAG, and here no associations were identified with both 
glaucoma and raised IOP. 
 
6.2  Results 
By using the algorithm tagger which was implemented in Haploview v.4.0 to select 
tSNPs that captured untyped SNPs with a minimum r
2 value of 0.8, 5 SNPs for BMP4 
(Figure 6-1), 22 SNPs for TGFβ2 (Figure 6-3), and 4 SNPs for FOXC1 (Figure 6-5) 
were chosen and their prevalence analysed. Selection was restricted to SNPs with a 
MAF of ≥10%. Selection was also focused on identifying functional SNPs and these 
included two 5’UTR SNPs for TGFβ2 (rs11466367 and rs17026738), and one non-
synonymous SNP for FOXC1 (rs1051933). However, either due to the presence of a 
deletion adjacent to a SNP (-/CAAA for rs11466367 and -/AAAC for rs17026738, both 
in  TGFβ2) or due to poor performing assays, as shown by indistinct cluster plots 
(rs2799085 in TGFβ), these SNPs were excluded from further analysis. In addition, as 
one SNP in FOXC1 (rs1051933) differed from that expected from HWE within the 
control group, this was excluded from further analysis. Hence a total of 5 tSNPs for 
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for TGFβ2, spanning a region of 98,075 bp (including the 95,108 bp TGFβ2 gene), and 
4 tSNPs for FOXC1 spanning a region of 12,012 bp (including the 1,661 bp FOXC1 
gene) were assessed in all individuals (Figure 6-1, 6-3 and 6-5 respectively). Using 
Sequenom iPLEX
TM Assay MassARRAY technology [except for 4 SNPs in FOXC1 
(rs2235715, rs2569889, rs1051933, and rs984253), and one SNP in BMP4 (rs17563), 
which were genotyped using TaqMan SNP genotyping assays], the genotyping success 
rate varied from 92.0 % and 99.0% for all genes. For TaqMan SNP genotyping assays, 
the genotyping success rate varied from 95.0% to 98%. The pairwise LD matrix 
revealed 2 main haplotype
 blocks for BMP4 (Figure 6-2) and 4 haplotypes blocks for 
TGFβ2 (Figure 6.4). Haplotype analysis of FOXC1 revealed no common haplotype 
between patients and variants of FOXC1 (Figure 6-6) due to lack of LD between SNPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6–1: The relative position of the 5 tSNPs in BMP4 spanning a region of 
15,272 bp. 
4 coding exons are indicated as solid boxes and numbered accordingly. Untranslated 
exons are shown as open boxes.  
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Figure 6–2: (A) Diagram of block structure of BMP4 generated using Haploview 
v.4.0. 
LD plots were identified by strong LD. Depth of red/pink colour indicates the computed 
pairwise D' value; deeper pink indicates a higher D' value. (B) The selected tSNPs and 
estimated haplotype frequencies in the two major haplotype blocks are shown. Marker 
numbers and arrows above the haplotypes indicate tSNPs. The frequency of each 
haplotype within a block is given to the right of the haplotype. The thickness of the lines 
connecting the haplotypes across blocks represents the relative frequency [i.e., high 
(thick) versus low (thin)] with which a given haplotype is associated with the haplotype 
in the neighboring block.    Chapter 6 The role of signalling molecules TGFβ2, BMP4 and transcription factor gene FOXC1 in OHT 
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Figure 6–3: The relative position of the remaining 19 tSNPs in TGFβ2 (labeled 
above with the respective haplotype) spanning a region of 98,075 bp after 
excluding tSNPs rs11466367 and rs17026738 due to a presence of a deletion 
adjacent to the SNPs, and rs2799085 due to poor performing assays.  
Excluded SNPs are shown in light grey font colour. 8 coding exons are indicated as 
solid boxes and numbered accordingly. Untranslated exons are shown as open boxes.  
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Figure 6–4 (A) Diagram of block structure of TGFβ2 generated using Haploview 
v.4.0. 
LD plots were identified by strong LD. Depth of red/pink colour indicates the computed 
pairwise D' value; deeper pink indicates a higher D' value. (B) The selected tSNPs and 
estimated haplotype frequencies in the four major haplotype blocks (1-4) are shown. 
Marker numbers above the haplotypes indicate tSNPs. The frequency of each haplotype 
within a block is given to the right of the haplotype. The thickness of the lines 
connecting the haplotypes across blocks represents the relative frequency [i.e., high 
(thick) versus low (thin)] with which a given haplotype is associated with the haplotype 
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Figure 6–5: The relative position of the remaining 4 tSNPs (labeled above with the 
respective haplotype) spanning a region of 12,012 bp in FOXC1, after excluding 
rs1051933 (shown in light grey font colour) as it differed from HWE. 
The coding exon is indicated as a solid box.  
 
 
 
 
 
 
                                                          
 
Figure 6–6: Diagram of block structure of FOXC1 generated using Haploview v.4.0 
showing absence of common haplotype due to low LD between tSNPs. 
Depth of red/pink colour indicates the computed pairwise D' value; deeper pink 
indicates a higher D' value.    Chapter 6 The role of signalling molecules TGFβ2, BMP4 and transcription factor gene FOXC1 in OHT 
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6.2.1  Lack of association between SNPs in TGFβ, BMP4 and FOXC1 and 
POAG 
The allele frequencies of the 19 tSNPs in TGFβ2, 5 tSNPs in BMP4 and 4 tSNPs in 
FOXC1 between the 5 separate case groups (HTG, NTG, OHT, HTG+OHT, 
HTG+NTG) and the controls were assessed. No significant associations were found 
(Table 6-1, 6-2 and 6-3) between TGFβ2, BMP4, and FOXC1 and glaucoma, except 
between the combined group HTG+OHT and BMP4  where there was a weak 
association which did not withstand permutation testing (uncorrected P = 0.040, 
corrected P = 0.1320, OR 1.26). 
 
 
 
 
 
 
Table 6–1: Distribution of TGFβ2  tSNPs showing no significant associations 
between HTG, OHT, NTG, HTG+OHT and HTG+NTG, compared to the wild 
type control group. 
All of the columns were generated using Haploview v.4.0. 
 
Phenotype   tSNP  SNP ID  Allele  Case Counts 
(%) 
Control counts 
(%) 
Chi-square  Uncorrected 
P value 
1  rs10495098  T  232 (43.8)  237 (43.2)  0.03  0.8619 
2  rs17047682  G  39 (7.4)    31 (5.7)  1.32  0.2502 
3  rs2799097  A  69 (13.3)    80 (15.0)  0.67  0.4108 
4  rs17047703  A  140 (26.8)    127 (23.2)  1.89  0.1685 
5  rs17558745  T  191 (36.6)     169 (31.2)  3.47  0.0623 
6  rs2796817  C  70 (13.2)    83 (15.1)  0.78  0.3749 
7  rs3892225  G  119 (22.5)   106 (19.3)  1.74  0.1873 
8  rs2009112  T  215 (40.6)    222 (40.4)  0.01  0.946 
9  rs10482751  C  145 (27.6)   153 (27.8)  0.01  0.9265 
10  rs2027566  C  167 (31.5)   172 (31.4)  0.00  0.9654 
11  rs2027567  G  116 (22.1)    124 (22.5)  0.04  0.8463 
12  rs2796814  G  132 (25.1)   118 (21.6)  1.82  0.1776 
13  rs947712  T  185 (35.6)   191 (35.1)  0.03  0.8735 
14  rs10779329  C  124 (23.6)    119 (21.7)  0.53  0.4667 
15  rs1317681  A  84 (15.9)   89 (16.4)  0.04  0.8409 
16  rs2796821  T  147 (27.8)   144 (26.2)  0.38  0.5396 
17  rs1342586  C  106 (20.0)   125 (22.8)  1.26  0.2609 
18  rs2798631  G  255 (48.7)   267 (48.9)  0.01  0.9382 
HTG 
19  rs1473526  C  138 (26.1)  150 (27.3)  0.18  0.6734 
1  rs10495098  G  72 (65.5)   311 (56.8)  2.85  0.0912 
2  rs17047682  A  105 (95.5)  517 (94.3)  0.22  0.6399 
3  rs2799097  A  17 (16.0)   80 (15.0)  0.07  0.7934 
4  rs17047703  C  89 (0.809)   421 (76.8)  0.88  0.3491 
5  rs17558745  C  78 (72.2)    373 (68.8)  0.49  0.4835 
6  rs2796817  G  19 (17.3)    83 (15.1)  0.33  0.5633 
7  rs3892225  A  90 (81.8)   444 (80.7)  0.07  0.7904 
8  rs2009112  C  68 (61.8)    328 (59.6)  0.18  0.6698 
9  rs10482751  C  80 (72.7)   397 (72.2)  0.01  0.9071 
10  rs2027566  C  35 (31.8)    172 (31.4)  0.01  0.9292 
OHT 
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12  rs2796814  G  26 (23.6)   118 (21.6)  0.22  0.6398 
13  rs947712  T  41 (37.3)   191 (35.1)  0.19  0.6655 
14  rs10779329  C  31 (28.2)    119 (21.7)  2.18  0.1401 
15  rs1317681  A  20 (18.5)   89 (16.4)  0.30  0.5830 
16  rs2796821  T  33 (30.0)    144 (26,2)  0.68  0.4093 
17  rs1342586  C  91 (82.7)   423 (77.2)  1.64  0.1999 
18  rs2798631  G  55 (50.0)    267 (48.9)  0.04  0.8334 
19  rs1473526  T  84 (76.4)   400 (72.7)  0.62  0.4311 
1  rs10495098  G  42 (60.0)   311 (56.8)  0.28  0.6051 
2  rs17047682  G  6 (8.3)   31 (5.7)  0.81  0.3674 
3  rs2799097  A  12 (16.7)   80 (15.0)  0.13  0.7181 
4  rs17047703  A  21 (30.0)   127 (23.2)  1.59  0.2077 
5  rs17558745  T  25 (35.7)    169 (31.2)  0.59  0.4430 
6  rs2796817  G  14 (19.4)   83 (15.1)  0.92  0.3383 
7  rs3892225  A  61 (84.7)   444 (80.7)  0.67  0.4147 
8  rs2009112  C  44 (62.9)    328 (59.6)  0.27  0.6044 
9  rs10482751  C  52 (72.2)   397 (72.2)  0.00  0.9943 
10  rs2027566  C  23 (31.9)   172 (31.4)  0.01  0.9237 
11  rs2027567  A  59 (81.9)   426 (77.5)  0.75  0.3873 
12  rs2796814  G  20 (27.8)   118 (21.6)  1.39  0.2377 
13  rs947712  C  49 (70.0)    353 (64.9)  0.72  0.3973 
14  rs10779329  T  57 (79.2)   429 (78.3)  0.03  0.8643 
15  rs1317681  G  63 (87.5)    455 (83.6)  0.71  0.4000 
16  rs2796821  C  56 (77.8)  406 (73.8)  0.52  0.4698 
17  rs1342586  C  55 (78.6)   423 (77.2)  0.07  0.7948 
18  rs2798631  A  37 (51.4)   279 (51.1)  0.00  0.9631 
NTG 
19  rs1473526  C  20 (27.8)   150 (27.3)  0.01  0.9280 
1  rs10495098  G  370 (57.8)  311 (56.8)  0.14  0.7125 
2  rs17047682  G  44 (6.9)   31 (5.7)  0.77  0.3819 
3  rs2799097  G  540 (86.3)    452 (85.0)  0.40  0.5294 
4  rs17047703  A  161 (25.5)    127 (23.2)  0.84  0.3591 
5  rs17558745  T  221 (35.1)  169 (31.2)  1.99  0.1579 
6  rs2796817  G  89 (13.9)   83 (15.1)  0.34  0.5623 
7  rs3892225  G  139 (21.8)   106 (19.3)  1.14  0.2855 
8  rs2009112  C  257 (40.2)   222 (40.4)  0.01  0.9420 
9  rs10482751  C  175 (27.5)   153 (27.8)  0.01  0.9076 
10  rs2027566  C  202 (31.6)   172 (31.4)  0.00  0.9482 
11  rs2027567  G  138 (21.7)    124 (22.5)  0.12  0.7258 
12  rs2796814  G  158 (24.8)   118 (21.6)  1.71  0.1905 
13  rs947712  T  226 (35.9)   191 (35.1)  0.07  0.7854 
14  rs10779329  C  155 (24.4)  119 (21.7)  1.17  0.2800 
15  rs1317681  G  104 (16.4)   89 (16.4)  0.00  0.9970 
16  rs2796821  T  180 (28.2)   144 (26.2)  0.61  0.4331 
17  rs1342586  C  125 (19.5)   125 (22.8)  1.91  0.1669 
18  rs2798631  G  310 (48.9)   267 (48.9)  0.00  0.9986 
HTG+OHT 
19  rs1473526  C  64 (25.7)   150 (27.3)  0.37  0.5413 
1  rs10495098  T  260 (43.3)    237 (43.2)  0.00  0.9768 
2  rs17047682  G  45 (7.5)   31 (5.7)  1.57  0.2097 
3  rs2799097  A  81 (13.7)   80 (15.0)  0.42  0.5173 
4  rs17047703  A  161 (27.2)   127 (23.2)  2.43  0.1185 
5  rs17558745  T  216 (36.5)   169 (31.2)  3.55  0.0595 
6  rs2796817  C  84 (14)   83 (15.1)  0.30  0.5839 
7  rs3892225  G  130 (21.7)    106 (19.3)  1.01  0.3153 
8  rs2009112  T  241 (40.2)     222 (40.4)  0.01  0.9458 
9  rs10482751  T  165 (27.6)   153 (27.8)  0.01  0.9318 
10  rs2027566  C  190 (31.6)    172 (31.4)  0.01  0.9492 
11  rs2027567  G  129 (21.6)   124 (22.5)  0.16  0.6910 
12  rs2796814  G  152 (25.4)   118 (21.6)  2.29  0.1299 
13  rs947712  T  206 (34.9)   191 (35.1)  0.01  0.9452 
14  rs10779329  C  139 (23.2)    119 (21.7)  0.38  0.5359 
15  rs1317681  A  93 (15.5)   89 (16.4)  0.16  0.6912 
16  rs2796821  T  163 (27.2)    144 (26.2)  0.14  0.7061 
17  rs1342586  T  121 (20.2)   125 (22.8)  1.19  0.2756 
18  rs2798631  G  290 (48.7)   267 (48.9)  0.01  0.9345 
HTG+NTG 
19  rs1473526  C  158 (26.3)   150 (27.3)  0.13  0.7193 
    Chapter 6 The role of signalling molecules TGFβ2, BMP4 and transcription factor gene FOXC1 in OHT 
and POAG  
  211
 
Table 6–2: Distribution of BMP4 tSNPs between HTG, OHT, NTG, HTG+OHT 
and HTG+NTG, compared to the wild type control group.  
tSNPs that are significantly distributed are high lighted in bold. All of the columns were 
generated using Haploview v.4.0. 
Phenotype  tSNP  SNP ID  Allele  Case Counts 
(%) 
Control 
counts (%) 
Chi-
square 
Uncorrected 
P value 
1  rs11623717  A  197 (62.4)    219 (60.0)  0.63  0.4264 
2  rs17563  A  315 (61.5)   298 (58.0)  1.34  0.2467 
3  rs2761884  T  265 (50.2)    243 (44.3)  3.69  0.0548 
4  rs8014071  C  342 (64.8)   344 (63.0)  0.36  0.5463 
HTG 
5  rs8014363  A  248 (49.6)  235 (47.6)  0.41  0.5222 
1  rs11623717  A  68 (61.8)    329 (60.0)  0.12  0.7274 
2  rs17563  A  60 (60.0)   298 (58.0)  0.14  0.7073 
3  rs2761884  T  56 (50.9)    243 (44.3)  1.59  0.2069 
4  rs8014071  C  74 (67.3)    344 (63.0)  0.72  0.3956 
OHT 
5  rs8014363  A  52 (48.1)   235 (47.6)  0.01  0.9134 
1  rs11623717  G  33 (45.8)   219 (40.0)  0.91  0.3404 
2  rs17563  G  29 (42.6)   216 (42.0)  0.01  0.9220 
3  rs2761884  T  35 (48.6)   243 (44.3)  0.47  0.4936 
4  rs8014071  T  30 (41.7)   202 (37.0)  0.59  0.4417 
NTG 
5  rs8014363  G  34 (53.1)   259 (52.4)  0.01  0.9165 
1  rs11623717  A  395 (62.3)  329 (60.0)  0.64  0.4251 
2  rs17563  A  375 (61.3)   298 (58.0)  1.26  0.2610 
3  rs2761884  T  321 (50.3)    243 (44.3)  4.21  0.0401 
4  rs8014071  C  416 (65.2)   344 (63.0)  0.62  0.4312 
HTG+OHT 
5  rs8014363  A  300 (49.3)   235 (47.6)  0.34  0.5585 
1  rs11623717  A  366 (61.4)  329 (60.0)  0.23  0.6347 
2  rs17563  A  354  (61.0)   298 (58.0)  1.06  0.3036 
3  rs2761884  T  300 (50.0)   243 (44.3)  3.68  0.0552 
4  rs8014071  C  384 (64.0)   344 (63.0)  0.12  0.7264 
HTG+NTG 
5  rs8014363  A  278 (49.3)   235 (47.6)  0.31  0.5765 
 
 
 
Table 6–3: Distribution of FOXC1 tSNPs showing no significant effects between 
HTG, OHT, NTG, HTG+OHT and HTG+NTG, compared to the wild type 
control group. 
All of the columns were generated using Haploview v.4.0. 
Phenotype  tSNP  SNP ID  Allele  Case Counts 
(%) 
Control counts 
(%) 
Chi-square  P value 
1  rs2235715  T  192 (88.9)   320 (83.3)  3.41  0.0648 
2  rs2569889  C  260 (49.6)  259 (48.7)  0.09  0.7614 
3  rs2235716  T  363 (69.3)  350 (65.1)  2.14  0.1433 
HTG 
4  rs984253  T  185 (35.7)    183 (34.4)  0.20  0.6550 
1  rs2235715  C  14 (21.2)    64 (16.7)  0.81  0.3675 
2  rs2569889  G  59 (52.7)   273 (51.3)  0.07  0.7931 
3  rs2235716  C  41 (37.3)   188 (34.9)  0.22  0.6416 
OHT 
4  rs984253  T  39 (34.8)   183 (34.4)  0.01  0.9318 
1  rs2235715  C  11 (21.2)   64 (16.7)  0.65  0.4210 
2  rs2569889  G  37 (54.4)  273 (51.3)  0.23  0.6305 
3  rs2235716  C  28 (40.0)   188 (34.9)  0.69  0.4057 
NTG 
4  rs984253  A  46 (65.7)  349 (65.6)  0.00  0.9851 
1  rs2235715  T  244 (86.5)    320 (83.3)  1.28  0.2585 
2  rs2569889  C  313 (49.2)   259 (48.7)  0.03  0.8569 
3  rs2235716  T  432 (68.1)   350 (65.1)  1.25  0.2643 
HTG+OHT 
4  rs984253  T  224 (35.6)   183 (34.4)  0.17  0.6804 
1  rs2235715  T  233 (86.9)   320 (83.3)  1.60  0.2067 
2  rs2569889  C  291 (49.2)    259 (48.7)  0.03  0.8746 
3  rs2235716  T  405 (68.2)   350 (65.1)  1.24  0.2651 
HTG+NTG 
4  rs984253  T  209 (35.5)   183 (34.4)  0.16  0.6881 
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6.2.2  Absence of association between haplotypes in TGFβ2 and BMP4 and 
HTG  
The difference in the distribution of all common haplotypes in TGFβ2 and BMP4 
between individuals with HTG and controls (Table 6-4 and 6-5) was assessed (but not 
for  FOXC1 as common haplotypes were not present) and no significant haplotype 
associations were identified for each haplotype blocks. The absence of common 
haplotypes between patients and FOXC1 can be explained by the small size of the 
FOXC1 gene (3,447 bp) which makes it less likely for the presence of any haplotype 
blocks in such a small region.  
 
 
 
Table 6–4: Distribution of TGFβ2 haplotypes showing no significant effects 
between HTG cases and controls. 
All of the columns were generated using Haploview v.4.0. 
 
Block   Haplotype  All subjects 
(%) 
Case 
(%) 
Control  
(%) 
 
Chi-square 
 
P value 
 
GAGC 42.2  42.9  41.6  0.19  0.6657 
TAGC 18.8  17.3  20.2  1.56  0.2112 
TAGA 18.3  19.1  17.5  0.49  0.4841 
GAAC 14.2  13.4  15.1  0.67  0.4123 
1 
(tSNPs 1 to 4) 
TGGA 6.5  7.4  5.6  1.39  0.2379 
TCAA 40.1  40.1  40.1  0.00  0.9891 
CCAA 28.4  28.3  28.5  0.01  0.9386 
CTCG 21.5  21.2  21.9  0.08  0.7746 
CTCA 6.0  6.3  5.7  0.20  0.6592 
2 
(tSNPs 8 to 11) 
CCCA 3.0  2.9  3.2  0.10  0.7473 
TG 77.4 76.5  78.3  0.47 0.4950 
CA 16.2 16.0  16.5  0.05 0.8175 
3 
(tSNPs 14 to 15) 
CG 6.3  7.5  5.2  2.32 0.1280 
CAT 51.1  51.1 51.1  0.00  0.9927 
CGT 22.1  22.7 21.5  0.21  0.6462 
TGC 21.2  19.8 22.6  1.28  0.2581 
4 
(tSNPs 17 to 19) 
CGC 5.5  6.2  4.7  1.16  0.2809 
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6.2.3  Absence of association between haplotypes in TGFβ2 and BMP4, and 
raised IOP (HTG+OHT)  
Here, assessment for possible common haplotype associations between combined raised 
IOP patient group (HTG+OHT) and the controls were performed for TGFβ2 (Table 6-6) 
and BMP4 (Table 6-7) (but not for FOXC1 as common haplotypes were not present) 
and no significant haplotype effects for each haplotype blocks were found. 
 
 
Table 6–6: Distribution of TGFβ2 haplotypes showing no significant effects 
between HTG+OHT cases and controls. 
All of the columns were generated using Haploview v.4.0. 
Block  Haplotype  All subjects (%)  Case (%)  Control (%)  Chi-square  P Value 
GAGC  42.9  44.0 41.6 0.70 0.4035 
TAGC  18.6  17.1 20.3 1.92 0.1664 
TAGA  17.8  18.1 17.4 0.10 0.7500 
GAAC  14.3  13.7 15.1 0.48 0.4866 
 
1 
(tSNPs 1 to 4) 
TGGA 6.3  6.9  5.6  0.82  0.3659 
TCAA  39.8  39.6 40.1 0.03 0.8680 
CCAA  28.7  28.8 28.5 0.01 0.9220 
CTCG  21.4  20.9 21.9 0.15 0.6992 
CTCA 6.0  6.3  5.7  0.22  0.6401 
 
2 
(tSNPs 8 to 11) 
CCCA 3.2  3.1  3.2  0.00  0.9491 
TG  76.9  75.7 78.3 1.08 0.2979 
CA 16.4  16.4 16.5 0.00 0.9485 
 
3 
(tSNPs 14 to 15)  CG 6.7  7.9  5.2  3.44 0.0636 
CAT  51.0  50.9 51.1 0.01 0.9415 
CGT  22.5  23.3 21.5 0.54 0.4606 
TGC  20.9  19.4 22.6 1.89 0.1691 
 
4 
(tSNPs 17 to 19) 
CGC 5.6  6.3  4.7  1.29  0.2556 
Table 6–5: Distribution of BMP4 haplotypes showing no significant effects 
between HTG cases and controls. 
All of the columns were generated using Haploview v.4.0. 
 
Block  Haplotype  All subjects (%)  Case (%)  Control (%)  Chi-square  P Value 
AA 57.9  59.1  56.9  0.53  0.4652 
GG 37.1  35.3  38.9  1.47  0.2255 
AG 3.2  3.2  3.2  0.00  0.9555 
 
1 
(tSNP 1 to 2) 
GA 1.7  2.4  1.1  2.73  0.0985 
TCA 46.1  48.0  44.3  1.55  0.2131 
GTG 35.6  34.2  36.9  0.87  0.3506 
GCG 14.9  13.8  5.9  0.92  0.3389 
 
2 
(tSNP 3 to 5) 
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Table 6–7: Distribution of BMP4 haplotypes showing no significant effects between 
HTG+OHT cases and controls. 
All of the columns were generated using Haploview v.4.0. 
Block  Haplotype 
 
All 
subjects 
(%) 
 
Case (%) 
 
Control (%) 
 
Chi Square  P Value 
AA 58.1  59.2  56.9  0.63  0.4270 
GG 37.0  35.5  38.9  1.47  0.2252 
AG 3.1 3.1  3.2  0.01  0.9151 
 
1 
(tSNP 1 to 2) 
GA 1.7 2.3  1.1  2.62  0.1055 
TCA 46.2 47.9  44.2  1.58  0.2084 
GTG 35.2  33.8  36.9  1.29  0.2565 
GCG 15.0  14.3  15.9  0.62  0.4322 
 
2 
(tSNP 3 to 5) 
GCA 2.1  1.5  2.8  2.54  0.1112 
 
 
6.2.4  Absence of associations between haplotypes in TGFβ2 and BMP4, and 
glaucoma (HTG+NTG) 
Finally, none of the common haplotypes within each haplotype block showed any 
significant difference in distribution between the combined POAG patients group 
(HTG+NTG) and the controls for TGFβ2 (Table 6-8) and BMP4 (Table 6-9). 
 
 
 
Table 6–8: Distribution of TGFβ2 haplotypes showing no significant effects 
between HTG+NTG cases and controls. 
All of the columns were generated using Haploview v.4.0.  
Block  Haplotype  All 
subjects 
(%) 
Case (%) 
 
Control 
(%) 
 
Chi Square 
 
P Value 
GAGC 42.3 
 
42.9 41.6 
 
0.21 0.6473 
 
TAGA 18.5 
 
19.4 17.5 
 
0.71 
 
0.3986 
 
TAGC 18.3 
 
16.4 
 
20.2 
 
2.78 
 
0.0955 
 
GAAC 14.4 
 
13.8 15.1 
 
0.43 
 
0.5147 
 
 
1 
(tSNPs 1 to 4) 
TGGA 6.6 
 
7.5 5.6 
 
1.65 
 
0.1993 
 
TCAA 40.0 
 
39.8 
 
40.1 
 
0.01 
 
0.9284 
 
CCAA 28.5  28.6  28.5 
 
0.00 0.9873 
CTCG 21.3 
 
20.8 21.9 
 
0.20 
 
0.6516 
 
CTCA 6.2 
 
6.7 5.7 
 
0.54 
 
0.4620 
 
 
2 
(tSNPs 8 to 11) 
CCCA 3.1 
 
3.0 3.2 
 
0.04 
 
0.8517 
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TG 77.5 
 
76.9 78.3 
 
0.34 
 
0.5629 
 
CA 16.0 
 
15.6 16.5 
 
0.19 
 
0.6662 
 
 
3 
(tSNPs 14 to 15) 
CG 6.4 
 
7.6 
 
5.2 
 
2.65 
 
0.1037 
 
CAT 51.1  51.1  51.1 
 
0.00 
 
0.9979 
 
CGT 22.0 
 
22.5 21.5 
 
0.15 
 
0.7006 
 
TGC 21.3  20.2  22.6 
 
1.01 
 
0.3150 
 
 
4 
(tSNPs 17 to 19) 
CGC 5.4 
 
6.1 4.7 
 
0.97 
 
0.3260 
 
 
 
Table 6–9: Distribution of BMP4 haplotypes showing no significant effects 
between HTG+NTG cases and controls. 
All of the columns were generated using Haploview v.4.0. 
Block  Haplotype  All subjects 
(%) 
Case (%)  Control (%)  Chi Square  P Value 
AA 57.7  58.5  56.9 0.30  0.5857 
GG 37.6  36.4  38.9 0.77  0.3815 
AG 3.0  2.8  3.2  0.09  0.7592 
 
1 
(tSNP 1 to 2) 
GA 1.7  2.3  1.1  2.54  0.1112 
TCA 46.2  47.9  44.2  1.55  0.2126 
GTG 36.0  35.1  36.9  0.40  0.5256 
GCG 14.4  13.1  15.9  1.78  0.1827 
 
2 
(tSNP 3 to 5) 
GCA 2.1 1.6  2.8  2.10  0.1474 
 
 
 
 
6.3  Discussion 
Despite recent progress in identifying genes associated with glaucoma, the pathogenesis 
of POAG continues to remain unclear. Given the relatively high prevalence of POAG 
within the normal population, and the fact that it is amendable to treatment when 
detected early, identification of genetic risk factors would offer the prospect of early 
POAG diagnosis and a significant reduction in the health care expenditure. However, 
such screening programmes are currently limited by the paucity of the identified 
causative genes  (Fan et al., 2005) and identification of the most significant disease-
associated alleles in different populations is of paramount importance. 
 
Genes that cause developmental glaucoma (Gould et al., 2004), with the exception of 
the CYP1B1 gene (Bhattacharjee et al., 2008; Hattula and Peranen, 2000; Melki et al.,    Chapter 6 The role of signalling molecules TGFβ2, BMP4 and transcription factor gene FOXC1 in OHT 
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2005) and LMX1B (see Chapter 5), have yet to be assessed as genetic susceptibility 
factors for POAG. Existing studies indicate that TGFβ2 and BMP4 act in concert to 
maintain a balance between extracellular matrix (ECM) deposition and degradation 
(Wordinger et al., 2007), and may play an role in glaucoma pathogenesis through mis-
regulation of ECM synthesis and cross-linkage of ECM components of the TM. All of 
these 3 genes (TGFβ2, BMP4 and  Foxc1) are expressed in the TM and cause 
developmental malformation of the anterior segment, and FOXC1 in particular, is 
associated with a high incidence of glaucoma to about 75% or above (Strungaru et al., 
2007). Hence, taking these into account, TGFβ2, BMP4 and FOXC1 appear to be strong 
candidates for glaucoma susceptibility.  
 
The most prevalent subgroup of POAG, the HTG group, is characterised by 
glaucomatous damage, and raised IOP. The other two patient groups each have only one 
of these characteristics, either glaucomatous damage without raised IOP (NTG), or 
raised IOP without glaucomatous damage (OHT). In order to test the relationship 
between the variant alleles of TGFβ2, BMP4 and FOXC1 and these two characteristics 
the patients have been grouped into those with raised IOP (HTG and OHT), or those 
with glaucomatous damage irrespective of IOP (HTG and NTG). 
 
In this study, no significant associations were identified between TGFβ2, BMP4 and 
FOXC1 alleles and haplotypes and POAG. This represents the first association analysis 
of TGFβ2, BMP4 and FOXC1 and the lack of association of common polymorphism 
suggests that these genes do not have a significant genetic role in the pathogenesis of 
glaucoma among white British subjects.  
 
A negative association, however, should be interpreted with caution unless proven by a 
replication study or by investigating a substantially larger sample of the population. 
This is because of the small possibility of such results being caused by a false-negative 
error. To illustrate this further, both a study power of 80% and a r
2 threshold of > 0.8 
would allow detection of an existing association in 80% of cases (i.e. there is a 20% 
chance of missing a true association) and the selected tSNP to resolve >80% (but not 
100%) of all existing haplotypes respectively. Hence the possibility cannot be excluded, 
albeit being small, of missing a true association despite careful attention to study design. 
In addition, the results obtained from this study reflect only one ethnic group (in this    Chapter 6 The role of signalling molecules TGFβ2, BMP4 and transcription factor gene FOXC1 in OHT 
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case white British adults) and not other ethnicity and it would be interesting to see if 
other ethnic groups showed the same negative results. 
 
In summary, this study is unable to demonstrate any significant allelic or haplotype 
associations between TGFβ2, BMP4 and FOXC1 and OHT/POAG. It is hence unlikely 
that TGFβ2, BMP4 and FOXC1 play a role in the genetic aetiology of POAG. 
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Chapter 7  General discussion 
 
7.1  Highlights of the work presented 
It has been proposed that POAG in the majority of cases, is inherited as a complex trait, 
where the disease results from the interaction of multiple genes and environmental 
factors (Fan et al., 2006b; Sieving and Collins, 2007). It is a complex disorder which 
results from diverse pathological process that is not just limited to involving the 
aqueous humor outflow, but the RGC, the optic nerve and even as suggested recently, 
the cerebrospinal fluid (Berdahl et al., 2008). 
 
Mutations in the three known POAG genes (MYOC, OPTN and WDR36) account for no 
more than 10% of all POAG patients and hence it is highly likely that other unidentified 
loci or genes still exist (Fan et al., 2006b). An obvious group of genes to test as genetic 
susceptibility factors for POAG are the developmental glaucoma genes which have not 
been analysed in any association studies to date with the exception of the CYP1B1 gene. 
They play an important role in normal morphogenesis of the anterior segment and 
provide important insight into the underlying genetic mechanism of glaucoma. Since 
ASD leads to malformation of the drainage structures and elevation of IOP, patients 
with ASD are consequently at an increased risk for developing glaucoma in 33-75% of 
cases. It is possible that some of the developmental glaucoma genes contribute to age-
related open angle glaucoma, where the ocular drainage structures have abnormalities 
that are not clinically visible but which cause dysfunction with age. The present study 
has examined the hypothesis that sub-clinical mutations/polymorphisms in LMX1B, 
FOXC1, TGFβ2 and BMP4 may produce subtle and undetected abnormalities in anterior 
segment structure and function, which predispose to glaucomatous optic neuropathy 
through the effects of raised IOP and may be a significant susceptibility factor for the 
development of OHT and POAG. In addition, the cohort of white British individuals 
recruited for this study has provided an ideal opportunity to assess further the role of 
OPTN E50K mutation in unrelated POAG/OHT cases.  
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7.1.1  Assessment of study design and data quality 
One fundamental problem with a genetic association study is the ability to distinguish 
causal from spurious association. To help distinguish this, tight standards for statistical 
significance were established for this study (Silverman and Palmer, 2000). 
 
7.1.1.1  Biological plausibility of candidate genes 
Developmental glaucoma genes LMX1B, TGFβ2, BMP4 and FOXC1 provide a unique 
entry point for studying POAG as they have demonstrated that they are biologically 
plausible as candidate genes for POAG. In addition, the associated glaucoma can 
present at any time from birth to adulthood and in some affected family members with 
developmental glaucoma, the phenotype of the anterior segment malformation can be 
very subtle and easily missed, both features of which further support the biological 
plausibility of these gene as candidates for POAG.  
 
7.1.1.2  Classification of cases and controls 
Mis-classification of recruited individuals can markedly reduce study power and bias 
the results towards lack of association. Hence, to avoid this from occurring, all 
participants (affected as well as controls) underwent a complete ophthalmic 
examination; the clinical diagnosis was made by  the same  consultant with a special 
interest in glaucoma and experience in anterior segment phenotyping. This ensured 
exclusion of individuals with glaucoma from the control group and made certain that 
cases were correctly classified either as HTG, OHT and NTG.  
  
In addition, individuals with borderline IOPs whose diagnosis would be uncertain were 
excluded from this study.  
 
7.1.1.3  Confounding factors; population stratification, age and sex 
Since population stratification is known to have major implications for the validity of 
genetic association studies (Hoggart et al., 2003), the cases and controls were carefully 
matched for ethnicity. Population stratification refers to differences in allele frequencies 
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association of genes with the disease, hence giving rise to a false positive association. 
The patients and controls enrolled in this study were of Caucasian origin and from the 
same geographical region from the North-East of England. However, cases and controls 
were not matched for sex (for all groups except between OHTs and controls) and age 
(for the OHTs and controls). This study has addressed this problem when assessing the 
prevalence of genetic variants between these specific groups by calculating P values 
that have been adjusted either for sex and age.  
 
7.1.1.4  Selection of informative tSNPs and assessment of Hardy-
Weinberg equilibrium 
In order to select a good subset of tSNPs from an extensive SNP set, tSNPs should 
ideally have a high degree of polymorphism and be able to capture the majority of the 
diversity within a region without having to genotype all the markers. Hence for this 
study, SNPs with a MAF of ≥10% with a minimum r
2 of 0.8 were chosen. This allowed 
for the maximization of information content and minimization of the sample size 
without losing the power to detect genetic association. In addition, since deviation of 
allele frequencies from those expected from HWE can be as a result of systematic 
genotyping errors, such SNPs were excluded from this study. 
 
7.1.1.5  Low genotyping errors with good quality control 
Genotyping errors, especially if they occur differentially between cases and controls, are 
an important cause of spurious associations. This study has shown a good genotyping 
success rate varying from 92% and 99%. In addition, a quality control measure was 
applied, whereby, selected primer assays were tested on CEPH DNAs and the 
genotypes compared with that of the HapMap data. In doing so, it was possible to assess 
whether the results were either concordant or disconcordant with the HapMap data, with 
any assays producing disconcordant results being excluded from the study. 
 
7.1.1.6  Adjustment for multiple testing 
Since the incidence of false positive error is proportional to the number of significance 
tests performed, multiple testing can lead to a potential increase in false-positive error.                                                                                                                            Chapter 7 General discussion 
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Hence, in order to correct for any spurious association that can arise as a result of this, 
permutation testing was performed with 1,000 simulations for any results with a 
significant P value. 
 
7.1.2  Absence of OPTN E50K mutation among HTG and OHT, in addition 
to NTG 
This study has investigated the contribution of OPTN E50K mutation to unrelated 
POAG/OHT cases of white British origin. Based on the current literature on OPTN 
E50K mutation, it can be concluded that OPTN may have a protective role in the 
anterior segment during raised IOP through its effect on the TM (Vittitow and Borras, 
2002) and its interaction with MYOC (Park et al., 2007), as well as a neuroprotective 
role in the posterior segment through affecting the TGFα signaling pathway. However, 
this study has demonstrated an absence of the E50K mutation in line with existing 
reports (Ariani et al., 2006; Baird et al., 2004; Funayama et al., 2004; Fuse et al., 2004; 
Leung et al., 2003; Lopez-Martinez et al., 2007; Sripriya et al., 2006; Tang et al., 2003; 
Toda et al., 2004; Umeda et al., 2004; Wiggs et al., 2003).  
 
7.1.3  Genetic risk for primary open angle glaucoma determined by LMX1B 
haplotypes 
 
This study has assessed whether variants of LMX1B play a role in POAG susceptibility 
in the general population and has identified significant associations between LMX1B 
alleles and haplotypes in intron 2 and POAG. Pathogenic mutations within LMX1B 
cause a rare autosomal condition, NPS, in which the prevalence of OAG, OHT and 
NTG were 11.1% (Mimiwati et al., 2006), 11.1% (Mimiwati et al., 2006) and 7.8% 
(Bongers et al., 2005) respectively. Moreover, the mean age of NPS cases with OAG or 
OHT was 63.4 (range 55-72) (Bongers et al., 2005) and 47.9 years (range 23-78) 
respectively (Sweeney et al., 2003), a feature more consistent with POAG. In this case-
control genetic association study of adult onset POAG patients in the general 
population, there was a significant under representation of two LMX1B haplotypes 
among individuals with POAG compared to a control population, consistent with a 0.3 
fold decreased risk of developing POAG in individuals carrying these haplotypes. In                                                                                                                            Chapter 7 General discussion 
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mice, Lmx1b is expressed in the TM and ciliary body, the sites of aqueous drainage and 
production respectively from embryonic day 10.5 and continues to be expressed at high 
levels post-natally (Pressman et al., 2000). Functional polymorphic variation within the 
gene may therefore play a role in influencing IOP. Together these data suggest that the 
developmental homeobox gene transcription factor LMX1B may influence the risk of 
POAG in the general population and is in agreement with the hypothesis that subtle 
abnormalities in the anterior segment structure and function may predispose to POAG. 
In addition, the effects of LMX1B on glaucoma susceptibility may involve functions that 
are broader than effects on IOP.  
 
With regards to the downstream targets of LMX1B, the current understanding is that 
LMX1B may have a role in POAG pathogenesis through its effect on the regulation of 
ECM. Recently Gould et al provided new insight into the possible role of Lmx1b in 
glaucoma pathology by showing mutations in the collagen Col4a1 gene resulted in ASD 
with optic nerve hypoplasia, with raised as well as low IOP (Gould et al., 2007). 
Although there is not yet evidence that Lmx1b regulates Col4a1, LMX1B has shown to 
play an important role in the expression of basement membrane collagens Col4α3 and 
Col4α4 (Morello et al., 2001; Rohr et al., 2002), a major constituent of ECM. 
Considering the important developmental contribution of ECM to the formation of the 
TM (reviewed by (Acott and Kelley, 2008; Gould et al., 2004), altered ECM regulation 
within the TM as a result of mutations in LMX1B may predispose to glaucoma.  
 
7.1.4  Variants of TGFβ2, BMP4 and FOXC1 do not confer susceptibility to 
POAG 
In this study, variants of TGFβ2,  BMP4 and FOXC1 were assessed to see if they 
conferred susceptibility to POAG, but no significant associations were identified. 
Existing studies indicate that TGFβ2, BMP4 and FOXC1 are strong candidate genes for 
POAG susceptibility. In particular, TGFβ2 and BMP4 act in concert to maintain a 
balance between ECM deposition and degradation (Wordinger et al., 2007), and may 
play an role in glaucoma pathogenesis through mis-regulation of ECM synthesis and 
cross-linkage of ECM components of the TM. All of these 3 genes (TGFβ2, BMP4 and 
Foxc1) are expressed in the TM and cause developmental malformation of the anterior 
segment, and FOXC1 in particular, is associated with a high incidence of glaucoma to                                                                                                                            Chapter 7 General discussion 
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about 75% or above (Strungaru et al., 2007). However, despite this evidence in favour 
of these genes as candidates for POAG, no significant allelic or haplotype associations 
with POAG were demonstrated by this study. 
 
7.2  Limitations of study 
7.2.1  Under representation of NTG 
The key determinant of quality in an association study is the sample size since the 
power to detect an association depends partly on this. For this study, with a sample size 
of 276 controls and 367 cases, an adequate study power of 80% was achieved if a 
difference in genotype and allele frequency was 10-18% between controls and cases at a 
significance level of P < 0.05. However, if the individual subgroups are considered, the 
NTG group (n = 37) was clearly under-represented, despite being adequate to produce a 
robust result as being part of the whole cohort. Hence, to improve the chances of 
detecting genetic variants that are associated with the NTG cases, the sample size of the 
relatively small NTG group should be increased, and this was achieved in the 
replication study where the number of NTG cases was increased to a total of 222 
individuals. 
 
7.2.2  Absence of central corneal thickness measurement 
Another limitation of this study is the absence of CCT measurement. CCT variation is 
known to affect the accuracy of IOP readings on applanation tonometry, with thick 
corneas giving falsely high IOP readings and thin corneas giving falsely low readings 
(Feltgen et al., 2001; Whitacre et al., 1993). In the current study, IOP measurements 
were checked by a Tono-Pen which is less affected by CCT (Bhan et al., 2002), in 
addition to performing applanation tonometry. Although normagrams, based on varying 
CCT, exist for adjusting IOP readings (Ehlers et al., 1975; Stodtmeister, 1998; Whitacre 
et al., 1993), as yet, there is no generally accepted correction formula (Brandt, 2004). 
However, two recent studies that adjusted IOP for CCT found that the correction did not 
alter the diagnosis of HTG or NTG (Miyazawa et al., 2007), and did not affect the 
relationship between the prevalence of POAG and IOP respectively (Francis et al., 
2008).  Furthermore, to be certain that the participants were correctly assigned to the                                                                                                                            Chapter 7 General discussion 
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appropriate case groups, individuals with borderline IOPs (21–23 mmHg) were 
excluded from this study. Even if a correction formulae were to be applied with a 10 µm 
change in the corneal thickness inducing a 0.2 mmHg change in IOP reading (Doughty 
and Zaman, 2000), a 2-3 mmHg IOP change (which would include the excluded 
individuals within the borderline IOP) would induce a 100 - 150 µm change in the CCT, 
which is a considerable amount. Hence it is still highly unlikely that the individuals with 
IOPs of 20 mmHg or below or IOPs of 24 mmHg or higher would have their diagnosis 
altered (assuming that the average CCT is approximately 537 – 550 µm) (Shah et al., 
1999; Wolfs et al., 1997) since these subjects would be require to have either an 
abnormally thin corneas or an unusually thick corneas.  
 
Several studies have shown that increased CCT may occur in certain types of 
dominantly inherited developmental glaucoma, including iris hypoplasia (FOXC1 
duplication) (Lehmann et al., 2003b), aniridia (PAX6/Pax6) (Brandt et al., 2004; 
Ramaesh et al., 2003) and dysgenic lens (Foxe3) (Lehmann et al., 2003b). Conversely, 
a reduced corneal thickness was associated with Axenfeld-Rieger malformation of the 
anterior segment from PITX2 mutation (Asai-Coakwell et al., 2006). A thinner CCT 
was also found to be a risk factor for developing POAG in individuals with OHT 
(Gordon et al., 2002). CCT data was not collected for the cases and controls in the 
current study since a pachymeter was not available at the time when this study was 
carried out. However, the analysis of the relationship between LMX1B haplotypes and 
CCT will be important in future work, as like these other developmental glaucoma 
genes, LMX1B may affect CCT.  
 
7.2.3  Arbitrary assessment of visual field defect 
The third limiting factor of this study is the lack of objective assessment of the severity 
of Humphrey visual fields using global indices (mean deviation, pattern standard 
deviation, corrected pattern standard deviation). However, all of the visual field tests 
showed reproducible field defects that were compatible with the degree of 
glaucomatous cupping of the optic nerve head (defined by loss of neuroretinal rim), and 
were ensured to have a satisfactory reliability score of ≤20% fixation loss, false positive 
of ≤33% and/or false negative of ≤33%. 
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7.2.4  Arbitrary assessment of cup-disc ratio 
The final limiting factor of this study is the lack of objective measurement of the C/D 
ratio as a measure of the severity of the disease, as clinical assessment of the C/D ratio 
can be quite subjective depending on the observer. Subsequent to the collection of data 
for this study, newer imaging methods of the optic nerve have been developed, in the 
form of Ocular Coherence Tomography and the Zeiss GDx nerve fibre analyser test. 
These are superior diagnostic tools, which allow earlier detection of structural damage, 
and provide a more objective measurement of the C/D ratio for research purposes. 
However, all of the recruited patients had photographs of the optic disc, which provides 
some measure of objectivity, as well as being carefully examined by a consultant 
ophthalmologist with a special interest in glaucoma and experience in glaucoma 
phenotyping. 
 
The definition for POAG should be ideally based on an objective criterion and not on 
clinical assessment only. Digital photographs of the optic discs, together with imaging 
reports of sophisticated instruments such as the nerve fibre analyser or the OCT, should 
be assessed by experts in reference centres, and ideally by the same observer, to assure 
firm and unbiased diagnosis as well as limiting inter-observer variability. 
 
7.3  Current and future status in glaucoma research 
With recent advances in high through-put genotyping, it is now possible to genotype 
one million SNPs on large datasets containing thousands of samples within a few days. 
Through this approach, common disease-associated genetic variants in chronic disorders 
including diabetes mellitus, cancer and heart disease have been identified (Feero et al., 
2008). In Ophthalmology, common genetic variants that predispose to 
pseudoexfoliation syndrome (LOXL1) have been recently identified by genome-wide 
association studies (Thorleifsson et al., 2007). 
 
Currently, only a small percentage of POAG is accounted for by genetic mutations. On 
the whole, there is still much to learn of the complex the genetics of POAG and even 
less insight of the underlying cellular biology. Linkage and association studies in large 
families have been essential and have accelerated genetic research into POAG. To                                                                                                                            Chapter 7 General discussion 
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further increase the chances of detection of glaucoma gene, animal experiments and 
genomics approaches are crucial components to human studies.  
 
7.3.1  Human genetics 
The polygenic complexity of POAG has potential to confound genetic association 
studies when assessing candidate genes. This can be minimized by implementing the 
full array of genetic approaches, including linkage analysis, candidate gene analysis and 
well-designed association studies. Given the likelihood of multifactorial interaction, it 
will be important to evaluate the roles of multiple genes or loci even when a single 
mutant gene is identified. Assessment of a large cohort of POAG individuals will 
provide greater statistical power and will assist detection of multifactorial interactions. 
It will be crucial to take note of environmental history and lifestyle data, in addition to 
family history of glaucoma and medical information. Whilst protecting individual’s 
confidentiality, it will be important to gather the genotype and any relevant data into a 
large shared database. This will aid progress by firstly allowing further assessment by 
other researchers using different techniques, and secondly by increasing the power of 
future human genetic analyses. 
 
7.3.2  Animal genetics 
Due to the complex nature of POAG in which there are no clear pattern of Mendelian 
inheritance animal experiments will be an essential complement to human studies. 
Animal studies offer the ability to study the effects of specific alleles in defined genetic 
backgrounds and controlled environments and will be extremely valuable (John et al., 
1999). To date, the mouse has been the best suited mammalian model for assessing the 
complex genetics of POAG (John et al., 1999). Although mouse studies have only 
marginally played a role towards the understanding of POAG, they will become an 
essential aspect of glaucoma research in the future. Mouse models with potential 
relevance to POAG include the Col1a1 mutant mouse and the C57BL/6J mouse. The 
Col1a1 mutant mouse has a mutation for the α1 subunit of collagen 1, a component of 
outflow pathway ECM, and has developed elevated IOP with almost 25% loss of their 
RGC (Mabuchi et al., 2004). The C57BL/6J mouse strain has extensive RGC loss in the 
presence of normal IOP and may be useful for studying NTG (Danias et al., 2003).                                                                                                                             Chapter 7 General discussion 
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7.3.3  Genomics 
Genomics can be applied to human tissue samples in addition to tissues from various 
model systems that are used to assess specific aspects of glaucomatous pathophysiology. 
Difference in the expression patterns between patients and controls will help to 
prioritise the assessment of candidate genes. For example, microarray analysis is being 
utilised to identify the molecular pathways involved in raised IOP in cultured TM cells 
and to identify changes in gene expression in response to raised IOP (Borras, 2003; 
Ishibashi et al., 2002). Identifying differences in expression patterns for specific genes 
will be helpful, especially when these genes are located within the implicated 
chromosomal regions. Genomics methods are also utilised to assess neuronal responses 
to elevated IOP in rats and primates (Ahmed et al., 2004; Miyahara et al., 2003). 
  
7.4  Concluding remarks 
Genes that contribute to POAG may influence the regulation of IOP or ganglion cell 
viability, or even both as suggested by the results of this study on LMX1B. Specifically, 
this study showed that variants of LMX1B are associated with both NTG and HTG and 
are correlated with a 0.3 fold decreased risk of developing POAG in the first cohort. 
This is in agreement with the idea that these two conditions HTG and NTG may simply 
be phenotypic variations of the same disease, rather than separate entities. However, 
these findings were not replicated in the smaller and ethnically more diverse cohort and 
further investigations are needed to fully understand the role of LMX1B in POAG. 
 
Clearly, the current understanding of the underlying genetic architecture of a complex 
inherited disorder such as POAG continues to be limited, with the genetic basis of the 
majority of glaucoma cases still largely unknown. It is highly probable, as in many 
complex inherited disorders, the condition result from the independent actions of 
multiple genes as well as from interactions of multiple genes. As shown by this study, 
with the implementation of SNP-based technologies, a substantial increase in research 
and understanding into the molecular basis of complex inherited disorders is underway. 
The ultimate goal would be to discover a complete panel of genes that contribute to 
glaucoma and acquire diagnostic and prognostic correlates for the mutations.                                                                                                                             Chapter 7 General discussion 
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7.5  Glaucoma screening 
One of the goals of identifying disease gene(s) is the development of predictive 
diagnostic tests. For a disease such as POAG, where early treatment is essential, 
diagnostic tests aimed at identifying individuals at risk of developing POAG will be 
valuable. Currently, identification of new glaucoma cases is achieved by routine 
screening which involves evaluation of the optic disc, IOP measurement and assessment 
of visual field deficit. However, such methods have not been shown to be cost effective 
(Tuck and Crick, 1997). Furthermore, these methods have provided at best a ‘snap shot’ 
where a negative result applies to a single time point. Hence many people are repeatedly 
reviewed unnecessarily, the majority of whom may never develop the disease of 
concern, and with a high likelihood of missing incident disease. A screening regimen 
should be highly sensitive and specific so that it only detects potentially serious disease 
and not so called ‘pseudo-disease’ (Harris, 2005). Since POAG is initially an 
asymptomatic disease, effective screening techniques should identify at risk individuals 
so that early treatment could be initiated before irreversible optic nerve damage occurs. 
 
Establishment of a genetic screening program offers many advantages and these are as 
follows (Pang, 1998): 
1)  It provides an unequivocal test of high specificity, 
2)  It enables identification of non-symptomatic carriers, who are at risk of 
developing POAG, 
3)  And it provides information for genetic counseling.  
 
However, to establish a molecular diagnostic service, the disease-causing mutations 
must be identified. Furthermore: 
1)  the clinical information about the onset of disease, course of disease and 
response to therapy needs to be collected, 
2)  the prevalence of the mutations in the population must be known to obtain a 
predictive value of the genetic testing, 
3)  and the pattern of inheritance of these mutations must be clarified in order for 
the genetic data to be used for genetic counseling (Pang, 1998). 
                                                                                                                            Chapter 7 General discussion 
  229
Current genetic screening for glaucoma genes is limited to genes that are already 
recognized to be associated with POAG (mainly MYOC) (Fan et al., 2006a) and is 
primarily diagnostic, rather than prognostic. With respect to OPTN  E50K mutation, 
since this mutation has never been detected in unaffected controls, diagnostic testing of 
sporadic NTG cases for E50K mutation may be of value in the UK population. 
However, the striking difference in the prevalence between familial and sporadic cases 
should favor the implementation of targeted diagnostic testing for individuals with a 
family history of NTG.  
  
Commercially available kits that have been utilized to screen for MYOC mutation (such 
as Ocugene test from InSite Vision) have also yielded low sensitivity as it tests for only 
3 out of the many identified disease causing variations (Alward et al., 2002), and 
demonstrates the current drawbacks of genetic screening for POAG. However, once it 
reaches a sufficient level of accuracy, genetic screening would provide a focused 
delivery of medical resources to a smaller proportion of at risk populations. 
 
7.6   Future work 
The main finding from this study is that variants of LMX1B influence the genetic risk 
for POAG. All data presented here will form the basis for future studies for further 
assessment of the association between LMX1B and POAG. 
 
Now that a potential new gene, LMX1B, is shown to be associated with POAG, the 
future aim will be to isolate the causative variant(s) by identifying all of the functional 
SNP(s) that influence the risk of developing POAG through fine mapping the LMX1B 
locus. This can be achieved by identifying potentially functional genetic variation at the 
LMX1B locus by sequencing all of the exons, splice sites and in particular, conserved 
non-coding sequences, including the proximal promoter region, as well as within and 
around the gene. Approximately 2.7kb upstream of the start of transcription of LMX1B 
has been shown to contain elements involved in the regulation of gene expression, in 
addition to several regions of high conservation (greater than 85% sequence identity) 
between human and mouse within intron 2, suggestive of a role in gene regulation 
(Dunston et al., 2004). In order to assess how many patients are required to achieve 
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sequencing a panel of 24 POAG patients should be able to achieve a power of >90% to 
detect all of the SNPs with a MAF of 5%. In doing so, there should be sufficient power 
to identify all SNPs with sufficient power to detect a significant association. In order to 
ascertain the resultant new haplotype structure that will include these additional 
polymorphic SNP(s), any novel variants that are identified will be combined together 
with those previously genotyped SNPs. Following this, the additional SNPs that have 
not already been genotyped and which are required to capture all of the remaining 
variation will be genotyped in the remaining cohort of 343 cases and all of 276 controls 
to test for genetic association. This should assist the rapid detection of all potential 
functional variants underlying the risk/protective haplotype. 
 
Functional analysis of these associated coding and/or non-coding SNPs could then be 
performed in order to isolate the causative variant(s) affecting the risk of developing 
POAG. This can be achieved in two ways. Firstly, identified non-synonymous amino 
acid variants can be investigated using DNA binding assays (e.g. electrophoretic 
mobility shift assay: this is an electrophoretic separation of a protein-DNA or protein-
RNA mixture on a polyacrylamide or agarose gel. It is a  common affinity 
electrophoresis technique used to study protein-DNA or protein-RNA interactions) and 
reporter assays to test differences between protein variants to activate transcription of 
artificial reporter genes and putative biological targets such as COL4A3 and COL4A4. 
Secondly, in order to assess whether non-coding variants are associated with altered 
expression levels of mRNA and protein levels of LMX1B and downstream target genes 
such as COL4A4, cadaver tissue and other appropriate cell lines can be analysed. RNA 
and protein can be extracted from genotyped tissue samples. This will be followed by 
application of real time quantitative PCR to assess for mRNA expression levels. 
Extracted proteins can be analysed by Western blotting for assessment of protein 
expression levels. In doing so, allelic differences in the expression levels of mRNA and 
proteins could be identified and therefore ascertain the responsible non-coding variants. 
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Chapter 8  Appendices 
8.1  Appendix I: Patient information sheet for control subjects 
 
Mr Soo Park                            Tel: 0191 565 6256                                   Version  5.0 
Mr Scott Fraser 
Dr Jane Sowden 
                                 PATIENT INFORMATION SHEET 
 
                          Searching for Genes for Glaucoma- control subjects 
 
Within the department of Ophthalmology we are carrying out research in order to discover the underlying 
cause of glaucoma. 
 
As part of this study we require a group of patients who do not have glaucoma who are willing to assist 
us. This group would act as a ‘control’ sample for comparison with those diagnosed with glaucoma. 
 
Before you decide, it is important for you to understand how the research is being done and what it will 
involve. Please take time to read the following information carefully. Ask us if there is anything which is 
not clear or if you would like more information. Take time to discuss this with your relatives and family 
doctor if you wish, to decide whether or not to take part. If you decide you do not wish to take part please 
contact us either by phone, email or letter and we will destroy any sample you have donated. We will 
acknowledge in writing that we have received your notification that you no longer wish to be part of the 
study. Thank you for reading this information sheet. 
 
What is the purpose of the study? 
Glaucoma is the third commonest cause of visual loss in the world. The most recent approach to 
preventing visual loss is to discover the underlying genes responsible in families and individuals with 
glaucoma. In order to confirm that a newly discovered gene causes glaucoma we need to compare the 
findings in patients who do not have glaucoma. Those who do not have glaucoma should not have the 
same abnormality in the gene. 
 
Why have I been chosen? 
You have been asked to help because you have been screened for glaucoma and found to be unaffected. 
Approximately 400 other people will be asked to assist in this study. 
 
Do I have to take part? 
This decision is up to you entirely. If you do decide to take part, please keep this information sheet. You 
will be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time 
and without giving any reason. This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
A brief summary of your eye findings will be prepared by your ophthalmologist for inclusion in the study. 
We will ask for a small blood sample taken from an arm by an experienced doctor. This blood sample 
will be sent to the Institute of Child Health where DNA will be extracted from this sample, and only the 
genes for glaucoma will be studied. This study may take us 2-3 years, since there are many genes 
involved. 
 
 
Are there any side effects of giving a blood sample? 
This procedure involves a momentary pain, like a mosquito bite, and may leave a small bruise. 
 
What are the possible benefits of taking part? 
We hope to find the cause of glaucoma in families in which there is a genetic cause. This should lead to 
preservation of vision in a more efficient way than was possible in the past. We also hope that by 
discovering the underlying genes causing glaucoma, we can use this new knowledge to find a more 
specific treatment or a screening test to identify those at risk of developing glaucoma. At present, we 
simply lower the eye pressure; we do not know why the visual loss occurs in the first place. 
It is unlikely that you will benefit directly from this research as you do not have glaucoma.                                                                                                                                                        Appendices 
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Will my taking part in this study be kept confidential? 
We request your permission to restricted access to your medical records and the information collected 
about you in the course of the study. All information which is collected about you will be kept strictly 
confidential. Any information about you which is included in a research publication will have all 
identifying features removed, so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
Once we find a new gene which causes glaucoma, the results will be published in a scientific journal 
dealing with such information. In this way, it will be made available internationally, and other 
investigators can look at their glaucoma families to see if they have the same gene. However, the results 
will not be made available to you unless you have specifically requested it.  
 
You will not be identified in the publication. 
 
Contact for further information? 
Please contact your ophthalmologist or a member of the genetics team on the number shown on page 1 
for further information. Thank you for taking part in this study. This is your copy of the information 
sheet.                                                                                                                                                         Appendices 
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8.2  Appendix II: Patient information sheet for cases 
 
Mr Soo Park                            Tel: 0191 565 6256                                    Version 5.0 
Mr Scott Fraser 
Dr Jane Sowden 
                                 PATIENT INFORMATION SHEET 
 
                                   Searching for Genes for Glaucoma 
 
Within the department of Ophthalmology we are carrying out research in order to discover the underlying 
cause of glaucoma. Before you decide, it is important for you to understand how the research is being 
done and what it will involve. Please take time to read the following information carefully. Ask us if there 
is anything which is not clear or if you would like more information. Take time to discuss this with your 
relatives and family doctor if you wish, to decide whether or not to take part. If you decide you do not 
wish to take part please contact us either by phone, email or letter and we will destroy any sample you 
have donated. We will acknowledge in writing that we have received your notification that you no longer 
wish to be part of the study. Thank you for reading this information sheet. 
 
What is the purpose of the study? 
Glaucoma is the third commonest cause of visual loss in the world. The most recent approach to 
preventing visual loss is to discover the underlying genes responsible in families and individuals with 
glaucoma, so that we may test the at-risk individual for visual loss, and treat at the earliest possible 
moment to prevent such loss. So far, through studying large family members who have inherited 
glaucoma through generations, 3 inherited genes have been identified which may be involved in 
glaucoma. However, up to date, several studies have shown that these are rare causes of glaucoma and 
their role in the underlying cause of glaucoma still remains uncertain. We request your help in 
discovering the remaining genes. 
 
Why have I been chosen? 
Your ophthalmologist has selected you because of your diagnosis of glaucoma. Approximately 400 other 
people will be asked to assist in this study. 
 
Do I have to take part? 
This decision is up to you entirely. If you do decide to take part, please keep this information sheet. You 
will be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time 
and without giving any reason. This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
A brief summary of your eye findings will be prepared by your ophthalmologist for inclusion in the study. 
We will ask for a small blood sample taken from an arm by an experienced doctor. This blood sample 
will be sent to the Institute of Child Health where DNA will be extracted from this sample, and only the 
genes for glaucoma will be studied. This study may take us 2-3 years, since there are many genes 
involved. 
 
Are there any side effects of giving a blood sample? 
This procedure involves a momentary pain, like a mosquito bite, and may leave a small bruise. 
 
What are the possible benefits of taking part? 
We hope to find the cause of glaucoma in families in which there is a genetic cause. This should lead to 
preservation of vision in a more efficient way than was possible in the past. We also hope that by 
discovering the underlying genes causing glaucoma, we can use this new knowledge to find a more 
specific treatment or a screening test to identify those at risk of developing glaucoma. At present, we 
simply lower the eye pressure; we do not know why the visual loss occurs in the first place. 
 
Will my taking part in this study be kept confidential? 
We request your permission to restricted access to your medical records and the information collected 
about you in the course of the study. All information which is collected about you will be kept strictly 
confidential. Any information about you which is included in a research publication will have all 
identifying features removed, so that you cannot be recognised from it.                                                                                                                                                        Appendices 
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What will happen to the results of the research study? 
Once we find a new gene which causes glaucoma, the results will be published in a scientific journal 
dealing with such information. In this way, it will be made available internationally, and other 
investigators can look at their glaucoma families to see if they have the same gene. However, the results 
will not be made available to you unless you have specifically requested it. 
 
You will not be identified in the publication. 
 
Who has reviewed the study? 
This study has been reviewed by your hospital Research Ethics Committee. 
 
Contact for further information? 
Please contact your ophthalmologist or a member of the genetics team on the number shown on page 1 
for further information. Thank you for taking part in this study. This is your copy of the information 
sheet.  
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8.3  Appendix III: Demographic and phenotypic features of control individuals 
 
Table 8–1: Demographic and phenotypic features of control individuals (n = 276) 
 
Best visual acuity  Highest recorded IOP 
 
Cup-disc ratio  Patient ID  Sex  Age  Family 
history of 
glaucoma 
Right Left  Right Left 
Anterior 
chamber angle 
 
Right Left   
Surgery 
1 female  55  nil  6/6 6/6  15  15  open 0.4  0.4 nil 
2 female  79  nil  6/9 6/9  15  15  open 0  0  nil 
4 female  78  nil  6/9 6/9  10  11  open 0  0  nil 
5 female  80  nil  6/9 6/9  16  13  open 0  0  nil 
7 female  74  nil  6/9 6/9  19  19  open 0  0  nil 
8 male  66  nil  6/6 6/6  13  13  open 0.4  0.4 nil 
9 male  67  nil  6/9 6/9  11  11  open 0.5  0.5 nil 
10 male  74  nil  6/9 6/9  15  15  open 0  0  nil 
11 male  69  nil  6/9 6/9  15  15  open 0  0  nil 
12 female  64  nil  6/9 6/9  17  17  open 0  0  nil 
14 female  77  nil  6/9 6/6  16  16  open 0.3  0.3 nil 
15 female  85  nil  6/9 6/9  17  17  open 0  0  nil 
16 female  76  nil  6/9 6/9  15  15  open 0  0  nil 
17 female  51  nil  6/12 6/9  17 17 open  0 0  nil 
18 female  80  nil  6/9 6/9  16  14  open 0.3  0.3 nil 
21 female  71  nil  6/9 6/9  17  16  open 0  0  nil 
40 male  78  nil  6/9 6/9  16  15  open 0.5  0.5 nil 
41 female  73  nil  6/9 6/9  16  16  open 0.4  0.4 nil 
43 female  75  nil  6/6 6/6  16  16  open 0.5  0.5 nil 
44 female  72  nil  6/9 6/9  13  13  open 0.5  0.4 nil 
45 female  83  nil  6/9 6/9  17  17  open 0  0  nil 
47 male  81  nil  6/9 6/9  11  10  open 0.4  0.4 nil 
48 male  77  nil  6/9 6/9  14  14  open 0  0  nil 
49 female  59  nil  6/9 6/6  17  17  open 0  0  nil 
50 male  63  nil  6/9 6/9  14  14  open 0.4  0.4 nil 
51_LG female  72  nil  6/9 6/9  15  15  open 0  0  nil 
51_SH female  61  nil  6/5 6/5  19  19  open 0  0  nil 
52 male  74  nil  6/6 6/6  19  18  open 0.5  0.5 nil 
53 male  70  nil  6/9 6/9  19  19  open 0  0  nil 
54 female  77  nil  6/9 6/9  16  16  open 0  0  nil 
55 male  60  nil  6/6 6/6  15  15  open 0.4  0.5 nil 
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56 male  69  nil  6/5 6/5  14  11  open 0  0  nil 
57 female  72  nil  6/9 6/9  19  18  open 0  0  nil 
58 male  70  nil  6/9 6/9  19  18  open 0.5  0.5 nil 
59 female  65  nil  6/6 6/6  13  13  open 0.4  0.4 nil 
60 female  67  nil  6/6 6/6  15  11  open 0.4  0.4 nil 
61 male  87  nil  6/9 6/9  14  14  open 0  0  nil 
62 male  75  nil  6/9 6/9  12  12  open 0  0  nil 
63 female  61  nil  6/9 6/9  17  16  open 0  0  nil 
64 male  66  nil  6/9 6/6  13  13  open 0  0  nil 
65 male  56  nil  6/5 6/6  18  18  open 0.2  0.2 nil 
66 female  84  nil  6/9 6/9  14  14  open 0  0  nil 
67 female  68  nil  6/9 6/9  16  16  open 0  0  nil 
68 male  73  nil  6/9 6/9  14  14  open 0.5  0.5 nil 
69 female  66  nil  6/9 6/9  16  16  open 0  0  nil 
70 male  69  nil  6/9 6/6  14  14  open 0.4  0.4 nil 
71 male  72  nil  6/9 6/9  16  16  open 0  0  nil 
72 female  75  nil  6/9 6/9  12  12  open 0  0  nil 
73 male  74  nil  6/5 6/5  13  12  open 0.3  0.3 nil 
74 male  76  nil  6/6 6/6  16  17  open 0  0  nil 
76_D male 80 nil  6/9 6/9  16  18  open 0.5  0.5 nil 
76_J male  58  nil  6/9 6/9  14  13  open 0.3  0.3 nil 
77 female  76  nil  6/6 6/6  17  16  open 0.2  0.2 nil 
78 male  77  nil  6/5 6/5  16  16  open 0  0  nil 
79 female  74  nil  6/9 6/9  16  18  open 0.4  0.4 nil 
80 female  64  nil  6/9 6/9  20  20  open 0.5  0.5 nil 
81_NG male  73  nil  6/6 6/6  13  13  open 0  0  nil 
82 male  81  nil  6/6 6/6  14  14  open 0  0  nil 
83 female  65  nil  6/9 6/9  17  13 open 0  0  nil 
85 male  74  nil  6/9 6/9  14  14  open 0  0  nil 
86 female  85  nil  6/9 6/9  18  18  open 0  0  nil 
87 female  58  nil  6/9 6/6  12  12  open 0  0  nil 
88 male  57  nil  6/4 6/5  17  17  open 0  0  nil 
89 male  64  nil  6/9 6/9  19  19  open 0  0  nil 
90 female  72  nil  6/9 6/9  19  18  open 0  0  nil 
91 female  61  nil  6/6 6/6  14  14  open 0  0  nil 
92 female  84  nil  6/6 6/6  15  15  open 0  0  nil 
93 male  67  nil  6/9 6/9  20  18  open 0  0  nil 
94 male  72  nil  6/9 6/9  14  14  open 0.4  0.4 nil 
95 female  89  nil  6/9 6/9  14  14  open 0.2  0.2 nil 
96 female  69  nil  6/9 6/6  18  18  open 0.3  0.3 nil 
97 female  65  nil  6/6 6/5  11  13  open 0.4  0.4 nil 
98 female  53  nil  6/6 6/6  14  14  open 0.2  0.2 nil 
99 female  75  nil  6/9 6/9  13  14  open 0  0  nil 
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100 male  69  nil  6/9 6/6  17  17  open 0.4  0.4 nil 
100_MH female  68  nil  6/9 6/9  14  19  open 0  0  nil 
101 female  76  nil  6/9 6/9  17  19  open 0  0  nil 
102 male  67  nil  6/12 6/9  15 17 open  0 0  nil 
103 female  87  nil  6/9 6/12  15  18  open 0  0  nil 
104 male  73  nil  6/9 6/9  18  18  open 0.4  0.4 nil 
105 male  78  nil  6/9 6/9  12  12  open 0  0  nil 
106 female  68  nil  6/9 6/9  17  15  open 0.4  0.4 nil 
107 male  70  nil  6/9 6/9  13  13  open 0  0  nil 
108 male  66  nil  6/6 6/6  10  18  open 0  0  nil 
109 female  84  nil  6/9 6/9  10  10  open 0  0  nil 
110 female  71  nil  6/9 6/9  17  18  open 0  0  nil 
111 female  82  nil  6/9 6/9  18  16  open 0.2  0.2 nil 
112 male  68  nil  6/9 6/9  18  14  open 0  0  nil 
113 male  71  nil  6/9 6/6  18  18  open 0  0  nil 
114 female  68  nil  6/9 6/9  16  16  open 0.4  0.4 nil 
115 female  85  nil  6/12 6/9  18 18 open  0.4  0.4  nil 
116 male  70  nil  6/9 6/9  13  12  open 0  0  nil 
117 female  70  nil  6/9 6/9  15  15  open 0.3  0.3 nil 
118 female  70  nil  6/9 6/9  16  19  open 0.3  0.3 nil 
119 female  61  nil  6/9 6/6  15  15  open 0  0  nil 
120 female  58  nil  6/5 6/6  16  14  open 0.5  0.5 nil 
122 female  52  nil  6/9 6/9  18  18  open 0.3  0.3 nil 
150p male  83  nil  6/9 6/9  12  12  open 0.5  0.5 nil 
351 female  78  nil  6/9 6/9  15  15  open 0  0  nil 
352 male  75  nil  6/9 6/9  15  7 open 0  0  nil 
353 female  75  nil  6/9 6/6  20  20  open 0  0  nil 
354 female  85  nil  6/9 6/9  16  17  open 0  0  nil 
355 male  72  nil  6/9 6/9  10  14  open 0  0  nil 
356 female  60  nil  6/6 6/6  16  16  open 0.5  0.5 nil 
357 female  76  nil  6/9 6/9  14  14  open 0  0  nil 
358 male  62  nil  6/9 6/9  13  14  open 0  0  nil 
359 female  82  nil  6/9 6/9  15  15  open 0  0  nil 
360 male  63  nil  6/9 6/9  16  16  open 0.5  0.5 nil 
361 female  82  nil  6/9 6/6  17  14  open 0  0  nil 
363 male  73  nil  6/9 6/9  13  14  open 0  0  nil 
364 male  76  nil  6/9 6/9  14  14  open 0  0  nil 
365 male  65  nil  6/6 6/6  15  15  open 0.4  0.4 nil 
366 male  52  nil  6/4 6/5  11  11  open 0.4  0.4 nil 
367 male  81  nil  6/4 6/4  14  14  open 0  0  nil 
368 female  40  nil  6/5 6/6  13  14  open 0  0  nil 
369 male  46  nil  6/4 6/4  16  18  open 0  0  nil 
370 male  82  nil  6/9 6/9  16  15  open 0  0  nil 
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371 female  73  nil  6/9 6/9  15  16  open 0  0  nil 
372 female  67  nil  6/9 6/6  15  14  open 0  0  nil 
373 female  63  nil  6/5 6/6  20  19  open 0  0  nil 
374 female  82  nil  6/9 6/9  15  16  open 0  0  nil 
375 female  56  nil  6/9 6/9  17  17  open 0  0  nil 
376 female  72  nil  6/9 6/9  15  16  open 0  0  nil 
377 male  76  nil  6/9 6/9  12  12  open 0  0  nil 
379 male  61  nil  6/9 6/6  19  19  open 0.3  0.3 nil 
380 male  72  nil  6/9 6/9  17  17  open 0  0  nil 
381 female  62  nil  6/9 6/9  15  15  open 0  0  nil 
382 female  76  nil  6/6 6/6  16  16  open 0  0  nil 
383 female  61  nil  6/9 6/9  20  21  open 0.3  0.3 nil 
384 male  60  nil  6/9 6/9  16  16  open 0  0  nil 
385 female  56  nil  6/9 6/9  16  16  open 0  0  nil 
386 male  62  nil  6/9 6/9  18  17  open 0.5  0.5 nil 
387 female  83  nil  6/9 6/6  17  18  open 0  0  nil 
388 female  77  nil  6/9 6/9  15  15  open 0  0  nil 
391 male  78  nil  6/9 6/9  10  11  open 0.5  0.5 nil 
392 male  69  nil  6/6 6/6  16  16  open 0  0  nil 
394 male  59  nil  6/4 6/5  10  11  open 0  0  nil 
396 female  60  nil  6/6 6/5  18  18  open 0  0  nil 
397 female  68  nil  6/5 6/6  16  15  open 0.5  0.5 nil 
398 female  57  nil  6/4 6/4  15  15  open 0  0  nil 
399 female  69  nil  6/9 6/9  18  17  open 0.3  0.3 nil 
400 female  73  nil  6/9 6/6  17  16  open 0.4  0.4 nil 
400_MM female  73  nil  6/5 6/6  13  13  open 0  0.4 nil 
400_P female  74  nil  6/9 6/9  14  19  open 0.4  0  nil 
401_JM female 59  nil  6/9 6/9  16  17  open 0  0  nil 
402 female  63  nil  6/9 6/9  19  17  open 0.5  0.5 nil 
402_VS female 53  nil  6/9 6/9  13  14  open 0  0  nil 
403_GM female  86  nil  6/9 6/6  19  19  open 0  0  nil 
404_VB female  60  nil  6/9 6/9  18  18  open 0  0  nil 
405 female  72  nil  6/9 6/9  19  19  open 0  0  nil 
408 male  78  nil  6/6 6/6  15  15  open 0.4  0.4 nil 
409 male  75  nil  6/9 6/9  18  17  open 0  0  nil 
410 female  71  nil  6/9 6/9  19  18  open 0  0  nil 
411 male  75  nil  6/9 6/9  11  13  open 0  0  nil 
412 male  70  nil  6/9 6/9  15  18  open 0  0  nil 
415 female  67  nil  6/9 6/6  17  16  open 0  0  nil 
416 female  67  nil  6/9 6/9  16  17  open 0  0  nil 
417 male  70  nil  6/9 6/9  16  18  open 0.3  0.3 nil 
418 male  88  nil  6/6 6/6  18  16  open 0.5  0.5 nil 
419 male  68  nil  6/6 6/5  16  16  open 0.5  0.5 nil 
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421 male  68  nil  6/6 6/5  16  16  open 0.4  0.4 nil 
422 female  70  nil  6/5 6/6  18  18  open 0.5  0.5 nil 
423 female  70  nil  6/6 6/9  17  18  open 0  0  nil 
424 male  70  nil  6/9 6/9  12  12  open 0.4  0.4 nil 
425 female  72  nil  6/9 6/9  17  17  open 0  0  nil 
426_JS female 77  nil  6/9 6/9  12  12  open 0  0  nil 
427 male  76  nil  6/9 6/6  13  14  open 0.3  0.3 nil 
428 female  76  nil  6/9 6/9  17  17  open 0  0  nil 
429 male  72  nil  6/9 6/12  17  19  open 0  0  nil 
430 male  84  nil  6/9 6/9  14  14  open 0.5  0.5 nil 
431 female  73  nil  6/9 6/9  12  12  open 0  0  nil 
432 female  61  nil  6/9 6/9  20  19  open 0  0  nil 
433 male  81  nil  6/9 6/6  12  12  open 0.5  0.5 nil 
434 female  64  nil  6/6 6/6  13  13  open 0  0  nil 
435 female  80  nil  6/9 6/9  14  13  open 0  0  nil 
436 female  71  nil  6/9 6/9  17  17  open 0  0  nil 
437 female  79  nil  6/9 6/9  19  19  open 0.5  0.5 nil 
438 male  59  nil  6/9 6/9  15  15  open 0  0  nil 
439 male  60  nil  6/9 6/6  14  14  open 0  0  nil 
441 male  63  nil  6/9 6/9  17  16  open 0  0  nil 
442 female  45  nil  6/9 6/9  16  17  open 0  0  nil 
443 male  62  nil  6/6 6/6  14  13  open 0.5  0.5 nil 
444 male  59  nil  6/9 6/9  15  14  open 0.3  0.3 nil 
445 female  76  nil  6/9 6/9  16  18  open 0.5  0.5 nil 
446 male  49  nil  6/6 6/6  9 9 open 0  0  nil 
447 male  63  nil  6/9 6/9  16  17  open 0.5  0.5 nil 
448 male  66  nil  6/9 6/6  16  14  open 0  0  nil 
449 male  76  nil  6/9 6/9  17  17  open 0.4  0.4 nil 
450 male  76  nil  6/9 6/9  13  13  open 0  0  nil 
451 female  69  nil  6/6 6/6  15  15  open 0  0  nil 
452 female  65  nil  6/5 6/5  15  16  open 0  0  nil 
453 female  53  nil  6/6 6/4  14  15  open 0  0  nil 
454 female  75  nil  6/5 6/6  14  15  open 0  0  nil 
455 female  78  nil  6/6 6/9  19  19  open 0  0  nil 
456 male  61  nil  6/9 6/9  16  18  open 0  0  nil 
457 female  64  nil  6/6 6/5  14  11  open 0  0  nil 
458 male  48  nil  6/5 6/6  17  18  open 0  0  nil 
460 male  75  nil  6/6 6/9  20  20  open 0.5  0.5 nil 
461 female  69  nil  6/9 6/9  16  15  open 0  0  nil 
462 female  71  nil  6/9 6/9  14  14  open 0  0  nil 
463 male  75  nil  6/9 6/9  16  16  open 0.4  0.4 nil 
464 female  68  nil  6/9 6/6  16  15  open 0  0  nil 
465 male  68  nil  6/9 6/9  20  20  open 0  0  nil 
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466 male  72  nil  6/9 6/12  14  14  open 0.5  0.5 nil 
467 male  85  nil  6/9 6/9  18  18  open 0.4  0.4 nil 
468p female  77  nil  6/9 6/9  11  13  open 0  0  nil 
468 male  55  nil  6/9 6/9  11  11  open 0.4  0.4 nil 
469 male  85  nil  6/9 6/6  11  14  open 0  0  nil 
470 male  60  nil  6/6 6/6  10  15  open 0  0  nil 
471 male  68  nil  6/9 6/9  16  16  open 0  0  nil 
473 female  66  nil  6/9 6/9  11  11  open 0.5  0.5 nil 
474 female  73  nil  6/9 6/9  15  15  open 0.5  0.5 nil 
475 male  64  nil  6/9 6/9  16  16  open 0.5  0.5 nil 
476 female  76  nil  6/9 6/6  14  14  open 0.5  0.5 nil 
478 male  62  nil  6/9 6/9  18  16  open 0.3  0.3 nil 
479 female  63  nil  6/9 6/9  15  15  open 0.3  0.3 nil 
C1 female  66  nil  6/6 6/6  15  15  open 0.2  0.2 nil 
C2 female  80  nil  6/9 6/9  16  15  open 0.3  0.3 nil 
C3 male  54  nil  6/9 6/9  14  14  open 0.4  0.4 nil 
C4 female  58  nil  6/6 6/6  11  10  open 0.2  0.2 nil 
C5 female  73  nil  6/9 6/9  16  16  open 0.4  0.4 nil 
C6 female  69  nil  6/9 6/6  15  15  open 0.5  0.5 nil 
C7 female  66  nil  6/9 6/9  17  16  open 0.3  0.3 nil 
C8 male  64  nil  6/9 6/9  14  14  open 0.3  0.3 nil 
C9 female  57  nil  6/6 6/6  13  13  open 0.2  0.2 nil 
C10 female  71  nil  6/5 6/5  12  11  open 0.4  0.4 nil 
C11 male  63  nil  6/6 6/4  16  16  open 0.3  0.3 nil 
C12 female  83  nil  6/5 6/6  13  12  open 0.2  0.2 nil 
C13 male  67  nil  6/6 6/9  17  17  open 0.2  0.2 nil 
C14 male  64  nil  6/9 6/9  16  16  open 0.4  0.4 nil 
C15 female  59  nil  6/6 6/6  18  18  open 0.5  0.5 nil 
C16 female  63  nil  6/9 6/9  15  14  open 0.3  0.3 nil 
C17 male  83  nil  6/9 6/6  14  14  open 0.3  0.3 nil 
C18 male  68  nil  6/9 6/9  13  13  open 0.4  0.4 nil 
C19 female  41  nil  6/5 6/4  11  11  open 0.2  0.2 nil 
C20 female  64  nil  6/9 6/9  18  18  open 0.2  0.2 nil 
C21 female  72  nil  6/9 6/9  16  15  open 0.2  0.2 nil 
C22 female  71  nil  6/6 6/6  17  17  open 0.3  0.3 nil 
C23 female  72  nil  6/9 6/9  13  13  open 0.3  0.3 nil 
C24 female  61  nil  6/9 6/6  17  15  open 0.1  0.1 nil 
C25 female  73  nil  6/9 6/9  18  18  open 0.2  0.2 nil 
C26 male  73  nil  6/9 6/9  14  14  open 0.4  0.4 nil 
C27 male  75  nil  6/6 6/6  13  13  open 0.3  0.3 nil 
C28 female  72  nil  6/9 6/5  17  17  open 0.4  0.4 nil 
C29 female  72  nil  6/9 6/9  13  13  open 0.3  0.3 nil 
C30 male  77  nil  6/9 6/9  13  13  open 0.2  0.2 nil 
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RVI87 male  77  nil  6/9 6/9  20  20  open 0.3  0.3 nil 
RVI89 male  83  nil  6/9 6/9  19  20  open 0.2  0.2 nil 
RVI90 female  89  nil  6/9 6/6  16  16  open 0.3  0.3 nil 
RVI92 female  75  nil  6/9 6/9  17  17  open 0.3  0.3 nil 
RVI107 female 76  nil  6/9 6/9  16  16  open 0.5  0.5 nil 
RVI108 female 75  nil  6/6 6/6  16  16  open 0.3  0.3 nil 
RVI109 female 83  nil  6/9 6/9  14  14  open 0.2  0.2 nil 
RVI111 male  68  nil  6/9 6/9  18  18  open 0.3  0.2 nil 
RVI115 female 75  nil  6/6 6/6  19  19  open 0.4  0.4 nil 
RVI116 female 75  nil  6/9 6/9  20  20  open 0.4  0.3 nil 
RVI117 female 78  nil  6/9 6/6  16  16  open 0.5  0.5 nil 
RVI119 female 80  nil  6/9 6/9  14  13  open 0.3  0.3 nil 
RVI120 female 87  nil  6/9 6/9  14  14  open 0.3  0.3 nil 
RVI124 female 85  nil  6/6 6/6  20  19  open 0.5  0.5 nil 
RVI125 female 80  nil  6/5 6/5  18  18  open 0.3  0.3 nil 
RVI126 female 89  nil  6/6 6/4  16  16  open 0.3  0.3 nil 
RVI128 male  87  nil  6/5 6/6  17  17  open 0.5  0.5 nil 
RVI130 male  78  nil  6/6 6/9  20  19  open 0.3  0.3 nil 
RVI131 female 77  nil  6/9 6/9  19  20  open 0.4  0.3 nil 
RVI145 male  82  nil  6/6 6/6  10  10  open 0.5  0.5 nil 
RVI177 male  90  nil  6/12 6/9  14 14 open  0.2  0.2  nil 
RVI220 female 70  nil  6/9 6/6  17  17  open 0.3  0.3 nil 
RVI221 female 81  nil  6/9 6/9  18  18  open 0.4  0.4 nil 
RVI228 female 87  nil  6/9 6/6  12  12  open 0.3  0.3 nil 
RVI239 male  75  nil  6/9 6/9  16  16  open 0.3  0.3 nil 
RVI240 male  77  nil  6/9 6/9  15  16  open 0.3  0.3 nil 
RVI241 male  87  nil  6/6 6/6  15  15  open 0.4  0.4 nil 
RVI242 female 78  nil  6/9 6/5  18  18  open 0.5  0.5 nil 
RVI243 male  77  nil  6/6 6/9  18  18  open 0.5  0.5 nil 
RVI244 male  78  nil  6/9 6/9  16  16  open 0.4  0.4 nil 
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8.4  Appendix IV: Demographic and phenotypic features of HTG individuals 
 
 
 
 
Table 8–2: Demographic and phenotypic features of HTG individuals (n = 272) 
Best visual 
acquity 
 
 Highest  
 recorded 
 IOP  
Anterio
chambe
angle 
Cup-disc ratio   Visual field defect  Patient 
ID 
Sex  Age  Age at 
diagnosis 
Family history of 
glaucoma 
Right Left  Right Left   Right   Left  Right Left 
Topical 
medication 
Laser  Surgery 
1p   female  87  83  nil  6/9  6/9  25  25  open  0.7  0.8  advanced   advanced   yes  nil  nil 
2a  female  63 55  yes  6/9 6/9  25  24 open  0.6  0.5 arcuate  arcuate  yes  nil  nil 
2p   female  80  76  nil  6/9  6/9  24  21  open  0.7  0.6  nasal step  early nasal step  yes  nil  nil 
3p   male  82  78  nil  6/9  6/9  26  20  open  0.8  0.7  nasal step  nasal step  yes  nil  nil 
6p    female  71 59  nil  6/9 6/6  29  28 open  0.5  0  paracentral  nil  yes  nil  nil 
7p   male  71  71  yes (sister)  6/9  6/9  27  21  open  0.6  0.4  arcuate  nil  yes  nil  nil 
8p   female  89  80  yes (sister and 
father) 
6/9  6/9  22  28  open  0.4  0.7  paracentral   advanced paracentral  yes  nil  nil 
9p   female  85  70  nil  6/6  6/6  25  24  open  0.8  0.8  paracentral   paracentral, nasal 
step  
yes nil  nil 
10p   male  75  67  yes (sister)  6/9  6/9  24  19  open  0.9  0.5  advanced  nasal step  yes  nil  nil 
11p   male  66  57  nil  6/9  6/9  54  42  open  0.9  0.8  advanced  nasal step  yes  nil  right trab 
12p   female  86  80  yes (father and 
sister) 
6/6 6/6 29  21 open  0.9  0.6 advanced  arcuate  yes  nil  nil 
14p   male  68  66  yes (uncle and aunt- 
maternal side) 
6/9 6/9 26  26 open  0.3  0.4 nil  paracentral  yes  nil  nil 
15p   male  60  54  yes (father and 
brother) 
6/9  6/6  35  36  open  0.7  0.7  nasal step  nasal step  yes  nil  nil 
16p    female  63 50  yes  6/9 6/9  24  25 open  0.8  0.7 advanced  nasal 
step 
arcuate nil  nil  bilateral  trab 
17p    female  71 70  yes  6/9 6/9  26  44 open  0.8  0.8 paracentral  and 
nasal step 
nasal step  yes  nil  nil 
18p    female  76 68  nil  6/6 6/6  25  25 open  0.7  0.6 paracentral  nasal  step  yes  nil  nil 
19p    female  66 65  yes  6/5 6/5  18  25 open  0.5  0.7 nil  nasal  step  yes  nil  nil 
20p   female  52  49  nil  6/6  6/4  44  45  open  0.9  0.8  advanced  advanced  yes  nil  right trab  
21p    female  84 57  nil  6/5 6/6  26  29 open  0.7  0.8 arcuate  advanced  yes  nil  left  trab 
22p   male  77  62  yes (cousin-  6/6  6/9  36  44  open  0.6  0.9  nasal step  advanced  yes  nil  bilateral trab 
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paternal side) 
23p   male  76  68  yes (brother)  6/9  6/9  32  26  open  1  1   advanced arcuate  advanced  yes  nil  bilateral trab 
24p   male  83  78  yes (son)  6/6  6/6  31  35  open  0.5  1  nil  arcuate and advanced 
nasal 
yes nil  left  trab 
25p    female  82 76  nil  6/9 6/9  26  22 open  0.4  0.2 arcuate  nil  yes  nil  nil 
26p    female  85 81  nil  6/9 6/6  32  24 open  0.5  0.4 arcuate  nasal  step  yes  nil  nil 
27p   male  66  66  yes (mother)  6/9  6/9  28  15  open  0.8  0.6  nasal step  nil  yes  nil  nil 
28p  male  76 70  nil  6/5 6/4  27  36 open  0.5  1  nil  advanced  yes  nil  nil 
29p    male  66 62  nil  6/9 6/9  30  38 open  0.5  0.7 nil  arcuate  yes  nil  nil 
30p    female  85 80  yes  6/9 6/9  31  28 open  0.7  0.4 nasal  step  nil  yes  nil  nil 
43p RT  female  83  81  yes (grandmother 
and 2 nieces) 
6/6  6/6  20  25  open  0.4  0.7  arcuate  nasal and arcuate  yes  nil  nil 
44p    male  73 66  nil  6/9 6/9  34  36 open  0.3  0.6 nil  nasal  yes  nil  nil 
45p    female  72 61  nil  6/9 6/6  28  23 open  0.7  0.5 arcuate  nil  yes  nil  right  trab 
46p    male  82 77  nil  6/9 6/9  29  20 open  1  0.8 advanced  nasal  and  arcuate  yes  nil  nil 
47p   male  64  61  yes (father)  6/9  6/9  18  28  open  0.3  0.7  nil  arcuate and 
paracentral 
yes nil  nil 
50p   female  56  45  nil  6/6  6/6  29  17  open  0.8  0.6  nasal step  nasal step  yes  nil  nil 
51p  mr female  70 69  nil  6/9 6/5  25  22 open  0.5  0.3 paracentral  nil  yes  nil  nil 
52p    female  80 69  nil  6/9 6/9  25  31 open  0.2  0.5 nil  arcuate  yes  nil  nil 
52p  ht  male  72 44  nil  6/9 6/9  28  36 open  0.5  0.6 nil  paracentral  scotoma  yes  nil  nil 
55p   male  77  65  yes (mother and 
son) 
6/9 6/9 28  26 open  0.8  0.7 nasal  and  arcuate  paracentral  yes  nil  nil 
59p    female  93 85  nil  6/6 6/6  29  30 open  0.4  0.7 paracentral  paracentral  and 
arcuate 
yes nil  nil 
60p  male  64 61  nil  6/9 6/9  27  27 open  0.7  0.7 nasal  step  arcuate  yes  nil  nil 
61p jcah  male  61  56  nil  6/9  6/6  29  29  open  0.7  0.7  nasal step  nasal step  yes  nil  nil 
62p  bug  male  61 58  nil  6/9 6/9  27  27 open  0.7  0.7 paracentral  arcuate  yes  nil  nil 
62p ws  male  74  62  yes (father)  6/5  6/6  25  29  open  0.6  0.7  arcuate  arcuate  yes  nil  bilateral trab 
65p   male  76  74  yes (brother)  6/9  6/9  34  27  open  0.6  0.3  nasal step  nil  yes  nil  nil 
67p    female  88 58  nil  6/9 6/9  30  30 open  0.9  0.9 advanced  advanced  yes  nil  bilateral  trab 
70p   male  72  71  yes (aunt and uncle-
paternal side) 
6/6 6/6 25  16 open  0.8  0.7 nasal  step  arcuate  yes  nil  nil 
71p    male  63 63  nil  6/9 6/9  44  14 open  1  0.4 advanced  nil  yes  nil  right  trab 
71p jc  female  65  52  yes (mother, uncle 
and grandfather- 
maternal side) 
6/9 6/6 30  29 open  0.5  0.5 paracentral  nasal  yes  nil  nil 
72p  male  84 81  nil  6/9 6/9  15  50 open  0.5  0.6 nil  nasal  step  yes  nil  nil 
72p rg  female  77  64  yes (sister)  6/9  6/9  26  33  open  0.8  0.9  arcuate  advanced arcuate  yes  nil  left trab 
76p    male  82 69  nil  6/6 6/6  24  28 open  0.9  1.0 advanced  arcuate 
and paracentral 
advanced yes  nil  left  trab 
80p    female  79 78  nil  6/9 6/5  26  22 open  0.8  0.5 nasal  step  nil  yes  nil  nil 
81p  male  76  69  yes (father and  6/9  6/9  23  27  open  0.7  0.9  nasal step and  advanced  yes  nil  right trab 
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brother) arcuate 
82p  male  75  59  yes (brother and 
sister) 
6/9 6/9 29  28 open  0.6  0.5 nasal  and  arcuate  arcuate  yes  nil  nil 
83p  male  76 67  nil  6/6 6/9  20  36 open  0.5  0.6 nil  nasal  step  yes  nil  nil 
84p  male  45 42  nil  6/4 6/5  34  34 open  0.7  0.6 arcuate  nasal  step  yes  nil  nil 
86p  female  85 74  nil  6/9 6/9  27  24 open  0.8  0.5 arcuate  arcuate  nil  nil  bilateral  trab 
90p   male  49  48  nil  6/5  6/4  28  30  open  0.9  0.9  paracentral   paracentral   yes  nil  right trab  
97p   female  77  66  yes (sister)  6/9  6/9  28  27  open  0.8  0.6  arcuate  nasal step  yes  nil  nil 
99p    male  82 71  nil  6/9 6/6  20  28 open  0.5  0.7 nil  nasal  and  paracentral  yes  nil  nil 
104p    female  67 58  nil  6/9 6/9  24  25 open  0.7  0.7 nasal  step  arcuate  yes  nil  nil 
106p    female  81 70  nil  6/5 6/6  31  32 open  0.8  0.9 paracentral  arcuate  nil  nil  bilateral  trab 
110p    male  56 53  nil  6/9 6/9  34  22 open  0.7  0.4 nasal  step  nil  yes  nil  nil 
113p  male  83 79  nil  6/9 6/9  25  20 open  0.8  0.3 arcuate  nil  yes  nil  nil 
114  male  50 41  yes  (father)  6/6 6/6  22  28 open  0.4  0.8 nil  nasal  step  and 
arcuate 
yes nil  nil 
116p  female  75 74  nil  6/9 6/9  31  33 open  0.8  0.8 nasal  arcuate  yes  nil  nil 
123p   male  81  65  nil  6/9  6/6  24  22  open  0.8  0.9  arcuate and nasal  temp wedge  yes  nil  nil 
124p female  75  53  yes  (grandmother-
paternal side) 
6/9 6/9 34  28 open  0.7  0.6 paracentral  nil  yes  nil  bilateral  trab 
125p  male  67 59  nil  6/9 6/6  23  27 open  0.2  0.4 nil  nasal  step  yes  nil  nil 
129p   female  59  51  yes (mother and 
father) 
6/9 6/9 29  31 open  0.3  0.5 nil  arcuate  yes  nil  nil 
134p   female  72  53  yes (father)  6/5  6/6  25  26  open  0.4  0.4  nasal step  nasal step  yes  nil  nil 
135p  male  79 75  nil  6/9 6/9  26  26 open  0.8  0.9 paracentral  arcuate  and  nasal 
step 
yes nil  nil 
136p    male  85 83  nil  6/9 6/9  34  34 open  0.5  0.6 temp  wedge  and 
nasal step 
temp wedge and 
nasal step 
yes nil  right  trab 
137p   female  68  59  yes (father)  6/6  6/6  25  22  open  0.6  0.4  arcuate  nil  yes  nil  nil 
140p    female  75 74  nil  6/9 6/9  20  26 open  0.3  0.8 nil  nasal  yes  nil  nil 
142p  female  79 64  nil  6/9 6/9  23  25 open  0.4  0.9 nil  advanced  yes  nil  bilateral  trab 
145p    female  76 47  nil  6/5 6/4  30  30 open  0.6  0.8 nil  nasal  step  yes  nil  nil 
146p  female  57  51  yes (aunt- maternal 
side) 
6/9 6/9 34  41 open  0.5  0.8 nasal    arcuate  yes  nil  nil 
147p   male  78  63  yes (brother)  6/9  6/6  26  30  open  0.5  0.9  nil  advanced  yes  nil  left trab 
149p   female  80  61  yes (grandfather)  6/9  6/9  26  28  open  0.9  0.9  nasal  advanced arcuate  yes  nil  nil 
152p   female  57  44  yes (mother, father, 
uncle (paternal 
side) and aunt 
(maternal side) 
6/5 6/6 24  36 open  0.3  0.6 nil  paracentral  yes  nil  nil 
153p   male  69  62  nil  6/9  6/9  18  26  open  0.8  0.9  nasal step  arcuate  nil  nil  bilateral trab 
157p    female  76 75  nil  6/9 6/9  25  33 open  0.6  0.6 arcuate  arcuate  yes  nil  nil 
158p   female  77  77  yes (brother)  6/6  6/6  17  25  open  0.4  0.8  nil  arcuate  yes  nil  nil 
160p  female  63 57  yes  (father  and  6/9 6/9  26  26 open  0.9  0.7 arcuate  and  nasal  yes  nil  nil 
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sister)  paracentral 
350p    male  85 76  nil  6/9 6/6  25  38 open  0.9  0.9 advanced  nasal 
step 
advanced yes  nil  bilateral  trab 
393  female  59 58  nil  6/6 6/9  22  30 open  0.4  0.7 nil  arcuate  and  nasal 
step 
yes nil  nil 
401p  male  67 58  nil  6/9 6/6  27  22 open  0.9  0.8 nasal  step  and 
paracentral 
nil yes  nil  nil 
403  female  77 72  nil  6/9 6/9  24  20 open  0.5  0.5 advanced  nasal  step  yes  nil  nil 
405p  male  81 75  yes  (brother)  6/5 6/6  31  29 open  0.7  0.3 arcuate  nil  yes  nil  nil 
408p   male  56  53  yes (grandmother-
maternal side) 
6/9  6/9  36  40  open  0.8  0.9  arcuate  arcuate   yes  nil  bilateral trab 
409p   female  79  55  yes (father)  6/9  6/9  29  34  open  0.9  0.9  advanced arcuate   arcuate  yes  nil  bilateral trab 
411p    male  68 62  nil  6/6 6/6  30  26 open  0.8  0.5 paracentral  and 
nasal step 
nil yes  nil  nil 
412p   female  69  52  yes (father and 
uncle-paternal side) 
6/9 6/9 27  28 open  0.4  0.6 nil  nasal  step  yes  nil  nil 
413p   female  82  72  nil  6/9  6/6  41  40  open  0.5  0.4  nasal step  nasal step  nil  nil  bilateral trab 
414p   female  57  55  nil  6/9  6/9  28  26  open  0.9  0.4  advanced arcuate   nil  yes  nil  right trab 
415p   female  69  64  yes (father)  6/9  6/6  29  26  open  0.8  0.8  paracentral and 
arcuate 
nasal step  yes  nil  right trab 
417p    male  57 54  nil  6/9 6/9  30  30 open  0.9  0.9 arcuate  and 
paracentral 
paracentral   yes  nil  nil 
418p    female  73 64  nil  6/5 6/4  28  26 open  0.4  0.3 nasal  step  paracentral  yes  nil  nil 
419p    female  77 71  nil  6/9 6/9  24  18 open  0.8  0.7 nasal  step  nil  yes  nil  nil 
420P   male  82  75  yes (grandmother-
maternal side) 
6/9 6/9 28  24 open  0.9  0.3 advanced  arcuate  nil  yes  nil  nil 
421p  male  78 63  nil  6/6 6/6  35  31 open  0.8  0.8 advanced  advanced  yes  nil  left  trab 
423p female  82  79  yes  (mother  and 
daughter) 
6/12 6/9  26 26  open 0.8  0.8  nasal  step  arcuate  yes  nil  nil 
425p    female  82 76  nil  6/9 6/6  27  28 open  0.7  0.8 arcuate  advanced  arcuate  yes  nil  nil 
427p  male  86 79  nil  6/9 6/9  30  30 open  0.7  0.6 nasal  step  paracentral  and  nasal 
step 
yes nil  nil 
428p   female  76  70  nil  6/9  6/9  26  24  open  0.9  0.8  arcuate   arcuate and nasal  yes  nil  nil 
430p   female  63  60  yes (father)  6/6  6/6  25  22  open  0.9  0.6  advanced nasal 
step 
temporal wedge  yes  nil  nil 
431p   male  46  44  yes (father)  6/9  6/5  26  26  open  0.8  0.8  advanced  advanced  yes  nil  nil 
432p male  79  72  yes  (mother  and 
sister) 
6/9 6/9 34  36 open  0.9  0.8 advanced  advanced  yes  nil  right  trab 
433p   female  72  62   yes (grandfather)  6/9  6/9  36  34  open  0.7  0.5  arcuate  nasal step  yes  nil  nil 
434p   female  80  76  nil  6/9  6/9  25  26  open  0.4  0.4  nasal step  nasal step  yes  nil  nil 
436p   female  53  53  yes (mother)  6/6  6/6  25  26  open  0.3  0.5  nil  nasal step  yes  nil  nil 
437p    female  89 86  nil  6/9 6/9  28  26 open  0.4  0.8 nasal  arcuate  yes  nil  nil 
438p  male  92 83  yes  (sister)  6/9 6/6  20  24 open  0.5  0.7 nasal  step  paracentral  yes  nil  nil 
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439p    female  90 84  nil  6/9 6/9  23  24 open  0.5  0.9 nasal  step  advanced  yes  nil  nil 
440p   male  77  64  yes (mother, sister 
and brother) 
6/6 6/6 24  26 open  0.6  0.8 nil  nasal  step  yes  nil  nil 
441p   female  45  44  yes (uncle- 
maternal side) 
6/9  6/9  38  42  open  0.8  1  nasal step  advanced nasal step 
and paracentral 
scotoma 
yes nil  left  trab 
442p   male  72  63  nil  6/9  6/9  22  33  open  0.5  0.9  nasal step  advanced  yes  nil  left trab 
443p    male  57 56  nil  6/6 6/6  28  42 open  0.5  0.9 nil  arcuate  and  nasal  yes  nil  nil 
444p   female  74  74  yes (sister and 
uncle- maternal 
side) 
6/9 6/9 23  27 open  0.6  0.9 nasal  step  paracentral  and 
arcuate 
yes nil  nil 
445p   male  76  58  yes (brother and 2 
sisters) 
6/9 6/6 32  32 open  0.3  0.7 nil  nasal  step  yes  nil  nil 
447p female  76  68  yes  (aunt,  aunt's 
daughter, uncle's 
son- all paternal 
side) 
6/9 6/9 30  26 open  1  0.9 arcuate  paracentral  yes  nil  nil 
448p  male  51 50  yes  (father)  6/4 6/5  20  29 open  0.2  0.9 nil  advanced  yes  nil  left  trab 
449p    female  70 53  nil  6/9 6/9  30  38 open  0.9  0.8 advanced  arcuate  nasal  step  yes  right 
ALT 
bilateral trab 
451p male  71  67  yes  (father  and 
sister) 
6/9 6/9 22  26 open  0.5  0.6 nil  nasal  step  yes  nil  nil 
452p   female  81  74  yes (mother)  6/6  6/6  26  26  open  0.9  0.8  advanced arcuate  arcuate  yes  nil  nil 
453p    male  86 70  nil  6/9 6/9  26  30 open  0.5  1  nil  advanced  nil  left 
ALT 
left trab 
458p female  68  47  yes  (aunt,  aunt's 
daughter- paternal 
side) 
6/6 6/6 30  36 open  0.9  0.9 advanced  advanced  yes  nil  bilateral  trab 
462p    male  80 72  nil  6/12  6/9  29  20 open  0.6  0.3 arcuate  nil  yes  nil  right  trab 
465p  female  76  74  yes (sister)  6/9  6/9  26  25  open  0.7  0.8  nasal step  nasal step  yes  nil  nil 
467p    male  59 55  nil  6/9 6/9  32  36 open  0.8  0.5 arcuate  nil  yes  nil  nil 
469p  male  76 74  yes  (grandfather)  6/6 6/6  20  27 open  0.2  0.5 nil  arcuate  yes  nil  nil 
470p   female  83  81  yes (2 cousin each 
from 2 separate 
aunt-paternal side) 
6/9  6/5  20  24  open  0.4  0.7  arcuate  nasal and arcuate  yes  nil  nil 
473p   female  71  61  nil  6/9  6/9  30  28  open  0.4  0.4  paracentral   nil  yes  nil  right trab 
474p    male  73 66  nil  6/9 6/9  16  24 open  0.6  0.8 nil  paracentral    yes  nil  nil 
477p   male  73  72  yes (aunt)  6/9  6/9  28  22  open  0.6  0.4  paracentral  nil  yes  nil  nil 
478p   female  71  58  yes (sister and 
mother) 
6/6  6/6  40  36  open  0.9  0.9  advanced  advanced  yes  nil  bilateral trab  
479p   female  82  63  yes (mother and 
daughter) 
6/9 6/9 30  35 open  0.8  0.7 paracentral  paracentral  yes  nil  nil 
480p    female  79 71  nil  6/9 6/6  30  24 open  1  0.8 advanced  nasal  step  yes  nil  nil 
482p   female  65  49  yes (mother)  6/9  6/9  26  26  open  0.6  0.3  arcuate  paracentral  yes  nil  nil 
2
4
6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
p
p
e
n
d
i
c
e
s
 
483p  male  67 41  nil  6/5 6/6  25  25 open  0.8  0.9 nil  paracentral  yes  nil  bilateral  trab 
484p    male  60 56  nil  6/6 6/9  25  20 open  0.9  0.9 advanced  nasal  step  yes  nil  nil 
485p    female  81 78  nil  6/9 6/9  26  30 open  0.9  0.9 paracentral    nil  yes  nil  nil 
488p   female  87  69  yes (father and 
grandfather- 
paternal side) 
6/9  6/9  29  29  open  0.7  0.9  paracentral   paracentral  nil  nil  bilateral trab 
489p   male  74  56  yes (cousin-paternal 
side) 
6/6 6/6 28  33 open  0.3  0.5 nasal    arcuate  yes  nil  nil 
491p   male  78  65  nil  6/9  6/9  18  40  open  0.4  0.9  nasal   paracentral and nasal  nil  nil  left trab 
492p   female  72  63  yes (brother)  6/9  6/6  28  20  open  0.4  0.2  nasal   nil  yes  nil  nil 
493p    female  78 62  nil  6/9 6/9  31  27 open  0.7  0.5 nasal    nil  yes  nil  nil 
494p    female  92 79  nil  6/12  6/12  24  23 open  0.9  0.7 advanced  arcuate  arcuate  nil  nil  bilateral  trab 
495p    male  71 70  nil  6/9 6/9  32  32 open  0.8  0.3 arcuate  nil  yes  nil  nil 
496p   female  87  70  nil  6/9  6/6  24  20  open  0.5  0.6  nasal step  nasal step  nil  nil  left trab 
498p    male  79 73  nil  6/9 6/9  32  32 open  0.4  0.4 arcuate  paracentral  yes  nil  nil 
500p   female  61  54  yes (grandfather, 
uncle and aunt- all 
maternal side) 
6/5  6/4  23  24  open  0.5  0.6  nasal step  nasal step  yes  nil  nil 
501p   female  75  74  yes (mother, 2 
aunts- maternal 
side) 
6/9 6/9 21  30 open  0.7  0.9 arcuate  advanced  arcuate  yes  nil  nil 
502p   male  82  81  yes (grandmother- 
paternal side) 
6/9 6/9 14  24 open  0.3  0.7 nil  nasal  step  yes  nil  nil 
503p    male  72 69  nil  6/6 6/6  29  24 open  0.4  0.3 nasal  step  nil  yes  nil  nil 
504p    male  44 44  nil  6/9 6/9  42  28 open  0.9  0.8 advanced  arcuate  yes  nil  nil 
505p   male  54  53  yes (mother and 
brother) 
6/9 6/6 23  30 open  0.5  0.7 nil  nasal  step  yes  nil  nil 
506p    female  62 53  nil  6/9 6/5  25  26 open  0.5  0.9 nil  advanced  arcuate    yes  nil  nil 
507p  male  60 50  nil  6/9 6/9  32  30 open  0.6  0.8 nil  nasal  yes  nil  nil 
508p  male  78 65  yes  (mother)  6/6 6/6  33  34 open  0.4  0.6 nil  arcuate  nil  nil  bilateral  trab 
512p   female  90  89  yes (brother)  6/9  6/5  21  27  open  0.7  0.8  nil  nasal step  yes  nil  nil 
516p    male  81 81  nil  6/9 6/9  23  25 open  0.7  0.8 nasal  step  arcuate  yes  nil  nil 
517p   female  67  64  yes (sister and 
sister's son) 
6/9 6/9 26  28 open  0.3  0.5 nasal  step  nil  yes  nil  nil 
520p    male  52 47  nil  6/6 6/5  26  29 open  0.9  0.9 advanced  arcuate  early  arcuate  yes  nil  right  trab 
521p    male  86 75  nil  6/6 6/6  24  28 open  0.7  0.8 arcuate  paracentral  yes  nil  nil 
523p    female  74 58  nil  6/9 6/9  26  26 open  0.4  0.6 nil  arcuate  yes  nil  nil 
525p    female  79 73  nil  6/9 6/6  23  37 open  0.9  1  nasal  step  advanced  yes  nil  nil 
530p   female  70  60  yes (sister, brother, 
father, grandfather, 
2 aunts –all paternal 
side) 
6/9  6/9  26  27  open  0.7  0.6  nasal step  nasal step  yes  nil  nil 
531p  male  62 56  nil  6/5 6/6  26  26 open  0.8  0.7 arcuate  paracentral  yes  nil  nil 
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532p  male  81 79  yes  6/9 6/9  24  25 open  0.6  0.6 nasal  step  nasal  step  yes  nil  nil 
533p  female  72 63  nil  6/9 6/9  27  27 open  0.7  0.7 arcuate  arcuate  yes  nil  nil 
sei1  female  84 69  nil  6/6 6/6  45  40 open  0.4  0.2 arcuate  nil  yes  nil  nil 
sei3  male  70 61  nil  6/9 6/9  24  35 open  0.3  0.9 nil  temporal  wedge  yes  nil  nil 
sei4  male  78 58  nil  6/9 6/6  48  48 open  0.4  0.5 nasal  step  nasal  step  yes  nil  nil 
sei5  female  71 76  yes  6/9 6/9  56  42 open  0.9  0.7 advanced  arcuate  nil  nil  bilateral  trab 
sei6  male  82 50  nil  6/6 6/6  30  32 open  0.8  0.8 arcuate  arcuate    yes  nil  nil 
sei7  male  69 40  nil  6/9 6/9  34  27 open  0.5  0.4 arcuate  nil  yes  nil  nil 
sei9  male  40 74  nil  6/9 6/6  28  32 open  0.4  0.5 nil  nasal  step  yes  nil  nil 
sei10  male  52 40  nil  6/9 6/9  36  30 open  0.6  0.4 nasal  step  nasal  step  yes  nil  nil 
sei11  male  74 69  nil  6/5 6/4  26  31 open  0.2  0.4 nil  nasal  step  yes  nil  nil 
sei12  female  53 71  nil  6/9 6/9  52  26 open  0.9  0.5 advanced  nil  yes    nil  right  trab 
sei13  male  75 67  nil  6/9 6/9  32  29 open  0.6  0.5 temporal  wedge nasal  step  yes  nil  nil 
sei14  male  73 58  nil  6/6 6/6  35  34 open  0.4  0.3 paracentral  nil  yes  nil  nil 
sei15  male  72 65  yes  6/9 6/9  26  38 open  0.4  0.5 nil  arcuate  yes  nil  nil 
sei16  female  71 59  nil  6/9 6/6  34  38 open  0.5  0.6 nil  nasal  step    yes  nil  nil 
sei17  male  59 63  nil  6/9 6/9  30  38 open  0.5  0.5 nil  nasal  step    yes  nil  nil 
sei18  male  68 50  yes  6/9 6/9  30  29 open  0.4  0.2 paracentral  nil  yes  nil  nil 
sei19  male  54 59  nil  6/6 6/6  30  32 open  0.5  0.5 arcuate  temporal  wedge  yes  nil  nil 
sei20  female  69 61  nil  6/9 6/5  34  35 open  0.5  0.5 nasal  step  nasal  step  yes  nil  nil 
sei21  female  61 40  nil  6/9 6/9  24  33 open  0.5  0.6 paracentral  nasal  step  yes  nil  nil 
sei22  male  66 70  nil  6/9 6/9  38  35 open  0.9  0.9 advanced  advanced  yes  nil  nil 
sei23  male  65 54  nil  6/9 6/9  26  30 open  0.6  0.7 nil  arcuate  yes  nil  nil 
sei24  male  80 66  nil  6/6 6/6  20  30 open  0.5  0.6 nil  paracentral  yes  nil  nil 
sei25  male  67 67  nil  6/9 6/9  39  22 open  0.6  0.4 nasal  step  nil  yes  nil  nil 
sei26  male  71 55  nil  6/9 6/6  32  18 open  0.7  0.3 arcuate  nil  yes  nil  nil 
sei27  male  80  65  nil  6/9  6/9  30  32  open  0.8  0.8  nasal step  nasal step  yes   nil  bilateral trab 
sei28  male  74 66  nil  6/5 6/6  33  33 open  0.8  0.8 paracentral  arcuate  yes  nil  nil 
sei29  male  75 65  nil  6/9 6/9  32  31 open  0.8  0.9 advanced  advanced  yes    nil  bilateral  trab 
sei30  male  74 66  nil  6/9 6/9  31  28 open  0.4  0.3 arcuate  nil  yes  nil  nil 
sei31  male  60 67  nil  6/6 6/6  30  28 open  0.7  0.6 nasal  step  nil  yes  nil  nil 
sei32  female  77 48  nil  6/9 6/9  36  65 open  0.9  1  advanced  advanced  yes    nil  bilateral  trab 
sei33  female  51 61  yes  6/9 6/6  38  31 open  0.9  0.1 arcuate  nil  yes  nil  nil 
sei34  male  64 60  nil  6/9 6/9  30  26 open  0.8  0.5 arcuate  nil  yes  nil  nil 
sei35  female  70 83  yes  6/9 6/9  33  32 open  0.8  0.7 paracentral  nil  yes  nil  nil 
sei36  male  71  79  nil  6/6  6/6  30  32  open  0.6  0.6  nasal step  nasal step  yes   nil  bilateral trab 
sei37  male  83 51  nil  6/9 6/5  18  32 open  0.2  0.7 nil  nasal  step  yes  nil  nil 
sei38  male  79 73  nil  6/9 6/9  26  30 open  0.4  0.5 nil  paracentral  yes  nil  nil 
sei39  female  56 77  nil  6/9 6/9  30  35 open  0.9  0.8 advanced  advanced  yes  nil  nil 
sei40  female  77 55  nil  6/6 6/9  24  34 open  0.4  0.8 nasal  step  arcuate  yes  nil  nil 
sei41  female  55 54  nil  6/6 6/6  30  27 open  0.8  0.6 arcuate  nil  yes  nil  nil 
sei42  female  62 73  nil  6/9 6/9  30  22 open  0.3  0.5 nil  nasal  step  yes  nil  nil 
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sei43  male  87 81  nil  6/9 6/6  30  28 open  0.8  0.6 arcuate  arcuate  yes  nil  nil 
sei44  male  87 47  nil  6/9 6/9  24  31 open  0.6  0.7 temporal  wedge arcuate  yes  nil  nil 
sei46  female  75 68  nil  6/5 6/6  32  34 open  0.5  0.6 nil  nasal  step  yes  nil  nil 
sei47  male  54 47  nil  6/6 6/9  38  27 open  0.8  0.7 arcuate  nasal  step  yes  nil  nil 
sei48  female  71 50  nil  6/9 6/9  30  36 open  0.4  0.7 nil  arcuate  yes  nil  nil 
sei49  female  61 55  yes  6/9 6/9  34  34 open  0.3  0.4 nil  nasal  step  yes  nil  nil 
sei50  female  61 61  nil  6/6 6/6  30  29 open  0.5  0.3 paracentral  nil  yes  nil  nil 
sei51  male  55 64  nil  6/9 6/9  29  29 open  0.5  0.5 arcuate  arcuate  yes  nil  nil 
sei52  male  68 64  nil  6/9 6/6  30  29 open  0.4  0.8 nil  nasal  step  yes  nil  nil 
sei53  male  61 61  nil  6/9 6/9  32  22 open  0.4  0.3 paracentral  nil  yes  nil  nil 
sei54  male  63 76  yes  6/12  6/9  27  30 open  0.7  0.8 nil  arcuate  yes  nil  nil 
sei55  female  74 55  yes  6/9 6/9  32  32 open  0.6  0.7 nasal  step  paracentral  yes  nil  nil 
sei56  female  68 59  nil  6/9 6/6  29  33 open  0.8  0.9 advanced  arcuate  advanced  nil  nil  bilateral  tab 
sei57  female  62 41  nil  6/6 6/9  31  30 open  0.8  0.8 arcuate  arcuate  yes  nil  nil 
sei58  female  76 64  nil  6/6 6/6  31  29 open  0.4  0.3 nasal  step  nil  yes  nil  nil 
sei59  male  41 60  nil  6/6 6/9  34  34 open  0.7  0.7 temporal  wedge nasal  step  yes  nil  nil 
sei60  male  68  75  nil  6/9  6/9  30  30  open  0.7  0.7  nasal step  nasal step  yes  nil  right trab 
sei61  female  78 46  nil  6/9 6/6  28  36 open  0.3  0.5 nil  arcuate  yes  nil  nil 
sei62  male  60 55  yes  6/9 6/9  24  40 open  0.3  0.6 nil  arcuate  yes  nil  nil 
sei63  male  82 57  nil  6/5 6/9  49  53 open  0.8  0.9 temp  wedge  advanced  nil  nil  bilateral  trab 
sei64  female  57 62  yes  6/9 6/9  24  36 open  0.3  0.7 nil  arcuate  yes  nil  nil 
sei65  female  77  66  nil  6/9  6/9  34  28  open  0.8  0.6  arcuate  temporal wedge  yes   ALT  bilateral trab 
sei66  male  72 51  yes  6/6 6/6  30  24 open  0.9  0.8 arcuate  and    nasal 
step 
arcuate nil  nil  bilateral  trab 
sei67  male  55 68  nil  6/9 6/9  50  26 open  0.8  0.3 arcuate  nil  yes  nil  nil 
sei68  male  74 59  yes  6/9 6/6  33  34 open  0.5  0.6 nasal  step  arcuate  nil  nil  bilateral  trab 
sei69  male  78 55  yes  6/9 6/9  35  29 open  0.6  0.3 arcuate  arcuate  nil  nil  bilateral  trab 
sei70  female  68 51  nil  6/9 6/9  30  23 open  0.6  0.4 paracentral  nil  yes    nil  right  trab 
sei71  female  55 62  yes  6/6 6/6  29  31 open  0.3  0.5 nil  arcuate  yes  nil  nil 
sei72  male  69 62  nil  6/9 6/5  19  54 open  0.4  0.9 nil  advanced  yes  nil  left  trab 
sei73  male  76 48  yes  6/9 6/9  34  31 open  0.4  0.3 nasal  step  nil  yes  nil  nil 
sei74  male  65 50  nil  6/9 6/9  30  30 open  0.9  0.8 advanced  arcuate  yes  nil  nil 
sei75  male  77 70  nil  6/9 6/9  32  30 open  0.4  0.3 paracentral  nil  yes  nil  nil 
sei76  male  73 67  nil  6/6 6/6  32  26 open  0.9  0.7 advanced  arcuate  yes  nil  nil 
sei77  female  73 66  nil  6/9 6/9  29  30 open  0.7  0.8 nil  nasal  step  yes  nil  nil 
sei78  male  71 51  nil  6/9 6/6  39  29 open  0.9  0.6 advanced  nasal  step  yes  nil  nil 
sei79  male  62 75  nil  6/9 6/9  36  33 open  0.9  0.7 advanced  paracentral  yes    nil  bilateral  trab 
sei81  male  74 62  nil  6/5 6/6  31  28 open  0.8  0.8 nasal  step  arcuate  yes  nil  nil 
sei82  female  72 51  nil  6/9 6/9  33  30 open  0.5  0.4 paracentral  nasal  step  yes  nil  nil 
sei83  female  64 48  yes  6/9 6/9  29  30 open  0.6  0.6 nasal  step  arcuate  yes  nil  nil 
sei84  male  59 62  nil  6/6 6/6  30  30 open  0.6  0.8 nil  temporal  wedge  nil  nil  bilateral  trab 
sei86  male  83 59  nil  6/9 6/9  30  30 open  0.4  0.4 nasal  step  nasal  step  yes  nil  nil 
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sei87  male  81 64  nil  6/9 6/9  28  30 open  0.9  0.9 advanced  advanced  nil  nil  bilateral  trab 
sei88  male  67 66  nil  6/9 6/9  21  34 open  0.5  0.9 nil  arcuate  yes  nil  nil 
sei89  female  70 72  nil  6/9 6/9  30  30 open  0.9  0.6 advanced  nasal 
step 
nil yes  nil  nil 
sei90  male  62 51  nil  6/6 6/6  30  26 open  0.5  0.3 arcuate  nil  yes  nil  nil 
sei91  male  72 61  nil  6/9 6/9  26  42 open  0.5  0.8 paracentral 
scotoma 
arcuate yes  nil  nil 
sei92  male  67 51  yes  6/9 6/6  32  30 open  0.5  0.6 nasal  step  nasal  step  yes  nil  nil 
sei93  female  79 66  nil  6/9 6/9  30  26 open  0.8  0.7 arcuate  paracentral    yes  nil  nil 
sei94  male  74 72  nil  6/9 6/9  30  28 open  0.7  0.6 nasal  step  nil  yes  nil  nil 
sei95  male  75 60  nil  6/6 6/6  23  37 open  0.8  1  arcuate  advanced  yes  nil  nil 
sei96  male  66 78  nil  6/9 6/5  30  29 open  0.7  0.5 arcuate  nil  yes  nil  nil 
sei97  male  67 71  nil  6/9 6/9  30  29 open  0.4  0.2 paracentral  nil  yes  nil  nil 
sei98  male  77 55  yes  6/9 6/9  24  42 open  0.5  0.8 nil  arcuate  yes  nil  nil 
sei99  male  55 58  nil  6/9 6/9  26  50 open  0.3  0.8 nil  arcuate  yes  nil  nil 
sei100  female  73 71  nil  6/6 6/6  34  28 open  0.7  0.6 nasal  step  nil  yes    nil  nil 
sei101  male  69 63  nil  6/9 6/9  30  38 open  0.3  0.4 nil  nasal  step  yes  nil  nil 
sei102  female  63 61  nil  6/9 6/6  32  30 open  0.6  0.5 paracentral  nil  yes  nil  nil 
sei103  male  82 43  nil  6/9 6/9  56  56 open  0.7  1  arcuate  advanced  nil  nil  bilateral  trab 
sei104  male  71 65  nil  6/6 6/9  30  30 open  0.5  0.6 nil  nasal  step  yes  nil  nil 
sei105  male  43 84  yes  6/6 6/5  22  46 open  0.5  0.9 nil  arcuate  yes    nil  left  trab 
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8.5  Appendix V: Demographic and phenotypic features of OHT individuals 
 
Table 8–3: Demographic and phenotypic features of OHT individuals (n = 58) 
Highest recorded 
IOP  
 
Cup/disc ratio  Visual field defect  Patient 
ID 
Sex  Age  Age at 
diagnosis 
Family history of 
glaucoma 
Best visual 
acquity 
Right   Left 
Anterior 
chamber 
angle 
  Right Left  Right  Left 
Medication  Surgery 
5p male  66  66  no  6/6  6/5  25  26  open  0.3  0.3  nil nil  yes  nil 
13p female  66  58  no  6/9  6/6  28  28  open  0.4  0.4  nil  nil  yes    nil 
42p male  76  74  yes  (mother)  6/9  6/9  20  27  open  0.2  0.2  nil  nil  yes    nil 
49p  female  86  69  yes (aunt- maternal 
side) 
6/12 6/9 28  30  open  0.3  0.4  nil  nil  yes  nil 
53p male  61  61  no  6/6  6/5  28  33  open  0.3  0.3  nil  nil  yes  nil 
54p female  73  66  no  6/9  6/9  27  27  open  0.2  0.2  nil  nil  yes    nil 
56p  female  45  45  yes (2 uncle- paternal 
side) 
6/5 6/6  24  25  open  0.2  0.2  nil  nil  nil  nil 
66p  male  53  74  yes (2 uncle, 1 aunt, 1 
cousin- all paternal 
side) 
6/9 6/9  25  22  open  0.4  0.4  nil  nil  yes    nil 
73p female  57  40  yes  (father  and 
grandfather-paternal 
side)  
6/6 6/6  25  25  open  0.4  0.4  nil  nil  yes    nil 
75p  male  67  59  yes (brother)  6/9  6/5  26  25  open  0.5 (healthy 
NRR) 
0.5 (healthy 
NRR) 
nil nil  yes  nil 
79p female  52  52  yes  (father  and 
grandmother-paternal 
side) 
6/5 6/6  36  37  open  0.3  0.3  nil  nil  yes  nil 
85p female  41  40  no  6/4  6/5  28  28  open  0.5  (healthy 
NRR) 
0.5 (healthy 
NRR) 
nil nil  yes  nil 
87p female  70  61  yes  (sister)  6/9  6/9  26  26  open  0.4  0.4  nil  nil  yes  nil 
91p female  75  61  no  6/6  6/6  28  28  open  0.5  (healthy 
NRR) 
0.5 (healthy 
NRR) 
nil nil  yes  nil   
94p male  53  40  no  6/6  6/5  30  27  open  0.4  0.4  nil  nil  yes  nil 
98p female  68  52  no  6/9  6/6  26  26  open  0.5  (healthy 
NRR) 
0.5 (healthy 
NRR) 
nil nil  yes  nil 
101p  male  78  64  yes (two sisters)  6/9  6/9  37  41  open  0.4  0.4  nil  nil  yes  nil 
105p male  59 58  no  6/5 6/6  26  21  open  0.4  0.4  nil  nil  yes  nil 
108p female  75 70  yes  (grandmother-
maternal side) 
6/9 6/9  25  26  open  0.5  (healthy 
NRR) 
0.5 (healthy 
NRR) 
nil nil  yes  nil 
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111p male  80 63  no  6/9 6/9  34  31  open  0.3  0.3  nil  nil  yes    nil 
117p female  74 67  no  6/6 6/6  28  19  open  0.3  0.3  nil  nil  yes  nil 
118p male  79 73  no  6/9 6/9  34  20  open  0.2  0.2  nil  nil  yes  nil 
121p female  57 56  no  6/9 6/6  27  27  open  0.4  0.4  nil  nil  yes  nil 
128p female  68 61  no  6/9 6/9  23  26  open  0.4  0.4  nil  nil  yes    nil 
130p  female  68  58  yes (2 uncle and 1 aunt- 
all maternal side) 
6/9 6/9  27  27  open  0.2  0.2  nil  nil  yes  nil 
132p  female  83  83  yes (aunt- maternal 
side) 
6/6 6/6  24  24  open  0.2  0.2  nil  nil  yes  nil 
133p female  41 41  no  6/5 6/5  25  25  open  0.3  0.3  nil  nil  nil  nil 
141p female  64 64  yes  (cousin)  6/9 6/9  23  26  open  0.4  0.4  nil  nil  yes  nil 
143p male  72 60  no  6/9 6/9  29  29  open  0.1  0.1  nil  nil  yes    nil 
154p male  63 61  no  6/6 6/9  32  29  open  0.4  0.4  nil  nil  yes  nil 
155p  female  78  56  yes (aunt and cousin)  6/6  6/6  32  24  open  0.1  0.1  nil  nil  yes  nil 
156p male  60 54  no  6/9 6/9  34  30  open  0.4  0.4  nil  nil  yes  nil 
404p male  60 43  yes  (sister)  6/9 6/6  26  28  open  0.1  0.1  nil  nil  yes  nil 
406p female  58 52  yes  (father)  6/9 6/9  30  25  open  0.3  0.3  nil  nil  yes  nil 
410p  female  76  76  yes (brother, sister, 
mother, uncle, aunt- 
maternal side) 
6/5 6/6  24  24  open  0.4  0.4  nil  nil  yes  nil 
416p female  87 75  no  6/6 6/9  25  24  open  0.2  0.2  nil  nil  nil  nil 
429p male  61 48  no  6/9 6/9  32  24  open  0.3  0.3  nil  nil  yes  nil 
455p male  52 52  yes  (grandfather-
maternal side) 
6/9 6/9  25  24  open  0.2  0.2  nil  nil  nil  nil 
457p female  59 54  yes  (grandfather, 
cousin- paternal side) 
6/6 6/6  25  24  open  0.3  0.3  nil  nil  nil  nil 
459p female  80 79  no  6/9 6/9  34  35  open  0.1  0.1  nil  nil  yes    nil 
461p female  51 49  no  6/6 6/6  24  26  open  0.4  0.4  nil  nil  yes  nil 
463p  female  60  54  yes (mother, sister, 
nephew) 
6/5 6/9  20  26  open  0.4  0.4  nil  nil  yes  nil 
464p male  61 59  no  6/9 6/9  22  27  open  0.3  0.3  nil  nil  yes  nil 
475p female  59 50  yes  (grandmother-
maternal side) 
6/9 6/9  30  22  open  0.4  0.4  nil  nil  yes    nil 
476p female  59 56  no  6/9 6/9  28  29  open  0.3  0.3  nil  nil  yes  nil 
481p male  53 47  no  6/9 6/9  25  24  open  0.4  0.4  nil  nil  yes    nil 
486p female  60 58  yes  (sister)  6/6 6/6  24  19  open  0.1  0.1  nil  nil  nil  nil 
487p male  81 51  no  6/9 6/9  32  30  open  0.3  0.3  nil  nil  yes  nil 
497p male  79 69  no  6/6 6/6  28  23  open  0.3  0.3  nil  nil  yes  nil 
509p male  48 47  no  6/6 6/6  30  30  open  0.4  0.4  nil  nil  yes    nil 
513p  female  60  58  yes (father)   6/9  6/9  20  38  open  0.4  0.4  nil  nil  yes   nil 
514p female  92 83  no  6/9 6/9  32  25  open  0.2  0.2  nil  nil  yes    nil 
515p  female  58  55  yes (2 aunts- paternal 
side) 
6/5 6/6  25  17  open  0.4  0.4  nil  nil  yes    nil 
518p  male  70  54  yes (sister, 2 cousins-  6/6  6/9  40  38  open  0.4  0.4  nil  nil  yes   nil 
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maternal side) 
524p male  60 55  no  6/5 6/6  28  29  open  0.1  0.1  nil  nil  yes  nil 
526p female  65 65  no  6/4 6/5  26  23  open  0.4  0.4  nil  nil  yes  nil 
527p male  48 42  yes  (mother)  6/4 6/5  34  34  open  0.2  0.2  nil  nil  yes  nil 
528p male  63 59  no  6/6 6/6  26  28  open  0.4  0.4  nil  nil  yes  nil 
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8.6  Appendix VI: Demographic and phenotypic features of NTG individuals 
 
Table 8–4: Demographic and phenotypic features of NTG individuals (n = 37) 
Highest 
recorded 
IOP 
Cup/disc 
ratio 
Visual field defect  Patient ID  Sex  Age  Age at 
diagnosis 
Family history of 
glaucoma 
Best 
visual 
acquity 
Right Left 
Anterior 
chamber 
angle 
Right Left Right  Left 
Medication  Laser  Surgery 
41p  male  80  75  no  6/9  6/5  18  19  open  0.7  0.8  nasal and paracentral  nasal step  yes  nil  nil 
57p  female  79  75  no  6/9  6/9  17 17  open  0.8 0.7  arcuate  nasal  step  yes  nil nil 
58p  male  75  72  yes (mother)  6/9  6/9  19  19  open  0.6  0.8  nil  nasal step and paracentral  yes  nil  nil 
63p  female  83  83  yes (male)  6/6  6/9  18  19  open  0.7  0.8  paracentral  nasal step  yes  nil  nil 
64p  female  83  83  yes (sister)  6/6  6/6  18  18  open  0.8  0.9  nasal step  nasal step  yes  nil  nil 
68p  female  60  56  no  6/9  6/9  17  17  open  0.5  0.6  nil  nasal step and paracentral 
scotoma 
yes nil  nil 
74p  female  80  74  no  6/9  6/6  19  17  open  0.6  0.4  arcuate and nasal step  nil  yes  nil  nil 
88p_51  male  60  58  yes (father)  6/9  6/9  16  16  open  0.5  0.5  paracentral  nasal step  yes  nil  nil 
88p_72  female  63  49    6/5  6/6  18 18  open  0.8 0.8  advanced  advanced  yes  nil yes 
89p  female  67  67  yes (father)  6/6  6/9  20  19  open  0.5  0.6  nasal step  arcuate  yes  nil  nil 
95p  male 85  85  no  6/9  6/9  14 15  open  0.8 0.8  arcuate  nasal  yes  nil nil 
96p  male  75  67  yes (mother)  6/9  6/9  17  19  open  0.7  0.7  paracentral  paracentral   yes  nil  nil 
100p  female  87  82  yes (brother)  6/6  6/6  20  19  open  0.8  0.6  arcuate  nasal step  yes  nil  nil 
102p  female  73  70  yes (brother)  6/9  6/9  14  14  open  0.8  0.7  paracentral and nasal step  nasal step  yes  nil  nil 
109p  male  70  65  yes (brother and 
nephew) 
6/9  6/6  19 15  open  0.8 0.6  paracentral  nasal  step  yes  nil nil 
112p  female  89  87  no  6/9  6/9  16  17  open  0.5  0.7  nil  arcuate and nasal step  yes  nil  nil 
115p  male  72  66  yes (father)  6/12  6/9  20  19  open  0.8  0.8  paracentral and nasal step  arcuate and nasal step  yes  nil  nil 
119p_ah  female  88  84  no  6/9  6/9  15 15  open  0.8 0.8  advanced  advanced  yes  nil nil 
126p  female  85  85  yes  (sister)  6/9  6/6  15 15  open  0.4 0.5  arcuate  paracentral  yes  nil nil 
131p  female  84  77  no  6/6  6/9  10 10  open  0.9 0.9  advanced  advanced  yes  nil nil 
138p female  71  64  yes  (uncle-maternal 
side, and nephew) 
6/6  6/6  20  18  open  0.9  0.8  arcuate   nasal step  yes  nil  nil 
139p  female  88  69  no  6/6  6/9  19 20  open  0.8 0.9  arcuate  and  paracentral arcuate  yes  nil nil 
148p  female  77  75  yes (sister)  6/9  6/9  19  19  open  0.7  0.7  nasal step and arcuate  arcuate  yes  yes  nil 
151p  female  64  59  yes (mother)  6/9  6/6  18  18  open  0.7  0.6  nasal step  paracentral   yes  nil  nil 
161p  female  75  70  yes  (mother)  6/9  6/9  19 17  open  0.3 0.5  nil  arcuate  yes  nil nil 
402p female  83  73  yes  (2  aunts- 
maternal side) 
6/5  6/9  16  16  open  0.7  0.4  nasal step and arcuate  nasal step  yes  nil  nil 
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424p male  66  61  yes  (5  aunts-paternal 
side) 
6/9  6/9  19 19  open  0.9 0.9  advanced  advanced  yes  nil nil 
426p  female  82  82  yes (father and aunt-
paternal side) 
6/9  6/9  15 18  open  0.5 0.7  paracentral  arcuate  yes  nil nil 
435p  female  92  88  yes (mother)  6/6  6/6  14  19  open  0.9  0.9  advanced nasal step  advanced arcuate  yes  nil  nil 
454p female  65  65  yes  (mother  and 
sister) 
6/9  6/9  16 19  open  0.6 0.7  nil  nasal  step  yes  nil nil 
456p  male 74  74  yes,  (father)  6/9  6/6  19 18  open  0.6 0.7  nil  arcuate  yes  nil nil 
460p  female  88  77  no  6/9  6/9  17  17  open  0.6  0.7  nasal step  nasal step and arcuate  yes  nil  nil 
472p  female  83  78  yes  (brother) 6/12  6/9  10  12  open  0.4  0.7  nil  paracentral  yes nil  nil 
490p male  73  71  yes  (uncle-maternal 
side) 
6/9  6/9  15  20  open  0.5  0.7  nasal step  paracentral   yes  nil  nil 
511p female  77  66  yes  (aunt-maternal 
side) 
6/9  6/9  19  19  open  0.7  0.7  nasal step  nasal step  yes  nil  nil 
519p female  84  67  yes  (sister  and 
mother) 
6/6  6/9  19  18  open  0.8  0.9  nasal step and arcuate  nasal step and arcuate  yes  nil  yes 
522p  female  86  78  no  6/9  6/6  16 14  open  0.8 0.9  advanced  advanced  yes  nil nil 
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